data_2mom_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mom _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.3 mm . . . . . 0 CA--C 1.529 0.168 0 CA-C-O 120.549 0.214 . . . . 0.0 111.069 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.09 -20.07 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.592 -0.277 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.4 p -59.94 -43.8 93.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.111 0 CA-C-O 120.818 0.342 . . . . 0.0 110.226 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.423 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.03 -36.3 93.28 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.86 -40.91 94.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 0.0 110.615 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.92 -36.31 83.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.467 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.9 tt -61.2 -45.42 94.65 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.135 0.493 . . . . 0.0 110.032 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.16 -36.65 80.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.403 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.03 -36.41 93.42 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.354 -0.699 . . . . 0.0 111.354 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.57 -42.11 92.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.983 0.421 . . . . 0.0 110.185 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 9.9 mt -62.1 -39.05 91.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.582 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.2 mm -63.04 -42.15 95.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -61.0 -41.24 96.13 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.404 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.3 t -65.3 -42.6 94.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.897 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.57 -41.89 98.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.621 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.45 -42.5 99.51 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.572 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.79 -49.22 75.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.818 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.29 -35.17 80.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.337 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.6 t80 -58.61 -45.44 89.16 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.385 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -64.0 -42.52 95.97 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.05 -33.82 88.16 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.6 tp . . . . . 0 C--N 1.328 -0.343 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.396 -179.77 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' B' ' 381' ' ' VAL . 42.9 mm . . . . . 0 CA--C 1.531 0.247 0 CA-C-O 120.474 0.178 . . . . 0.0 111.151 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.15 -19.96 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.661 0.267 . . . . 0.0 110.786 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' B' ' 379' ' ' ILE . 57.7 t -64.06 -43.52 97.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.328 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.72 -38.28 95.42 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.93 -39.99 93.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.769 0.319 . . . . 0.0 110.554 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.25 -35.49 81.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.486 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.49 -44.6 96.79 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.049 0.452 . . . . 0.0 110.01 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.29 -37.51 87.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.424 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.13 -39.68 97.47 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 91.5 t -64.32 -41.97 93.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.55 -38.72 81.82 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.245 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.63 -42.09 94.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.815 0.34 . . . . 0.0 110.221 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.27 -40.72 95.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.692 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 73.6 t -62.98 -41.34 92.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.755 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.21 -41.8 97.48 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.613 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.88 -41.75 98.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.32 -48.6 76.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.876 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -62.83 -35.78 81.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.449 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.48 -44.58 85.01 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.219 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . 0.411 HG23 HD12 ' B' ' 398' ' ' ILE . 42.2 mm -65.83 -41.32 89.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.814 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.8 mt . . . . . 0 CA--C 1.531 0.22 0 CA-C-O 120.435 0.16 . . . . 0.0 111.169 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.7 -19.82 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.831 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.547 ' N ' ' O ' ' C' ' 379' ' ' ILE . 9.1 p -61.13 -43.64 96.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . 0.421 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -63.39 -40.07 98.48 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.85 -39.99 91.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 110.598 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.45 -35.19 80.19 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.623 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.5 tt -61.18 -44.84 96.65 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.108 0.48 . . . . 0.0 110.005 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.36 -36.73 84.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.377 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.71 97.77 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.0 -43.15 98.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -58.91 -37.42 76.59 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.067 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.01 -42.69 96.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.26 -40.14 92.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.433 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.1 t -63.46 -40.66 89.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.664 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.8 mt -61.99 -41.65 98.27 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.709 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.84 -42.35 98.93 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.17 -48.87 75.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.93 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.9 t80 -64.93 -34.56 78.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.435 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -58.81 -44.86 90.9 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.255 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . 0.405 HG23 HD13 ' C' ' 398' ' ' ILE . 88.4 mt -65.04 -42.41 94.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.442 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 -179.78 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.5 mt . . . . . 0 CA--C 1.53 0.209 0 CA-C-O 120.596 0.236 . . . . 0.0 111.134 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.18 -20.25 60.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.851 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.1 t -67.02 -43.54 88.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.116 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.317 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.07 -41.05 99.9 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.16 96.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.462 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.68 -35.95 82.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.529 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.9 tt -61.38 -44.32 97.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.865 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -37.5 87.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.488 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.72 -40.67 98.76 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.81 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.783 0.325 . . . . 0.0 110.225 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.7 tt -59.74 -38.6 82.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -179.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 31.4 mm -64.29 -42.59 95.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 0.0 110.183 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.75 -40.95 96.91 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.584 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 91.1 t -64.17 -41.02 91.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.79 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.34 -40.87 95.84 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.527 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.23 -42.12 98.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.02 -48.19 79.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.827 179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 21.5 t80 -66.76 -34.25 77.41 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.258 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -58.35 -45.65 87.78 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.196 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -64.54 -42.62 95.7 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.081 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.69 -33.52 87.47 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 8.6 mt . . . . . 0 C--N 1.325 -0.459 0 CA-C-O 120.646 0.26 . . . . 0.0 110.553 179.809 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 CA--C 1.533 0.311 0 CA-C-O 120.609 0.242 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -51.49 -20.38 1.85 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.61 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 76.2 t -66.29 -43.11 91.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.38 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.85 -37.84 94.81 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.61 94.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 0.0 110.689 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.46 -38.74 92.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.313 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -62.5 -47.64 83.09 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.436 -179.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -37.31 86.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.947 0.404 . . . . 0.0 110.519 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.24 -42.51 99.8 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 93.6 t -66.54 -42.85 90.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.299 . . . . 0.0 110.76 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.84 -40.44 88.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.282 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . 0.411 HG22 HD12 ' B' ' 390' ' ' ILE . 78.7 mt -65.6 -42.26 92.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.832 0.349 . . . . 0.0 110.221 178.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.6 mt -60.7 -40.92 94.05 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.594 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 78.6 t -62.72 -41.7 93.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.691 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.24 -41.7 97.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.472 -179.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.77 -42.27 98.77 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.28 75.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.857 179.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -66.01 -35.04 79.49 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.342 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.45 -45.94 84.16 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.331 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . 0.429 HG21 HD12 ' B' ' 398' ' ' ILE . 91.4 mt -64.27 -42.45 95.48 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.989 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.658 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.927 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.529 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt . . . . . 0 CA--C 1.53 0.197 0 CA-C-O 120.608 0.242 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.64 -19.88 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.529 ' N ' ' O ' ' C' ' 379' ' ' ILE . 55.1 t -64.77 -43.52 96.47 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.269 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.68 -36.89 93.92 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.56 -40.8 96.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 110.544 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.19 83.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.467 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.3 tt -61.38 -45.15 95.57 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.941 -179.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.49 -37.11 86.02 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.529 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.5 98.89 Favored Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -63.47 -42.51 96.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -60.1 -38.63 83.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.871 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.0 mm -63.33 -42.52 96.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.899 0.38 . . . . 0.0 110.061 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.0 -40.85 95.12 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.479 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.17 -41.79 93.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.794 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.28 -41.17 96.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.426 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.71 -43.13 99.44 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.547 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.15 90.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.01 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -60.97 -44.94 96.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.668 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -63.58 -43.72 96.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.545 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 31.8 mm -63.9 -42.23 95.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.85 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.547 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.956 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.558 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.532 0.251 0 CA-C-O 120.479 0.18 . . . . 0.0 111.085 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.13 -20.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.959 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.558 ' N ' ' O ' ' A' ' 379' ' ' ILE . 37.2 t -63.82 -43.46 97.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.453 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.63 -41.29 98.82 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.79 82.98 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.773 0.321 . . . . 0.0 110.698 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.02 -45.08 91.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.711 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.31 -40.82 96.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.393 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.68 88.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.238 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -67.16 -40.88 92.66 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 92.1 t -66.5 -41.88 89.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.106 0.479 . . . . 0.0 110.042 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -58.81 -41.0 85.74 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.778 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.412 HG21 HD12 ' A' ' 390' ' ' ILE . 79.1 mt -66.4 -42.08 89.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.963 0.411 . . . . 0.0 110.073 178.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.89 -41.59 96.33 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.549 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.09 -41.46 92.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.698 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.35 -41.63 97.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.448 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -61.96 -42.61 99.32 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.28 -0.568 . . . . 0.0 109.476 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.65 -47.89 82.92 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.881 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.37 -36.31 83.3 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.43 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.02 -45.13 79.21 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.16 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -64.45 -42.09 94.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.915 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.06 -32.54 80.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.1 tp . . . . . 0 C--N 1.328 -0.369 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.405 -179.825 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt . . . . . 0 CA--C 1.533 0.301 0 CA-C-O 120.491 0.186 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.91 -20.3 58.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.799 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.1 -43.32 92.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.256 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.86 99.0 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.03 93.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.744 0.307 . . . . 0.0 110.65 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.81 -45.75 91.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.669 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.31 -40.23 93.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.412 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.58 -38.06 88.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.24 -37.97 95.26 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 88.4 t -66.15 -42.89 92.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.569 0.224 . . . . 0.0 110.66 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -58.92 -39.22 80.87 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.835 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.9 mm -63.74 -42.68 96.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.228 179.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.6 -40.27 94.21 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.588 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.42 -39.12 83.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.513 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.48 -41.23 96.95 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.502 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -60.69 -42.86 98.0 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.9 -46.91 87.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.859 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -62.41 -34.49 76.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.347 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -59.46 -44.99 92.87 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.467 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . 0.406 HG22 HD13 ' B' ' 398' ' ' ILE . 38.2 mm -68.2 -41.6 84.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.032 179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.585 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.957 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 CA--C 1.533 0.29 0 CA-C-O 120.574 0.226 . . . . 0.0 111.349 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.721 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -67.19 -43.43 88.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.33 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.24 -39.36 97.8 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -40.61 97.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.865 0.364 . . . . 0.0 110.489 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.21 -35.79 82.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.506 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.3 tt -61.07 -45.13 96.02 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-O 121.053 0.454 . . . . 0.0 110.008 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.96 -37.33 87.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.649 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.96 -39.6 98.27 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 88.5 t -63.83 -42.68 96.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 110.272 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.5 tt -60.08 -38.61 83.42 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.996 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -63.5 -42.46 96.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.899 0.381 . . . . 0.0 110.117 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 9.7 mt -61.54 -40.4 94.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.479 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.0 t -63.26 -40.57 89.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.6 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.91 -41.77 96.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.338 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.03 -44.0 97.63 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.613 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.89 83.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.179 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -59.67 -44.45 93.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.662 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -62.97 -45.15 93.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.616 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -63.94 -42.52 96.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.816 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.595 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.817 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 72.7 mt . . . . . 0 C--O 1.232 0.173 0 CA-C-O 120.67 0.271 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -53.33 -20.38 4.31 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.599 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -67.89 -43.66 85.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.623 0.249 . . . . 0.0 110.472 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -67.39 -43.95 86.04 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.87 -39.87 87.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.751 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.13 -43.6 94.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.728 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -66.12 -41.43 90.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.49 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.54 93.61 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.48 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.75 -43.45 98.93 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 94.8 t -67.41 -42.0 86.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.723 0.297 . . . . 0.0 110.851 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tp -59.59 -40.87 88.89 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.073 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.07 -42.76 95.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.85 0.357 . . . . 0.0 110.23 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -61.89 -42.74 99.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.831 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.2 t -65.55 -41.97 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.84 -41.18 97.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.559 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -61.49 -44.06 97.76 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -62.28 -47.45 84.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.972 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.13 -35.72 79.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.224 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -57.92 -45.91 85.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.307 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.66 -41.15 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.162 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.53 -27.37 60.98 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.4 tp . . . . . 0 C--N 1.327 -0.386 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.397 179.958 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.5 mt . . . . . 0 CA--C 1.53 0.21 0 CA-C-O 120.661 0.267 . . . . 0.0 110.817 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.93 -20.0 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.613 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.459 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.2 t -64.15 -43.3 97.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.14 -40.49 99.22 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.64 -37.42 86.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.803 0.335 . . . . 0.0 110.673 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.7 91.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.787 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -64.92 -41.78 95.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.49 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.92 89.19 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.465 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.98 99.52 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 85.5 t -66.92 -43.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.903 0.382 . . . . 0.0 110.189 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.63 -41.26 90.06 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.503 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.3 mt -65.68 -42.11 91.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.98 0.419 . . . . 0.0 110.194 179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -60.04 -41.27 91.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.563 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 82.4 t -64.43 -41.43 92.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.68 -42.2 98.6 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.48 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.13 -42.4 99.2 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.05 -49.26 76.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.799 179.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -64.38 -35.45 80.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.36 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -57.37 -45.57 84.29 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.322 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 5.2 mm -63.93 -42.4 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.074 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.69 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 179.675 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.529 0.141 0 CA-C-O 120.781 0.324 . . . . 0.0 110.808 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.94 -19.88 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.737 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.4 p -59.68 -42.84 89.85 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 CA-C-O 120.615 0.245 . . . . 0.0 110.419 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . 0.43 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -63.81 -39.79 97.77 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.22 -40.9 97.65 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.886 0.374 . . . . 0.0 110.542 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.47 -35.9 82.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.546 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.19 -44.33 97.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.876 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.4 90.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.605 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.73 -41.63 99.63 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 91.2 t -67.08 -42.48 88.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.629 0.252 . . . . 0.0 110.453 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.69 -41.43 90.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.156 -179.001 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . 0.407 HG22 HD12 ' C' ' 390' ' ' ILE . 82.7 mt -64.45 -42.45 95.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.857 0.36 . . . . 0.0 110.28 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.01 -41.2 96.07 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 -179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.1 -40.68 89.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.59 -40.32 94.36 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.326 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.8 -42.84 99.52 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -49.18 77.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.933 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -63.93 -34.8 78.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.392 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.89 -45.31 82.67 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.16 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 84.8 mt -64.7 -42.27 94.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.068 178.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.679 0 N-CA-C 111.014 -0.835 . . . . 0.0 111.014 -179.994 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.525 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 120.553 0.216 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.97 -20.01 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.936 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.4 p -61.04 -43.12 95.51 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 120.679 0.276 . . . . 0.0 110.392 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.423 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.68 -38.92 96.95 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.92 -41.06 95.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.703 0.287 . . . . 0.0 110.563 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.66 -35.71 81.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.518 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.14 -44.35 97.46 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.024 0.44 . . . . 0.0 109.963 -179.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.35 86.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.408 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.74 97.9 Favored Glycine 0 CA--C 1.531 1.066 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.3 t -63.52 -42.17 95.25 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.73 -37.53 79.17 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.467 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.0 mm -64.6 -42.22 94.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.884 0.374 . . . . 0.0 110.072 179.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.14 -40.02 92.24 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.602 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.7 t -62.69 -41.1 91.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.784 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.15 -40.93 95.71 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.444 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.88 -41.84 98.36 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.548 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.82 -48.84 77.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.766 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -64.09 -35.88 82.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.424 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -57.47 -45.52 84.71 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.392 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . 0.421 HD13 HG21 ' A' ' 398' ' ' ILE . 89.8 mt -63.74 -42.46 96.04 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.88 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.88 -35.47 92.05 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.1 tp . . . . . 0 C--N 1.329 -0.297 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.614 -179.825 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.497 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.0 mt . . . . . 0 CA--C 1.53 0.197 0 CA-C-O 120.665 0.269 . . . . 0.0 111.309 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.51 -20.21 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.808 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.0 t -64.68 -44.06 96.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.435 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.25 -40.83 96.89 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.04 85.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.738 0.304 . . . . 0.0 110.655 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.45 -45.77 92.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.659 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.91 -42.3 94.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.509 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.81 -37.26 87.02 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.48 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.63 -40.6 99.36 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -67.14 -42.72 88.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.485 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.6 tt -59.36 -40.56 86.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.486 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.2 mt -65.72 -42.21 92.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.829 0.347 . . . . 0.0 110.188 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.25 -40.58 94.57 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.632 -179.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.7 t -62.4 -41.15 90.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.783 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.17 -41.16 96.28 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.471 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -42.85 99.36 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.978 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -64.37 -37.27 86.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.346 179.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -58.22 -45.41 87.75 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.0 mt -63.35 -41.96 94.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.567 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 179.904 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.401 HD11 HG22 ' C' ' 379' ' ' ILE . 97.3 mt . . . . . 0 CA--C 1.531 0.247 0 CA-C-O 120.618 0.247 . . . . 0.0 111.182 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.55 -20.22 60.69 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.995 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.64 -43.5 90.33 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.394 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.04 -39.24 97.04 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.06 -41.69 98.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.814 0.34 . . . . 0.0 110.545 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.3 83.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.467 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.59 -45.23 95.01 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.136 0.493 . . . . 0.0 110.051 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.17 -36.76 85.11 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.45 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.07 -42.26 98.37 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 62.7 t -67.43 -42.61 87.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.787 0.327 . . . . 0.0 110.429 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.3 tt -61.02 -41.54 96.75 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.182 -179.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.0 mt -64.38 -41.95 93.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.241 178.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -60.49 -41.44 94.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.683 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 78.7 t -64.71 -41.4 92.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.735 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.8 mt -61.7 -41.58 97.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.611 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.84 -42.83 99.51 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.368 -0.533 . . . . 0.0 109.687 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.59 93.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.841 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -63.75 -39.29 93.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.553 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -56.61 -45.36 81.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.337 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.7 mm -66.71 -40.83 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.895 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.572 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.861 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 CA--C 1.534 0.357 0 CA-C-O 120.534 0.206 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -74.52 -20.3 60.03 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.644 0.259 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.32 -43.68 87.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.79 0.329 . . . . 0.0 110.397 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.05 -42.96 99.48 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.876 -0.889 . . . . 0.0 110.876 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.79 -39.49 93.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.747 0.308 . . . . 0.0 110.777 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.4 -44.37 97.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.7 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.62 -41.63 92.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.53 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.72 -40.25 91.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.377 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.36 -42.83 99.04 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.43 -42.5 87.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.825 0.345 . . . . 0.0 110.567 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.26 -41.11 88.07 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.406 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.404 HG23 HD11 ' A' ' 390' ' ' ILE . 84.5 mt -65.4 -42.55 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 CA-C-O 120.934 0.397 . . . . 0.0 110.326 179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 13.0 mt -60.7 -40.0 90.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.51 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.4 t -63.02 -41.34 92.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.721 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -60.96 -40.84 94.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.494 -179.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.51 -42.53 98.94 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.424 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.31 -47.91 82.19 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.829 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.2 t80 -63.92 -34.83 78.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.512 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -57.22 -45.56 83.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.291 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 29.8 mm -64.73 -42.61 95.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.75 -34.01 88.75 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.0 tp . . . . . 0 C--N 1.328 -0.365 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.571 -179.827 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 45.5 mm . . . . . 0 CA--C 1.532 0.285 0 CA-C-O 120.467 0.175 . . . . 0.0 111.391 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.79 -20.31 61.88 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.759 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -66.98 -43.59 89.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 CA-C-O 120.811 0.339 . . . . 0.0 110.21 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.61 -40.78 96.15 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.23 -39.22 92.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.83 0.348 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.83 -45.11 91.08 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.585 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -66.57 -41.41 88.62 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.558 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.67 -38.29 90.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.26 -39.16 96.8 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -66.71 -41.76 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.15 0.5 . . . . 0.0 110.103 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -58.62 -40.22 82.72 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.857 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.59 -42.07 86.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.142 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.1 mt -61.09 -41.89 97.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.721 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.52 -41.46 92.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.714 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.29 -40.83 95.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.611 -179.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.42 -42.45 98.77 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.459 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.49 -49.79 76.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.866 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -63.89 -34.29 77.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.357 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -58.32 -44.67 88.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.269 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 30.8 mm -64.64 -42.64 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.855 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.382 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.865 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.502 ' O ' ' N ' ' C' ' 381' ' ' VAL . 94.6 mt . . . . . 0 CA--C 1.533 0.29 0 CA-C-O 120.429 0.157 . . . . 0.0 111.167 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.11 -19.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.829 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.502 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.9 p -58.97 -44.34 90.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . 0.439 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -63.46 -39.11 97.35 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.5 -41.47 98.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.56 -35.39 80.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.359 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.45 -44.28 97.39 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.111 0.482 . . . . 0.0 110.086 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.63 -37.4 87.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.519 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.76 -41.71 97.48 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 97.9 t -65.75 -41.55 90.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.898 0.38 . . . . 0.0 110.28 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 tt -58.39 -41.7 85.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.618 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . 0.411 HG22 HD11 ' C' ' 390' ' ' ILE . 80.7 mt -65.85 -42.44 92.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.857 0.36 . . . . 0.0 110.393 179.031 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -60.88 -39.43 89.22 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.547 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 61.9 t -62.23 -41.7 92.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.675 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -60.92 -41.44 96.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.399 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.45 -44.46 96.36 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 120.09 -0.644 . . . . 0.0 109.648 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.35 -36.54 84.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.108 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -59.52 -43.65 93.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.604 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -63.87 -41.0 97.85 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.562 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 83.2 mt -63.53 -42.39 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.778 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.565 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.581 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.538 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.5 mt . . . . . 0 CA--C 1.531 0.244 0 CA-C-O 120.546 0.212 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.07 -20.0 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.871 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.3 p -60.82 -42.53 92.76 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 120.717 0.294 . . . . 0.0 110.362 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.81 -39.25 97.23 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.77 -40.89 94.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.819 0.342 . . . . 0.0 110.581 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.77 -35.69 81.89 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.474 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.5 tt -61.59 -44.38 97.12 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 121.057 0.456 . . . . 0.0 110.002 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.81 -36.53 83.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.445 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.8 -37.38 94.76 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.2 t -67.53 -42.08 86.53 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-O 121.076 0.465 . . . . 0.0 109.943 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.18 -41.7 89.09 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.778 -179.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.423 HG21 HD11 ' A' ' 390' ' ' ILE . 82.6 mt -66.72 -42.0 88.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.35 -41.26 93.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.613 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.3 t -64.29 -40.94 90.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.63 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.3 mt -61.6 -40.35 94.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.515 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -62.04 -43.76 98.15 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.31 -0.556 . . . . 0.0 109.581 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.55 -36.77 84.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.018 179.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -60.69 -44.22 96.79 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.657 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -62.32 -43.47 98.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.658 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 86.6 mt -63.83 -42.7 96.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.799 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.06 -38.18 93.79 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.0 tp . . . . . 0 C--N 1.328 -0.349 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.438 -179.803 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt . . . . . 0 CA--C 1.531 0.221 0 CA-C-O 120.425 0.155 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.71 -19.93 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.897 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.537 ' N ' ' O ' ' B' ' 379' ' ' ILE . 7.8 p -60.97 -40.96 87.25 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-O 120.773 0.321 . . . . 0.0 110.265 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.75 -38.57 96.7 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.27 -40.4 93.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.802 0.334 . . . . 0.0 110.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -35.46 81.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.503 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.12 -45.32 95.18 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.065 0.459 . . . . 0.0 110.004 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.26 -35.88 82.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.422 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.86 -40.6 98.5 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -66.55 -42.3 89.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.85 0.357 . . . . 0.0 110.276 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -60.1 -41.36 92.35 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.419 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -65.73 -41.98 91.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.78 0.324 . . . . 0.0 110.156 179.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -60.06 -41.4 92.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.626 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.3 t -63.77 -41.62 93.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.754 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.11 -41.27 96.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.477 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.48 -43.56 98.65 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 120.276 -0.569 . . . . 0.0 109.573 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.3 -36.98 84.34 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.144 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -60.48 -44.09 96.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.647 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -62.94 -41.81 99.61 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.605 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.8 mt -63.09 -42.55 97.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.742 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.541 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.839 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 95.0 mt . . . . . 0 N--CA 1.464 0.256 0 CA-C-O 120.662 0.268 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.19 -20.15 60.95 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.899 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -64.3 -43.21 97.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.245 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.94 -41.97 99.7 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.98 -37.58 88.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.757 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.16 -44.77 94.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.45 -40.4 93.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.424 179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.47 91.31 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.46 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.99 -41.37 97.34 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 88.9 t -64.56 -42.87 96.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-O 120.77 0.319 . . . . 0.0 110.296 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.29 -39.06 85.54 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.897 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 6.5 mm -63.41 -42.27 95.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.07 -40.82 95.13 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.651 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.1 t -62.61 -41.9 93.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.69 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.37 -42.28 98.44 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.67 -42.4 99.6 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.16 -48.57 73.55 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.0 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -63.97 -34.86 78.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.547 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -58.17 -44.33 87.93 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.366 -179.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.4 mm -65.52 -41.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.797 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.486 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -179.828 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.377 0.132 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.16 -20.23 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.347 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.832 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' A' ' 379' ' ' ILE . 45.4 t -65.6 -43.98 93.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.515 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.32 -37.39 94.44 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.8 -42.28 98.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.77 0.319 . . . . 0.0 110.471 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.57 -37.17 85.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.568 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.3 tt -61.53 -44.17 97.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.419 . . . . 0.0 109.976 -179.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.94 -37.08 85.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.592 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.84 -39.96 97.57 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.0 t -64.0 -43.39 97.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.756 0.312 . . . . 0.0 110.541 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.0 tt -60.6 -39.31 87.66 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 7.7 mm -63.75 -42.54 96.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.12 -40.36 93.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.351 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.5 t -63.99 -41.41 92.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.758 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.42 97.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.441 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.68 -41.56 97.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.49 -48.93 73.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.808 179.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.67 -35.34 80.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.31 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.1 t80 -58.34 -46.11 86.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.388 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.1 mt -64.45 -42.56 95.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.225 179.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.99 -32.65 84.88 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.2 tp . . . . . 0 C--N 1.329 -0.303 0 C-N-CA 120.925 -0.31 . . . . 0.0 110.383 -179.529 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.8 mt . . . . . 0 CA--C 1.531 0.218 0 CA-C-O 120.46 0.171 . . . . 0.0 110.782 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.61 -19.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.583 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.8 t -63.9 -43.65 97.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 C-N-CA 120.941 -0.304 . . . . 0.0 110.377 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.48 -43.02 98.78 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.89 87.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.758 0.313 . . . . 0.0 110.697 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.26 -44.85 96.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.698 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.26 -40.68 94.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.416 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.8 -37.41 84.3 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.376 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -39.21 96.01 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 88.0 t -63.87 -42.12 94.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 11.9 mt -62.75 -42.03 99.49 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.807 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . 0.411 HD12 HG23 ' B' ' 390' ' ' ILE . 84.6 mt -66.79 -40.62 86.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.942 0.401 . . . . 0.0 110.067 179.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -59.15 -41.97 89.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.472 -179.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.04 -42.08 93.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.814 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.55 -41.6 97.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.454 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.82 -44.02 97.69 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.308 -0.557 . . . . 0.0 109.646 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.27 -36.61 83.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.143 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.22 -44.29 95.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.527 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -62.99 -44.45 95.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.405 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.27 -42.69 97.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.21 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.636 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.856 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.426 HD13 HG21 ' C' ' 379' ' ' ILE . 97.2 mt . . . . . 0 CA--C 1.532 0.274 0 CA-C-O 120.441 0.162 . . . . 0.0 111.1 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.41 -19.94 60.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 121.044 -0.262 . . . . 0.0 110.846 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.5 t -66.26 -43.16 91.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.084 0 CA-C-O 120.761 0.315 . . . . 0.0 110.484 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.38 -36.65 93.68 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.59 -41.0 98.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.424 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.13 83.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.8 tt -61.3 -43.74 98.37 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.45 -36.92 85.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.591 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.97 -39.99 97.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.52 -42.72 96.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.5 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -60.5 -39.22 86.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.914 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.98 -42.32 95.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.0 -41.8 97.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.589 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -63.91 -41.27 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.14 -41.37 96.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.559 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.4 -44.41 97.19 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.418 -0.513 . . . . 0.0 109.663 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.78 84.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.189 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -60.33 -43.97 95.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.477 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -64.56 -45.56 86.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.365 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -64.54 -42.15 94.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.371 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.608 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.505 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 46.7 mm . . . . . 0 CA--C 1.527 0.093 0 CA-C-O 120.599 0.238 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.17 -20.18 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 120.518 0.199 . . . . 0.0 110.791 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.0 p -60.78 -42.03 90.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.412 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -60.28 -43.16 98.82 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.57 -37.49 85.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.752 0.31 . . . . 0.0 110.738 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.64 -43.52 97.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.694 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.41 -41.38 93.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.395 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.49 -39.06 89.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.174 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.48 -41.04 96.52 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.0 t -67.34 -42.04 87.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.845 0.355 . . . . 0.0 110.245 179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.61 -41.74 91.08 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.41 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.409 HG23 HD13 ' A' ' 390' ' ' ILE . 85.9 mt -65.58 -42.11 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-O 120.931 0.396 . . . . 0.0 110.231 178.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.51 -40.89 96.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.601 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.6 t -64.18 -41.38 92.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.45 -41.55 97.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.434 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.92 -42.58 99.26 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.458 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.64 -47.0 77.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.804 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -64.19 -35.23 80.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.514 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -57.7 -46.22 84.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.396 -179.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 92.1 mt -64.66 -42.43 95.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.49 -33.05 86.2 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.5 tp . . . . . 0 C--N 1.328 -0.364 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.437 -179.496 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.532 0.285 0 CA-C-O 120.72 0.295 . . . . 0.0 111.099 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.25 -20.26 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.618 -0.264 . . . . 0.0 111.007 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' B' ' 379' ' ' ILE . 10.6 p -59.36 -42.77 88.51 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . 0.402 ' N ' ' CG1' ' B' ' 381' ' ' VAL . . . -63.14 -40.23 98.9 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -67.95 -35.84 79.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.716 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.16 -44.04 95.32 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.683 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.51 -40.45 93.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.42 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.17 -37.86 88.71 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.526 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.33 -39.6 97.99 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 99.3 t -67.94 -42.13 85.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.675 0.274 . . . . 0.0 110.4 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -60.0 -40.86 90.68 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.209 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.8 mt -64.93 -42.26 94.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.913 0.387 . . . . 0.0 110.366 179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.35 -40.03 89.28 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.516 -179.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 68.9 t -62.06 -41.25 90.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.652 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.48 -41.03 93.36 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.433 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.79 -43.99 97.41 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.646 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.48 86.44 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.118 179.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.49 -44.34 96.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.888 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -62.24 -44.48 96.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.692 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . 0.404 HG23 HD11 ' B' ' 398' ' ' ILE . 86.0 mt -63.27 -42.35 96.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.616 179.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.496 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.887 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.445 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt . . . . . 0 CA--C 1.533 0.292 0 CA-C-O 120.657 0.265 . . . . 0.0 111.117 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -44.43 -19.87 0.03 OUTLIER 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.8 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.445 ' N ' ' O ' ' C' ' 379' ' ' ILE . 61.3 t -64.28 -43.15 97.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.196 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.13 -42.06 99.67 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.19 85.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.756 0.313 . . . . 0.0 110.777 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.31 -44.96 95.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.796 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.2 -42.08 93.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.547 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.47 87.74 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.514 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.51 99.82 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 80.1 t -66.43 -42.09 89.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 0.0 110.336 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -60.74 -40.93 94.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.518 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . 0.425 HD11 HG22 ' C' ' 390' ' ' ILE . 84.9 mt -66.47 -42.06 89.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.935 0.397 . . . . 0.0 110.275 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.3 -40.97 87.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.517 -179.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 72.5 t -63.11 -42.06 95.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.726 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.9 -41.59 96.36 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.588 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.11 -42.52 99.3 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.565 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.44 -48.01 75.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.099 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 93.9 t80 -63.36 -36.34 83.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.664 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -57.7 -44.56 85.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.492 -179.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . 0.423 HG21 HD13 ' C' ' 398' ' ' ILE . 39.7 mm -66.75 -40.45 86.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.779 179.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.797 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 CA--C 1.532 0.258 0 CA-C-O 120.542 0.211 . . . . 0.0 110.981 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.05 -20.03 61.06 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.872 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.4 t -66.4 -43.55 91.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.072 0 CA-C-O 120.633 0.254 . . . . 0.0 110.359 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.15 -40.97 97.19 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.98 -39.2 90.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.742 0.306 . . . . 0.0 110.77 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.35 -44.68 96.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.651 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.2 mt -65.2 -40.6 94.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.386 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.77 -37.26 86.71 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.44 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.65 -39.72 97.84 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.03 -42.24 95.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.62 -38.09 80.38 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.353 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.99 -42.76 95.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.396 . . . . 0.0 110.093 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.9 mt -61.61 -42.18 98.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.58 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.7 t -66.07 -41.94 90.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.89 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.73 -41.13 97.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.463 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.48 -44.1 97.69 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.347 -0.541 . . . . 0.0 109.688 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.42 -37.37 86.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.98 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -61.89 -44.78 96.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.696 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -62.94 -45.37 92.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.49 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.9 mt -64.26 -42.58 95.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.062 179.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.42 -42.8 95.73 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.6 tp . . . . . 0 C--N 1.327 -0.385 0 CA-C-O 120.781 0.324 . . . . 0.0 110.534 -179.919 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 CA--C 1.532 0.258 0 CA-C-O 120.485 0.183 . . . . 0.0 111.049 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -72.2 -20.44 61.57 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.742 -0.208 . . . . 0.0 110.652 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 60.3 t -66.89 -43.39 89.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.658 0.266 . . . . 0.0 110.414 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.1 -39.55 98.13 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.04 -41.61 96.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.86 -35.38 80.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.511 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.41 -44.29 97.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.295 -0.412 . . . . 0.0 109.92 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.98 -36.91 85.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.567 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.45 -39.48 97.35 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.67 -42.36 94.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.922 0.392 . . . . 0.0 110.191 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.3 tt -59.63 -38.32 81.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.263 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.11 -42.16 94.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.853 0.359 . . . . 0.0 110.207 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.09 -41.03 95.9 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.625 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 86.3 t -63.5 -41.07 91.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.665 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.31 -41.44 96.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.503 -179.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.74 -42.7 99.31 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.89 75.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.833 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -65.0 -35.59 81.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.431 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.9 t80 -57.53 -45.94 84.45 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.273 -179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.04 -42.3 95.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.128 179.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.643 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.914 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.2 mt . . . . . 0 CA--C 1.53 0.186 0 CA-C-O 120.578 0.227 . . . . 0.0 110.718 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.63 -19.79 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.766 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.3 p -60.88 -43.06 94.9 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.62 0.248 . . . . 0.0 110.474 -179.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . 0.427 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -62.51 -45.53 95.68 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.2 85.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.79 0.329 . . . . 0.0 110.719 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.22 -43.66 98.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.654 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.82 -41.14 92.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.485 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.38 94.21 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.452 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.81 -41.11 98.96 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -66.0 -42.73 92.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 110.645 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.59 -41.39 90.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.088 -179.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.0 mt -65.43 -42.08 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.9 0.381 . . . . 0.0 110.367 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.7 mt -60.45 -40.86 92.66 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.534 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.06 -41.41 92.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.685 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.09 -41.43 96.65 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.487 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.74 -41.94 98.31 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.87 -48.93 74.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.763 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -63.69 -36.27 83.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.483 179.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -57.64 -45.32 85.61 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.269 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . 0.415 HG23 HD13 ' C' ' 398' ' ' ILE . 88.7 mt -63.57 -42.29 95.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.094 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.678 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.639 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.467 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.528 0.112 0 CA-C-O 120.593 0.235 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.87 -19.62 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.545 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.467 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.2 t -64.83 -43.4 96.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.446 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.78 -36.72 93.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.66 -40.86 98.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.408 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.63 -36.47 83.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.633 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.42 -44.04 97.82 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.992 0.425 . . . . 0.0 109.925 -179.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.82 -37.06 85.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.447 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.56 -39.32 97.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.2 t -65.99 -42.0 90.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.115 0.483 . . . . 0.0 110.243 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -59.55 -41.01 89.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.595 -179.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 390' ' ' ILE . 86.8 mt -67.75 -41.63 85.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.053 0.454 . . . . 0.0 110.387 179.066 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.03 -41.23 91.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.636 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.8 t -64.3 -41.81 93.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.796 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.39 -41.52 97.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.497 -179.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.72 -42.08 98.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.1 -48.52 75.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.537 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -64.89 -36.5 84.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.373 179.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -57.26 -45.65 83.81 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.182 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -63.7 -42.59 96.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.63 -37.17 94.33 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 43.7 tp . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 120.812 0.339 . . . . 0.0 110.553 -179.92 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt . . . . . 0 CA--C 1.528 0.121 0 CA-C-O 120.534 0.207 . . . . 0.0 110.914 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.13 -19.77 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 121.013 -0.275 . . . . 0.0 110.651 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.521 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.2 t -64.31 -43.71 97.19 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.41 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.69 -38.43 96.21 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.15 -41.14 97.99 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.912 0.387 . . . . 0.0 110.404 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.55 -36.24 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.511 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 2.6 tt -61.5 -44.43 97.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.02 0.438 . . . . 0.0 110.021 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.81 82.76 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.392 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.15 -37.72 95.37 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.68 -41.99 93.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.991 0.424 . . . . 0.0 110.075 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -60.57 -38.1 83.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.224 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.87 -42.12 94.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.822 0.344 . . . . 0.0 110.201 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.86 -40.38 92.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.471 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 92.9 t -63.86 -40.92 90.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.822 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.32 -41.15 96.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.394 -179.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.46 -42.18 98.37 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.21 -46.19 89.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.772 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -63.62 -37.68 88.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.357 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.52 -45.96 84.39 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.243 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -63.52 -42.4 96.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.194 179.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.618 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -179.79 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 37.9 mm . . . . . 0 CA--C 1.529 0.149 0 CA-C-O 120.628 0.251 . . . . 0.0 110.777 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -80.17 -19.73 46.47 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.528 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 52.4 t -65.4 -43.37 94.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.292 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.62 -41.62 99.61 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -38.07 88.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.743 0.306 . . . . 0.0 110.643 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.16 -43.91 96.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.674 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -66.0 -40.7 91.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.497 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.95 91.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.549 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.05 -39.35 97.14 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.8 t -64.06 -42.52 95.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 0.0 110.457 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.5 tt -60.26 -38.37 83.3 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.772 -179.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.03 -42.48 95.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-O 120.846 0.355 . . . . 0.0 110.052 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.18 -40.41 93.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.436 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.6 -41.08 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.742 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.27 -41.27 96.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.435 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.5 -42.24 98.5 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -47.96 81.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.916 -0.583 . . . . 0.0 109.832 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -63.12 -35.82 81.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.217 179.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -59.1 -45.26 91.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.321 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.1 mt -63.15 -42.5 96.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.244 179.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.685 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.862 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.8 mm . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.696 0.284 . . . . 0.0 111.57 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.4 -20.26 62.95 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.804 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.37 -42.32 90.35 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.992 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.52 -40.17 98.33 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.15 -38.21 90.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.74 0.305 . . . . 0.0 110.743 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.7 -45.7 91.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.671 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.28 -41.57 94.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.511 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.35 -38.17 90.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.293 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.6 -41.79 99.77 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.7 t -67.11 -42.36 88.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.823 0.344 . . . . 0.0 110.159 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -60.0 -40.8 90.44 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.3 -179.021 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.408 HD12 HG23 ' A' ' 390' ' ' ILE . 86.7 mt -66.42 -41.75 89.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.959 0.409 . . . . 0.0 110.351 178.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.54 -40.55 91.95 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.579 -179.292 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.4 t -64.33 -41.15 91.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.752 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.93 -41.57 98.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.537 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.41 -42.49 99.48 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.242 -0.583 . . . . 0.0 109.476 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.09 -48.95 72.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.981 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -64.13 -35.79 81.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.422 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -57.38 -45.8 84.07 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.282 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.2 mt -64.89 -42.43 94.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.48 -33.69 87.92 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.8 tp . . . . . 0 C--N 1.327 -0.387 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.411 -179.572 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.507 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.9 mt . . . . . 0 CA--C 1.529 0.169 0 CA-C-O 120.786 0.327 . . . . 0.0 111.315 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.14 -20.1 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.752 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.507 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.38 -43.9 94.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 120.904 0.383 . . . . 0.0 110.178 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.73 -35.77 91.42 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.23 -41.86 98.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.861 0.363 . . . . 0.0 110.662 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.4 84.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.45 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.3 tt -61.23 -44.47 97.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.922 -179.372 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.23 83.65 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.548 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.74 -41.09 97.37 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 62.1 t -67.24 -43.35 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.668 0.27 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.29 -40.37 93.91 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 119.536 -0.866 . . . . 0.0 109.771 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . 0.409 HG21 HD12 ' B' ' 390' ' ' ILE . 79.2 mt -64.04 -42.4 95.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 120.872 0.368 . . . . 0.0 110.572 178.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.08 -41.4 96.59 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.588 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.6 t -65.94 -42.33 91.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.076 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.67 -40.47 95.08 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.4 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.18 -42.94 99.75 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.588 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.74 -36.82 84.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.157 179.395 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -60.36 -44.38 95.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.601 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.0 -43.79 98.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.61 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . 0.415 HD11 HG21 ' B' ' 398' ' ' ILE . 91.2 mt -63.55 -42.61 96.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.717 179.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.494 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.862 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.0 mt . . . . . 0 CA--C 1.531 0.212 0 CA-C-O 120.77 0.319 . . . . 0.0 111.234 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.42 -20.02 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.816 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.9 p -61.82 -42.72 95.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -64.46 -42.15 97.69 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.19 86.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.86 0.362 . . . . 0.0 110.787 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.56 -45.34 94.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.676 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -64.5 -40.43 95.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.433 179.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.93 -37.26 87.05 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.466 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.95 -40.2 97.02 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.98 -43.27 96.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.926 0.394 . . . . 0.0 110.318 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.8 -38.59 88.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.17 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.86 -42.09 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.9 mt -61.41 -41.68 97.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.573 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 90.2 t -65.73 -42.24 92.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.51 -41.82 97.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.625 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -62.27 -43.55 98.56 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.66 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.58 -36.42 82.59 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -61.12 -44.96 96.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.805 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -62.47 -43.69 98.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.645 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . 0.426 HG21 HD13 ' C' ' 398' ' ' ILE . 89.4 mt -64.92 -42.69 95.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.882 179.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.376 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 180.0 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt . . . . . 0 C--O 1.233 0.216 0 CA-C-O 120.566 0.222 . . . . 0.0 110.847 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.87 -20.48 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.657 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' A' ' 379' ' ' ILE . 43.6 t -67.97 -43.62 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.413 179.144 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 379' ' ' ILE . . . -64.96 -38.15 95.13 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.94 98.46 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.713 0.292 . . . . 0.0 110.743 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.76 -48.07 82.35 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.92 0.391 . . . . 0.0 110.565 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.6 -40.95 93.22 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.37 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.51 -39.14 89.91 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.232 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.56 -37.57 94.97 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -63.74 -43.14 97.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.989 0.423 . . . . 0.0 110.243 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.4 mp -61.89 -38.0 86.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.345 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 28.9 mm -63.13 -42.13 95.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -61.16 -42.47 98.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.569 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.3 t -65.62 -42.17 92.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.983 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.94 -40.62 96.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.596 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -60.88 -41.89 96.89 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.95 -49.47 73.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.877 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -65.72 -35.41 80.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.329 179.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -58.0 -45.8 86.26 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.308 -179.415 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.04 -42.94 97.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.231 179.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.84 -41.83 98.66 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.4 tp . . . . . 0 C--N 1.327 -0.375 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.302 -179.981 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.2 mt . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.57 0.224 . . . . 0.0 110.797 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -39.93 -20.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.665 -179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.4 t -67.23 -43.8 88.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 CA-C-O 120.659 0.266 . . . . 0.0 110.567 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' B' ' 379' ' ' ILE . . . -65.26 -37.74 94.32 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.1 -38.53 91.54 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.327 . . . . 0.0 110.66 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.28 -48.05 79.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.848 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.54 -41.6 92.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.429 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.84 -36.98 85.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.327 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.62 -40.09 98.26 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 77.9 t -63.2 -43.46 98.81 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.975 0.417 . . . . 0.0 110.244 179.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.2 -38.01 87.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.361 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.77 -42.15 95.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.4 mt -60.84 -42.63 98.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.557 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.62 -42.31 92.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.56 -41.4 97.33 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.374 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.97 -42.44 99.13 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 120.288 -0.565 . . . . 0.0 109.546 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.59 -38.16 86.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.017 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -62.13 -44.8 95.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.477 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -68.43 -45.54 72.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.866 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.11 -42.03 94.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.068 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.612 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.941 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt . . . . . 0 CA--C 1.531 0.225 0 CA-C-O 120.651 0.262 . . . . 0.0 111.085 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -58.44 -24.65 60.76 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.653 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 56.0 t -68.86 -43.55 82.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.094 0 CA-C-O 120.73 0.3 . . . . 0.0 110.585 179.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.17 -36.17 92.9 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.58 -40.15 95.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.718 0.294 . . . . 0.0 110.751 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.82 -48.59 81.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.8 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.97 -40.86 95.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.47 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.11 -37.74 86.27 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.422 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.11 -38.01 94.81 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 98.3 t -65.03 -43.17 96.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 120.75 0.309 . . . . 0.0 110.539 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 mp -61.36 -39.39 90.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.042 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.12 -42.42 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.073 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -61.11 -41.76 97.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.529 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.6 t -65.43 -41.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.53 -40.44 94.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.439 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.42 -42.06 98.15 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.47 76.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.725 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -64.59 -35.88 82.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.373 179.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -57.67 -45.12 85.99 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.275 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.8 mt -63.81 -42.65 96.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.117 179.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.603 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.673 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 381' ' ' VAL . 94.9 mt . . . . . 0 CA--C 1.53 0.205 0 CA-C-O 120.535 0.207 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.48 -19.81 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.962 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.526 ' N ' ' O ' ' A' ' 379' ' ' ILE . 7.8 p -60.53 -43.65 94.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.749 0.309 . . . . 0.0 110.41 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.43 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -64.81 -36.45 93.12 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -41.3 98.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.738 0.304 . . . . 0.0 110.669 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.36 -36.24 83.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.612 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.4 tt -61.65 -45.31 94.58 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.056 0.455 . . . . 0.0 110.106 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -37.7 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.5 -42.44 97.64 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.2 t -67.12 -42.49 88.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.738 0.304 . . . . 0.0 110.627 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -59.97 -40.99 90.99 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.223 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -65.33 -42.17 93.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.872 0.368 . . . . 0.0 110.234 179.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.85 -41.14 95.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.685 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.1 t -63.88 -41.49 92.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.682 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.34 -41.02 96.36 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.598 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.46 -41.8 97.79 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.295 -0.562 . . . . 0.0 109.545 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.54 -49.63 74.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.882 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -65.01 -34.88 79.5 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.365 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -58.21 -45.56 87.43 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.351 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.3 mt -63.63 -42.74 97.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.34 -38.53 95.97 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.9 tp . . . . . 0 C--N 1.327 -0.391 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.434 -179.905 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.496 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.532 0.284 0 CA-C-O 120.658 0.266 . . . . 0.0 111.044 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.62 -20.06 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.682 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.496 ' N ' ' O ' ' B' ' 379' ' ' ILE . 62.2 t -65.17 -43.11 95.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.361 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.19 -39.63 98.15 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -40.48 96.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.513 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.49 -35.48 81.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.512 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 2.8 tt -61.41 -44.05 97.81 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 121.1 0.476 . . . . 0.0 109.988 -179.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -37.05 85.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.421 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.11 -39.97 96.52 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.96 -43.2 92.85 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.938 0.399 . . . . 0.0 110.218 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -60.36 -40.67 91.63 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.806 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 80.1 mt -67.33 -41.37 86.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.146 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -60.12 -40.93 91.44 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.696 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 75.7 t -63.84 -41.38 92.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.666 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.27 -41.29 96.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.521 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.4 -42.82 99.33 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.558 179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.25 -47.9 74.76 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.836 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 85.0 t80 -64.36 -34.7 78.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.448 179.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -58.57 -44.87 89.91 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.41 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . 0.402 HG23 HD12 ' B' ' 398' ' ' ILE . 42.3 mm -65.09 -40.99 90.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.83 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.619 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.869 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.6 mm . . . . . 0 CA--C 1.53 0.191 0 CA-C-O 120.631 0.253 . . . . 0.0 111.352 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.95 -20.08 61.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.005 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 54.5 t -65.9 -43.71 92.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 CA-C-O 120.744 0.307 . . . . 0.0 110.344 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.72 -41.86 99.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.04 -36.98 86.09 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.792 0.329 . . . . 0.0 110.713 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.43 -46.04 89.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.672 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -64.7 -41.05 96.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.416 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.23 -37.51 85.67 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.397 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.26 -36.41 92.76 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.4 t -64.23 -43.59 97.29 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-O 120.746 0.307 . . . . 0.0 110.458 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 mp -61.63 -39.02 89.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.222 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.24 -41.94 93.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 8.4 mt -60.76 -42.51 97.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.729 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 82.0 t -65.15 -42.44 94.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.834 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.98 -42.73 99.46 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.731 -179.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.08 -43.81 98.03 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.04 -36.86 84.39 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.087 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -61.53 -44.59 96.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.67 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -62.73 -45.34 93.17 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.566 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . 0.412 HD13 HG22 ' C' ' 398' ' ' ILE . 87.7 mt -64.55 -42.67 95.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.867 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.564 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -179.78 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 44.2 mm . . . . . 0 CA--C 1.531 0.249 0 CA-C-O 120.634 0.254 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.07 -20.51 63.22 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.784 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.3 t -66.8 -42.98 90.03 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.372 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.24 -37.68 94.94 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.24 96.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.871 0.367 . . . . 0.0 110.439 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.8 -36.11 82.83 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.416 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.7 tt -62.17 -44.1 97.35 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.085 0.469 . . . . 0.0 110.018 -179.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.03 -37.07 81.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.594 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.82 -39.07 96.99 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 95.5 t -63.63 -42.07 94.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.217 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -60.7 -37.81 82.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.511 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.8 mm -64.4 -41.79 93.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.97 0.414 . . . . 0.0 110.196 179.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.4 mt -60.75 -40.94 94.31 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.53 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.8 t -64.26 -40.8 90.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.45 -40.78 95.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.407 -179.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.03 -41.54 96.76 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.41 -48.35 74.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.756 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.7 t80 -65.57 -35.61 81.35 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.602 -0.727 . . . . 0.0 110.488 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -56.78 -45.69 81.98 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.381 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.01 -42.27 94.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.137 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.63 -33.24 84.33 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.5 tp . . . . . 0 C--N 1.328 -0.348 0 C-N-CA 120.801 -0.359 . . . . 0.0 110.469 -179.824 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.417 HD11 HG23 ' B' ' 379' ' ' ILE . 96.8 mt . . . . . 0 CA--C 1.53 0.203 0 CA-C-O 120.516 0.198 . . . . 0.0 111.267 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -74.62 -19.99 60.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.763 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.09 -43.19 88.94 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.21 -40.62 97.53 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.63 -37.87 89.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.743 0.306 . . . . 0.0 110.659 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.88 -46.63 88.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.602 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.68 -41.87 91.95 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.539 179.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -39.05 93.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.433 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.8 -42.85 99.66 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 89.5 t -66.51 -43.17 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 121.168 -0.213 . . . . 0.0 111.02 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.0 tt -60.64 -41.27 94.6 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.349 -0.541 . . . . 0.0 109.739 -179.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -63.87 -42.23 95.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 0.0 110.319 178.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.8 -40.09 91.35 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.507 -179.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.8 t -63.95 -41.86 93.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.97 -40.8 94.78 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.238 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.45 -43.42 98.91 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.132 -0.627 . . . . 0.0 109.502 179.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.16 -37.11 86.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.125 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -61.62 -44.86 96.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.621 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 36.5 m-85 -63.43 -41.67 98.68 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.578 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.3 mm -63.76 -42.16 95.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.013 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.688 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.857 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.1 mm . . . . . 0 CA--C 1.53 0.206 0 CA-C-O 120.54 0.21 . . . . 0.0 111.137 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.86 -20.34 62.54 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.783 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 63.5 t -67.5 -43.2 87.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.87 -38.49 96.19 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.46 95.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.734 0.302 . . . . 0.0 110.731 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.29 88.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.772 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -64.98 -41.93 94.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.417 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.7 -36.46 83.92 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.346 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.8 -42.21 99.72 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 94.2 t -64.0 -42.96 97.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.885 0.374 . . . . 0.0 110.242 179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.1 tt -60.89 -37.99 84.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.832 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.8 mm -63.4 -42.59 96.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.138 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.42 -40.4 94.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.414 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 91.0 t -63.01 -40.8 90.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.666 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.95 -41.24 95.91 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.435 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.48 -43.5 98.75 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.524 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.5 -37.39 84.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -60.17 -43.96 95.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -62.65 -45.22 93.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.492 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.9 -42.87 97.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.976 179.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.541 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.779 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.4 mm . . . . . 0 CA--C 1.528 0.112 0 CA-C-O 120.623 0.249 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.44 -20.1 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.738 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -67.19 -43.45 88.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.442 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.62 93.43 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.11 -41.71 98.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.847 0.356 . . . . 0.0 110.4 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -36.52 83.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.646 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.2 tt -61.47 -43.9 98.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.42 -37.4 87.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.87 -42.62 99.76 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.56 -42.78 93.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.91 0.386 . . . . 0.0 110.522 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -61.04 -40.94 95.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.493 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.402 HG22 HD13 ' A' ' 390' ' ' ILE . 86.2 mt -66.24 -41.7 89.63 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.107 0 CA-C-O 120.896 0.379 . . . . 0.0 110.268 179.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.8 -40.84 89.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.557 -179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.9 -41.7 93.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.682 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.12 -41.57 96.95 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.485 -179.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.55 -41.93 98.08 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.81 -48.55 79.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.707 179.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -64.43 -35.32 80.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.211 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -57.58 -46.02 84.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.19 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.6 mt -63.77 -42.68 96.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.69 -32.55 84.57 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp . . . . . 0 C--N 1.329 -0.297 0 C-N-CA 121.106 -0.238 . . . . 0.0 110.359 -179.501 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 120.569 0.223 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.22 -20.08 62.3 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.79 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 61.4 t -67.84 -43.21 86.26 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.473 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -37.76 95.02 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.56 -40.67 97.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.395 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.02 -36.04 83.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.583 179.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 2.7 tt -61.52 -44.13 97.61 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.431 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -38.26 90.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.491 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.3 -43.15 99.49 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 90.7 t -67.11 -42.83 88.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.738 0.304 . . . . 0.0 110.715 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.97 -41.07 91.17 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.021 -178.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . 0.408 HD12 HG21 ' B' ' 390' ' ' ILE . 85.4 mt -64.9 -42.16 94.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.829 0.347 . . . . 0.0 110.296 178.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.7 mt -60.71 -41.49 95.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.603 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 80.0 t -64.05 -40.96 90.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.689 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.47 97.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.384 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 7.2 tt -61.67 -42.09 98.44 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.6 -47.8 78.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.532 . . . . 0.0 109.732 179.423 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.98 -35.99 82.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.392 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -57.34 -45.38 84.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.231 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . 0.412 HG21 HD11 ' B' ' 398' ' ' ILE . 44.3 mm -64.94 -41.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.123 179.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.759 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.991 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' C' ' 381' ' ' VAL . 95.2 mt . . . . . 0 C--O 1.23 0.061 0 CA-C-O 120.694 0.283 . . . . 0.0 110.626 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.75 -19.6 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.65 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.534 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.8 p -61.72 -38.46 80.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.745 0.307 . . . . 0.0 110.541 -179.492 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.37 -40.51 98.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.36 98.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.882 0.372 . . . . 0.0 110.301 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.81 -35.81 82.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.5 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.9 tt -61.41 -43.2 99.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.908 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.47 -39.19 92.61 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.517 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.85 -42.18 98.54 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 86.6 t -66.71 -42.46 89.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.828 0.347 . . . . 0.0 110.769 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.5 -40.56 91.83 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.29 -179.374 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . 0.417 HG21 HD11 ' C' ' 390' ' ' ILE . 83.7 mt -66.08 -42.04 90.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 120.903 0.382 . . . . 0.0 110.173 179.055 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.4 -40.91 92.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.594 -179.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 70.4 t -63.36 -41.65 93.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.703 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.99 -41.81 97.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.478 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.1 -42.43 99.22 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.62 -48.4 81.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.636 179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -64.06 -35.38 80.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.417 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.34 -46.56 79.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.28 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.57 -42.48 95.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.219 179.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.544 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.868 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.405 HG22 HD11 ' A' ' 379' ' ' ILE . 96.4 mt . . . . . 0 CA--C 1.532 0.259 0 CA-C-O 120.58 0.228 . . . . 0.0 111.261 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.86 -20.26 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.837 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.39 -43.19 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.262 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.84 -41.61 99.65 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -38.97 93.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.826 0.346 . . . . 0.0 110.719 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.63 -44.91 92.51 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.675 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.64 -40.19 92.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.389 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.3 -40.06 95.03 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.428 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -38.91 96.81 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 79.3 t -64.69 -41.85 93.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.887 0.375 . . . . 0.0 110.188 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.94 -37.8 80.57 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.206 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.74 -42.52 95.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.926 0.394 . . . . 0.0 110.121 179.127 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.51 -42.5 98.89 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.703 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.5 t -65.94 -42.51 92.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -62.04 -42.06 98.77 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.57 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.4 -43.19 99.41 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.635 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.02 -47.53 82.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.918 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -65.57 -34.29 77.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.493 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -56.99 -45.87 82.66 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.322 -179.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.48 -42.35 93.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.36 -31.15 79.78 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.1 tp . . . . . 0 C--N 1.326 -0.438 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.474 -179.594 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.468 ' O ' ' N ' ' B' ' 381' ' ' VAL . 45.8 mm . . . . . 0 CA--C 1.53 0.195 0 CA-C-O 120.548 0.213 . . . . 0.0 111.118 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.37 -20.26 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.71 -0.223 . . . . 0.0 110.766 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.468 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.35 -42.97 94.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.266 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -36.12 92.85 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.3 -43.26 99.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.814 0.34 . . . . 0.0 110.587 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.64 -36.77 84.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.436 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -62.41 -43.68 98.25 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.938 -179.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.7 88.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.491 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.31 -42.1 99.72 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 56.3 t -66.1 -43.98 92.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.895 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -60.88 -41.71 96.54 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.922 -179.242 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 92.7 mt -65.73 -42.2 92.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 CA-C-O 121.003 0.43 . . . . 0.0 110.431 179.063 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -58.42 -41.59 85.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.518 -178.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.71 -40.99 90.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.596 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.94 -41.4 96.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.485 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.23 -42.89 99.39 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.94 -48.31 80.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.972 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.06 -35.65 80.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.49 179.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -56.59 -44.82 81.45 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.316 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.2 mm -65.7 -41.54 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.544 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.858 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.534 0.349 0 CA-C-O 120.48 0.181 . . . . 0.0 110.991 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.33 -20.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.647 0.26 . . . . 0.0 110.803 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.471 ' N ' ' O ' ' C' ' 379' ' ' ILE . 54.3 t -63.8 -43.76 98.0 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.183 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.68 -39.75 98.31 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.62 -39.9 95.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.868 0.366 . . . . 0.0 110.659 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -66.12 -34.31 77.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.457 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.87 -45.17 94.92 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.998 -179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.01 -36.51 84.22 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.2 -40.37 98.47 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 83.9 t -67.27 -42.76 88.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.807 0.337 . . . . 0.0 110.314 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.5 tt -60.46 -41.08 93.41 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.561 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . 0.417 HD11 HG22 ' C' ' 390' ' ' ILE . 82.7 mt -66.04 -42.01 90.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.85 0.357 . . . . 0.0 110.342 178.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.02 -40.05 87.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 74.9 t -63.73 -42.19 95.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.5 -41.16 96.87 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.483 -179.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.3 tt -62.28 -43.71 98.21 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.608 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.46 -36.7 84.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.072 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -60.22 -44.53 95.11 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.652 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 27.6 m-85 -62.11 -43.77 98.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.664 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.0 mt -63.23 -41.88 94.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.521 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.512 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.916 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 44.6 mm . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 120.477 0.179 . . . . 0.0 110.744 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.33 -20.02 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.59 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 54.9 t -65.27 -42.9 95.02 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 C-N-CA 121.026 -0.27 . . . . 0.0 110.468 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.13 -40.15 96.79 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.16 -41.99 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.835 0.35 . . . . 0.0 110.579 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.0 -35.66 81.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.57 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.3 -43.47 98.83 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.68 -39.78 95.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.886 0.374 . . . . 0.0 110.51 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.15 97.81 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 72.8 t -63.79 -43.31 97.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 O-C-N 122.946 -0.15 . . . . 0.0 111.332 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.22 -37.86 81.59 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.336 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -62.94 -42.34 96.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 178.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.5 mt -60.86 -39.85 90.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.392 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.2 t -61.09 -40.72 86.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.468 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.99 -41.6 96.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.323 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.79 -44.2 97.33 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.335 -0.546 . . . . 0.0 109.73 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.22 -36.73 83.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.002 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -60.09 -44.79 94.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.685 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -62.42 -44.9 95.33 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.331 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.45 -42.86 97.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.05 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.09 -33.08 84.34 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 43.9 tp . . . . . 0 C--N 1.331 -0.223 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.502 -179.659 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 CA--C 1.531 0.218 0 CA-C-O 120.51 0.195 . . . . 0.0 111.008 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.96 -20.11 61.79 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.987 -0.285 . . . . 0.0 110.828 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 52.9 t -67.06 -43.12 89.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.419 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.29 -41.57 99.73 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.54 84.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.729 0.3 . . . . 0.0 110.65 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.17 -43.85 98.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.721 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.49 -40.96 93.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.291 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.14 -37.83 88.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -38.97 97.12 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 84.6 t -64.3 -42.12 94.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.108 0.48 . . . . 0.0 110.167 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.2 tp -60.38 -38.08 82.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.247 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -63.5 -42.53 96.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -61.6 -42.07 98.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.495 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 88.5 t -66.03 -42.19 91.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.985 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.67 -41.2 97.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.405 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.66 -43.07 99.55 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.99 -47.82 83.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.695 179.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -63.9 -35.81 81.87 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.86 -45.55 82.37 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.084 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.72 -42.6 96.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.222 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.635 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.945 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt . . . . . 0 CA--C 1.531 0.23 0 CA-C-O 120.508 0.194 . . . . 0.0 111.04 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.03 -20.16 59.72 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 121.053 -0.259 . . . . 0.0 110.736 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.28 -43.38 91.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 121.001 -0.28 . . . . 0.0 110.557 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.59 -37.62 95.04 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.68 -41.03 98.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.857 0.36 . . . . 0.0 110.564 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.79 -35.56 81.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.459 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.6 tt -61.68 -43.62 98.5 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.896 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.12 -38.7 92.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.674 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -40.2 98.72 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.52 -42.65 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.509 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -59.71 -39.07 83.4 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.823 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.38 -42.38 95.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.829 0.347 . . . . 0.0 110.141 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.34 -41.07 96.45 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.414 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.21 -41.52 92.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.717 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.67 -41.99 98.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.542 -179.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.04 -41.96 98.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.67 -49.28 77.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.627 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -64.83 -35.01 79.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.229 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.98 -45.66 86.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.349 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.1 mt -63.55 -42.72 97.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.733 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.989 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.474 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.8 mt . . . . . 0 CA--C 1.528 0.109 0 CA-C-O 120.546 0.212 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.57 -19.63 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.654 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.474 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.2 p -59.15 -44.26 91.32 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-O 120.682 0.277 . . . . 0.0 110.806 -179.34 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.453 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.2 -41.35 99.66 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.11 98.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.842 0.353 . . . . 0.0 110.284 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -66.42 -35.93 81.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.722 179.72 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.6 tt -60.53 -44.52 95.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.931 -179.208 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.11 93.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.421 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.41 -42.91 97.44 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.6 t -65.6 -43.19 94.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.223 -179.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.55 -39.88 89.54 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.448 -0.501 . . . . 0.0 110.114 -179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.409 HG23 HD12 ' A' ' 390' ' ' ILE . 77.1 mt -64.9 -42.05 93.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.81 0.338 . . . . 0.0 110.11 178.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.87 -40.65 93.78 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.664 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.9 t -62.2 -41.18 90.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.725 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.1 mt -61.09 -41.31 96.42 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.421 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.64 -43.21 99.28 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.8 82.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.25 179.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . 0.418 ' CZ ' ' CD1' ' A' ' 400' ' ' LEU . 92.6 t80 -60.3 -44.52 95.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.5 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -63.89 -46.56 84.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.417 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.5 mt -64.43 -42.1 94.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.377 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -53.14 -57.2 15.69 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . 0.418 ' CD1' ' CZ ' ' A' ' 396' ' ' TYR . 8.7 mt . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 110.432 179.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . 0.423 HG23 HD11 ' B' ' 379' ' ' ILE . 97.2 mt . . . . . 0 CA--C 1.529 0.153 0 CA-C-O 120.583 0.23 . . . . 0.0 111.18 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.47 -20.06 60.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.626 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.2 -43.39 88.39 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-O 120.72 0.295 . . . . 0.0 110.461 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.86 -41.59 99.84 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.16 89.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.855 0.36 . . . . 0.0 110.67 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.79 -44.14 96.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.71 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -65.71 -39.6 91.37 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.338 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.96 -38.79 89.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.398 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.09 -42.57 99.5 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 87.4 t -66.88 -42.66 89.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.651 0.263 . . . . 0.0 111.081 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.3 tt -60.08 -41.53 92.64 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.076 -179.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 87.8 mt -64.31 -42.25 94.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.897 0.379 . . . . 0.0 110.26 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.97 -41.28 96.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.564 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.7 t -63.69 -41.09 91.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.738 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.12 -40.94 95.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.421 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -41.59 97.25 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.75 80.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.652 179.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.11 -36.01 82.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.668 -0.697 . . . . 0.0 110.338 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -56.86 -45.87 82.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.165 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.0 mt -63.88 -42.62 96.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.308 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.633 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.95 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.5 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.51 0.195 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.59 -19.64 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' C' ' 379' ' ' ILE . 51.1 t -63.47 -43.87 98.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.85 -36.1 92.86 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.78 -40.71 96.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.791 0.329 . . . . 0.0 110.301 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -36.88 85.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.373 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.57 -44.48 96.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.903 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -36.98 85.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.539 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.16 -38.38 95.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 85.2 t -65.76 -42.62 92.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.879 0.371 . . . . 0.0 110.528 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 5.3 tt -61.1 -38.92 88.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.019 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.85 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.14 -40.97 95.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.64 -40.91 90.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.649 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.68 -41.6 97.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.591 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.56 -42.62 99.12 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.57 -49.14 78.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.74 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.71 -34.74 78.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.273 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -58.05 -45.56 86.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.151 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.3 mt -63.44 -42.4 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.1 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.643 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.779 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 379' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.9 mm . . . . . 0 CA--C 1.528 0.134 0 CA-C-O 120.652 0.263 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.1 -20.25 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.708 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.506 ' N ' ' O ' ' A' ' 379' ' ' ILE . 55.7 t -65.27 -43.51 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.335 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -66.27 -40.78 94.86 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.3 -38.96 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.763 0.316 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.37 -44.86 95.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.33 -40.17 89.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.405 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.81 -37.68 88.3 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.555 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.28 -39.93 97.46 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 80.5 t -66.24 -42.86 91.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.912 0.387 . . . . 0.0 110.596 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.3 mt -62.15 -41.85 98.68 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.413 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.4 mt -64.11 -41.9 93.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.35 -42.61 96.07 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.698 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.1 t -65.34 -41.86 92.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.52 -39.93 92.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.472 -179.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.72 -44.23 96.86 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.52 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.94 -38.02 89.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.077 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -61.76 -43.74 98.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.717 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -63.02 -41.53 99.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.65 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 30.2 mm -63.61 -42.52 96.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.891 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -77.14 -21.08 74.45 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.4 tp . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 120.807 0.337 . . . . 0.0 110.543 -179.836 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 78.8 mt . . . . . 0 CA--C 1.531 0.229 0 CA-C-O 120.576 0.227 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -57.85 -20.26 35.03 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.881 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 381' ' ' VAL . . . . . 0.444 ' CG1' ' N ' ' B' ' 382' ' ' GLY . 8.9 p -60.87 -43.48 95.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-O 120.783 0.325 . . . . 0.0 110.371 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 382' ' ' GLY . . . . . 0.444 ' N ' ' CG1' ' B' ' 381' ' ' VAL . . . -64.68 -42.34 97.29 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.404 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.77 88.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.805 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.04 -46.5 89.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.625 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -64.09 -41.05 97.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.412 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.95 89.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.46 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.96 -36.34 93.16 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 95.1 t -64.82 -42.23 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-O 121.069 0.462 . . . . 0.0 110.243 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 10.9 mt -62.18 -39.78 93.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.35 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.6 mm -65.16 -41.67 92.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.329 -0.396 . . . . 0.0 109.964 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.52 -41.86 95.26 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.622 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 90.0 t -65.06 -42.7 95.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.874 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.7 mt -62.13 -43.32 99.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 -179.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.74 -42.89 99.89 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.93 85.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.169 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.61 -44.37 96.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.847 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 30.6 m-85 -62.2 -42.47 99.32 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.508 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 83.6 mt -63.66 -42.33 95.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.844 179.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.576 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 -179.554 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' C' C ' 379' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' C' ' 381' ' ' VAL . 45.1 mm . . . . . 0 N--CA 1.462 0.154 0 CA-C-O 120.593 0.235 . . . . 0.0 111.361 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.55 -19.9 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.799 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 381' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' C' ' 379' ' ' ILE . 8.1 p -59.57 -43.98 92.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 120.737 0.303 . . . . 0.0 110.294 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 382' ' ' GLY . . . . . 0.432 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -63.62 -43.0 98.6 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.47 -38.78 88.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.744 0.307 . . . . 0.0 110.845 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.84 -44.49 96.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.683 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.14 -40.15 94.0 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.413 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.55 -38.86 89.02 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.411 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.42 -38.46 94.92 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.3 t -62.97 -43.51 99.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.738 0.304 . . . . 0.0 110.281 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -60.59 -39.44 88.13 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.089 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.9 mm -64.01 -42.02 94.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.07 -40.58 94.23 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.581 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 83.6 t -61.85 -41.02 89.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.699 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.17 -42.12 98.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.426 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.85 -42.93 99.94 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.618 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.95 82.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.259 179.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -59.78 -44.97 93.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -63.04 -46.74 86.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.623 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.5 mt -64.88 -42.1 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.857 179.444 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.447 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.557 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 44.9 m . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -68.62 143.5 54.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.62 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 55.34 35.59 25.29 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.572 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.429 ' OD1' ' O ' ' A' ' 372' ' ' ASP . 64.6 t0 -62.23 -36.26 81.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.446 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -62.34 -42.39 99.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.434 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 376' ' ' LEU . 57.8 t-20 -85.01 109.88 18.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.55 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -62.77 -40.84 98.53 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.669 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.475 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 9.6 mp -88.66 130.99 35.18 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.308 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.518 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 18.6 m -153.08 50.25 0.58 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.244 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.518 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 30.1 Cg_endo -63.89 142.14 80.84 Favored 'Trans proline' 0 N--CA 1.497 1.678 0 C-N-CA 122.764 2.31 . . . . 0.0 111.894 179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.3 mm -65.99 -43.2 92.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.069 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.09 -20.07 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.592 -0.277 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.4 p -59.94 -43.8 93.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.111 0 CA-C-O 120.818 0.342 . . . . 0.0 110.226 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.423 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.03 -36.3 93.28 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.86 -40.91 94.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 0.0 110.615 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.92 -36.31 83.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.467 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.9 tt -61.2 -45.42 94.65 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.135 0.493 . . . . 0.0 110.032 -179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.16 -36.65 80.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.403 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.03 -36.41 93.42 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.354 -0.699 . . . . 0.0 111.354 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.57 -42.11 92.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.983 0.421 . . . . 0.0 110.185 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 9.9 mt -62.1 -39.05 91.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.582 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.2 mm -63.04 -42.15 95.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -61.0 -41.24 96.13 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.404 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.3 t -65.3 -42.6 94.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.897 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.57 -41.89 98.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.621 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.45 -42.5 99.51 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.572 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.79 -49.22 75.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.818 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.29 -35.17 80.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.337 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.6 t80 -58.61 -45.44 89.16 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.385 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -64.0 -42.52 95.97 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.05 -33.82 88.16 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . 0.495 ' O ' ' CE1' ' A' ' 403' ' ' HIS . 56.6 tp -62.35 -40.76 97.47 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.396 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 57.35 10.88 1.0 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.609 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 83.3 t60 43.59 82.76 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.662 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . 0.495 ' CE1' ' O ' ' A' ' 400' ' ' LEU . 78.4 m80 -77.61 135.47 38.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.429 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -82.35 134.23 35.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.549 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.92 -11.61 60.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.505 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.01 -37.59 95.21 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -111.6 136.94 50.12 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.526 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.5 mp0 -102.16 127.33 49.13 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 110.218 -0.29 . . . . 0.0 110.218 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -52.63 145.25 12.24 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.574 -179.93 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 14.2 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -161.28 154.21 20.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.431 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -139.6 101.08 4.13 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.404 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 51.5 t0 56.63 47.08 19.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.715 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . 0.412 ' OD1' ' O ' ' B' ' 373' ' ' ASP . 64.2 t0 -62.22 -38.87 90.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.389 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -83.09 109.72 17.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.458 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -60.3 -43.2 96.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.479 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . 0.404 ' N ' ' CD1' ' B' ' 376' ' ' LEU . 10.6 mp -98.33 126.81 43.98 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.024 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.538 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 16.1 m -146.17 49.29 0.85 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.233 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . 0.538 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 24.8 Cg_endo -61.79 145.77 97.02 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 122.917 2.411 . . . . 0.0 111.986 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' B' ' 381' ' ' VAL . 42.9 mm -69.34 -26.73 32.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.151 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.15 -19.96 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.661 0.267 . . . . 0.0 110.786 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' B' ' 379' ' ' ILE . 57.7 t -64.06 -43.52 97.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.328 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.72 -38.28 95.42 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.93 -39.99 93.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.769 0.319 . . . . 0.0 110.554 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.25 -35.49 81.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.486 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.49 -44.6 96.79 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.049 0.452 . . . . 0.0 110.01 -179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.29 -37.51 87.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.424 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.13 -39.68 97.47 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 91.5 t -64.32 -41.97 93.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.55 -38.72 81.82 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.245 -179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.63 -42.09 94.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.815 0.34 . . . . 0.0 110.221 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.27 -40.72 95.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.692 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 73.6 t -62.98 -41.34 92.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.755 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.21 -41.8 97.48 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.613 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.88 -41.75 98.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.32 -48.6 76.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.876 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -62.83 -35.78 81.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.449 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.48 -44.58 85.01 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.219 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . 0.411 HG23 HD12 ' B' ' 398' ' ' ILE . 42.2 mm -65.83 -41.32 89.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.2 -37.34 94.73 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 57.0 tp -62.84 -41.3 99.29 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.386 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 64.2 tttp 57.76 113.01 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.558 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -72.42 133.99 45.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.475 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -75.98 128.45 35.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.31 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -74.88 135.54 41.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.436 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.02 -11.3 59.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.598 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.91 -35.22 91.73 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -107.79 134.95 50.01 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . 0.527 ' OE1' ' N ' ' B' ' 408' ' ' GLU . 56.0 mp0 -105.13 125.33 50.86 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.485 ' NE2' ' O ' ' B' ' 408' ' ' GLU . 83.0 mm-40 -128.52 129.28 45.8 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.885 0.374 . . . . 0.0 110.063 -179.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . 0.477 ' CD2' ' O ' ' B' ' 410' ' ' PHE . 91.7 t80 . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.51 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 83.5 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.54 -38.93 91.04 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.45 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . 0.407 ' O ' ' OD1' ' C' ' 371' ' ' ASP . 38.2 p-10 -93.84 109.25 20.95 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.352 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -66.43 143.66 56.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.582 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -62.16 -41.48 98.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.631 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 10.9 m120 57.99 35.38 25.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.604 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 91.3 t80 -60.75 -46.24 91.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.64 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 57.5 tp -82.92 126.09 32.1 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.49 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 60.8 t 44.12 73.34 0.97 Allowed Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.509 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -74.0 -13.91 23.77 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.491 2.127 . . . . 0.0 112.141 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.8 mt -62.91 -43.24 98.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.169 -178.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.7 -19.82 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.831 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.547 ' N ' ' O ' ' C' ' 379' ' ' ILE . 9.1 p -61.13 -43.64 96.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . 0.421 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -63.39 -40.07 98.48 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.85 -39.99 91.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 110.598 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.45 -35.19 80.19 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.623 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.5 tt -61.18 -44.84 96.65 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.108 0.48 . . . . 0.0 110.005 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.36 -36.73 84.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.377 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.71 97.77 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.0 -43.15 98.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -58.91 -37.42 76.59 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.067 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.01 -42.69 96.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.26 -40.14 92.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.433 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.1 t -63.46 -40.66 89.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.664 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.8 mt -61.99 -41.65 98.27 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.709 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.84 -42.35 98.93 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.17 -48.87 75.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.93 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.9 t80 -64.93 -34.56 78.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.435 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -58.81 -44.86 90.9 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.255 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . 0.405 HG23 HD13 ' C' ' 398' ' ' ILE . 88.4 mt -65.04 -42.41 94.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.86 -19.32 69.48 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 44.2 tp -61.65 -40.26 94.27 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.936 -0.306 . . . . 0.0 110.515 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -36.48 151.2 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.917 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 49.47 92.24 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.55 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -77.16 143.68 38.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.346 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -75.12 141.33 43.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.549 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.3 -12.89 60.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.568 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.29 -35.89 92.09 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -85.56 128.49 34.77 Favored 'General case' 0 C--N 1.33 -0.269 0 O-C-N 122.87 -0.194 . . . . 0.0 110.513 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -91.17 117.0 29.26 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.658 0.266 . . . . 0.0 110.313 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.506 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 1.9 pm0 -75.05 137.14 41.26 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.66 179.901 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 44.6 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -153.5 154.58 34.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.442 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -99.76 108.18 20.44 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.42 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 54.3 p-10 -75.31 148.53 39.26 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.74 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.448 ' O ' ' O ' ' A' ' 376' ' ' LEU . 98.9 m-20 -69.3 142.66 54.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.674 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -65.05 -40.81 95.32 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.716 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -61.8 -45.39 94.05 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.966 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.448 ' O ' ' O ' ' A' ' 373' ' ' ASP . 62.7 mt -118.42 126.79 52.81 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.356 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 3.5 m -135.84 150.0 70.35 Favored Pre-proline 0 CA--C 1.532 0.271 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.615 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -65.29 -22.48 60.39 Favored 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.465 2.11 . . . . 0.0 112.055 179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.95 -44.56 97.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.867 -0.333 . . . . 0.0 111.134 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.18 -20.25 60.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.851 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.1 t -67.02 -43.54 88.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.116 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.317 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.07 -41.05 99.9 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.16 96.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.462 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.68 -35.95 82.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.529 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.9 tt -61.38 -44.32 97.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.865 -179.286 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -37.5 87.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.488 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.72 -40.67 98.76 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.81 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.783 0.325 . . . . 0.0 110.225 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.7 tt -59.74 -38.6 82.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -179.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 31.4 mm -64.29 -42.59 95.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 0.0 110.183 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.75 -40.95 96.91 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.584 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 91.1 t -64.17 -41.02 91.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.79 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.34 -40.87 95.84 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.527 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.23 -42.12 98.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.02 -48.19 79.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.827 179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 21.5 t80 -66.76 -34.25 77.41 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.258 179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -58.35 -45.65 87.78 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.196 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -64.54 -42.62 95.7 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.081 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.69 -33.52 87.47 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 8.6 mt -63.19 -39.86 95.85 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.646 0.26 . . . . 0.0 110.553 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 65.0 mttp 56.96 22.36 7.13 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.492 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 54.6 t-80 43.76 88.84 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.736 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -75.19 136.72 41.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.593 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -81.82 135.97 35.42 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.31 -11.78 59.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.494 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.68 -38.9 96.91 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 83.4 t80 -80.98 132.55 35.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.602 0.239 . . . . 0.0 110.411 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 48.0 tp10 -73.24 121.69 20.74 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.221 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -54.02 142.82 23.76 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.688 -0.405 . . . . 0.0 109.982 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.493 179.523 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 6.0 t . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.72 145.95 51.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.722 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -61.09 -44.02 97.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.378 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -70.76 143.29 51.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.645 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 48.3 t0 56.82 35.42 26.24 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.4 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 48.5 t30 -64.35 -39.75 94.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.575 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -62.53 83.94 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.628 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 54.4 mt -119.49 131.02 55.5 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.62 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 5.9 t 47.65 72.2 1.34 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.528 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -55.2 -34.61 88.58 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.744 2.296 . . . . 0.0 111.935 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.84 -43.41 97.84 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.184 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -51.49 -20.38 1.85 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.61 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 76.2 t -66.29 -43.11 91.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.38 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.85 -37.84 94.81 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.61 94.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 0.0 110.689 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.46 -38.74 92.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.313 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -62.5 -47.64 83.09 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.436 -179.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -37.31 86.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.947 0.404 . . . . 0.0 110.519 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.24 -42.51 99.8 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 93.6 t -66.54 -42.85 90.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.299 . . . . 0.0 110.76 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.84 -40.44 88.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.282 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . 0.411 HG22 HD12 ' B' ' 390' ' ' ILE . 78.7 mt -65.6 -42.26 92.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.832 0.349 . . . . 0.0 110.221 178.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.6 mt -60.7 -40.92 94.05 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.594 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 78.6 t -62.72 -41.7 93.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.691 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.24 -41.7 97.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.472 -179.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.77 -42.27 98.77 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.28 75.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.857 179.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -66.01 -35.04 79.49 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.342 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.45 -45.94 84.16 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.331 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . 0.429 HG21 HD12 ' B' ' 398' ' ' ILE . 91.4 mt -64.27 -42.45 95.48 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.989 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.52 -33.76 87.43 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp -62.22 -40.46 96.2 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.471 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 68.7 mttm 57.67 86.35 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.647 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -70.48 131.28 43.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.384 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 54.5 p-80 -68.46 140.55 55.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.575 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -72.41 138.68 47.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.437 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.41 -11.42 59.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.623 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.54 -38.27 96.05 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -81.21 133.46 35.45 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 54.7 mp0 -105.98 118.76 37.45 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.748 0.309 . . . . 0.0 110.518 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -52.69 145.24 12.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.958 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . 0.401 ' OXT' ' CG ' ' B' ' 410' ' ' PHE . 85.1 t80 . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.872 -1.061 . . . . 0.0 110.463 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 41.6 t . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -156.63 150.23 24.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.445 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 46.1 t0 -130.89 97.96 4.48 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.345 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 54.99 30.25 13.79 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.457 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -66.77 141.93 57.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.579 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -83.36 133.47 34.95 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.4 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -102.24 7.92 40.64 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.501 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 61.4 mt -114.89 132.38 56.55 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.584 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 7.6 p -156.16 77.42 4.44 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.433 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -60.86 145.13 99.48 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 122.643 2.229 . . . . 0.0 111.926 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.529 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt -63.8 -43.7 97.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.916 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.64 -19.88 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.529 ' N ' ' O ' ' C' ' 379' ' ' ILE . 55.1 t -64.77 -43.52 96.47 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.269 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.68 -36.89 93.92 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.56 -40.8 96.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 110.544 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.19 83.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.467 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.3 tt -61.38 -45.15 95.57 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.941 -179.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.49 -37.11 86.02 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.529 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.5 98.89 Favored Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -63.47 -42.51 96.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -60.1 -38.63 83.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.871 -179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.0 mm -63.33 -42.52 96.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.899 0.38 . . . . 0.0 110.061 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.0 -40.85 95.12 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.479 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.17 -41.79 93.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.794 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.28 -41.17 96.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.426 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.71 -43.13 99.44 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.547 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.15 90.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.01 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -60.97 -44.94 96.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.668 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -63.58 -43.72 96.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.545 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 31.8 mm -63.9 -42.23 95.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.85 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.46 -36.06 92.61 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' C' ' 401' ' ' LYS . 55.1 tp -62.74 -41.96 99.44 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.508 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . 0.428 ' O ' ' O ' ' C' ' 400' ' ' LEU . 38.8 ttmt 54.81 111.61 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.62 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -66.87 -38.06 85.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.496 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 80.1 t60 -73.8 132.64 42.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.388 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -70.85 138.13 50.0 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.506 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.59 -11.65 59.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.481 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.44 -38.78 96.9 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 83.2 t80 -82.38 136.89 34.88 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 121.164 -0.215 . . . . 0.0 110.422 179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -85.06 117.56 24.1 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.709 0.29 . . . . 0.0 110.402 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.501 ' N ' ' CD ' ' C' ' 409' ' ' GLN . 0.0 OUTLIER -62.58 140.18 58.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.086 179.717 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . 0.416 ' O ' ' O ' ' C' ' 409' ' ' GLN . 93.6 t80 . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.4 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 51.1 m . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.64 -36.98 85.61 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.284 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -84.61 107.15 16.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.207 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 37.1 p-10 -92.48 1.25 57.35 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.519 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.426 ' O ' ' O ' ' A' ' 376' ' ' LEU . 41.9 p-10 -80.8 -1.44 43.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.249 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.59 -42.01 99.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.379 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -62.37 -44.47 96.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.482 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' A' ' 373' ' ' ASP . 6.0 tp -107.57 112.79 25.71 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.36 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.619 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 0.3 OUTLIER -105.77 -40.6 0.17 Allowed Pre-proline 0 N--CA 1.464 0.247 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.314 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.619 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 38.0 Cg_endo -84.8 111.92 1.48 Allowed 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.652 2.235 . . . . 0.0 112.012 -179.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.558 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -65.44 -42.86 94.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.085 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.13 -20.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.959 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.558 ' N ' ' O ' ' A' ' 379' ' ' ILE . 37.2 t -63.82 -43.46 97.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.453 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.63 -41.29 98.82 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.79 82.98 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.773 0.321 . . . . 0.0 110.698 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.02 -45.08 91.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.711 -179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.31 -40.82 96.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.393 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.68 88.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.238 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -67.16 -40.88 92.66 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 92.1 t -66.5 -41.88 89.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.106 0.479 . . . . 0.0 110.042 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -58.81 -41.0 85.74 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.778 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.412 HG21 HD12 ' A' ' 390' ' ' ILE . 79.1 mt -66.4 -42.08 89.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.963 0.411 . . . . 0.0 110.073 178.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.89 -41.59 96.33 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.549 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.09 -41.46 92.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.698 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.35 -41.63 97.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.448 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -61.96 -42.61 99.32 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.28 -0.568 . . . . 0.0 109.476 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.65 -47.89 82.92 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.881 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.37 -36.31 83.3 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.43 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.02 -45.13 79.21 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.16 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -64.45 -42.09 94.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.915 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.06 -32.54 80.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.1 tp -61.84 -40.01 93.83 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.405 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -50.67 133.67 25.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.603 -179.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.0 t60 44.61 85.48 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.703 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 62.8 t-80 -79.12 129.05 34.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.506 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . 0.539 ' H ' ' CD2' ' A' ' 404' ' ' HIS . 3.1 p80 -70.0 131.49 44.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.405 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.87 -11.34 59.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.44 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.17 -38.84 97.17 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . 0.471 ' CE2' ' O ' ' A' ' 408' ' ' GLU . 81.9 t80 -78.85 135.66 37.1 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.337 -0.246 . . . . 0.0 110.337 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.471 ' O ' ' CE2' ' A' ' 407' ' ' TYR . 85.2 tt0 -73.24 117.78 15.39 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.838 -0.345 . . . . 0.0 110.396 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.508 ' OE1' ' N ' ' A' ' 410' ' ' PHE . 4.2 tp-100 -67.59 123.57 20.83 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.699 -0.401 . . . . 0.0 109.968 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . 0.508 ' N ' ' OE1' ' A' ' 409' ' ' GLN . 90.3 t80 . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.467 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 95.6 p . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.62 -37.8 88.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.412 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 53.4 t0 58.58 38.42 25.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.41 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -71.19 -19.24 62.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.709 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 55.18 34.44 22.68 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.332 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . 0.423 ' ND2' ' O ' ' B' ' 376' ' ' LEU . 67.0 t30 -75.89 147.7 38.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.666 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -60.95 -42.99 99.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.612 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . 0.423 ' O ' ' ND2' ' B' ' 374' ' ' ASN . 58.9 mt -116.61 131.09 57.04 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.616 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.434 ' CG1' ' O ' ' B' ' 377' ' ' VAL . 10.5 p -157.07 75.02 4.36 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.319 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -59.02 -23.75 70.14 Favored 'Trans proline' 0 C--N 1.303 -1.867 0 C-N-CA 122.66 2.24 . . . . 0.0 111.871 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt -62.92 -44.54 99.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.223 -178.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.91 -20.3 58.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.799 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.1 -43.32 92.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.256 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.86 99.0 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.03 93.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.744 0.307 . . . . 0.0 110.65 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.81 -45.75 91.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.669 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.31 -40.23 93.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.412 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.58 -38.06 88.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.24 -37.97 95.26 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 88.4 t -66.15 -42.89 92.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.569 0.224 . . . . 0.0 110.66 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -58.92 -39.22 80.87 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.835 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.9 mm -63.74 -42.68 96.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.228 179.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.6 -40.27 94.21 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.588 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.42 -39.12 83.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.513 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.48 -41.23 96.95 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.502 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -60.69 -42.86 98.0 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.9 -46.91 87.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.859 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -62.41 -34.49 76.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.347 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -59.46 -44.99 92.87 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.467 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . 0.406 HG22 HD13 ' B' ' 398' ' ' ILE . 38.2 mm -68.2 -41.6 84.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.032 179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.67 -33.14 86.45 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 49.1 tp -62.28 -41.47 98.51 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.473 -179.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 63.8 tttp -89.39 119.91 30.27 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.889 0.376 . . . . 0.0 110.227 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 64.2 t-80 -158.35 142.26 15.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.183 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -106.57 125.87 51.55 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.152 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -105.41 128.17 53.38 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.361 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . 0.437 ' O ' ' OE2' ' B' ' 408' ' ' GLU . . . -76.89 -37.38 55.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.566 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.43 -35.15 91.67 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -104.96 136.44 44.44 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.703 0.287 . . . . 0.0 110.42 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' B' ' 408' ' ' GLU . 55.2 mp0 -130.91 146.41 52.32 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.165 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.434 ' NE2' ' N ' ' B' ' 410' ' ' PHE . 43.5 tp60 -70.67 130.58 42.15 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.631 -0.428 . . . . 0.0 109.978 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . 0.434 ' N ' ' NE2' ' B' ' 409' ' ' GLN . 81.6 t80 . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.422 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 369' ' ' SER . . . . . 0.41 ' H2 ' ' H ' ' C' ' 370' ' ' ALA . 7.1 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . 0.41 ' H ' ' H2 ' ' C' ' 369' ' ' SER . . . -155.42 153.81 30.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.462 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 54.3 p30 -150.59 175.54 11.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.245 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -89.41 110.78 21.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.502 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' C' ' 376' ' ' LEU . 98.0 m-20 -64.13 141.36 58.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.693 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -64.26 -40.24 95.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.643 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -60.47 -41.93 95.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.409 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . 0.443 ' O ' ' O ' ' C' ' 373' ' ' ASP . 22.9 tp -104.17 120.77 41.85 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.337 -179.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . 0.469 ' O ' ' CG1' ' C' ' 377' ' ' VAL . 7.1 p -172.8 58.33 0.23 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.353 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -67.18 -19.7 50.43 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 C-N-CA 122.308 2.006 . . . . 0.0 111.965 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.6 mt -63.81 -44.84 98.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 C-N-CA 120.824 -0.35 . . . . 0.0 111.349 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.721 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -67.19 -43.43 88.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.33 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.24 -39.36 97.8 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -40.61 97.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.865 0.364 . . . . 0.0 110.489 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.21 -35.79 82.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.506 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.3 tt -61.07 -45.13 96.02 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-O 121.053 0.454 . . . . 0.0 110.008 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.96 -37.33 87.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.649 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.96 -39.6 98.27 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 88.5 t -63.83 -42.68 96.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 110.272 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.5 tt -60.08 -38.61 83.42 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.996 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -63.5 -42.46 96.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.899 0.381 . . . . 0.0 110.117 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 9.7 mt -61.54 -40.4 94.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.479 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.0 t -63.26 -40.57 89.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.6 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.91 -41.77 96.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.338 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.03 -44.0 97.63 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.613 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.89 83.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.179 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -59.67 -44.45 93.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.662 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -62.97 -45.15 93.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.616 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -63.94 -42.52 96.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.816 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.16 -36.13 92.85 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 47.6 tp -62.45 -42.07 99.2 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.563 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -84.66 100.48 11.48 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.853 0.359 . . . . 0.0 110.654 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -67.96 -37.58 81.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.449 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -98.78 135.51 40.14 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.433 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -73.85 149.55 41.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.604 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.23 -12.26 59.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.514 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.59 -36.32 93.2 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -81.84 131.66 35.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.74 0.305 . . . . 0.0 110.404 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -135.57 146.44 48.0 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.714 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.535 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 0.4 OUTLIER -52.8 146.28 10.86 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.92 179.707 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.427 -179.801 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 84.8 p . . . . . 0 N--CA 1.492 1.65 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.81 -37.43 87.59 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.377 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -98.28 110.95 23.45 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.47 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -63.3 -38.36 90.85 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.705 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -67.32 144.58 55.78 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.63 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 375' ' ' PHE . 58.6 t-20 -60.39 144.9 49.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.501 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . 0.472 ' N ' ' OD1' ' A' ' 374' ' ' ASN . 95.7 m-85 -61.77 -43.33 99.07 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.701 -179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 47.0 mt -115.53 132.72 56.54 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.556 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.426 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 3.4 t 60.94 54.99 3.36 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.453 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.426 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 37.8 Cg_endo -66.56 148.24 83.24 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.823 2.349 . . . . 0.0 111.935 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 72.7 mt -67.7 -26.11 34.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.064 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -53.33 -20.38 4.31 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.599 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -67.89 -43.66 85.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.623 0.249 . . . . 0.0 110.472 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -67.39 -43.95 86.04 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.87 -39.87 87.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.751 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.13 -43.6 94.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.728 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -66.12 -41.43 90.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.49 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.54 93.61 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.48 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.75 -43.45 98.93 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 94.8 t -67.41 -42.0 86.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.723 0.297 . . . . 0.0 110.851 -179.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tp -59.59 -40.87 88.89 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.073 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.07 -42.76 95.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.85 0.357 . . . . 0.0 110.23 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -61.89 -42.74 99.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.831 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.2 t -65.55 -41.97 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.84 -41.18 97.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.559 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -61.49 -44.06 97.76 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -62.28 -47.45 84.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.972 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.13 -35.72 79.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.224 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -57.92 -45.91 85.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.307 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.66 -41.15 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.162 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.53 -27.37 60.98 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.4 tp -63.18 -39.23 94.05 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.397 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -65.94 148.54 51.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.68 -179.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 53.29 97.1 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.513 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -75.24 139.9 42.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.551 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -72.98 141.01 47.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.488 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.23 -13.6 59.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.554 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.3 -38.89 97.15 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -118.02 140.08 50.27 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -82.67 118.25 23.2 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.152 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 44.9 tp60 -96.68 131.9 42.89 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.837 0.351 . . . . 0.0 110.087 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 87.7 t80 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.452 179.991 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 27.2 t . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -62.15 -41.14 98.0 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.464 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 53.5 p-10 -154.55 172.51 17.7 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.243 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -70.59 144.75 51.11 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.792 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -62.55 -42.16 99.36 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.591 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -83.75 144.53 29.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.356 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -114.76 102.74 10.3 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.466 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 57.2 tp -63.04 -41.86 99.61 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.275 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 2.7 m -129.63 80.46 71.69 Favored Pre-proline 0 N--CA 1.465 0.325 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.219 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -59.25 146.07 95.81 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 C-N-CA 122.818 2.345 . . . . 0.0 111.884 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.5 mt -63.67 -43.6 98.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.817 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.93 -20.0 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.613 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.459 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.2 t -64.15 -43.3 97.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.14 -40.49 99.22 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.64 -37.42 86.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.803 0.335 . . . . 0.0 110.673 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.7 91.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.787 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -64.92 -41.78 95.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.49 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.92 89.19 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.465 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.98 99.52 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 85.5 t -66.92 -43.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.903 0.382 . . . . 0.0 110.189 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.63 -41.26 90.06 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.503 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.3 mt -65.68 -42.11 91.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.98 0.419 . . . . 0.0 110.194 179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -60.04 -41.27 91.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.563 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 82.4 t -64.43 -41.43 92.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.68 -42.2 98.6 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.48 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.13 -42.4 99.2 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.05 -49.26 76.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.799 179.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -64.38 -35.45 80.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.36 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -57.37 -45.57 84.29 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.322 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 5.2 mm -63.93 -42.4 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.074 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.13 -35.11 91.56 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 52.0 tp -62.55 -41.33 98.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.876 0.369 . . . . 0.0 110.391 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 88.5 tttt 55.95 103.73 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.573 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 59.9 t-80 -80.66 129.67 34.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.328 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 63.5 t-80 -84.38 126.37 33.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.534 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -79.5 141.88 36.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.581 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.37 -14.62 59.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.655 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.65 -37.62 95.01 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -78.84 133.87 36.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.538 0.209 . . . . 0.0 110.508 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -83.25 118.21 23.48 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 120.734 0.302 . . . . 0.0 110.376 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.505 ' O ' ' NE2' ' B' ' 409' ' ' GLN . 1.8 pm0 -68.07 134.4 50.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.169 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 93.5 t80 . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.528 179.936 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 369' ' ' SER . . . . . 0.42 ' O ' ' OD1' ' C' ' 372' ' ' ASP . 5.5 t . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.04 -36.92 85.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.326 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 38.1 p30 -66.63 -24.66 66.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.527 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 99.7 m-20 55.5 35.84 25.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.57 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 39.2 p-10 -86.24 -0.97 57.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.516 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -91.59 0.86 57.46 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.435 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' C' ' 376' ' ' LEU . 90.1 t80 -60.14 -45.91 91.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.518 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' C' ' 375' ' ' PHE . 45.5 tp 58.81 145.18 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.642 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 2.0 m -71.11 151.01 94.79 Favored Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.644 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.4 146.53 85.73 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.712 2.275 . . . . 0.0 111.874 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt -63.99 -43.87 97.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.808 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.94 -19.88 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.737 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.4 p -59.68 -42.84 89.85 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 CA-C-O 120.615 0.245 . . . . 0.0 110.419 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . 0.43 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -63.81 -39.79 97.77 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.22 -40.9 97.65 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.886 0.374 . . . . 0.0 110.542 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.47 -35.9 82.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.546 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.19 -44.33 97.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.876 -179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.4 90.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.605 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.73 -41.63 99.63 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 91.2 t -67.08 -42.48 88.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.629 0.252 . . . . 0.0 110.453 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.69 -41.43 90.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.156 -179.001 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . 0.407 HG22 HD12 ' C' ' 390' ' ' ILE . 82.7 mt -64.45 -42.45 95.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.857 0.36 . . . . 0.0 110.28 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.01 -41.2 96.07 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 -179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.1 -40.68 89.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.59 -40.32 94.36 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.326 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.8 -42.84 99.52 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -49.18 77.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.933 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -63.93 -34.8 78.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.392 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.89 -45.31 82.67 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.16 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 84.8 mt -64.7 -42.27 94.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.068 178.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.42 -30.28 75.85 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.014 -0.835 . . . . 0.0 111.014 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 54.4 tp -61.85 -40.07 94.06 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.304 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -50.77 136.26 22.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.596 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . 0.611 ' CE1' ' CE1' ' C' ' 403' ' ' HIS . 6.7 p80 -78.49 -13.68 59.72 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.437 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . 0.611 ' CE1' ' CE1' ' C' ' 402' ' ' HIS . 73.1 m80 -69.89 134.9 48.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.35 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . 0.444 ' O ' ' CD2' ' C' ' 404' ' ' HIS . 11.8 p-80 -98.21 124.94 43.05 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.469 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -103.05 -26.54 13.02 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.334 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.4 -39.74 97.19 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 82.7 t80 -85.31 130.26 34.63 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.63 0.252 . . . . 0.0 110.384 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -135.38 148.67 49.45 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.815 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.5 ' NE2' ' N ' ' C' ' 410' ' ' PHE . 38.3 tp60 -70.83 127.96 34.42 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.705 -0.398 . . . . 0.0 109.941 179.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . 0.5 ' N ' ' NE2' ' C' ' 409' ' ' GLN . 84.6 t80 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.555 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 21.7 m . . . . . 0 N--CA 1.492 1.656 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.47 -37.42 87.22 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.348 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -61.13 -39.66 90.88 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.175 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -64.33 -37.26 86.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.596 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -89.2 108.85 19.84 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.383 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -86.99 103.7 15.6 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.441 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -63.8 -41.48 97.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.735 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.417 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 10.7 mp -63.21 -40.24 96.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.206 -179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 35.0 t 59.08 74.65 0.57 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.496 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.24 147.85 94.48 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.915 2.41 . . . . 0.0 111.998 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.525 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -63.17 -43.59 98.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.855 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.97 -20.01 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.936 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.4 p -61.04 -43.12 95.51 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 120.679 0.276 . . . . 0.0 110.392 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.423 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.68 -38.92 96.95 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.92 -41.06 95.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.703 0.287 . . . . 0.0 110.563 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.66 -35.71 81.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.518 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.14 -44.35 97.46 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.024 0.44 . . . . 0.0 109.963 -179.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.35 86.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.408 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.74 97.9 Favored Glycine 0 CA--C 1.531 1.066 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.3 t -63.52 -42.17 95.25 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.73 -37.53 79.17 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.467 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.0 mm -64.6 -42.22 94.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.884 0.374 . . . . 0.0 110.072 179.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.14 -40.02 92.24 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.602 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.7 t -62.69 -41.1 91.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.784 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.15 -40.93 95.71 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.444 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.88 -41.84 98.36 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.548 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.82 -48.84 77.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.766 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -64.09 -35.88 82.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.424 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -57.47 -45.52 84.71 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.392 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . 0.421 HD13 HG21 ' A' ' 398' ' ' ILE . 89.8 mt -63.74 -42.46 96.04 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.88 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.88 -35.47 92.05 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.1 tp -63.14 -41.69 99.33 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.614 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.3 134.46 52.66 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.619 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 85.3 t60 52.71 79.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.607 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 23.2 p80 -69.14 145.37 53.38 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.483 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -74.51 143.68 44.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.531 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.23 -16.63 58.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.511 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.21 -38.99 97.39 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.941 -0.863 . . . . 0.0 110.941 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 84.7 t80 -104.46 130.24 52.38 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.772 0.32 . . . . 0.0 110.388 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -135.49 143.65 45.93 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.842 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -56.53 141.97 40.89 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.078 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.9 t80 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.45 179.626 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 369' ' ' SER . . . . . 0.737 ' HG ' ' H ' ' B' ' 370' ' ' ALA . 38.9 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . 0.737 ' H ' ' HG ' ' B' ' 369' ' ' SER . . . -66.88 142.76 57.2 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.402 179.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -132.41 99.48 4.68 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.355 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 38.8 p-10 -91.61 110.76 22.09 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.448 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -85.88 98.96 11.07 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.289 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 54.9 t30 -154.43 11.47 0.39 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.604 -179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -61.68 -42.15 98.53 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.333 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . 0.542 ' N ' ' CD2' ' B' ' 376' ' ' LEU . 3.5 mm? -66.86 135.47 53.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.158 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.442 ' C ' ' O ' ' B' ' 376' ' ' LEU . 4.0 m 29.97 69.05 0.66 Allowed Pre-proline 0 N--CA 1.468 0.458 0 O-C-N 123.834 0.709 . . . . 0.0 110.936 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_exo -53.56 -38.89 84.15 Favored 'Trans proline' 0 C--N 1.302 -1.897 0 C-N-CA 122.431 2.087 . . . . 0.0 112.081 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.497 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.0 mt -63.61 -44.45 98.55 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.309 -178.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.51 -20.21 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.808 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.0 t -64.68 -44.06 96.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.435 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.25 -40.83 96.89 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.04 85.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.738 0.304 . . . . 0.0 110.655 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.45 -45.77 92.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.659 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.91 -42.3 94.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.509 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.81 -37.26 87.02 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.48 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.63 -40.6 99.36 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -67.14 -42.72 88.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.485 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.6 tt -59.36 -40.56 86.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.486 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.2 mt -65.72 -42.21 92.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.829 0.347 . . . . 0.0 110.188 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.25 -40.58 94.57 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.632 -179.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.7 t -62.4 -41.15 90.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.783 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.17 -41.16 96.28 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.471 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -42.85 99.36 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.978 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -64.37 -37.27 86.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.346 179.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -58.22 -45.41 87.75 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.0 mt -63.35 -41.96 94.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.93 -31.71 77.24 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 59.8 tp -62.39 -40.57 96.93 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.363 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -57.68 136.72 56.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.601 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 86.3 t60 45.63 79.15 0.05 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.515 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -81.43 153.44 26.91 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.544 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -77.1 137.14 38.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.556 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.87 -12.46 59.98 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.524 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.49 -37.43 94.78 Favored Glycine 0 CA--C 1.529 0.936 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -114.58 141.08 48.22 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.754 0.312 . . . . 0.0 110.173 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . 0.52 ' OE1' ' N ' ' B' ' 408' ' ' GLU . 55.4 mp0 -104.42 123.12 46.89 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.052 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.478 ' NE2' ' O ' ' B' ' 408' ' ' GLU . 86.4 mm-40 -130.45 140.16 50.55 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.305 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 88.1 t80 . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.534 -179.708 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 96.8 p . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . 59.15 117.03 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.621 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 34.4 p-10 -64.49 -35.09 79.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.506 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.483 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 99.0 m-20 54.85 31.33 15.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.559 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -62.22 -41.32 98.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.522 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . 0.437 ' O ' ' O ' ' C' ' 375' ' ' PHE . 49.6 p-10 -96.89 10.09 40.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.504 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . 0.437 ' O ' ' O ' ' C' ' 374' ' ' ASN . 97.7 m-85 49.78 102.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.56 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 59.5 mt -115.68 132.66 56.57 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.504 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . 0.469 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 3.7 t 59.68 53.25 3.97 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.345 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . 0.469 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 35.6 Cg_endo -65.62 -20.66 59.91 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.585 2.19 . . . . 0.0 112.046 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.401 HD11 HG22 ' C' ' 379' ' ' ILE . 97.3 mt -63.91 -44.63 98.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.182 -179.237 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.55 -20.22 60.69 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.995 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.64 -43.5 90.33 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.394 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.04 -39.24 97.04 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.06 -41.69 98.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.814 0.34 . . . . 0.0 110.545 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.3 83.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.467 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.59 -45.23 95.01 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.136 0.493 . . . . 0.0 110.051 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.17 -36.76 85.11 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.45 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.07 -42.26 98.37 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 62.7 t -67.43 -42.61 87.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.787 0.327 . . . . 0.0 110.429 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.3 tt -61.02 -41.54 96.75 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.182 -179.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.0 mt -64.38 -41.95 93.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.241 178.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -60.49 -41.44 94.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.683 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 78.7 t -64.71 -41.4 92.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.735 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.8 mt -61.7 -41.58 97.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.611 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.84 -42.83 99.51 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.368 -0.533 . . . . 0.0 109.687 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.59 93.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.841 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -63.75 -39.29 93.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.553 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -56.61 -45.36 81.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.337 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.7 mm -66.71 -40.83 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.895 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.74 -28.64 71.96 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 50.9 tp -62.53 -40.13 95.81 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.445 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -63.62 136.68 57.69 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.671 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -78.65 157.66 28.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.524 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -69.83 143.57 52.84 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.593 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -74.76 137.29 41.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.605 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.46 -11.89 59.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.587 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.96 -35.2 91.74 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -108.2 136.37 47.98 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.82 0.343 . . . . 0.0 110.284 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -135.42 145.48 47.31 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.688 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.528 ' OE1' ' N ' ' C' ' 410' ' ' PHE . 4.2 tp-100 -71.42 123.6 22.72 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.413 -0.515 . . . . 0.0 109.895 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . 0.528 ' N ' ' OE1' ' C' ' 409' ' ' GLN . 94.3 t80 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.494 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 48.2 m . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 48.11 41.84 16.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.478 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 34.4 p30 -86.47 -1.78 57.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.399 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 55.1 33.39 20.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.564 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.522 ' OD1' ' CZ ' ' A' ' 375' ' ' PHE . 54.5 p-10 -80.7 166.79 20.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.456 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 52.8 t30 -86.89 112.74 22.06 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.469 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . 0.522 ' CZ ' ' OD1' ' A' ' 373' ' ' ASP . 86.0 m-85 -83.95 -146.18 0.09 Allowed 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 120.964 0.411 . . . . 0.0 110.469 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 51.7 tp -64.05 -44.36 92.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.317 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.2 t 39.66 74.58 0.67 Allowed Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.738 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -52.64 -34.39 63.39 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.733 2.289 . . . . 0.0 112.04 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt -63.07 -44.2 99.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.121 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -74.52 -20.3 60.03 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.644 0.259 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.32 -43.68 87.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.79 0.329 . . . . 0.0 110.397 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.05 -42.96 99.48 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.876 -0.889 . . . . 0.0 110.876 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.79 -39.49 93.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.747 0.308 . . . . 0.0 110.777 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.4 -44.37 97.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.7 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.62 -41.63 92.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.53 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.72 -40.25 91.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.377 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.36 -42.83 99.04 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.43 -42.5 87.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.825 0.345 . . . . 0.0 110.567 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.26 -41.11 88.07 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.406 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.404 HG23 HD11 ' A' ' 390' ' ' ILE . 84.5 mt -65.4 -42.55 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 CA-C-O 120.934 0.397 . . . . 0.0 110.326 179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 13.0 mt -60.7 -40.0 90.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.51 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.4 t -63.02 -41.34 92.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.721 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -60.96 -40.84 94.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.494 -179.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.51 -42.53 98.94 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.424 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.31 -47.91 82.19 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.829 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.2 t80 -63.92 -34.83 78.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.512 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -57.22 -45.56 83.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.291 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 29.8 mm -64.73 -42.61 95.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.75 -34.01 88.75 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . 0.44 ' O ' ' O ' ' A' ' 401' ' ' LYS . 49.0 tp -62.93 -41.84 99.6 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.571 -179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' A' ' 400' ' ' LEU . 87.5 tttt 59.19 140.65 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.542 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -67.54 132.85 48.38 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.202 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 15.8 p80 -115.37 156.99 24.53 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.436 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -75.68 148.7 38.45 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.545 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.09 -11.1 59.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.484 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.85 -39.27 97.8 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -79.83 131.88 35.99 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 64.5 mm-40 -135.38 146.31 48.21 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.454 0.169 . . . . 0.0 110.555 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.477 ' NE2' ' N ' ' A' ' 410' ' ' PHE . 39.3 tp60 -72.57 128.39 35.44 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 120.627 -0.429 . . . . 0.0 109.858 179.509 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . 0.477 ' N ' ' NE2' ' A' ' 409' ' ' GLN . 88.0 t80 . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.507 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -151.66 152.3 32.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.51 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -62.46 -40.31 96.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.257 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -68.62 142.16 55.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.698 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 55.17 37.09 28.37 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.501 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . 0.433 ' OD1' ' CD2' ' B' ' 375' ' ' PHE . 50.5 p30 -98.5 6.52 47.1 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.64 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . 0.433 ' CD2' ' OD1' ' B' ' 374' ' ' ASN . 99.0 m-85 -98.14 -3.72 37.17 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.403 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . 0.442 ' CD1' ' N ' ' B' ' 376' ' ' LEU . 10.3 mp -63.41 -40.36 96.99 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.241 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 2.4 m -45.43 150.64 0.84 Allowed Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.768 -179.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -64.18 -22.32 67.17 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.575 2.183 . . . . 0.0 112.258 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 45.5 mm -64.88 -46.2 92.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.391 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.79 -20.31 61.88 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.759 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -66.98 -43.59 89.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 CA-C-O 120.811 0.339 . . . . 0.0 110.21 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.61 -40.78 96.15 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.23 -39.22 92.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.83 0.348 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.83 -45.11 91.08 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.585 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -66.57 -41.41 88.62 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.558 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.67 -38.29 90.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.26 -39.16 96.8 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -66.71 -41.76 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.15 0.5 . . . . 0.0 110.103 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -58.62 -40.22 82.72 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.857 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.59 -42.07 86.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.142 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.1 mt -61.09 -41.89 97.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.721 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.52 -41.46 92.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.714 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.29 -40.83 95.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.611 -179.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.42 -42.45 98.77 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.459 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.49 -49.79 76.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.866 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -63.89 -34.29 77.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.357 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -58.32 -44.67 88.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.269 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 30.8 mm -64.64 -42.64 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.855 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.25 -37.2 94.2 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' B' ' 402' ' ' HIS . 51.8 tp -63.4 -42.27 98.78 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.498 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' B' ' 400' ' ' LEU . 61.5 pttt 35.16 32.61 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 121.005 0.431 . . . . 0.0 111.084 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . 0.459 ' N ' ' O ' ' B' ' 400' ' ' LEU . 49.7 t-80 -148.41 141.83 25.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.349 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -118.22 123.53 45.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.482 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -77.71 133.1 38.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.47 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.04 -34.78 57.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.547 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.9 -35.27 91.78 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 84.0 t80 -78.35 134.14 37.49 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 110.414 -0.217 . . . . 0.0 110.414 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -135.39 146.33 48.22 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 120.425 0.155 . . . . 0.0 110.61 179.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.616 ' NE2' ' N ' ' B' ' 410' ' ' PHE . 35.7 tp60 -68.35 132.79 47.68 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . 0.616 ' N ' ' NE2' ' B' ' 409' ' ' GLN . 96.5 m-85 . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.511 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 6.9 t . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.66 -37.72 87.32 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.438 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 59.1 t0 55.93 33.39 21.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.418 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -87.56 112.68 22.52 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.675 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -87.62 113.3 23.18 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.343 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -63.39 -41.5 98.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.663 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -118.28 102.39 8.93 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.644 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . 0.436 ' N ' ' CD1' ' C' ' 376' ' ' LEU . 10.4 mp -64.46 -40.98 96.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.361 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 2.8 m -134.75 77.38 57.84 Favored Pre-proline 0 N--CA 1.464 0.236 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.397 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -75.83 -14.74 19.28 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.629 2.219 . . . . 0.0 111.972 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.502 ' O ' ' N ' ' C' ' 381' ' ' VAL . 94.6 mt -63.07 -44.05 99.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.167 -179.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.11 -19.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.829 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.502 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.9 p -58.97 -44.34 90.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . 0.439 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -63.46 -39.11 97.35 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.5 -41.47 98.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.56 -35.39 80.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.359 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.45 -44.28 97.39 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.111 0.482 . . . . 0.0 110.086 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.63 -37.4 87.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.519 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.76 -41.71 97.48 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 97.9 t -65.75 -41.55 90.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.898 0.38 . . . . 0.0 110.28 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 tt -58.39 -41.7 85.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.618 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . 0.411 HG22 HD11 ' C' ' 390' ' ' ILE . 80.7 mt -65.85 -42.44 92.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.857 0.36 . . . . 0.0 110.393 179.031 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -60.88 -39.43 89.22 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.547 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 61.9 t -62.23 -41.7 92.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.675 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -60.92 -41.44 96.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.399 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.45 -44.46 96.36 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 120.09 -0.644 . . . . 0.0 109.648 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.35 -36.54 84.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.108 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -59.52 -43.65 93.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.604 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -63.87 -41.0 97.85 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.562 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 83.2 mt -63.53 -42.39 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.778 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -59.65 -58.95 11.61 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . 0.471 ' N ' ' CD2' ' C' ' 400' ' ' LEU . 3.9 mm? -65.43 -42.86 92.0 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.806 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . 0.413 ' C ' ' O ' ' C' ' 400' ' ' LEU . 24.5 pttm 34.88 39.82 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.941 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -70.23 127.56 33.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.194 -179.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' C' ' 404' ' ' HIS . 61.0 t-80 -75.76 151.98 37.48 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.524 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . 0.401 ' O ' ' ND1' ' C' ' 403' ' ' HIS . 39.0 t60 -76.54 132.38 39.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.543 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.88 -12.64 60.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.616 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.08 -36.67 93.77 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 75.2 m-85 -105.31 134.58 48.19 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -88.32 116.58 26.63 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -52.59 138.38 28.34 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.675 -0.41 . . . . 0.0 109.913 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 55.2 p90 . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.563 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 369' ' ' SER . . . . . 0.504 ' N ' ' CE1' ' A' ' 375' ' ' PHE . 40.3 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 48.79 12.93 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.545 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.485 ' H ' ' C ' ' A' ' 369' ' ' SER . 99.1 m-20 55.94 33.68 22.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.445 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -67.16 142.45 57.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.627 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -67.97 144.26 55.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.656 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.518 ' C ' ' H ' ' A' ' 376' ' ' LEU . 65.7 t30 56.64 42.38 27.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.584 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . 0.561 ' C ' ' H ' ' A' ' 377' ' ' VAL . 68.9 t80 -69.21 8.68 0.54 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.535 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.518 ' H ' ' C ' ' A' ' 374' ' ' ASN . 4.0 tp 70.83 -15.96 0.36 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.467 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.561 ' H ' ' C ' ' A' ' 375' ' ' PHE . 7.3 t 45.05 72.66 1.16 Allowed Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.689 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 33.4 Cg_exo -59.78 145.6 97.79 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.87 2.38 . . . . 0.0 111.824 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.538 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.5 mt -63.1 -43.28 98.85 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.968 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.07 -20.0 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.871 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.3 p -60.82 -42.53 92.76 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 120.717 0.294 . . . . 0.0 110.362 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.81 -39.25 97.23 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.77 -40.89 94.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.819 0.342 . . . . 0.0 110.581 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.77 -35.69 81.89 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.474 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.5 tt -61.59 -44.38 97.12 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 121.057 0.456 . . . . 0.0 110.002 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.81 -36.53 83.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.445 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.8 -37.38 94.76 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.2 t -67.53 -42.08 86.53 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-O 121.076 0.465 . . . . 0.0 109.943 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.18 -41.7 89.09 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.778 -179.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.423 HG21 HD11 ' A' ' 390' ' ' ILE . 82.6 mt -66.72 -42.0 88.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.35 -41.26 93.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.613 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.3 t -64.29 -40.94 90.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.63 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.3 mt -61.6 -40.35 94.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.515 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -62.04 -43.76 98.15 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.31 -0.556 . . . . 0.0 109.581 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.55 -36.77 84.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.018 179.34 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -60.69 -44.22 96.79 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.657 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -62.32 -43.47 98.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.658 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 86.6 mt -63.83 -42.7 96.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.799 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.06 -38.18 93.79 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.0 tp -62.58 -41.37 98.91 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.438 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 49.7 tttp 57.87 164.25 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.59 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 54.47 93.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.443 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -79.86 144.41 33.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.515 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 75.9 m80 -77.73 139.9 39.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.547 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.26 -13.25 59.97 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.537 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.45 -39.37 97.64 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 81.9 t80 -82.5 134.33 35.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.582 0.23 . . . . 0.0 110.428 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -83.45 117.22 22.93 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.406 179.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.486 ' CD ' ' N ' ' A' ' 409' ' ' GLN . 2.0 pm0 -66.41 136.16 55.35 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . 0.508 ' CG ' ' O ' ' A' ' 410' ' ' PHE . 93.7 t80 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.339 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 13.3 p . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.15 141.4 54.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.552 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -62.11 -34.49 76.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.181 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -67.65 143.18 56.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.551 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -90.94 -0.66 57.79 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.58 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 12.4 m120 56.24 35.23 25.42 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.56 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 51.7 t80 -60.65 -43.31 97.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.484 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 27.1 mt -100.29 133.81 44.15 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.441 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 3.7 m -137.79 74.92 44.08 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.419 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -61.16 150.47 84.35 Favored 'Trans proline' 0 N--CA 1.494 1.55 0 C-N-CA 122.98 2.453 . . . . 0.0 111.805 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt -63.03 -43.18 98.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.929 -179.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.71 -19.93 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.897 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.537 ' N ' ' O ' ' B' ' 379' ' ' ILE . 7.8 p -60.97 -40.96 87.25 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-O 120.773 0.321 . . . . 0.0 110.265 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.75 -38.57 96.7 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.27 -40.4 93.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.802 0.334 . . . . 0.0 110.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -35.46 81.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.503 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.12 -45.32 95.18 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.065 0.459 . . . . 0.0 110.004 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.26 -35.88 82.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.422 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.86 -40.6 98.5 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -66.55 -42.3 89.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.85 0.357 . . . . 0.0 110.276 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -60.1 -41.36 92.35 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.419 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -65.73 -41.98 91.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.78 0.324 . . . . 0.0 110.156 179.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -60.06 -41.4 92.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.626 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.3 t -63.77 -41.62 93.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.754 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.11 -41.27 96.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.477 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.48 -43.56 98.65 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 120.276 -0.569 . . . . 0.0 109.573 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.3 -36.98 84.34 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.144 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -60.48 -44.09 96.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.647 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -62.94 -41.81 99.61 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.605 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.8 mt -63.09 -42.55 97.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.742 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.71 -35.65 92.2 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 53.3 tp -62.6 -41.18 98.82 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.51 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -64.62 135.94 56.47 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.607 -179.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 84.4 t60 48.82 93.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.517 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -69.91 143.33 52.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.547 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 61.1 m170 -73.54 142.66 46.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.59 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.14 -11.43 59.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.561 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.76 -36.86 93.62 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 90.6 t80 -82.26 132.75 35.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.621 0.248 . . . . 0.0 110.507 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.5 146.99 48.69 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.78 0.324 . . . . 0.0 110.756 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.562 ' CD ' ' H ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -52.6 146.03 10.78 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.611 -0.435 . . . . 0.0 109.923 179.712 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.368 -179.642 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 25.5 p . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.68 -38.58 91.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.447 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -99.06 110.62 23.18 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.351 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -62.72 -39.23 93.42 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.608 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -88.2 113.91 24.29 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.456 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' C' ' 376' ' ' LEU . 42.7 p-10 -83.96 138.98 32.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.553 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -62.54 -43.79 97.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.615 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . 0.464 ' O ' ' ND2' ' C' ' 374' ' ' ASN . 33.1 tp -104.86 131.62 52.12 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.076 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 27.0 t -118.71 83.43 22.31 Favored Pre-proline 0 CA--C 1.534 0.329 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.344 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -81.05 109.89 2.24 Favored 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.635 2.223 . . . . 0.0 111.859 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 95.0 mt -94.64 -75.28 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.9 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.19 -20.15 60.95 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.899 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -64.3 -43.21 97.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.245 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.94 -41.97 99.7 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.98 -37.58 88.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.757 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.16 -44.77 94.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.45 -40.4 93.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.424 179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.47 91.31 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.46 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.99 -41.37 97.34 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 88.9 t -64.56 -42.87 96.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-O 120.77 0.319 . . . . 0.0 110.296 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.29 -39.06 85.54 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.897 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 6.5 mm -63.41 -42.27 95.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.07 -40.82 95.13 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.651 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.1 t -62.61 -41.9 93.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.69 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.37 -42.28 98.44 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.67 -42.4 99.6 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.16 -48.57 73.55 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.0 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -63.97 -34.86 78.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.547 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -58.17 -44.33 87.93 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.366 -179.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.4 mm -65.52 -41.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.797 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.86 -35.61 92.24 Favored Glycine 0 CA--C 1.522 0.486 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . 0.437 ' O ' ' O ' ' C' ' 401' ' ' LYS . 51.9 tp -62.52 -42.25 99.39 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.597 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . 0.437 ' O ' ' O ' ' C' ' 400' ' ' LEU . 38.6 ttmt 59.49 140.85 0.01 OUTLIER 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.694 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -66.95 140.66 57.75 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.403 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -77.39 129.82 36.29 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.261 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -102.83 125.31 49.52 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.527 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.25 -11.33 59.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.428 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.14 -39.34 97.86 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -82.31 132.87 35.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.64 0.257 . . . . 0.0 110.42 179.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -81.31 118.68 22.84 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.245 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -52.69 144.39 14.14 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.657 -0.417 . . . . 0.0 109.967 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 54.8 p90 . . . . . 0 C--O 1.219 -0.543 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.552 179.914 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 68.6 m . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.66 -39.58 94.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.472 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -100.39 113.24 25.84 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.42 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -90.1 113.22 24.92 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.649 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -62.67 -40.79 98.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.492 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.439 ' O ' ' O ' ' A' ' 375' ' ' PHE . 98.3 m-20 -85.92 142.28 28.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.484 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' A' ' 374' ' ' ASN . 82.3 t80 56.99 118.08 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.431 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 97.9 mt -133.39 131.3 39.85 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.934 0.397 . . . . 0.0 110.37 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 1.3 m -54.61 152.03 13.42 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.707 -179.352 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -64.61 149.55 89.65 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.604 2.202 . . . . 0.0 111.94 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -63.94 -42.58 96.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.874 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.16 -20.23 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.347 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.832 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' A' ' 379' ' ' ILE . 45.4 t -65.6 -43.98 93.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.515 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.32 -37.39 94.44 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.8 -42.28 98.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.77 0.319 . . . . 0.0 110.471 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.57 -37.17 85.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.568 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.3 tt -61.53 -44.17 97.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.419 . . . . 0.0 109.976 -179.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.94 -37.08 85.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.592 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.84 -39.96 97.57 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.0 t -64.0 -43.39 97.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.756 0.312 . . . . 0.0 110.541 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.0 tt -60.6 -39.31 87.66 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 7.7 mm -63.75 -42.54 96.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.12 -40.36 93.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.351 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.5 t -63.99 -41.41 92.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.758 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.42 97.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.441 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.68 -41.56 97.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.49 -48.93 73.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.808 179.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.67 -35.34 80.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.31 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . 0.476 ' CZ ' ' NE2' ' A' ' 402' ' ' HIS . 24.1 t80 -58.34 -46.11 86.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.388 -179.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.1 mt -64.45 -42.56 95.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.225 179.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.99 -32.65 84.88 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.2 tp -61.31 -41.44 97.0 Favored 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 120.925 -0.31 . . . . 0.0 110.383 -179.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . 0.556 ' HZ1' ' HE2' ' B' ' 402' ' ' HIS . 99.1 mttt 55.32 95.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.539 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . 0.476 ' NE2' ' CZ ' ' A' ' 397' ' ' PHE . 95.0 m-70 -73.77 141.22 46.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.362 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . 0.432 ' O ' ' CG ' ' A' ' 403' ' ' HIS . 55.3 p-80 -83.1 120.43 25.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.523 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -78.57 133.62 37.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.545 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.2 -12.12 59.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.63 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.93 -34.92 91.22 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -82.06 130.37 35.06 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.39 -0.226 . . . . 0.0 110.39 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -91.87 117.08 29.45 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.359 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 43.3 tp60 -78.65 131.06 36.53 Favored 'General case' 0 C--N 1.333 -0.131 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.393 179.96 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 10.9 p . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -68.63 146.82 52.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.709 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -60.91 -42.53 98.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.291 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' B' ' 373' ' ' ASP . 42.5 p-10 -66.83 -33.78 76.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.704 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' B' ' 372' ' ' ASP . 47.3 t0 -90.65 108.89 20.1 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.451 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -147.9 105.82 3.72 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.394 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -116.45 101.49 8.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.836 0.35 . . . . 0.0 110.25 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 53.0 mt -116.86 128.47 55.28 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.328 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 15.3 t 51.17 72.89 1.09 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.633 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -60.36 147.09 95.17 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 122.935 2.423 . . . . 0.0 111.857 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.8 mt -63.9 -43.63 97.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.782 -179.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.61 -19.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.583 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.8 t -63.9 -43.65 97.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 C-N-CA 120.941 -0.304 . . . . 0.0 110.377 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.48 -43.02 98.78 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.89 87.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.758 0.313 . . . . 0.0 110.697 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.26 -44.85 96.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.698 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.26 -40.68 94.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.416 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.8 -37.41 84.3 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.376 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -39.21 96.01 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 88.0 t -63.87 -42.12 94.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 11.9 mt -62.75 -42.03 99.49 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.807 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . 0.411 HD12 HG23 ' B' ' 390' ' ' ILE . 84.6 mt -66.79 -40.62 86.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.942 0.401 . . . . 0.0 110.067 179.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -59.15 -41.97 89.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.472 -179.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.04 -42.08 93.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.814 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.55 -41.6 97.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.454 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.82 -44.02 97.69 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.308 -0.557 . . . . 0.0 109.646 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.27 -36.61 83.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.143 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.22 -44.29 95.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.527 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -62.99 -44.45 95.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.405 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.27 -42.69 97.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.21 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.57 -34.79 90.89 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.43 -43.42 98.87 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.029 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -142.61 123.43 14.3 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.477 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . 0.556 ' HE2' ' HZ1' ' A' ' 401' ' ' LYS . 43.9 p-80 -157.7 159.7 37.16 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.061 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -124.17 128.33 49.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.227 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . 0.471 ' O ' ' ND1' ' B' ' 404' ' ' HIS . 21.6 p80 -125.97 124.84 41.64 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.203 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -101.77 -22.53 14.37 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.334 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.07 -40.93 97.32 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -83.66 133.43 34.82 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 110.351 -0.241 . . . . 0.0 110.351 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -70.83 117.78 12.78 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.222 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -53.48 146.26 13.08 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.035 -0.984 . . . . 0.0 110.291 179.694 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 68.5 m . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -155.39 150.51 26.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.445 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 34.6 p30 -89.72 -1.93 58.13 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.354 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 37.8 p30 -88.99 -0.61 57.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.355 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . 0.444 ' O ' ' O ' ' C' ' 376' ' ' LEU . 97.6 m-20 -68.12 140.66 56.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.521 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -63.62 -40.14 96.15 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.514 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 90.7 t80 -59.88 -46.37 89.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.85 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . 0.444 ' O ' ' O ' ' C' ' 373' ' ' ASP . 42.9 tp -100.03 125.18 46.05 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 120.871 0.367 . . . . 0.0 110.28 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 1.2 m -94.43 151.85 39.65 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.479 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.84 -21.56 57.55 Favored 'Trans proline' 0 N--CA 1.495 1.579 0 C-N-CA 122.612 2.208 . . . . 0.0 112.023 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.426 HD13 HG21 ' C' ' 379' ' ' ILE . 97.2 mt -64.68 -44.58 96.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.1 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.41 -19.94 60.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 121.044 -0.262 . . . . 0.0 110.846 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.5 t -66.26 -43.16 91.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.084 0 CA-C-O 120.761 0.315 . . . . 0.0 110.484 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.38 -36.65 93.68 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.59 -41.0 98.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.424 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.13 83.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.8 tt -61.3 -43.74 98.37 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.45 -36.92 85.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.591 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.97 -39.99 97.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.52 -42.72 96.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.5 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -60.5 -39.22 86.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.914 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.98 -42.32 95.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.0 -41.8 97.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.589 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -63.91 -41.27 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.14 -41.37 96.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.559 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.4 -44.41 97.19 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.418 -0.513 . . . . 0.0 109.663 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.78 84.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.189 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -60.33 -43.97 95.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.477 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -64.56 -45.56 86.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.365 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -64.54 -42.15 94.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.371 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.51 -36.02 90.35 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . 0.532 ' C ' ' H ' ' C' ' 402' ' ' HIS . 8.2 mt -63.88 -38.82 92.5 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.376 -0.231 . . . . 0.0 110.376 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 99.7 mttt 58.63 1.88 0.2 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.67 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . 0.582 ' HD1' ' CE1' ' C' ' 404' ' ' HIS . 56.3 t-80 -152.62 135.64 15.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.408 179.676 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . 0.421 ' O ' ' CG ' ' C' ' 403' ' ' HIS . 44.4 p-80 -106.48 117.78 34.94 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.264 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . 0.582 ' CE1' ' HD1' ' C' ' 402' ' ' HIS . 77.5 m80 -102.59 124.89 48.97 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.409 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.06 -14.69 59.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.581 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.23 -38.75 96.99 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 79.4 m-85 -107.44 137.55 45.28 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 110.382 -0.229 . . . . 0.0 110.382 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -84.06 118.14 23.88 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.146 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.533 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 0.4 OUTLIER -52.97 145.97 11.86 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.816 -0.353 . . . . 0.0 110.049 179.835 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 91.5 t80 . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.755 -179.797 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.64 148.01 20.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.364 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -100.03 109.47 21.79 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.042 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -64.19 -38.21 90.25 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.521 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -85.89 110.34 19.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.417 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -95.67 142.17 28.3 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.374 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -62.29 -43.05 99.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.583 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.443 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 10.2 mp -84.64 131.31 34.61 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.443 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 2.1 m -79.64 150.91 73.68 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.608 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.51 150.41 84.11 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.766 2.31 . . . . 0.0 112.215 179.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 46.7 mm -64.21 -44.14 97.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.969 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.17 -20.18 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 120.518 0.199 . . . . 0.0 110.791 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.0 p -60.78 -42.03 90.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.412 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -60.28 -43.16 98.82 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.57 -37.49 85.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.752 0.31 . . . . 0.0 110.738 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.64 -43.52 97.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.694 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.41 -41.38 93.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.395 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.49 -39.06 89.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.174 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.48 -41.04 96.52 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.0 t -67.34 -42.04 87.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.845 0.355 . . . . 0.0 110.245 179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.61 -41.74 91.08 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.41 -179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.409 HG23 HD13 ' A' ' 390' ' ' ILE . 85.9 mt -65.58 -42.11 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-O 120.931 0.396 . . . . 0.0 110.231 178.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.51 -40.89 96.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.601 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.6 t -64.18 -41.38 92.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.45 -41.55 97.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.434 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.92 -42.58 99.26 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.458 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.64 -47.0 77.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.804 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -64.19 -35.23 80.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.514 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -57.7 -46.22 84.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.396 -179.202 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 92.1 mt -64.66 -42.43 95.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.49 -33.05 86.2 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.5 tp -61.67 -40.67 95.77 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.437 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 63.6 mttp 56.81 104.95 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.707 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 59.9 t-80 -60.62 -41.79 95.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.341 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -76.73 130.56 37.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.286 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -70.63 140.07 51.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.64 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.17 -11.25 59.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.497 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.59 -40.09 98.29 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 79.6 t80 -80.43 131.15 35.55 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 121.094 -0.243 . . . . 0.0 110.495 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 68.1 mm-40 -135.68 144.79 46.18 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-O 120.763 0.316 . . . . 0.0 110.576 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 43.8 tp60 -68.81 131.06 44.53 Favored 'General case' 0 C--N 1.332 -0.179 0 C-N-CA 120.477 -0.489 . . . . 0.0 109.812 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 55.8 p90 . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.607 -179.959 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.85 -39.11 93.45 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.539 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -99.77 112.08 24.36 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.416 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -67.02 140.6 57.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.559 -179.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -61.73 -42.62 99.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.495 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 60.9 t-20 -88.86 109.38 20.15 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.501 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -61.85 -43.25 99.23 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.665 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 2.2 mt 55.42 85.09 0.07 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.322 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 20.3 t -146.23 73.08 13.22 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.303 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -59.78 144.31 99.47 Favored 'Trans proline' 0 N--CA 1.496 1.667 0 C-N-CA 122.876 2.384 . . . . 0.0 111.988 179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt -64.29 -43.48 97.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.099 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.25 -20.26 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.618 -0.264 . . . . 0.0 111.007 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' B' ' 379' ' ' ILE . 10.6 p -59.36 -42.77 88.51 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . 0.402 ' N ' ' CG1' ' B' ' 381' ' ' VAL . . . -63.14 -40.23 98.9 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -67.95 -35.84 79.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.716 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.16 -44.04 95.32 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.683 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.51 -40.45 93.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.42 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.17 -37.86 88.71 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.526 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.33 -39.6 97.99 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 99.3 t -67.94 -42.13 85.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.675 0.274 . . . . 0.0 110.4 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -60.0 -40.86 90.68 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.209 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.8 mt -64.93 -42.26 94.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.913 0.387 . . . . 0.0 110.366 179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.35 -40.03 89.28 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.516 -179.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 68.9 t -62.06 -41.25 90.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.652 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.48 -41.03 93.36 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.433 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.79 -43.99 97.41 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.646 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.48 86.44 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.118 179.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.49 -44.34 96.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.888 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -62.24 -44.48 96.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.692 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . 0.404 HG23 HD11 ' B' ' 398' ' ' ILE . 86.0 mt -63.27 -42.35 96.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.616 179.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.6 -33.08 85.2 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 54.3 tp -61.79 -40.03 93.76 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.986 -0.286 . . . . 0.0 110.456 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 69.0 mttm 55.6 92.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.714 -179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -65.02 -42.66 94.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.334 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -81.85 128.0 33.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.453 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -78.58 131.05 36.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.598 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.93 -11.87 59.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.425 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.88 -37.59 94.87 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -108.63 132.17 54.16 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -93.02 119.08 31.89 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 46.7 tp60 -73.11 132.0 42.76 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.58 -0.448 . . . . 0.0 109.958 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 88.0 t80 . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.85 -1.071 . . . . 0.0 110.512 -179.972 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 50.7 m . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . 48.13 37.04 7.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.076 0.465 . . . . 0.0 110.521 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -61.96 -38.69 89.46 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.357 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -64.62 -37.97 89.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.519 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -61.49 -42.15 98.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.384 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -83.34 105.97 14.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.379 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -94.17 0.72 55.94 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.374 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 58.1 tp -63.23 -42.47 99.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.415 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 7.4 p -172.03 77.06 0.48 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.01 -179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -59.52 145.15 98.85 Favored 'Trans proline' 0 C--N 1.302 -1.916 0 C-N-CA 122.564 2.176 . . . . 0.0 112.05 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.445 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt -63.77 -43.68 98.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.117 -179.592 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -44.43 -19.87 0.03 OUTLIER 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.8 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.445 ' N ' ' O ' ' C' ' 379' ' ' ILE . 61.3 t -64.28 -43.15 97.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.196 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.13 -42.06 99.67 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.19 85.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.756 0.313 . . . . 0.0 110.777 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.31 -44.96 95.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.796 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.2 -42.08 93.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.547 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.47 87.74 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.514 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.51 99.82 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 80.1 t -66.43 -42.09 89.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 0.0 110.336 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -60.74 -40.93 94.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.518 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . 0.425 HD11 HG22 ' C' ' 390' ' ' ILE . 84.9 mt -66.47 -42.06 89.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.935 0.397 . . . . 0.0 110.275 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.3 -40.97 87.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.517 -179.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 72.5 t -63.11 -42.06 95.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.726 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.9 -41.59 96.36 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.588 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.11 -42.52 99.3 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.565 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.44 -48.01 75.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.099 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 93.9 t80 -63.36 -36.34 83.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.664 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -57.7 -44.56 85.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.492 -179.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . 0.423 HG21 HD13 ' C' ' 398' ' ' ILE . 39.7 mm -66.75 -40.45 86.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.779 179.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.02 -30.31 73.17 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 54.7 tp -63.16 -39.97 96.21 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.494 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -61.83 141.61 57.83 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.488 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 70.0 m80 54.9 92.48 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.589 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -76.03 137.46 40.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.526 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -79.55 129.53 34.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.369 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.47 -11.67 59.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.431 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.33 -38.95 96.55 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.868 -0.893 . . . . 0.0 110.868 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 77.0 t80 -83.43 129.42 34.99 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -135.47 146.57 48.31 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.526 ' O ' ' CG ' ' C' ' 410' ' ' PHE . 45.1 tp60 -126.01 120.55 30.59 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.932 0.396 . . . . 0.0 110.186 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' C' ' 409' ' ' GLN . 90.0 m-85 . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.454 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -156.04 154.18 30.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.536 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.407 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 37.5 p-10 -86.24 -1.5 57.53 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.36 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.437 ' OD1' ' O ' ' A' ' 372' ' ' ASP . 43.4 p-10 -134.53 106.11 6.86 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.557 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -70.26 140.31 52.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.486 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -63.49 -40.64 97.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.793 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -109.23 101.77 10.77 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.202 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 42.8 tp -111.51 111.65 22.81 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.152 179.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 10.6 t 39.26 58.64 6.18 Favored Pre-proline 0 N--CA 1.462 0.15 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.68 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -67.04 -19.68 51.31 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.526 2.15 . . . . 0.0 112.124 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt -64.51 -44.46 96.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.981 -179.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.05 -20.03 61.06 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.872 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.4 t -66.4 -43.55 91.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.072 0 CA-C-O 120.633 0.254 . . . . 0.0 110.359 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.15 -40.97 97.19 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.98 -39.2 90.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.742 0.306 . . . . 0.0 110.77 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.35 -44.68 96.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.651 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.2 mt -65.2 -40.6 94.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.386 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.77 -37.26 86.71 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.44 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.65 -39.72 97.84 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.03 -42.24 95.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.62 -38.09 80.38 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.353 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.99 -42.76 95.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.396 . . . . 0.0 110.093 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.9 mt -61.61 -42.18 98.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.58 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.7 t -66.07 -41.94 90.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.89 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.73 -41.13 97.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.463 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.48 -44.1 97.69 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.347 -0.541 . . . . 0.0 109.688 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.42 -37.37 86.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.98 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -61.89 -44.78 96.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.696 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -62.94 -45.37 92.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.49 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.9 mt -64.26 -42.58 95.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.062 179.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.42 -42.8 95.73 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.6 tp -63.83 -41.85 97.75 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.781 0.324 . . . . 0.0 110.534 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.45 131.93 47.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.687 -179.554 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -167.18 134.14 2.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.286 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -107.93 122.91 47.78 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.312 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -81.55 127.88 33.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.415 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -76.92 -37.68 54.92 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.678 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.2 -38.34 96.35 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -80.71 133.64 35.72 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -84.86 116.26 23.22 Favored 'General case' 0 C--O 1.232 0.145 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 43.7 tp60 -73.6 134.24 43.66 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 92.2 t80 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.31 -179.902 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 56.2 p . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . 0.536 ' O ' ' N ' ' B' ' 372' ' ' ASP . . . -65.04 -37.68 88.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.496 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 65.8 t0 46.48 -87.69 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.685 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' B' ' 370' ' ' ALA . 57.2 t0 -90.37 113.49 25.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.447 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' B' ' 373' ' ' ASP . 44.2 p-10 -90.46 107.07 18.92 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.402 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 51.6 p30 -89.48 162.45 15.71 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.265 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -111.26 101.11 9.63 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.925 0.393 . . . . 0.0 110.329 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 34.5 mt -105.26 -1.04 25.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.475 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.433 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 4.1 t -129.32 55.08 16.35 Favored Pre-proline 0 C--N 1.331 -0.205 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.328 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . 0.433 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 36.0 Cg_endo -66.11 -18.47 56.52 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.606 2.204 . . . . 0.0 111.999 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.9 mt -64.19 -44.57 97.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.049 -179.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -72.2 -20.44 61.57 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.742 -0.208 . . . . 0.0 110.652 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 60.3 t -66.89 -43.39 89.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.658 0.266 . . . . 0.0 110.414 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.1 -39.55 98.13 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.04 -41.61 96.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.86 -35.38 80.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.511 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.41 -44.29 97.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.295 -0.412 . . . . 0.0 109.92 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.98 -36.91 85.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.567 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.45 -39.48 97.35 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.67 -42.36 94.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.922 0.392 . . . . 0.0 110.191 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.3 tt -59.63 -38.32 81.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.263 -179.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.11 -42.16 94.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.853 0.359 . . . . 0.0 110.207 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.09 -41.03 95.9 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.625 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 86.3 t -63.5 -41.07 91.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.665 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.31 -41.44 96.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.503 -179.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.74 -42.7 99.31 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.89 75.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.833 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -65.0 -35.59 81.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.431 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.9 t80 -57.53 -45.94 84.45 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.273 -179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.04 -42.3 95.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.128 179.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.89 -37.08 94.31 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 44.8 tp -62.96 -41.64 99.59 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.438 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . 0.407 ' O ' ' O ' ' B' ' 402' ' ' HIS . 62.5 tttp 59.13 80.1 0.2 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.654 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . 0.486 ' CG ' ' N ' ' B' ' 403' ' ' HIS . 56.5 t-80 55.42 163.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.632 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . 0.486 ' N ' ' CG ' ' B' ' 402' ' ' HIS . 80.6 m80 -74.52 139.98 44.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.577 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . 0.621 ' HD1' ' N ' ' B' ' 404' ' ' HIS . 0.0 OUTLIER -70.03 142.51 52.74 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.579 179.99 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.14 -12.71 59.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.535 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.19 -37.95 95.73 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 87.2 t80 -77.92 133.15 38.13 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.566 0.222 . . . . 0.0 110.428 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -135.41 147.1 48.89 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.718 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 44.1 tp60 -66.87 128.48 36.49 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 91.1 t80 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.07 -0.966 . . . . 0.0 110.607 -179.89 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 85.5 p . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.5 152.11 25.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.539 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -88.58 -2.89 58.84 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.318 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' C' ' 373' ' ' ASP . 40.2 p-10 -64.84 -35.7 81.96 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.788 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . 0.52 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 95.8 m-20 -62.8 -39.93 95.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 64.1 t30 58.96 51.01 7.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.684 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . 0.46 ' CE2' ' CB ' ' C' ' 373' ' ' ASP . 73.7 m-85 -60.63 -43.34 97.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.631 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 5.0 tp -94.17 133.27 37.85 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.298 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . 0.477 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 3.3 t 65.59 51.79 0.87 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.421 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . 0.477 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 36.4 Cg_endo -65.05 151.44 85.75 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.912 2.408 . . . . 0.0 111.877 179.657 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.2 mt -63.53 -43.55 98.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.718 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.63 -19.79 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.766 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.3 p -60.88 -43.06 94.9 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.62 0.248 . . . . 0.0 110.474 -179.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . 0.427 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -62.51 -45.53 95.68 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.2 85.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.79 0.329 . . . . 0.0 110.719 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.22 -43.66 98.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.654 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.82 -41.14 92.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.485 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.38 94.21 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.452 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.81 -41.11 98.96 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -66.0 -42.73 92.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 110.645 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -59.59 -41.39 90.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.088 -179.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.0 mt -65.43 -42.08 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.9 0.381 . . . . 0.0 110.367 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.7 mt -60.45 -40.86 92.66 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.534 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.06 -41.41 92.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.685 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.09 -41.43 96.65 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.487 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.74 -41.94 98.31 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.87 -48.93 74.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.763 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -63.69 -36.27 83.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.483 179.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -57.64 -45.32 85.61 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.269 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . 0.415 HG23 HD13 ' C' ' 398' ' ' ILE . 88.7 mt -63.57 -42.29 95.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.094 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.64 -34.04 88.86 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 49.6 tp -62.09 -41.92 98.69 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.811 0.339 . . . . 0.0 110.407 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 66.0 tttm 53.81 95.9 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.575 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 57.1 p-80 -77.38 132.23 38.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.361 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -77.66 136.1 38.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.577 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -78.57 140.22 38.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.416 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.53 -11.9 59.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.411 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.18 -37.57 94.73 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 83.6 m-85 -109.65 136.67 48.63 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 110.255 -0.276 . . . . 0.0 110.255 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -88.4 117.64 27.47 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 45.0 tp60 -70.85 130.4 41.56 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 94.5 t80 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.444 179.973 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 45.95 41.93 8.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.564 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.44 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 32.9 p-10 -88.41 111.79 22.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.426 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.403 ' OD1' ' O ' ' A' ' 372' ' ' ASP . 62.5 t0 -62.9 -35.88 81.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.585 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -92.52 110.95 22.38 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.463 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -62.67 -40.96 98.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.644 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -114.95 101.98 9.54 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.23 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 34.2 tp -115.6 134.0 55.48 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.041 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 16.4 t -117.8 81.37 15.21 Favored Pre-proline 0 N--CA 1.466 0.341 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.637 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.55 -10.94 17.26 Favored 'Trans proline' 0 N--CA 1.491 1.329 0 C-N-CA 122.381 2.054 . . . . 0.0 112.362 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.467 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -63.77 -43.54 97.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.974 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.87 -19.62 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.545 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.467 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.2 t -64.83 -43.4 96.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.446 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.78 -36.72 93.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.66 -40.86 98.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.408 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.63 -36.47 83.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.633 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.42 -44.04 97.82 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.992 0.425 . . . . 0.0 109.925 -179.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.82 -37.06 85.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.447 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.56 -39.32 97.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.2 t -65.99 -42.0 90.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.115 0.483 . . . . 0.0 110.243 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -59.55 -41.01 89.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.595 -179.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.413 HG21 HD13 ' A' ' 390' ' ' ILE . 86.8 mt -67.75 -41.63 85.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.053 0.454 . . . . 0.0 110.387 179.066 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.03 -41.23 91.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.636 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.8 t -64.3 -41.81 93.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.796 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.39 -41.52 97.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.497 -179.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.72 -42.08 98.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.1 -48.52 75.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.537 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -64.89 -36.5 84.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.373 179.176 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -57.26 -45.65 83.81 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.182 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -63.7 -42.59 96.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.63 -37.17 94.33 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 43.7 tp -62.85 -42.07 99.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.812 0.339 . . . . 0.0 110.553 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -65.95 136.42 56.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.734 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 63.6 t-80 46.79 87.74 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.526 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -69.87 141.82 53.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.567 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.9 m-70 -75.96 137.12 40.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.583 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.21 -13.12 60.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.625 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.26 -36.98 94.15 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -78.46 132.39 37.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.716 0.293 . . . . 0.0 110.537 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.505 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.5 mp0 -104.12 125.14 50.2 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.463 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.487 ' CD ' ' N ' ' A' ' 409' ' ' GLN . 1.9 pm0 -63.84 135.4 56.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.224 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . 0.438 ' OXT' ' CG ' ' A' ' 410' ' ' PHE . 91.7 t80 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.014 -0.993 . . . . 0.0 110.323 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 46.3 t . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.81 -38.14 89.98 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.488 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -93.96 110.43 22.11 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.364 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -70.25 141.5 52.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.634 -179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -65.8 138.16 57.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.618 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . 0.505 ' O ' ' N ' ' B' ' 378' ' ' PRO . 95.2 m-20 -64.27 -39.82 94.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.718 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -59.72 -46.57 88.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.737 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . 0.428 ' CD1' ' N ' ' B' ' 376' ' ' LEU . 9.8 mp -64.6 -40.32 95.3 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.449 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 3.3 m -144.0 75.35 15.81 Favored Pre-proline 0 CA--C 1.531 0.221 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.389 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . 0.505 ' N ' ' O ' ' B' ' 374' ' ' ASN . 57.7 Cg_endo -75.36 -11.17 20.85 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 122.571 2.181 . . . . 0.0 112.156 -179.513 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt -63.6 -43.65 98.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.914 -179.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.13 -19.77 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 121.013 -0.275 . . . . 0.0 110.651 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.521 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.2 t -64.31 -43.71 97.19 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.41 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.69 -38.43 96.21 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.15 -41.14 97.99 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.912 0.387 . . . . 0.0 110.404 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.55 -36.24 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.511 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 2.6 tt -61.5 -44.43 97.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.02 0.438 . . . . 0.0 110.021 -179.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.81 82.76 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.392 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.15 -37.72 95.37 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.68 -41.99 93.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.991 0.424 . . . . 0.0 110.075 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -60.57 -38.1 83.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.224 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.87 -42.12 94.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.822 0.344 . . . . 0.0 110.201 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.86 -40.38 92.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.471 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 92.9 t -63.86 -40.92 90.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.822 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.32 -41.15 96.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.394 -179.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.46 -42.18 98.37 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.21 -46.19 89.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.772 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -63.62 -37.68 88.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.357 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.52 -45.96 84.39 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.243 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -63.52 -42.4 96.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.194 179.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.75 -24.62 62.55 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.63 -41.88 99.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.893 0.378 . . . . 0.0 110.039 -179.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -70.11 152.04 44.78 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.506 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 55.1 t-80 45.83 92.87 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.579 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 81.1 t60 -78.67 128.2 33.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.282 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -76.27 137.58 40.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.515 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.85 -11.67 60.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.644 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.05 -36.86 94.04 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 83.6 t80 -84.86 132.16 34.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.727 0.298 . . . . 0.0 110.419 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -81.72 119.56 24.01 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.193 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.594 ' NE2' ' N ' ' B' ' 410' ' ' PHE . 38.2 tp60 -66.43 133.35 50.25 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . 0.594 ' N ' ' NE2' ' B' ' 409' ' ' GLN . 88.3 t80 . . . . . 0 C--O 1.219 -0.539 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.515 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 1.5 t . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . 0.438 ' O ' ' OD1' ' C' ' 373' ' ' ASP . . . -69.42 140.1 54.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.653 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -64.15 -35.23 80.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.297 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.437 ' O ' ' OD1' ' C' ' 372' ' ' ASP . 66.3 t0 -61.87 -35.55 78.62 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.585 -179.724 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' C' ' 370' ' ' ALA . 99.5 m-20 56.8 34.33 24.51 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.475 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 58.6 t-20 -87.0 105.41 17.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.375 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -113.98 103.43 11.15 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.182 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 86.1 mt -130.4 139.39 50.62 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.412 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . 0.416 ' O ' ' CG1' ' C' ' 377' ' ' VAL . 12.6 p -171.05 62.64 0.38 Allowed Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.365 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -74.65 89.08 1.14 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.557 2.171 . . . . 0.0 111.823 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 37.9 mm -76.68 -70.43 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.777 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -80.17 -19.73 46.47 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.528 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 52.4 t -65.4 -43.37 94.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.292 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.62 -41.62 99.61 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -38.07 88.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.743 0.306 . . . . 0.0 110.643 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.16 -43.91 96.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.674 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -66.0 -40.7 91.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.497 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.95 91.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.549 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.05 -39.35 97.14 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.8 t -64.06 -42.52 95.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 0.0 110.457 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.5 tt -60.26 -38.37 83.3 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.772 -179.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.03 -42.48 95.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-O 120.846 0.355 . . . . 0.0 110.052 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.18 -40.41 93.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.436 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.6 -41.08 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.742 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.27 -41.27 96.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.435 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.5 -42.24 98.5 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -47.96 81.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.916 -0.583 . . . . 0.0 109.832 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -63.12 -35.82 81.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.217 179.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -59.1 -45.26 91.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.321 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.1 mt -63.15 -42.5 96.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.244 179.445 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.71 -37.4 94.31 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 49.0 tp -62.89 -42.18 99.68 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.368 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 52.8 tttp 54.1 103.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.441 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -75.59 129.33 37.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.103 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 33.3 p80 -127.63 142.96 51.21 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.432 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -75.64 139.63 42.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.485 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.37 -12.02 59.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.695 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.01 -37.11 94.43 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 79.4 t80 -78.14 132.41 37.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.773 0.321 . . . . 0.0 110.488 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -87.18 117.36 25.87 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.772 0.32 . . . . 0.0 110.278 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -52.94 142.24 19.99 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.011 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 89.4 t80 . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.773 179.997 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 65.2 p . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.32 151.53 29.19 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.546 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.505 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 36.7 p-10 -66.29 -36.0 81.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.553 179.852 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.505 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 68.3 t0 -91.53 111.99 23.73 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.542 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 52.4 p30 -79.31 166.34 22.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.458 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -94.21 6.38 48.79 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.522 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -115.78 102.78 10.03 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.319 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.456 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 9.9 mp -95.55 131.48 41.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.162 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.483 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 14.7 m -149.36 52.74 1.17 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.344 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.483 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 26.0 Cg_endo -62.81 -23.24 74.36 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.733 2.288 . . . . 0.0 111.844 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.8 mm -66.92 -44.83 88.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.57 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.4 -20.26 62.95 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.804 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.37 -42.32 90.35 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.992 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.52 -40.17 98.33 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.15 -38.21 90.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.74 0.305 . . . . 0.0 110.743 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.7 -45.7 91.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.671 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.28 -41.57 94.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.511 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.35 -38.17 90.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.293 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.6 -41.79 99.77 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.7 t -67.11 -42.36 88.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.823 0.344 . . . . 0.0 110.159 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.8 tt -60.0 -40.8 90.44 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.3 -179.021 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.408 HD12 HG23 ' A' ' 390' ' ' ILE . 86.7 mt -66.42 -41.75 89.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.959 0.409 . . . . 0.0 110.351 178.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.54 -40.55 91.95 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.579 -179.292 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.4 t -64.33 -41.15 91.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.752 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.93 -41.57 98.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.537 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.41 -42.49 99.48 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.242 -0.583 . . . . 0.0 109.476 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.09 -48.95 72.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.981 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -64.13 -35.79 81.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.422 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -57.38 -45.8 84.07 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.282 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.2 mt -64.89 -42.43 94.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.48 -33.69 87.92 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.8 tp -61.33 -40.81 95.59 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.411 -179.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 57.17 45.19 21.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.796 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . 0.48 ' CE1' ' O ' ' A' ' 403' ' ' HIS . 39.7 t-80 -70.45 124.61 24.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.194 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . 0.48 ' O ' ' CE1' ' A' ' 402' ' ' HIS . 99.4 m-70 -78.4 142.52 37.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.547 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -78.47 142.49 37.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.506 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.36 -14.07 59.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.537 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.59 -40.58 96.09 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -109.42 133.47 53.03 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 55.3 mp0 -106.73 123.97 48.92 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 120.893 0.378 . . . . 0.0 110.064 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.546 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 0.4 OUTLIER -52.86 146.21 11.14 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . 0.498 ' CG ' ' O ' ' A' ' 410' ' ' PHE . 91.1 t80 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.111 -0.947 . . . . 0.0 110.38 -179.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 369' ' ' SER . . . . . 0.414 ' H1 ' ' H ' ' B' ' 370' ' ' ALA . 6.5 t . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . 0.414 ' H ' ' H1 ' ' B' ' 369' ' ' SER . . . -65.0 -38.16 90.03 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.449 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 55.0 t0 55.06 33.36 20.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.554 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -68.9 141.88 54.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.629 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -61.66 -41.33 97.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.457 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . 0.429 ' ND2' ' O ' ' B' ' 377' ' ' VAL . 63.9 t30 59.79 39.19 21.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.693 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 92.4 t80 -65.26 -23.52 67.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.469 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 46.6 tp -64.51 -43.75 93.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.463 -179.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.429 ' O ' ' ND2' ' B' ' 374' ' ' ASN . 0.9 OUTLIER -148.15 69.25 10.68 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.239 -179.449 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -74.95 -16.17 20.48 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.717 2.278 . . . . 0.0 112.025 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.507 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.9 mt -63.36 -43.88 98.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.315 -178.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.14 -20.1 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.752 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.507 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.38 -43.9 94.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 120.904 0.383 . . . . 0.0 110.178 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.73 -35.77 91.42 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.23 -41.86 98.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.861 0.363 . . . . 0.0 110.662 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.4 84.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.45 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.3 tt -61.23 -44.47 97.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.922 -179.372 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.23 83.65 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.548 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.74 -41.09 97.37 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 62.1 t -67.24 -43.35 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.668 0.27 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.29 -40.37 93.91 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 119.536 -0.866 . . . . 0.0 109.771 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . 0.409 HG21 HD12 ' B' ' 390' ' ' ILE . 79.2 mt -64.04 -42.4 95.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 120.872 0.368 . . . . 0.0 110.572 178.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.08 -41.4 96.59 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.588 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.6 t -65.94 -42.33 91.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.076 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.67 -40.47 95.08 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.4 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.18 -42.94 99.75 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.588 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.74 -36.82 84.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.157 179.395 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -60.36 -44.38 95.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.601 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.0 -43.79 98.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.61 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . 0.415 HG21 HD11 ' B' ' 398' ' ' ILE . 91.2 mt -63.55 -42.61 96.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.717 179.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.98 -34.28 89.46 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 52.5 tp -62.26 -39.65 93.61 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 121.006 -0.277 . . . . 0.0 110.397 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . 0.437 ' O ' ' O ' ' B' ' 402' ' ' HIS . 99.2 mttt 56.91 103.73 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.596 -179.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' B' ' 401' ' ' LYS . 78.9 m80 55.48 160.61 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.548 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -73.96 141.25 45.92 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.498 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 45.6 t60 -78.24 131.37 37.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.474 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.52 -12.67 59.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.538 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.45 -36.09 92.92 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 73.9 m-85 -103.02 135.1 45.32 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.325 -0.25 . . . . 0.0 110.325 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.42 148.61 49.37 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 120.718 0.294 . . . . 0.0 110.514 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.53 ' OE1' ' N ' ' B' ' 410' ' ' PHE . 3.9 tp-100 -74.02 123.7 24.85 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.476 -0.49 . . . . 0.0 109.795 179.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . 0.53 ' N ' ' OE1' ' B' ' 409' ' ' GLN . 96.5 m-85 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.11 -0.948 . . . . 0.0 110.618 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -61.78 -39.09 90.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.397 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.79 33.09 18.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.435 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -62.31 -38.48 89.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.44 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -65.79 141.58 58.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.573 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . 0.537 ' C ' ' H ' ' C' ' 376' ' ' LEU . 10.0 m120 -91.21 6.75 43.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.44 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 49.48 10.77 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.668 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . 0.537 ' H ' ' C ' ' C' ' 374' ' ' ASN . 99.4 mt -137.46 105.38 5.64 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.263 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . 0.425 ' O ' ' CG1' ' C' ' 377' ' ' VAL . 9.0 p -174.94 74.28 0.3 Allowed Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.198 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_exo -60.55 143.5 99.44 Favored 'Trans proline' 0 C--N 1.302 -1.913 0 C-N-CA 122.709 2.273 . . . . 0.0 112.033 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.0 mt -64.84 -43.69 96.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.234 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.42 -20.02 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.816 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.9 p -61.82 -42.72 95.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -64.46 -42.15 97.69 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.19 86.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.86 0.362 . . . . 0.0 110.787 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.56 -45.34 94.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.676 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -64.5 -40.43 95.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.433 179.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.93 -37.26 87.05 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.466 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.95 -40.2 97.02 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.98 -43.27 96.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.926 0.394 . . . . 0.0 110.318 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.8 -38.59 88.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.17 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.86 -42.09 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.9 mt -61.41 -41.68 97.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.573 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 90.2 t -65.73 -42.24 92.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.51 -41.82 97.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.625 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -62.27 -43.55 98.56 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.66 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.58 -36.42 82.59 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -61.12 -44.96 96.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.805 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -62.47 -43.69 98.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.645 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . 0.426 HG21 HD13 ' C' ' 398' ' ' ILE . 89.4 mt -64.92 -42.69 95.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.882 179.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.47 -39.65 97.93 Favored Glycine 0 CA--C 1.52 0.376 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . 0.522 ' O ' ' CD2' ' C' ' 403' ' ' HIS . 57.4 tp -62.81 -41.16 99.18 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.876 -0.329 . . . . 0.0 110.418 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 49.9 tttm 44.56 19.43 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.681 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . 0.45 ' N ' ' O ' ' C' ' 400' ' ' LEU . 98.1 m-70 43.47 90.53 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.553 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . 0.522 ' CD2' ' O ' ' C' ' 400' ' ' LEU . 96.3 m-70 -102.32 127.8 49.15 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.479 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -80.43 144.2 32.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.475 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.0 -35.1 57.39 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.508 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.02 -35.09 91.62 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 53.6 t80 -81.49 134.65 35.56 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 121.059 -0.256 . . . . 0.0 110.381 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . 0.517 ' N ' ' OE1' ' C' ' 408' ' ' GLU . 56.6 mp0 -109.71 129.18 55.63 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-O 120.863 0.363 . . . . 0.0 110.316 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.526 ' OE1' ' N ' ' C' ' 410' ' ' PHE . 3.8 tp-100 -70.54 120.97 16.95 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.575 -0.45 . . . . 0.0 109.883 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . 0.526 ' N ' ' OE1' ' C' ' 409' ' ' GLN . 89.1 t80 . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.605 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 84.1 p . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -159.93 153.21 22.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.6 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -60.58 -43.96 96.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.33 -179.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -62.91 -37.27 86.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.529 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -86.8 113.44 22.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.493 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -95.5 143.44 26.82 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.32 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -59.61 -45.63 91.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.465 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 34.6 mt -119.88 125.42 48.45 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.474 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.541 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 7.5 p -173.42 48.79 0.08 OUTLIER Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.385 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 21.8 Cg_endo -60.7 143.43 99.4 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 C-N-CA 122.669 2.246 . . . . 0.0 111.872 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt -64.44 -43.39 96.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.847 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.87 -20.48 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.657 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' A' ' 379' ' ' ILE . 43.6 t -67.97 -43.62 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.413 179.144 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 379' ' ' ILE . . . -64.96 -38.15 95.13 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.94 98.46 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.713 0.292 . . . . 0.0 110.743 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.76 -48.07 82.35 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.92 0.391 . . . . 0.0 110.565 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.6 -40.95 93.22 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.37 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.51 -39.14 89.91 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.232 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.56 -37.57 94.97 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -63.74 -43.14 97.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.989 0.423 . . . . 0.0 110.243 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.4 mp -61.89 -38.0 86.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.345 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 28.9 mm -63.13 -42.13 95.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -61.16 -42.47 98.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.569 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.3 t -65.62 -42.17 92.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.983 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.94 -40.62 96.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.596 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -60.88 -41.89 96.89 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.95 -49.47 73.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.877 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -65.72 -35.41 80.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.329 179.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . 0.487 ' CE2' ' CE1' ' A' ' 402' ' ' HIS . 24.4 t80 -58.0 -45.8 86.26 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.308 -179.415 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.04 -42.94 97.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.231 179.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.84 -41.83 98.66 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.4 tp -62.75 -41.03 99.02 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.302 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 62.4 tttp 58.54 94.0 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.549 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . 0.487 ' CE1' ' CE2' ' A' ' 397' ' ' PHE . 77.8 m80 -76.73 135.47 39.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.369 179.73 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -78.88 128.36 33.23 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.316 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.9 m-70 -77.18 139.84 40.02 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.539 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.56 -14.21 59.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.518 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.36 -40.26 96.34 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -105.39 133.65 49.8 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.919 0.39 . . . . 0.0 110.15 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -135.32 145.29 47.32 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.71 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -52.77 142.55 18.54 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.427 179.841 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 369' ' ' SER . . . . . 0.401 ' H3 ' ' H ' ' B' ' 370' ' ' ALA . 19.4 p . . . . . 0 N--CA 1.489 1.509 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . 0.401 ' H ' ' H3 ' ' B' ' 369' ' ' SER . . . 51.97 100.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.45 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -100.0 111.54 23.84 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.337 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 37.8 p30 -71.63 -10.15 59.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.623 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -63.1 -43.63 97.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.652 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -156.32 167.99 28.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.263 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 89.0 t80 -138.19 111.92 8.28 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.082 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 49.4 tp -107.9 129.28 55.1 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 120.967 0.413 . . . . 0.0 110.256 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 1.4 m -43.87 151.89 0.49 Allowed Pre-proline 0 CA--C 1.535 0.402 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.765 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.51 152.3 82.29 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 122.536 2.158 . . . . 0.0 111.954 179.566 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.2 mt -63.31 -42.85 97.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.797 -179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -39.93 -20.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.665 -179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.4 t -67.23 -43.8 88.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 CA-C-O 120.659 0.266 . . . . 0.0 110.567 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' B' ' 379' ' ' ILE . . . -65.26 -37.74 94.32 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.1 -38.53 91.54 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.327 . . . . 0.0 110.66 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.28 -48.05 79.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.848 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.54 -41.6 92.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.429 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.84 -36.98 85.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.327 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.62 -40.09 98.26 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 77.9 t -63.2 -43.46 98.81 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.975 0.417 . . . . 0.0 110.244 179.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.2 -38.01 87.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.361 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.77 -42.15 95.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.4 mt -60.84 -42.63 98.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.557 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.62 -42.31 92.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.56 -41.4 97.33 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.374 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.97 -42.44 99.13 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 120.288 -0.565 . . . . 0.0 109.546 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.59 -38.16 86.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.017 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -62.13 -44.8 95.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.477 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -68.43 -45.54 72.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.866 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.11 -42.03 94.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.068 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.85 -42.37 96.59 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . 0.5 ' O ' ' CE1' ' B' ' 403' ' ' HIS . 9.8 mt -64.68 -40.78 95.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.955 0.407 . . . . 0.0 110.535 179.503 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -67.71 -3.26 8.68 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.691 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -58.24 -44.27 88.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.519 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . 0.5 ' CE1' ' O ' ' B' ' 400' ' ' LEU . 52.7 p-80 -92.57 119.13 31.72 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.223 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -82.65 132.0 35.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.542 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.12 -12.7 60.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.442 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.02 -37.46 95.0 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 83.7 t80 -81.81 131.78 35.27 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.816 0.341 . . . . 0.0 110.341 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -135.41 148.44 49.33 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.544 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.413 ' NE2' ' N ' ' B' ' 410' ' ' PHE . 44.5 tp60 -101.02 129.14 46.82 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.887 0.375 . . . . 0.0 110.263 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . 0.413 ' N ' ' NE2' ' B' ' 409' ' ' GLN . 88.7 t80 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.585 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 33.4 t . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . 0.443 ' O ' ' OD1' ' C' ' 374' ' ' ASN . . . -155.03 156.91 36.78 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.547 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 40.1 p-10 -65.49 -35.42 80.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.532 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.512 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 54.7 p-10 -80.62 150.81 29.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.522 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 55.17 49.13 17.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.464 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . 0.481 ' ND2' ' O ' ' C' ' 371' ' ' ASP . 99.2 m-20 -75.27 138.51 41.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.652 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -62.19 -44.06 97.43 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.603 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 89.8 mt -133.38 145.63 50.52 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.493 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 1.5 m -49.71 155.33 1.46 Allowed Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.927 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -48.48 147.6 8.95 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 122.227 1.951 . . . . 0.0 112.419 178.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt -65.52 -43.56 94.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.085 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -58.44 -24.65 60.76 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.653 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 56.0 t -68.86 -43.55 82.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.094 0 CA-C-O 120.73 0.3 . . . . 0.0 110.585 179.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.17 -36.17 92.9 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.58 -40.15 95.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.718 0.294 . . . . 0.0 110.751 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.82 -48.59 81.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.8 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.97 -40.86 95.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.47 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.11 -37.74 86.27 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.422 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.11 -38.01 94.81 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 98.3 t -65.03 -43.17 96.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 120.75 0.309 . . . . 0.0 110.539 179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 mp -61.36 -39.39 90.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.042 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.12 -42.42 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.073 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -61.11 -41.76 97.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.529 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.6 t -65.43 -41.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.53 -40.44 94.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.439 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.42 -42.06 98.15 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.47 76.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.725 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -64.59 -35.88 82.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.373 179.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -57.67 -45.12 85.99 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.275 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.8 mt -63.81 -42.65 96.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.117 179.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.93 -39.27 97.84 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 54.7 tp -63.72 -42.37 97.92 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.529 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -73.95 132.83 42.83 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.744 -179.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -76.71 138.67 40.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.293 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -80.36 139.6 36.47 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.493 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -106.42 127.35 53.22 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.251 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.0 -37.57 54.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.413 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.28 -39.52 97.95 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 80.8 m-85 -107.75 133.76 51.68 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 46.1 tp10 -90.75 118.41 30.15 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.007 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 8.4 pt20 -52.83 140.6 23.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.051 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 88.1 t80 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.443 179.891 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 13.1 m . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.85 152.69 30.1 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.605 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.538 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 40.2 p-10 -65.09 -37.4 87.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.507 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.538 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 99.6 m-20 -67.5 142.47 56.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.609 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -68.66 143.42 54.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.59 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.409 ' OD1' ' O ' ' A' ' 374' ' ' ASN . 48.8 t-20 -62.34 -39.87 94.53 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.582 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -60.33 -42.13 94.98 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.595 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.541 ' CD2' ' N ' ' A' ' 376' ' ' LEU . 3.2 mm? -80.5 140.41 35.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.722 -179.463 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 1.5 m -70.55 155.12 93.88 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.827 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -49.53 137.57 32.56 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.252 1.968 . . . . 0.0 112.119 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 381' ' ' VAL . 94.9 mt -63.73 -43.15 97.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.008 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.48 -19.81 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.962 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.526 ' N ' ' O ' ' A' ' 379' ' ' ILE . 7.8 p -60.53 -43.65 94.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.749 0.309 . . . . 0.0 110.41 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.43 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -64.81 -36.45 93.12 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -41.3 98.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.738 0.304 . . . . 0.0 110.669 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.36 -36.24 83.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.612 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.4 tt -61.65 -45.31 94.58 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.056 0.455 . . . . 0.0 110.106 -179.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -37.7 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.5 -42.44 97.64 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.2 t -67.12 -42.49 88.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.738 0.304 . . . . 0.0 110.627 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -59.97 -40.99 90.99 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.223 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -65.33 -42.17 93.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.872 0.368 . . . . 0.0 110.234 179.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.85 -41.14 95.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.685 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.1 t -63.88 -41.49 92.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.682 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.34 -41.02 96.36 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.598 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.46 -41.8 97.79 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.295 -0.562 . . . . 0.0 109.545 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.54 -49.63 74.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.882 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -65.01 -34.88 79.5 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.365 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -58.21 -45.56 87.43 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.351 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.3 mt -63.63 -42.74 97.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.34 -38.53 95.97 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.9 tp -63.38 -41.54 98.79 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.434 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 54.4 tttm 59.1 69.72 0.7 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.601 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . 0.511 ' ND1' ' N ' ' A' ' 403' ' ' HIS . 64.5 t-80 57.86 162.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.455 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . 0.511 ' N ' ' ND1' ' A' ' 402' ' ' HIS . 54.9 t-80 -83.85 126.6 33.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.491 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . 0.625 ' ND1' ' H ' ' A' ' 406' ' ' GLY . 21.4 t-80 -82.24 132.38 35.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.612 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.22 -11.37 59.81 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.524 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . 0.625 ' H ' ' ND1' ' A' ' 404' ' ' HIS . . . -63.21 -40.35 98.98 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -81.67 136.22 35.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.627 0.251 . . . . 0.0 110.371 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -85.23 117.35 24.12 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.8 0.334 . . . . 0.0 110.345 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.567 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 3.0 pm0 -53.9 145.27 16.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.112 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.5 t80 . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.969 -1.015 . . . . 0.0 110.59 -179.86 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 369' ' ' SER . . . . . 0.588 ' HG ' ' H ' ' B' ' 370' ' ' ALA . 16.6 t . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . 0.588 ' H ' ' HG ' ' B' ' 369' ' ' SER . . . -69.38 144.53 53.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.559 179.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' B' ' 372' ' ' ASP . 35.2 p-10 -64.51 -34.97 79.47 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.422 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . 0.466 ' N ' ' OD1' ' B' ' 371' ' ' ASP . 52.7 t0 -88.93 111.66 22.38 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.405 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 52.1 p-10 -77.46 167.35 21.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.397 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -94.06 9.34 38.07 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.561 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -129.03 104.63 7.69 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.538 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 90.3 mt -135.86 140.97 44.55 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.175 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 19.7 t -143.31 72.82 17.91 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.415 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_exo -60.86 145.02 99.64 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 C-N-CA 123.01 2.473 . . . . 0.0 111.929 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.496 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt -64.27 -44.14 97.3 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.044 -179.627 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.62 -20.06 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.682 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.496 ' N ' ' O ' ' B' ' 379' ' ' ILE . 62.2 t -65.17 -43.11 95.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.361 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.19 -39.63 98.15 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -40.48 96.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.513 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.49 -35.48 81.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.512 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 2.8 tt -61.41 -44.05 97.81 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 121.1 0.476 . . . . 0.0 109.988 -179.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -37.05 85.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.421 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.11 -39.97 96.52 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.96 -43.2 92.85 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.938 0.399 . . . . 0.0 110.218 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -60.36 -40.67 91.63 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.806 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 80.1 mt -67.33 -41.37 86.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.146 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -60.12 -40.93 91.44 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.696 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 75.7 t -63.84 -41.38 92.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.666 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.27 -41.29 96.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.521 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.4 -42.82 99.33 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.558 179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.25 -47.9 74.76 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.836 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 85.0 t80 -64.36 -34.7 78.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.448 179.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -58.57 -44.87 89.91 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.41 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . 0.402 HG23 HD12 ' B' ' 398' ' ' ILE . 42.3 mm -65.09 -40.99 90.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.83 179.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.55 -34.86 87.59 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . 0.429 ' O ' ' O ' ' B' ' 401' ' ' LYS . 53.4 tp -62.14 -40.93 97.58 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.458 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' B' ' 400' ' ' LEU . 88.5 tttt 59.76 139.67 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.772 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 70.5 m80 -75.36 137.55 41.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.265 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -82.17 126.13 31.7 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.099 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 70.4 t60 -121.06 124.87 45.87 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.279 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.23 -15.34 58.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.598 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.6 -36.56 92.59 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -78.23 131.72 37.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.755 0.312 . . . . 0.0 110.419 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -135.44 144.97 46.76 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.815 0.34 . . . . 0.0 110.755 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -52.74 144.0 15.16 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.58 -0.448 . . . . 0.0 109.82 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 117.965 -1.016 . . . . 0.0 110.514 179.646 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 9.3 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.58 154.36 28.37 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.613 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 54.71 37.85 29.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.46 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' C' ' 374' ' ' ASN . 55.4 t0 -89.24 109.96 20.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.515 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -62.27 -42.05 99.0 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.49 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . 0.432 ' O ' ' OD1' ' C' ' 372' ' ' ASP . 20.5 p30 -155.73 162.44 40.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.499 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.78 -59.19 2.58 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.66 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 93.8 mt -136.35 133.54 36.92 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.459 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . 0.475 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 18.2 m -152.46 52.16 0.85 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.411 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . 0.475 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 36.3 Cg_endo -65.78 -21.59 57.97 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.76 2.307 . . . . 0.0 111.998 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.6 mm -65.69 -44.41 93.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.352 -179.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.95 -20.08 61.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.005 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 54.5 t -65.9 -43.71 92.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 CA-C-O 120.744 0.307 . . . . 0.0 110.344 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.72 -41.86 99.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.04 -36.98 86.09 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.792 0.329 . . . . 0.0 110.713 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.43 -46.04 89.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.672 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -64.7 -41.05 96.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.416 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.23 -37.51 85.67 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.397 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.26 -36.41 92.76 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.4 t -64.23 -43.59 97.29 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-O 120.746 0.307 . . . . 0.0 110.458 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 mp -61.63 -39.02 89.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.222 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.24 -41.94 93.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 8.4 mt -60.76 -42.51 97.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.729 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 82.0 t -65.15 -42.44 94.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.834 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.98 -42.73 99.46 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.731 -179.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.08 -43.81 98.03 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.04 -36.86 84.39 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.087 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -61.53 -44.59 96.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.67 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -62.73 -45.34 93.17 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.566 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' C' ' 401' ' ' LYS . 87.7 mt -64.55 -42.67 95.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.867 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.23 -41.84 96.6 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 48.4 tp -63.17 -42.18 99.36 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.606 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' C' ' 398' ' ' ILE . 68.7 mttm -91.25 143.76 26.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.502 -179.635 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 66.1 t-80 46.12 94.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.647 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 56.8 p-80 -71.91 141.65 49.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.567 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -78.14 125.67 29.69 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.47 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -89.46 -11.13 43.92 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.507 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.92 -39.02 97.52 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -79.03 130.22 35.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.792 0.33 . . . . 0.0 110.347 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -135.43 143.86 46.18 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.77 0.319 . . . . 0.0 110.894 179.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 44.0 tp60 -74.7 129.62 38.04 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.537 -0.465 . . . . 0.0 109.914 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 94.1 t80 . . . . . 0 C--N 1.326 -0.44 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.466 179.996 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.4 t . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.88 154.6 32.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.41 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -105.74 106.9 17.61 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.368 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.534 ' OD1' ' N ' ' A' ' 373' ' ' ASP . 42.4 p-10 -63.68 -34.85 78.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.62 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.534 ' N ' ' OD1' ' A' ' 372' ' ' ASP . 53.9 t0 -89.35 109.25 20.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.214 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -98.02 8.46 44.72 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.638 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -93.92 1.21 56.37 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.4 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 47.3 mt -106.89 5.64 28.55 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.383 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.429 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 2.7 t -129.78 54.6 14.94 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.482 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.429 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 36.3 Cg_endo -66.63 -17.57 52.93 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.573 2.182 . . . . 0.0 111.789 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 44.2 mm -66.43 -44.97 90.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.211 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.07 -20.51 63.22 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.784 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.3 t -66.8 -42.98 90.03 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.372 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.24 -37.68 94.94 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.24 96.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.871 0.367 . . . . 0.0 110.439 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.8 -36.11 82.83 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.416 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.7 tt -62.17 -44.1 97.35 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.085 0.469 . . . . 0.0 110.018 -179.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.03 -37.07 81.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.594 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.82 -39.07 96.99 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 95.5 t -63.63 -42.07 94.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.217 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.9 tt -60.7 -37.81 82.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.511 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.8 mm -64.4 -41.79 93.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.97 0.414 . . . . 0.0 110.196 179.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.4 mt -60.75 -40.94 94.31 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.53 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.8 t -64.26 -40.8 90.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.45 -40.78 95.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.407 -179.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.03 -41.54 96.76 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.41 -48.35 74.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.756 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.7 t80 -65.57 -35.61 81.35 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.602 -0.727 . . . . 0.0 110.488 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -56.78 -45.69 81.98 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.381 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.01 -42.27 94.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.137 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.63 -33.24 84.33 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.5 tp -61.84 -42.02 98.53 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.801 -0.359 . . . . 0.0 110.469 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -84.69 153.25 23.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.693 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . 0.529 ' O ' ' CG ' ' A' ' 402' ' ' HIS . 86.4 t60 49.91 43.72 25.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.535 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -79.14 133.78 36.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.351 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -75.11 140.31 43.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.541 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.24 -11.43 59.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.522 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.48 -36.36 93.27 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -111.34 138.2 48.12 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.866 0.365 . . . . 0.0 110.304 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.34 145.07 47.04 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.714 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 47.6 tp60 -73.27 130.87 41.16 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.489 -0.485 . . . . 0.0 109.894 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.2 t80 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.045 -0.978 . . . . 0.0 110.25 -179.699 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 4.4 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.86 149.75 26.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.414 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -99.9 112.3 24.57 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.182 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -88.63 107.01 18.69 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.515 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' B' ' 373' ' ' ASP . 33.2 p-10 -88.38 0.11 56.57 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.374 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 58.0 t-20 -82.21 110.76 17.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.343 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -61.19 -43.12 99.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.664 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . 0.452 ' CD1' ' N ' ' B' ' 376' ' ' LEU . 10.1 mp -90.25 131.66 35.94 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.316 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.423 HG22 ' H ' ' B' ' 379' ' ' ILE . 9.2 p -69.81 129.5 91.05 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.824 -179.254 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -70.81 -18.01 32.4 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.115 1.877 . . . . 0.0 112.396 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.423 ' H ' HG22 ' B' ' 377' ' ' VAL . 96.8 mt -63.27 -44.67 99.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 121.019 -0.273 . . . . 0.0 111.267 -178.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -74.62 -19.99 60.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.763 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.09 -43.19 88.94 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.21 -40.62 97.53 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.63 -37.87 89.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.743 0.306 . . . . 0.0 110.659 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.88 -46.63 88.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.602 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.68 -41.87 91.95 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.539 179.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -39.05 93.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.433 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.8 -42.85 99.66 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 89.5 t -66.51 -43.17 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 121.168 -0.213 . . . . 0.0 111.02 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.0 tt -60.64 -41.27 94.6 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.349 -0.541 . . . . 0.0 109.739 -179.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -63.87 -42.23 95.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 0.0 110.319 178.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.8 -40.09 91.35 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.507 -179.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.8 t -63.95 -41.86 93.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.97 -40.8 94.78 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.238 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.45 -43.42 98.91 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.132 -0.627 . . . . 0.0 109.502 179.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.16 -37.11 86.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.125 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -61.62 -44.86 96.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.621 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 36.5 m-85 -63.43 -41.67 98.68 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.578 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.3 mm -63.76 -42.16 95.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.013 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.22 -58.6 13.7 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . 0.558 ' C ' ' H ' ' B' ' 402' ' ' HIS . 4.0 mm? -64.45 -40.91 96.63 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 121.027 -0.269 . . . . 0.0 110.44 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 47.9 tttp 70.61 -34.52 0.3 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.644 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . 0.558 ' H ' ' C ' ' B' ' 400' ' ' LEU . 49.1 p-80 -152.74 149.24 28.15 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.327 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -84.29 129.72 34.86 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.365 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -71.45 140.78 50.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.541 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.24 -12.01 59.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.586 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.27 -39.31 97.72 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 81.8 t80 -83.12 132.05 35.11 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 56.3 mp0 -99.01 133.36 43.39 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.267 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.516 ' CD ' ' H ' ' B' ' 409' ' ' GLN . 0.5 OUTLIER -52.85 145.97 11.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.007 -179.925 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 93.8 t80 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.487 -179.734 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 41.4 t . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.29 -39.01 93.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.572 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 48.3 t0 -121.86 110.17 15.55 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.398 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -87.69 114.77 24.62 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.413 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -91.14 107.59 19.3 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.334 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . 0.556 ' O ' ' N ' ' C' ' 376' ' ' LEU . 54.9 p30 -102.86 8.79 39.17 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.536 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 50.47 -83.97 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.727 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . 0.556 ' N ' ' O ' ' C' ' 374' ' ' ASN . 3.8 tp 68.07 1.42 2.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.33 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 3.9 t 61.46 75.31 0.45 Allowed Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.511 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -55.37 -31.44 77.36 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.792 2.328 . . . . 0.0 112.053 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.1 mm -64.29 -44.5 97.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.137 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.86 -20.34 62.54 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.783 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 63.5 t -67.5 -43.2 87.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.87 -38.49 96.19 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.46 95.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.734 0.302 . . . . 0.0 110.731 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.29 88.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.772 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -64.98 -41.93 94.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.417 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.7 -36.46 83.92 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.346 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.8 -42.21 99.72 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 94.2 t -64.0 -42.96 97.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.885 0.374 . . . . 0.0 110.242 179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 4.1 tt -60.89 -37.99 84.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.832 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.8 mm -63.4 -42.59 96.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.138 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.42 -40.4 94.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.414 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 91.0 t -63.01 -40.8 90.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.666 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.95 -41.24 95.91 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.435 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.48 -43.5 98.75 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.524 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.5 -37.39 84.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -60.17 -43.96 95.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -62.65 -45.22 93.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.492 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.9 -42.87 97.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.976 179.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.22 -34.89 90.79 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.01 -42.93 99.96 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.002 0.43 . . . . 0.0 110.027 -179.119 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 66.0 tttm 54.9 101.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.491 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 66.6 t-80 -75.92 129.83 37.55 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.3 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -79.24 145.1 33.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.65 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -78.86 147.54 33.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.462 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.2 -11.2 59.79 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.562 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.13 -36.84 93.99 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -78.87 135.44 37.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.568 0.223 . . . . 0.0 110.404 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -77.96 116.92 18.81 Favored 'General case' 0 N--CA 1.463 0.205 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.367 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.527 ' OE1' ' N ' ' C' ' 410' ' ' PHE . 4.5 tp-100 -75.34 123.19 24.92 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 120.684 -0.407 . . . . 0.0 109.99 179.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . 0.527 ' N ' ' OE1' ' C' ' 409' ' ' GLN . 54.4 p90 . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.482 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 52.3 p . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.23 -37.54 87.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.479 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.427 ' OD1' ' O ' ' A' ' 373' ' ' ASP . 66.9 t0 -131.94 97.4 4.16 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.315 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 373' ' ' ASP . 35.6 p-10 -66.71 -40.52 88.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.881 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 372' ' ' ASP . 42.3 p-10 -98.76 110.7 23.26 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.676 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -90.84 107.41 19.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.539 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . 0.509 ' C ' ' H ' ' A' ' 377' ' ' VAL . 86.3 m-85 -62.44 -41.43 98.72 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.607 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 4.8 tp 70.52 -40.19 0.46 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.379 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.509 ' H ' ' C ' ' A' ' 375' ' ' PHE . 5.5 t -140.54 56.7 7.45 Favored Pre-proline 0 N--CA 1.464 0.258 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.188 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.406 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 41.0 Cg_endo -68.18 -18.11 45.23 Favored 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.634 2.223 . . . . 0.0 112.09 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.4 mm -65.59 -45.48 92.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.168 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.44 -20.1 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.738 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -67.19 -43.45 88.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.442 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.62 93.43 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.11 -41.71 98.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.847 0.356 . . . . 0.0 110.4 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -36.52 83.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.646 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.2 tt -61.47 -43.9 98.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.42 -37.4 87.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.87 -42.62 99.76 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.56 -42.78 93.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.91 0.386 . . . . 0.0 110.522 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -61.04 -40.94 95.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.493 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.402 HG22 HD13 ' A' ' 390' ' ' ILE . 86.2 mt -66.24 -41.7 89.63 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.107 0 CA-C-O 120.896 0.379 . . . . 0.0 110.268 179.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.8 -40.84 89.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.557 -179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.9 -41.7 93.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.682 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.12 -41.57 96.95 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.485 -179.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.55 -41.93 98.08 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.81 -48.55 79.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.707 179.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -64.43 -35.32 80.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.211 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -57.58 -46.02 84.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.19 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.6 mt -63.77 -42.68 96.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.69 -32.55 84.57 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp -61.54 -41.07 96.8 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 121.106 -0.238 . . . . 0.0 110.359 -179.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.6 mttt 55.58 35.93 26.17 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.579 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 49.27 94.28 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.717 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 49.0 p-80 -70.85 135.59 48.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.438 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -77.66 137.52 38.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.546 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.34 -12.38 59.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.61 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.29 -39.35 97.74 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 82.2 m-85 -109.62 135.88 49.88 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 120.817 0.342 . . . . 0.0 110.315 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -86.04 115.98 23.97 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.344 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 47.2 tp60 -80.0 129.85 34.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.075 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 88.9 t80 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.589 -179.856 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . 49.05 49.99 18.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.351 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -61.44 -43.43 98.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.377 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -90.4 110.23 21.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.569 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -68.55 142.41 55.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.555 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -101.53 140.77 35.37 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.362 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -101.53 8.11 42.06 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.502 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . 0.449 ' CD1' ' N ' ' B' ' 376' ' ' LEU . 10.0 mp -92.97 -1.39 56.73 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.305 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.459 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 8.6 m -141.53 53.04 3.1 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.439 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . 0.459 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 36.4 Cg_endo -65.44 -20.98 61.06 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.764 2.309 . . . . 0.0 112.01 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt -64.96 -44.41 96.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 C-N-CA 120.866 -0.333 . . . . 0.0 110.88 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.22 -20.08 62.3 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.79 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 61.4 t -67.84 -43.21 86.26 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.473 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -37.76 95.02 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.56 -40.67 97.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.395 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.02 -36.04 83.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.583 179.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 2.7 tt -61.52 -44.13 97.61 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.431 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -38.26 90.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.491 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.3 -43.15 99.49 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 90.7 t -67.11 -42.83 88.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.738 0.304 . . . . 0.0 110.715 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.97 -41.07 91.17 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.021 -178.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . 0.408 HD12 HG21 ' B' ' 390' ' ' ILE . 85.4 mt -64.9 -42.16 94.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.829 0.347 . . . . 0.0 110.296 178.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.7 mt -60.71 -41.49 95.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.603 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 80.0 t -64.05 -40.96 90.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.689 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.47 97.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.384 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 7.2 tt -61.67 -42.09 98.44 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.6 -47.8 78.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.532 . . . . 0.0 109.732 179.423 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.98 -35.99 82.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.392 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -57.34 -45.38 84.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.231 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . 0.412 HG21 HD11 ' B' ' 398' ' ' ILE . 44.3 mm -64.94 -41.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.123 179.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.58 -33.23 85.94 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . 0.439 ' O ' ' O ' ' B' ' 401' ' ' LYS . 0.2 OUTLIER -62.37 -42.17 99.2 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 -179.547 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . 0.439 ' O ' ' O ' ' B' ' 400' ' ' LEU . 52.5 mtmt 58.78 145.27 0.01 OUTLIER 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.46 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -58.84 -41.68 87.49 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.468 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -82.23 134.78 35.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.503 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -76.86 133.12 39.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.514 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.19 -12.53 59.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.653 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.67 -37.05 94.14 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -106.36 135.69 47.41 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 120.752 0.311 . . . . 0.0 110.347 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -99.49 117.72 34.5 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.219 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.483 ' N ' ' CD ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -129.83 146.24 51.56 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.326 179.901 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . 0.437 ' CD2' ' O ' ' B' ' 410' ' ' PHE . 54.6 p90 . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.658 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 60.9 m . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -150.61 154.06 36.83 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.363 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . 0.523 ' OD1' ' ND2' ' C' ' 374' ' ' ASN . 60.4 t0 -122.77 26.86 8.02 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.185 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.417 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 34.3 p-10 -88.44 3.35 50.36 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.564 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -86.83 1.0 53.86 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.423 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . 0.523 ' ND2' ' OD1' ' C' ' 371' ' ' ASP . 95.3 m-20 -62.63 -41.2 98.88 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.583 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -122.14 102.22 8.01 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.529 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 57.2 tp -114.73 125.87 54.21 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.042 179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 7.5 p -174.35 77.22 0.35 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.411 179.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -60.02 148.56 88.61 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.649 2.232 . . . . 0.0 111.656 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' C' ' 381' ' ' VAL . 95.2 mt -63.08 -43.06 98.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.626 -179.512 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.75 -19.6 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.65 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.534 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.8 p -61.72 -38.46 80.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.745 0.307 . . . . 0.0 110.541 -179.492 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.37 -40.51 98.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.36 98.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.882 0.372 . . . . 0.0 110.301 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.81 -35.81 82.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.5 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.9 tt -61.41 -43.2 99.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.908 -179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.47 -39.19 92.61 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.517 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.85 -42.18 98.54 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 86.6 t -66.71 -42.46 89.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.828 0.347 . . . . 0.0 110.769 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.5 -40.56 91.83 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.29 -179.374 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . 0.417 HG21 HD11 ' C' ' 390' ' ' ILE . 83.7 mt -66.08 -42.04 90.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 120.903 0.382 . . . . 0.0 110.173 179.055 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.4 -40.91 92.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.594 -179.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 70.4 t -63.36 -41.65 93.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.703 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.99 -41.81 97.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.478 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.1 -42.43 99.22 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.62 -48.4 81.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.636 179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -64.06 -35.38 80.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.417 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.34 -46.56 79.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.28 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.57 -42.48 95.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.219 179.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.29 -33.47 87.32 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 55.2 tp -61.82 -42.57 99.19 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.914 -0.314 . . . . 0.0 110.332 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -90.22 134.62 34.18 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.669 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 43.2 p-80 -157.95 161.73 38.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.371 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 79.9 t60 -85.99 122.07 29.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.82 0.343 . . . . 0.0 110.202 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . 0.571 ' H ' ' ND1' ' C' ' 404' ' ' HIS . 16.5 p-80 -74.69 138.78 43.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.529 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.6 -11.12 59.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.648 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.9 -38.7 96.99 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 65.9 t80 -84.7 130.63 34.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 110.309 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.33 149.35 49.72 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.496 179.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -53.08 137.91 32.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.974 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 55.2 p90 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.456 -179.997 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 35.8 t . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -71.32 140.82 50.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.403 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -99.29 110.9 23.37 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.453 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 65.9 t0 56.53 53.68 8.3 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.66 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 37.2 p-10 -62.07 -36.33 81.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.53 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.521 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 3.1 t-20 -87.55 93.1 9.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.605 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -64.21 -43.4 95.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.737 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.464 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 10.0 mp -84.25 133.47 34.57 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.226 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.495 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 16.3 m -147.79 51.42 1.07 Allowed Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.314 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 32.8 Cg_endo -64.87 -22.36 63.3 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 C-N-CA 122.741 2.294 . . . . 0.0 112.02 179.707 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.405 HG22 HD11 ' A' ' 379' ' ' ILE . 96.4 mt -63.67 -44.53 98.48 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.261 -179.153 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.86 -20.26 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.837 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.39 -43.19 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.262 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.84 -41.61 99.65 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -38.97 93.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.826 0.346 . . . . 0.0 110.719 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.63 -44.91 92.51 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.675 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.64 -40.19 92.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.389 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.3 -40.06 95.03 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.428 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -38.91 96.81 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 79.3 t -64.69 -41.85 93.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.887 0.375 . . . . 0.0 110.188 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.94 -37.8 80.57 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.206 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.74 -42.52 95.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.926 0.394 . . . . 0.0 110.121 179.127 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.51 -42.5 98.89 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.703 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.5 t -65.94 -42.51 92.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -62.04 -42.06 98.77 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.57 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.4 -43.19 99.41 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.635 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.02 -47.53 82.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.918 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -65.57 -34.29 77.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.493 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -56.99 -45.87 82.66 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.322 -179.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.48 -42.35 93.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.36 -31.15 79.78 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.1 tp -62.22 -41.65 98.58 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.474 -179.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -105.39 136.12 45.51 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.899 0.381 . . . . 0.0 110.423 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 51.8 p-80 -156.56 159.52 38.61 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.102 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -112.16 127.25 55.88 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.422 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -87.14 125.84 34.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.274 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.61 -12.24 59.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.366 -179.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.79 -36.77 93.74 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 85.7 t80 -79.33 131.91 36.28 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.54 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.8 mp0 -103.77 119.53 39.1 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-O 120.859 0.362 . . . . 0.0 110.309 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 41.1 tp60 -77.98 136.62 38.0 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.689 -0.404 . . . . 0.0 109.927 179.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.8 t80 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.936 -1.031 . . . . 0.0 110.46 179.95 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 69.6 p . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . 53.28 40.22 30.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.484 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -105.04 112.09 25.09 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.491 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 54.2 t0 55.99 30.81 16.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.588 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 58.5 t0 58.46 32.12 21.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.52 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -63.22 -39.88 95.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.473 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 58.1 t80 42.01 72.93 0.15 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.628 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 40.8 tp -108.5 101.0 10.21 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.198 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 3.9 m -151.11 74.86 8.28 Favored Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.385 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -60.73 145.11 99.45 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.944 2.43 . . . . 0.0 111.831 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.468 ' O ' ' N ' ' B' ' 381' ' ' VAL . 45.8 mm -64.24 -43.65 97.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.118 -179.72 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.37 -20.26 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.71 -0.223 . . . . 0.0 110.766 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.468 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.35 -42.97 94.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.266 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -36.12 92.85 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.3 -43.26 99.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.814 0.34 . . . . 0.0 110.587 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.64 -36.77 84.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.436 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -62.41 -43.68 98.25 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.938 -179.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.7 88.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.491 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.31 -42.1 99.72 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 56.3 t -66.1 -43.98 92.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.895 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -60.88 -41.71 96.54 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.922 -179.242 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 92.7 mt -65.73 -42.2 92.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 CA-C-O 121.003 0.43 . . . . 0.0 110.431 179.063 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -58.42 -41.59 85.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.518 -178.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.71 -40.99 90.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.596 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.94 -41.4 96.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.485 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.23 -42.89 99.39 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.94 -48.31 80.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.972 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.06 -35.65 80.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.49 179.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -56.59 -44.82 81.45 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.316 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.2 mm -65.7 -41.54 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.33 -33.52 86.89 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 53.2 tp -61.9 -42.1 98.68 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.904 -0.318 . . . . 0.0 110.533 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -101.09 144.12 30.38 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.805 0.336 . . . . 0.0 110.315 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . 0.454 ' CE1' ' CE1' ' B' ' 403' ' ' HIS . 56.6 p-80 -95.12 -3.51 47.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.423 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . 0.454 ' CE1' ' CE1' ' B' ' 402' ' ' HIS . 70.7 m80 -74.89 138.61 42.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.293 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -107.32 134.04 50.98 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.557 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.33 -12.91 60.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.466 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.18 -37.9 95.65 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . 0.432 ' CE2' ' O ' ' B' ' 408' ' ' GLU . 75.7 t80 -82.35 136.4 35.0 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . 0.432 ' O ' ' CE2' ' B' ' 407' ' ' TYR . 80.8 tt0 -72.05 118.3 14.75 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.317 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.531 ' CD ' ' H ' ' B' ' 409' ' ' GLN . 0.1 OUTLIER -52.91 146.1 11.46 Favored 'General case' 0 N--CA 1.462 0.146 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.082 179.643 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.516 -179.625 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 6.0 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -62.7 -40.25 96.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.482 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -139.78 102.68 4.48 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.152 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.421 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 35.8 p-10 -89.06 -0.17 57.2 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.502 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 47.4 t0 59.54 30.2 19.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.48 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -97.07 7.62 46.24 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.555 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -61.85 -41.05 97.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.62 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 29.7 mt -102.12 2.75 37.81 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.377 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 14.3 t 49.33 72.47 1.25 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.482 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.56 146.14 96.04 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.865 2.376 . . . . 0.0 112.085 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt -63.52 -43.96 98.52 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.991 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.33 -20.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.647 0.26 . . . . 0.0 110.803 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.471 ' N ' ' O ' ' C' ' 379' ' ' ILE . 54.3 t -63.8 -43.76 98.0 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.183 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.68 -39.75 98.31 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.62 -39.9 95.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.868 0.366 . . . . 0.0 110.659 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -66.12 -34.31 77.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.457 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.87 -45.17 94.92 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.998 -179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.01 -36.51 84.22 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.2 -40.37 98.47 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 83.9 t -67.27 -42.76 88.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.807 0.337 . . . . 0.0 110.314 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.5 tt -60.46 -41.08 93.41 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.561 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . 0.417 HD11 HG22 ' C' ' 390' ' ' ILE . 82.7 mt -66.04 -42.01 90.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.85 0.357 . . . . 0.0 110.342 178.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.02 -40.05 87.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 74.9 t -63.73 -42.19 95.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.5 -41.16 96.87 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.483 -179.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.3 tt -62.28 -43.71 98.21 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.608 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.46 -36.7 84.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.072 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -60.22 -44.53 95.11 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.652 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 27.6 m-85 -62.11 -43.77 98.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.664 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.0 mt -63.23 -41.88 94.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.521 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.89 -34.82 90.97 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 50.1 tp -62.9 -41.48 99.45 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.485 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 88.8 tttt 54.44 105.73 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.629 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -77.44 140.64 39.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.16 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -106.38 127.19 53.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.293 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -104.64 128.72 52.75 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.383 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.09 -12.77 60.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.457 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.31 -40.66 98.08 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . 0.62 ' CZ ' ' NE2' ' C' ' 409' ' ' GLN . 88.1 t80 -92.67 117.66 30.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.772 0.32 . . . . 0.0 110.302 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . 0.503 ' O ' ' NE2' ' C' ' 409' ' ' GLN . 0.0 OUTLIER -135.43 144.66 46.6 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.558 179.709 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.62 ' NE2' ' CZ ' ' C' ' 407' ' ' TYR . 90.9 mm-40 -130.61 126.69 37.3 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.556 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . 0.439 ' CG ' ' O ' ' C' ' 410' ' ' PHE . 92.3 t80 . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.485 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 61.29 129.02 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.605 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 55.4 t0 57.07 44.66 22.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.452 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -88.38 114.04 24.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.728 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 52.4 t0 -66.21 144.05 56.87 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.801 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.509 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 65.8 t30 55.91 42.21 29.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.679 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -120.85 102.57 8.46 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.331 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 94.8 mt -135.7 146.55 47.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.435 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 11.4 t -143.79 71.65 17.09 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.456 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -60.88 146.77 97.08 Favored 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.877 2.385 . . . . 0.0 111.826 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 44.6 mm -65.44 -43.7 94.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.744 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.33 -20.02 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.59 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 54.9 t -65.27 -42.9 95.02 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 C-N-CA 121.026 -0.27 . . . . 0.0 110.468 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.13 -40.15 96.79 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.16 -41.99 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.835 0.35 . . . . 0.0 110.579 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.0 -35.66 81.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.57 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 3.1 tt -61.3 -43.47 98.83 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.68 -39.78 95.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.886 0.374 . . . . 0.0 110.51 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.15 97.81 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 72.8 t -63.79 -43.31 97.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 O-C-N 122.946 -0.15 . . . . 0.0 111.332 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.22 -37.86 81.59 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.336 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -62.94 -42.34 96.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 178.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.5 mt -60.86 -39.85 90.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.392 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.2 t -61.09 -40.72 86.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.468 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.99 -41.6 96.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.323 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.79 -44.2 97.33 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.335 -0.546 . . . . 0.0 109.73 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.22 -36.73 83.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.002 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -60.09 -44.79 94.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.685 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -62.42 -44.9 95.33 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.331 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.45 -42.86 97.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.05 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.09 -33.08 84.34 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . 0.411 ' O ' ' O ' ' A' ' 401' ' ' LYS . 43.9 tp -61.81 -41.69 98.08 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.502 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . 0.411 ' O ' ' O ' ' A' ' 400' ' ' LEU . 62.1 tttm 51.08 101.98 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.337 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 60.4 t-80 -58.45 -40.86 83.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.425 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -73.68 141.14 46.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.502 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -76.83 134.13 39.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.611 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.89 -11.22 59.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.616 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.0 -33.83 88.32 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -107.61 133.65 51.75 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.653 0.263 . . . . 0.0 110.46 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -86.91 117.48 25.67 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.218 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.656 ' H ' ' NE2' ' A' ' 409' ' ' GLN . 0.0 OUTLIER -62.68 141.15 58.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.093 179.815 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.0 t80 . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.001 -0.999 . . . . 0.0 110.458 179.866 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 86.3 p . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -158.75 153.58 24.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.542 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 56.9 m-20 -93.17 111.49 23.14 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.203 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . 0.512 ' OD2' ' ND2' ' B' ' 374' ' ' ASN . 36.6 p-10 -87.73 1.12 54.63 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.652 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 52.3 t0 58.62 52.05 7.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.58 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . 0.512 ' ND2' ' OD2' ' B' ' 372' ' ' ASP . 99.1 m-20 -67.81 150.25 48.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.484 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . 0.521 ' O ' ' CD2' ' B' ' 375' ' ' PHE . 40.1 p90 -146.79 121.42 9.8 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.189 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 45.8 mt -110.17 4.01 20.66 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.362 179.785 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.43 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 15.5 m -131.24 54.82 15.72 Favored Pre-proline 0 N--CA 1.464 0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.435 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . 0.43 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 36.5 Cg_endo -65.62 -20.06 59.95 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.745 2.296 . . . . 0.0 111.933 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt -64.6 -44.23 96.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 C-N-CA 120.883 -0.327 . . . . 0.0 111.008 -179.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.96 -20.11 61.79 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.987 -0.285 . . . . 0.0 110.828 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 52.9 t -67.06 -43.12 89.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.419 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.29 -41.57 99.73 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.54 84.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.729 0.3 . . . . 0.0 110.65 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.17 -43.85 98.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.721 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.49 -40.96 93.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.291 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.14 -37.83 88.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -38.97 97.12 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 84.6 t -64.3 -42.12 94.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.108 0.48 . . . . 0.0 110.167 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.2 tp -60.38 -38.08 82.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.247 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -63.5 -42.53 96.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -61.6 -42.07 98.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.495 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 88.5 t -66.03 -42.19 91.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.985 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.67 -41.2 97.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.405 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.66 -43.07 99.55 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.99 -47.82 83.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.695 179.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -63.9 -35.81 81.87 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.86 -45.55 82.37 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.084 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.72 -42.6 96.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.222 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.22 -31.22 80.13 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 54.1 tp -61.71 -40.58 95.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.721 0.296 . . . . 0.0 110.348 -179.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -48.78 142.07 6.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.57 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 54.6 t-80 -69.38 136.99 52.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.542 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -79.44 149.35 31.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.627 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 10.5 p-80 -66.21 162.77 19.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.489 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.08 -11.84 59.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.454 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.2 -33.57 87.61 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . 0.514 ' OH ' ' NE2' ' B' ' 409' ' ' GLN . 72.9 t80 -83.83 126.13 32.65 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.693 0.283 . . . . 0.0 110.456 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . 0.431 ' O ' ' OE1' ' B' ' 409' ' ' GLN . 92.8 mt-10 -135.43 149.19 49.55 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.526 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.514 ' NE2' ' OH ' ' B' ' 407' ' ' TYR . 11.5 mm100 -120.19 125.97 49.5 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.073 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 . . . . . 0 C--O 1.219 -0.5 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.68 -179.926 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' C' C ' 369' ' ' SER . . . . . 0.42 ' H1 ' ' H ' ' C' ' 370' ' ' ALA . 56.3 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . 0.42 ' H ' ' H1 ' ' C' ' 369' ' ' SER . . . -63.74 -37.57 87.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.331 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 37.1 p-10 -64.44 -36.49 84.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.555 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.52 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 45.0 t0 -89.27 106.9 18.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.38 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -80.77 164.75 22.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.373 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -85.01 136.94 33.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.382 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . 0.495 ' CZ ' ' CG2' ' C' ' 377' ' ' VAL . 82.5 t80 -88.62 78.98 7.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.372 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 22.3 tp -108.19 103.08 12.19 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . 0.495 ' CG2' ' CZ ' ' C' ' 375' ' ' PHE . 16.1 m -157.74 51.92 0.52 Allowed Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.039 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . 0.484 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 26.5 Cg_endo -62.25 -22.75 74.63 Favored 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.759 2.306 . . . . 0.0 112.04 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt -64.19 -44.55 97.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.04 -179.645 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.03 -20.16 59.72 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 121.053 -0.259 . . . . 0.0 110.736 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.28 -43.38 91.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 121.001 -0.28 . . . . 0.0 110.557 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.59 -37.62 95.04 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.68 -41.03 98.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.857 0.36 . . . . 0.0 110.564 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.79 -35.56 81.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.459 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 2.6 tt -61.68 -43.62 98.5 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.896 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.12 -38.7 92.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.674 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -40.2 98.72 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.52 -42.65 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.509 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -59.71 -39.07 83.4 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.823 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.38 -42.38 95.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.829 0.347 . . . . 0.0 110.141 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.34 -41.07 96.45 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.414 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.21 -41.52 92.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.717 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.67 -41.99 98.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.542 -179.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.04 -41.96 98.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.67 -49.28 77.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.627 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -64.83 -35.01 79.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.229 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.98 -45.66 86.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.349 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.1 mt -63.55 -42.72 97.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.13 -38.61 95.48 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp -62.83 -42.28 99.67 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.898 -0.321 . . . . 0.0 110.353 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . 0.434 ' O ' ' O ' ' C' ' 402' ' ' HIS . 29.9 ttmt 56.96 59.25 3.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.806 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . 0.434 ' O ' ' O ' ' C' ' 401' ' ' LYS . 95.7 m-70 56.41 158.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.563 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -78.37 145.81 35.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.426 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 99.4 m-70 -79.34 142.81 35.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.617 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.51 -11.97 59.91 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.538 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.19 -36.76 93.87 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -82.48 132.21 35.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.631 0.253 . . . . 0.0 110.491 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -77.76 117.65 19.36 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.091 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -52.89 137.62 31.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.32 -0.4 . . . . 0.0 109.961 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 83.1 t80 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.474 -179.998 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 19.9 p . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -152.2 152.13 31.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.492 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 47.9 t0 -101.52 107.61 18.95 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.345 179.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 35.7 p30 -90.2 2.4 55.42 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.391 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -62.58 -42.91 99.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.566 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 69.3 m-20 56.96 36.13 27.35 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.522 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 53.6 t80 -60.69 -44.3 96.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.403 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 23.0 mt -102.04 131.24 48.6 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.373 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 4.6 m -141.99 71.27 23.67 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.363 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -55.64 -33.47 87.27 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.876 2.384 . . . . 0.0 112.114 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.474 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.8 mt -62.83 -43.76 99.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.905 -179.109 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.57 -19.63 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.654 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.474 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.2 p -59.15 -44.26 91.32 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-O 120.682 0.277 . . . . 0.0 110.806 -179.34 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.453 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.2 -41.35 99.66 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.11 98.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.842 0.353 . . . . 0.0 110.284 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -66.42 -35.93 81.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.722 179.72 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.6 tt -60.53 -44.52 95.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.931 -179.208 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.11 93.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.421 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.41 -42.91 97.44 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.6 t -65.6 -43.19 94.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.223 -179.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.55 -39.88 89.54 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.448 -0.501 . . . . 0.0 110.114 -179.222 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.409 HG23 HD12 ' A' ' 390' ' ' ILE . 77.1 mt -64.9 -42.05 93.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.81 0.338 . . . . 0.0 110.11 178.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.87 -40.65 93.78 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.664 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.9 t -62.2 -41.18 90.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.725 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.1 mt -61.09 -41.31 96.42 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.421 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.64 -43.21 99.28 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.8 82.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.25 179.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . 0.418 ' CZ ' ' CD1' ' A' ' 400' ' ' LEU . 92.6 t80 -60.3 -44.52 95.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.5 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -63.89 -46.56 84.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.417 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.5 mt -64.43 -42.1 94.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.377 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -53.14 -57.2 15.69 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . 0.516 ' C ' ' H ' ' A' ' 402' ' ' HIS . 8.7 mt -65.31 -40.93 94.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 110.432 179.403 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 52.1 tttm 51.25 9.86 0.07 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.412 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . 0.516 ' H ' ' C ' ' A' ' 400' ' ' LEU . 64.1 t-80 -154.14 139.36 17.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.518 179.742 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 63.9 t-80 -79.43 126.67 31.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.271 179.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 69.9 t60 -89.87 124.87 35.06 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.373 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.15 -18.22 53.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.687 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.62 -36.82 93.85 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 86.3 t80 -86.41 129.16 34.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.602 0.239 . . . . 0.0 110.39 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 43.8 tp10 -108.58 120.39 42.3 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -52.87 141.71 21.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.026 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 . . . . . 0 C--N 1.325 -0.485 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.289 179.863 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 86.3 p . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -149.22 148.52 29.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.542 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -94.7 100.12 12.1 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.256 179.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -96.18 83.78 3.67 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.574 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 53.87 34.47 19.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.678 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 40.7 t-20 -90.64 108.49 19.85 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.567 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -119.86 103.44 9.34 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.393 179.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 35.7 tp -97.59 86.18 3.77 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.466 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 16.4 m -152.93 53.05 0.95 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.291 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . 0.466 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 34.9 Cg_endo -65.25 -21.44 61.85 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.758 2.305 . . . . 0.0 112.072 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . 0.423 HG23 HD11 ' B' ' 379' ' ' ILE . 97.2 mt -64.37 -44.69 97.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.529 -0.305 . . . . 0.0 111.18 -179.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.47 -20.06 60.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.626 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.2 -43.39 88.39 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-O 120.72 0.295 . . . . 0.0 110.461 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.86 -41.59 99.84 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.16 89.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.855 0.36 . . . . 0.0 110.67 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.79 -44.14 96.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.71 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -65.71 -39.6 91.37 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.338 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.96 -38.79 89.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.398 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.09 -42.57 99.5 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 87.4 t -66.88 -42.66 89.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.651 0.263 . . . . 0.0 111.081 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.3 tt -60.08 -41.53 92.64 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.076 -179.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 87.8 mt -64.31 -42.25 94.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.897 0.379 . . . . 0.0 110.26 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.97 -41.28 96.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.564 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.7 t -63.69 -41.09 91.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.738 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.12 -40.94 95.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.421 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -41.59 97.25 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.75 80.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.652 179.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.11 -36.01 82.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.668 -0.697 . . . . 0.0 110.338 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -56.86 -45.87 82.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.165 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.0 mt -63.88 -42.62 96.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.308 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.02 -36.65 93.3 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 45.6 tp -62.68 -42.12 99.46 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.75 0.31 . . . . 0.0 110.51 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -77.73 134.83 38.0 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.441 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -148.33 139.37 23.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.415 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -74.74 131.19 40.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.231 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -100.91 125.01 47.44 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.311 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.3 -11.41 59.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.632 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.07 -34.68 90.61 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 82.8 t80 -135.93 152.9 51.47 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.83 0.347 . . . . 0.0 110.433 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -135.26 148.37 49.54 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.332 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.485 ' CD ' ' N ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -130.63 144.84 51.7 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.935 -179.718 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.355 179.722 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 14.2 m . . . . . 0 N--CA 1.489 1.476 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -66.09 -39.86 90.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.481 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 49.5 t0 56.36 37.41 28.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.481 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -85.77 110.9 19.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.5 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -92.43 110.14 21.54 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.302 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -92.65 5.46 50.92 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.214 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -62.07 -43.76 98.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.515 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 7.0 tp -112.46 133.53 54.48 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.286 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 3.5 m -123.33 74.6 51.51 Favored Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.579 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -75.1 161.64 38.15 Favored 'Trans proline' 0 N--CA 1.491 1.356 0 C-N-CA 122.658 2.239 . . . . 0.0 112.065 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.5 mt -63.68 -42.85 97.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.683 -179.486 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.59 -19.64 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' C' ' 379' ' ' ILE . 51.1 t -63.47 -43.87 98.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.85 -36.1 92.86 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.78 -40.71 96.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.791 0.329 . . . . 0.0 110.301 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -36.88 85.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.373 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 3.0 tt -61.57 -44.48 96.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.903 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -36.98 85.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.539 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.16 -38.38 95.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 85.2 t -65.76 -42.62 92.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.879 0.371 . . . . 0.0 110.528 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 5.3 tt -61.1 -38.92 88.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.019 -179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.85 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.14 -40.97 95.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.64 -40.91 90.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.649 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.68 -41.6 97.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.591 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.56 -42.62 99.12 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.57 -49.14 78.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.74 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.71 -34.74 78.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.273 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -58.05 -45.56 86.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.151 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.3 mt -63.44 -42.4 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.1 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.62 -36.28 92.96 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . 0.436 ' O ' ' O ' ' C' ' 401' ' ' LYS . 53.0 tp -62.91 -41.79 99.57 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.323 -179.841 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' C' ' 400' ' ' LEU . 75.6 tttt 53.95 166.68 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 64.2 t-80 -61.42 -43.24 99.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.454 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -77.19 140.57 40.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.333 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -98.96 131.65 44.86 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.417 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.21 -12.24 59.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.505 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.56 -39.42 97.61 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -81.93 131.47 35.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.603 0.239 . . . . 0.0 110.416 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -89.56 114.55 26.13 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.214 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -54.37 141.89 28.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.898 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 85.5 t80 . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.516 179.859 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 67.4 m . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -150.68 149.04 29.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.503 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.411 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 37.7 p-10 -90.44 0.92 57.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.341 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -89.78 107.27 19.0 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.493 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 59.9 m-20 -64.42 -37.5 87.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.037 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -86.61 107.22 18.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.405 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -95.11 -0.44 53.47 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.46 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.408 ' N ' ' CD1' ' A' ' 376' ' ' LEU . 10.7 mp -62.57 -41.73 99.11 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.305 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.41 ' O ' ' CG1' ' A' ' 377' ' ' VAL . 8.3 p -153.57 78.07 5.73 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.27 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -59.74 143.7 99.58 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.631 2.22 . . . . 0.0 111.916 179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.9 mm -65.06 -44.02 95.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.083 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.1 -20.25 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.708 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.506 ' N ' ' O ' ' A' ' 379' ' ' ILE . 55.7 t -65.27 -43.51 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.335 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -66.27 -40.78 94.86 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.3 -38.96 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.763 0.316 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.37 -44.86 95.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.33 -40.17 89.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.405 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.81 -37.68 88.3 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.555 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.28 -39.93 97.46 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 80.5 t -66.24 -42.86 91.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.912 0.387 . . . . 0.0 110.596 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.3 mt -62.15 -41.85 98.68 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.413 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.4 mt -64.11 -41.9 93.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.35 -42.61 96.07 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.698 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.1 t -65.34 -41.86 92.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.52 -39.93 92.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.472 -179.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.72 -44.23 96.86 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.52 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.94 -38.02 89.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.077 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -61.76 -43.74 98.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.717 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -63.02 -41.53 99.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.65 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 30.2 mm -63.61 -42.52 96.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.891 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -77.14 -21.08 74.45 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.4 tp -63.73 -40.79 97.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.807 0.337 . . . . 0.0 110.543 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -55.72 132.76 49.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.447 -179.264 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . 0.409 ' CE1' ' O ' ' A' ' 403' ' ' HIS . 60.9 t-80 -91.46 128.5 37.31 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.571 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . 0.661 ' CG ' ' HZ2' ' C' ' 401' ' ' LYS . 80.2 m80 -74.14 144.68 44.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.452 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -69.54 132.77 46.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.449 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.73 -11.31 59.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.584 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.86 -34.77 90.76 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . 0.69 ' HH ' ' H ' ' C' ' 409' ' ' GLN . 86.4 t80 -82.66 132.14 35.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.599 0.238 . . . . 0.0 110.465 179.645 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 91.3 mt-10 -135.49 147.66 48.94 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.681 0.277 . . . . 0.0 110.694 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.481 ' CD ' ' N ' ' A' ' 409' ' ' GLN . 1.9 pm0 -71.05 134.93 47.47 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.039 179.522 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.9 t80 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.366 -179.915 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 84.4 p . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.381 -0.599 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -67.73 142.25 56.35 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.537 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 371' ' ' ASP . . . . . 0.426 ' N ' ' OD1' ' B' ' 371' ' ' ASP . 33.5 p-10 -88.36 -1.11 57.85 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.348 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -64.0 -38.3 90.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.591 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 373' ' ' ASP . . . . . 0.429 ' OD1' ' O ' ' B' ' 373' ' ' ASP . 64.5 t0 57.37 36.28 26.98 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.438 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -87.71 141.56 28.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.436 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -98.97 2.59 46.54 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.416 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 60.0 tp -62.29 -43.51 98.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.357 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 377' ' ' VAL . . . . . 0.409 ' O ' ' CG1' ' B' ' 377' ' ' VAL . 14.2 p -171.96 61.48 0.31 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.15 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -69.38 148.03 66.63 Favored 'Trans proline' 0 C--N 1.302 -1.885 0 C-N-CA 122.302 2.001 . . . . 0.0 112.001 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 78.8 mt -67.31 -26.49 36.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.045 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -57.85 -20.26 35.03 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.881 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 381' ' ' VAL . . . . . 0.444 ' CG1' ' N ' ' B' ' 382' ' ' GLY . 8.9 p -60.87 -43.48 95.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-O 120.783 0.325 . . . . 0.0 110.371 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 382' ' ' GLY . . . . . 0.444 ' N ' ' CG1' ' B' ' 381' ' ' VAL . . . -64.68 -42.34 97.29 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.404 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.77 88.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.805 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.04 -46.5 89.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.625 -179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -64.09 -41.05 97.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.412 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.95 89.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.46 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.96 -36.34 93.16 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 95.1 t -64.82 -42.23 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-O 121.069 0.462 . . . . 0.0 110.243 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 10.9 mt -62.18 -39.78 93.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.35 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.6 mm -65.16 -41.67 92.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.329 -0.396 . . . . 0.0 109.964 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.52 -41.86 95.26 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.622 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 90.0 t -65.06 -42.7 95.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.874 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.7 mt -62.13 -43.32 99.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 -179.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.74 -42.89 99.89 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.93 85.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.169 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.61 -44.37 96.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.847 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 30.6 m-85 -62.2 -42.47 99.32 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.508 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 398' ' ' ILE . . . . . 0.44 ' O ' ' O ' ' B' ' 401' ' ' LYS . 83.6 mt -63.66 -42.33 95.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.844 179.341 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.89 -45.18 95.42 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 35.1 tp -65.08 -41.55 94.95 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.477 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 401' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 398' ' ' ILE . 99.2 mttt -135.31 135.16 40.58 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.318 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 402' ' ' HIS . . . . . 0.4 ' O ' ' CE1' ' C' ' 404' ' ' HIS . 45.0 t-80 -158.48 104.87 1.84 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.195 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -109.4 121.3 44.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.201 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 404' ' ' HIS . . . . . 0.539 ' O ' ' ND1' ' B' ' 404' ' ' HIS . 33.7 p80 -126.2 124.96 41.63 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.404 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -103.89 -42.04 5.71 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.358 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.64 -40.53 98.71 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 88.9 t80 -78.54 135.97 37.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.628 0.251 . . . . 0.0 110.384 179.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.47 146.74 48.47 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.729 0.299 . . . . 0.0 110.803 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 409' ' ' GLN . . . . . 0.544 ' CD ' ' H ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -53.94 145.99 15.27 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.664 -0.414 . . . . 0.0 109.95 179.641 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.571 -179.859 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 58.0 p . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.15 -38.85 92.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.517 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 55.39 32.25 18.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.435 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 372' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' C' ' 373' ' ' ASP . 42.0 p-10 -64.98 -34.61 78.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.688 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 373' ' ' ASP . . . . . 0.516 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 98.9 m-20 54.97 32.83 18.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.474 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 374' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' C' ' 376' ' ' LEU . 61.5 t-20 -90.42 116.95 28.75 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.616 -179.83 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -61.7 -44.36 97.09 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.814 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 376' ' ' LEU . . . . . 0.422 ' O ' ' OD1' ' C' ' 374' ' ' ASN . 53.2 mt -113.74 131.15 56.3 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.397 -179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 377' ' ' VAL . . . . . 0.489 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 17.7 m -145.7 51.72 1.36 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.3 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 378' ' ' PRO . . . . . 0.489 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 28.9 Cg_endo -63.6 -22.05 70.37 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.706 2.271 . . . . 0.0 112.0 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 379' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' C' ' 381' ' ' VAL . 45.1 mm -64.88 -43.91 96.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.361 -179.336 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.55 -19.9 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.799 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 381' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' C' ' 379' ' ' ILE . 8.1 p -59.57 -43.98 92.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 120.737 0.303 . . . . 0.0 110.294 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 382' ' ' GLY . . . . . 0.432 ' N ' ' CG1' ' C' ' 381' ' ' VAL . . . -63.62 -43.0 98.6 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.47 -38.78 88.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.744 0.307 . . . . 0.0 110.845 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.84 -44.49 96.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.683 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.14 -40.15 94.0 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.413 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.55 -38.86 89.02 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.411 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.42 -38.46 94.92 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.3 t -62.97 -43.51 99.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.738 0.304 . . . . 0.0 110.281 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -60.59 -39.44 88.13 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.089 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.9 mm -64.01 -42.02 94.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.07 -40.58 94.23 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.581 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 83.6 t -61.85 -41.02 89.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.699 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.17 -42.12 98.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.426 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.85 -42.93 99.94 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.618 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.95 82.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.259 179.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -59.78 -44.97 93.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -63.04 -46.74 86.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.623 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.5 mt -64.88 -42.1 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.857 179.444 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -59.4 -32.71 73.38 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 400' ' ' LEU . . . . . 0.453 ' O ' ' O ' ' C' ' 401' ' ' LYS . 50.7 tp -61.69 -42.3 98.74 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.527 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 401' ' ' LYS . . . . . 0.661 ' HZ2' ' CG ' ' A' ' 403' ' ' HIS . 83.9 tttt 56.17 121.53 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.529 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -59.62 -44.33 93.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.475 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -88.98 131.73 35.04 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.507 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 404' ' ' HIS . . . . . 0.4 ' CE1' ' O ' ' B' ' 402' ' ' HIS . 74.9 t60 -70.34 125.75 27.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -100.34 -11.39 20.33 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.56 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.65 -37.7 95.2 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 87.0 t80 -78.41 125.48 29.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.651 0.262 . . . . 0.0 110.395 179.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 70.1 mm-40 -135.63 148.18 48.89 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 120.676 0.274 . . . . 0.0 110.81 179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 409' ' ' GLN . . . . . 0.69 ' H ' ' HH ' ' A' ' 407' ' ' TYR . 48.7 tp60 -75.27 130.84 39.77 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 120.499 -0.48 . . . . 0.0 109.821 179.727 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.614 179.889 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.3 mm . . . . . 0 CA--C 1.529 0.168 0 CA-C-O 120.549 0.214 . . . . 0.0 111.069 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.09 -20.07 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.592 -0.277 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.4 p -59.94 -43.8 93.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.111 0 CA-C-O 120.818 0.342 . . . . 0.0 110.226 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.516 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.03 -36.3 93.28 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.86 -40.91 94.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 0.0 110.615 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.92 -36.31 83.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.467 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.9 tt -61.2 -45.42 94.65 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.135 0.493 . . . . 0.0 110.032 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.16 -36.65 80.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.403 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.03 -36.41 93.42 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.354 -0.699 . . . . 0.0 111.354 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.57 -42.11 92.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.983 0.421 . . . . 0.0 110.185 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 9.9 mt -62.1 -39.05 91.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.582 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.2 mm -63.04 -42.15 95.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -61.0 -41.24 96.13 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.404 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.3 t -65.3 -42.6 94.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.897 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.57 -41.89 98.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.621 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.45 -42.5 99.51 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.572 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.79 -49.22 75.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.818 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.29 -35.17 80.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.337 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.6 t80 -58.61 -45.44 89.16 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.385 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -64.0 -42.52 95.97 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.05 -33.82 88.16 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.6 tp . . . . . 0 C--N 1.328 -0.343 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.396 -179.77 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' B' ' 381' ' ' VAL . 42.9 mm . . . . . 0 CA--C 1.531 0.247 0 CA-C-O 120.474 0.178 . . . . 0.0 111.151 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.15 -19.96 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.661 0.267 . . . . 0.0 110.786 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' B' ' 379' ' ' ILE . 57.7 t -64.06 -43.52 97.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.328 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.72 -38.28 95.42 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.93 -39.99 93.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.769 0.319 . . . . 0.0 110.554 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.25 -35.49 81.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.486 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 385' ' ' LEU . . . . . 0.638 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.0 tt -61.49 -44.6 96.79 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.049 0.452 . . . . 0.0 110.01 -179.577 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.29 -37.51 87.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.424 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.13 -39.68 97.47 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 91.5 t -64.32 -41.97 93.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 389' ' ' LEU . . . . . 0.594 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.8 tt -59.55 -38.72 81.82 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.245 -179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.63 -42.09 94.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.815 0.34 . . . . 0.0 110.221 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.27 -40.72 95.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.692 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 73.6 t -62.98 -41.34 92.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.755 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.21 -41.8 97.48 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.613 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.88 -41.75 98.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.32 -48.6 76.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.876 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -62.83 -35.78 81.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.449 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.48 -44.58 85.01 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.219 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 42.2 mm -65.83 -41.32 89.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.337 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.814 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.8 mt . . . . . 0 CA--C 1.531 0.22 0 CA-C-O 120.435 0.16 . . . . 0.0 111.169 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.7 -19.82 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.831 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.547 ' N ' ' O ' ' C' ' 379' ' ' ILE . 9.1 p -61.13 -43.64 96.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 382' ' ' GLY . . . . . 0.51 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.39 -40.07 98.48 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.85 -39.99 91.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 110.598 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.45 -35.19 80.19 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.623 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.652 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.5 tt -61.18 -44.84 96.65 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.108 0.48 . . . . 0.0 110.005 -179.498 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.36 -36.73 84.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.377 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.71 97.77 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.0 -43.15 98.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.666 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.6 tt -58.91 -37.42 76.59 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.067 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.01 -42.69 96.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.26 -40.14 92.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.433 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.1 t -63.46 -40.66 89.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.664 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.8 mt -61.99 -41.65 98.27 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.709 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.84 -42.35 98.93 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.17 -48.87 75.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.93 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.9 t80 -64.93 -34.56 78.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.435 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -58.81 -44.86 90.9 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.255 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.4 mt -65.04 -42.41 94.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.442 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 -179.78 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.5 mt . . . . . 0 CA--C 1.53 0.209 0 CA-C-O 120.596 0.236 . . . . 0.0 111.134 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.18 -20.25 60.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.851 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.1 t -67.02 -43.54 88.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.116 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.317 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.07 -41.05 99.9 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.16 96.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.462 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.68 -35.95 82.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.529 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.625 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.9 tt -61.38 -44.32 97.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.865 -179.286 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -37.5 87.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.488 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.72 -40.67 98.76 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.81 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.783 0.325 . . . . 0.0 110.225 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.521 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.7 tt -59.74 -38.6 82.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 31.4 mm -64.29 -42.59 95.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 0.0 110.183 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.75 -40.95 96.91 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.584 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 91.1 t -64.17 -41.02 91.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.79 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.34 -40.87 95.84 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.527 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.23 -42.12 98.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.02 -48.19 79.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.827 179.529 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 396' ' ' TYR . . . . . 0.429 ' CD2' HD11 ' A' ' 400' ' ' LEU . 21.5 t80 -66.76 -34.25 77.41 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.258 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -58.35 -45.65 87.78 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.196 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -64.54 -42.62 95.7 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.081 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.69 -33.52 87.47 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 400' ' ' LEU . . . . . 0.429 HD11 ' CD2' ' A' ' 396' ' ' TYR . 8.6 mt . . . . . 0 C--N 1.325 -0.459 0 CA-C-O 120.646 0.26 . . . . 0.0 110.553 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 CA--C 1.533 0.311 0 CA-C-O 120.609 0.242 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -51.49 -20.38 1.85 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.61 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 76.2 t -66.29 -43.11 91.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.38 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.85 -37.84 94.81 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.61 94.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 0.0 110.689 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 384' ' ' ALA . . . . . 0.4 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -63.46 -38.74 92.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.313 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 385' ' ' LEU . . . . . 0.656 HD13 ' O ' ' B' ' 385' ' ' LEU . 1.7 tm? -62.5 -47.64 83.09 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.436 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -37.31 86.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.947 0.404 . . . . 0.0 110.519 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.24 -42.51 99.8 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 388' ' ' VAL . . . . . 0.4 HG23 ' O ' ' B' ' 384' ' ' ALA . 93.6 t -66.54 -42.85 90.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.299 . . . . 0.0 110.76 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.84 -40.44 88.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.282 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.7 mt -65.6 -42.26 92.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.832 0.349 . . . . 0.0 110.221 178.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.6 mt -60.7 -40.92 94.05 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.594 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 78.6 t -62.72 -41.7 93.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.691 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.24 -41.7 97.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.472 -179.402 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.77 -42.27 98.77 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.28 75.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.857 179.602 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -66.01 -35.04 79.49 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.342 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.45 -45.94 84.16 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.331 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.27 -42.45 95.48 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.989 179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.658 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.927 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.529 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt . . . . . 0 CA--C 1.53 0.197 0 CA-C-O 120.608 0.242 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.64 -19.88 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.529 ' N ' ' O ' ' C' ' 379' ' ' ILE . 55.1 t -64.77 -43.52 96.47 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.269 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.68 -36.89 93.92 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.56 -40.8 96.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 110.544 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.19 83.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.467 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.661 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.3 tt -61.38 -45.15 95.57 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.49 -37.11 86.02 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.529 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.5 98.89 Favored Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -63.47 -42.51 96.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.505 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.9 tt -60.1 -38.63 83.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.871 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.0 mm -63.33 -42.52 96.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.899 0.38 . . . . 0.0 110.061 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.0 -40.85 95.12 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.479 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.17 -41.79 93.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.794 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.28 -41.17 96.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.426 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.71 -43.13 99.44 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.547 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.15 90.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.01 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -60.97 -44.94 96.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.668 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -63.58 -43.72 96.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.545 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 31.8 mm -63.9 -42.23 95.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.85 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.547 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.956 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.558 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.532 0.251 0 CA-C-O 120.479 0.18 . . . . 0.0 111.085 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.13 -20.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.959 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.558 ' N ' ' O ' ' A' ' 379' ' ' ILE . 37.2 t -63.82 -43.46 97.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.453 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.63 -41.29 98.82 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.79 82.98 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.773 0.321 . . . . 0.0 110.698 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 384' ' ' ALA . . . . . 0.458 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -59.02 -45.08 91.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.711 -179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.31 -40.82 96.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.393 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.68 88.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.238 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -67.16 -40.88 92.66 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 388' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 384' ' ' ALA . 92.1 t -66.5 -41.88 89.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.106 0.479 . . . . 0.0 110.042 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.552 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.6 tt -58.81 -41.0 85.74 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.778 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.1 mt -66.4 -42.08 89.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.963 0.411 . . . . 0.0 110.073 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.89 -41.59 96.33 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.549 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.09 -41.46 92.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.698 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.35 -41.63 97.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.448 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -61.96 -42.61 99.32 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.28 -0.568 . . . . 0.0 109.476 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.65 -47.89 82.92 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.881 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.37 -36.31 83.3 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.43 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.02 -45.13 79.21 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.16 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -64.45 -42.09 94.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.915 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.06 -32.54 80.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.1 tp . . . . . 0 C--N 1.328 -0.369 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.405 -179.825 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt . . . . . 0 CA--C 1.533 0.301 0 CA-C-O 120.491 0.186 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.91 -20.3 58.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.799 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.1 -43.32 92.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.256 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.86 99.0 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.03 93.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.744 0.307 . . . . 0.0 110.65 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.81 -45.75 91.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.669 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.31 -40.23 93.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.412 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.58 -38.06 88.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.24 -37.97 95.26 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 88.4 t -66.15 -42.89 92.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.569 0.224 . . . . 0.0 110.66 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -58.92 -39.22 80.87 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.835 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.9 mm -63.74 -42.68 96.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.228 179.469 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.6 -40.27 94.21 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.588 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.42 -39.12 83.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.513 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.48 -41.23 96.95 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.502 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -60.69 -42.86 98.0 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.9 -46.91 87.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.859 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -62.41 -34.49 76.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.347 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -59.46 -44.99 92.87 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.467 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 38.2 mm -68.2 -41.6 84.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.032 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.585 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.957 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 CA--C 1.533 0.29 0 CA-C-O 120.574 0.226 . . . . 0.0 111.349 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.721 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -67.19 -43.43 88.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.33 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.24 -39.36 97.8 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -40.61 97.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.865 0.364 . . . . 0.0 110.489 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 384' ' ' ALA . . . . . 0.401 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -65.21 -35.79 82.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.506 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.624 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.3 tt -61.07 -45.13 96.02 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-O 121.053 0.454 . . . . 0.0 110.008 -179.371 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.96 -37.33 87.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.649 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.96 -39.6 98.27 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 388' ' ' VAL . . . . . 0.401 HG23 ' O ' ' C' ' 384' ' ' ALA . 88.5 t -63.83 -42.68 96.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 110.272 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.6 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.5 tt -60.08 -38.61 83.42 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.996 -179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -63.5 -42.46 96.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.899 0.381 . . . . 0.0 110.117 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 9.7 mt -61.54 -40.4 94.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.479 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.0 t -63.26 -40.57 89.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.6 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.91 -41.77 96.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.338 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.03 -44.0 97.63 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.613 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.89 83.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.179 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -59.67 -44.45 93.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.662 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -62.97 -45.15 93.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.616 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -63.94 -42.52 96.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.816 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.595 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.817 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 72.7 mt . . . . . 0 C--O 1.232 0.173 0 CA-C-O 120.67 0.271 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -53.33 -20.38 4.31 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.599 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -67.89 -43.66 85.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.623 0.249 . . . . 0.0 110.472 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -67.39 -43.95 86.04 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.87 -39.87 87.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.751 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 384' ' ' ALA . . . . . 0.43 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -64.13 -43.6 94.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.728 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -66.12 -41.43 90.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.49 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.54 93.61 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.48 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.75 -43.45 98.93 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 388' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 384' ' ' ALA . 94.8 t -67.41 -42.0 86.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.723 0.297 . . . . 0.0 110.851 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tp -59.59 -40.87 88.89 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.073 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.07 -42.76 95.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.85 0.357 . . . . 0.0 110.23 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -61.89 -42.74 99.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.831 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.2 t -65.55 -41.97 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.84 -41.18 97.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.559 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -61.49 -44.06 97.76 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -62.28 -47.45 84.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.972 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.13 -35.72 79.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.224 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -57.92 -45.91 85.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.307 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.66 -41.15 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.162 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.53 -27.37 60.98 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.4 tp . . . . . 0 C--N 1.327 -0.386 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.397 179.958 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.5 mt . . . . . 0 CA--C 1.53 0.21 0 CA-C-O 120.661 0.267 . . . . 0.0 110.817 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.93 -20.0 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.613 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.459 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.2 t -64.15 -43.3 97.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.14 -40.49 99.22 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.64 -37.42 86.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.803 0.335 . . . . 0.0 110.673 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.7 91.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.787 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -64.92 -41.78 95.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.49 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.92 89.19 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.465 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.98 99.52 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 85.5 t -66.92 -43.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.903 0.382 . . . . 0.0 110.189 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 389' ' ' LEU . . . . . 0.547 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.8 tt -59.63 -41.26 90.06 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.503 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.3 mt -65.68 -42.11 91.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.98 0.419 . . . . 0.0 110.194 179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -60.04 -41.27 91.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.563 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 82.4 t -64.43 -41.43 92.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.68 -42.2 98.6 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.48 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.13 -42.4 99.2 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.05 -49.26 76.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.799 179.639 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -64.38 -35.45 80.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.36 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -57.37 -45.57 84.29 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.322 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 5.2 mm -63.93 -42.4 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.074 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.69 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 179.675 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.529 0.141 0 CA-C-O 120.781 0.324 . . . . 0.0 110.808 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.94 -19.88 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.737 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.4 p -59.68 -42.84 89.85 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 CA-C-O 120.615 0.245 . . . . 0.0 110.419 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 382' ' ' GLY . . . . . 0.5 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.81 -39.79 97.77 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.22 -40.9 97.65 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.886 0.374 . . . . 0.0 110.542 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.47 -35.9 82.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.546 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.666 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.19 -44.33 97.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.876 -179.441 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.4 90.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.605 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.73 -41.63 99.63 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 91.2 t -67.08 -42.48 88.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.629 0.252 . . . . 0.0 110.453 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.538 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.6 tt -59.69 -41.43 90.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.156 -179.001 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.7 mt -64.45 -42.45 95.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.857 0.36 . . . . 0.0 110.28 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.01 -41.2 96.07 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 -179.722 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.1 -40.68 89.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.59 -40.32 94.36 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.326 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.8 -42.84 99.52 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -49.18 77.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.933 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -63.93 -34.8 78.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.392 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.89 -45.31 82.67 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.16 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 84.8 mt -64.7 -42.27 94.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.068 178.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.679 0 N-CA-C 111.014 -0.835 . . . . 0.0 111.014 -179.994 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.525 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 120.553 0.216 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.97 -20.01 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.936 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.4 p -61.04 -43.12 95.51 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 120.679 0.276 . . . . 0.0 110.392 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.514 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.68 -38.92 96.95 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.92 -41.06 95.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.703 0.287 . . . . 0.0 110.563 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.66 -35.71 81.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.518 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.1 tt -61.14 -44.35 97.46 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.024 0.44 . . . . 0.0 109.963 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.35 86.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.408 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.74 97.9 Favored Glycine 0 CA--C 1.531 1.066 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.3 t -63.52 -42.17 95.25 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.706 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -59.73 -37.53 79.17 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.467 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.0 mm -64.6 -42.22 94.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.884 0.374 . . . . 0.0 110.072 179.266 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.14 -40.02 92.24 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.602 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.7 t -62.69 -41.1 91.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.784 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.15 -40.93 95.71 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.444 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.88 -41.84 98.36 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.548 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.82 -48.84 77.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.766 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -64.09 -35.88 82.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.424 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -57.47 -45.52 84.71 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.392 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.74 -42.46 96.04 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.88 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.88 -35.47 92.05 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.1 tp . . . . . 0 C--N 1.329 -0.297 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.614 -179.825 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.497 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.0 mt . . . . . 0 CA--C 1.53 0.197 0 CA-C-O 120.665 0.269 . . . . 0.0 111.309 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.51 -20.21 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.808 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.0 t -64.68 -44.06 96.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.435 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.25 -40.83 96.89 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.04 85.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.738 0.304 . . . . 0.0 110.655 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.45 -45.77 92.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.659 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.91 -42.3 94.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.509 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.81 -37.26 87.02 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.48 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.63 -40.6 99.36 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -67.14 -42.72 88.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.485 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.6 tt -59.36 -40.56 86.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.486 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.2 mt -65.72 -42.21 92.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.829 0.347 . . . . 0.0 110.188 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.25 -40.58 94.57 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.632 -179.364 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.7 t -62.4 -41.15 90.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.783 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.17 -41.16 96.28 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.471 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -42.85 99.36 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.978 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -64.37 -37.27 86.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.346 179.499 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -58.22 -45.41 87.75 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.0 mt -63.35 -41.96 94.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.567 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 179.904 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 CA--C 1.531 0.247 0 CA-C-O 120.618 0.247 . . . . 0.0 111.182 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.55 -20.22 60.69 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.995 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.64 -43.5 90.33 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.394 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.04 -39.24 97.04 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.06 -41.69 98.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.814 0.34 . . . . 0.0 110.545 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.3 83.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.467 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.632 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.0 tt -61.59 -45.23 95.01 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.136 0.493 . . . . 0.0 110.051 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.17 -36.76 85.11 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.45 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.07 -42.26 98.37 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 62.7 t -67.43 -42.61 87.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.787 0.327 . . . . 0.0 110.429 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.509 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.3 tt -61.02 -41.54 96.75 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.182 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.0 mt -64.38 -41.95 93.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.241 178.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -60.49 -41.44 94.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.683 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 78.7 t -64.71 -41.4 92.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.735 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.8 mt -61.7 -41.58 97.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.611 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.84 -42.83 99.51 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.368 -0.533 . . . . 0.0 109.687 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.59 93.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.841 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -63.75 -39.29 93.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.553 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -56.61 -45.36 81.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.337 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.7 mm -66.71 -40.83 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.895 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.572 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.861 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 CA--C 1.534 0.357 0 CA-C-O 120.534 0.206 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -74.52 -20.3 60.03 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.644 0.259 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.32 -43.68 87.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.79 0.329 . . . . 0.0 110.397 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.05 -42.96 99.48 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.876 -0.889 . . . . 0.0 110.876 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.79 -39.49 93.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.747 0.308 . . . . 0.0 110.777 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.4 -44.37 97.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.7 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.62 -41.63 92.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.53 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.72 -40.25 91.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.377 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.36 -42.83 99.04 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.43 -42.5 87.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.825 0.345 . . . . 0.0 110.567 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.26 -41.11 88.07 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.406 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 84.5 mt -65.4 -42.55 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 CA-C-O 120.934 0.397 . . . . 0.0 110.326 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 13.0 mt -60.7 -40.0 90.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.51 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.4 t -63.02 -41.34 92.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.721 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -60.96 -40.84 94.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.494 -179.494 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.51 -42.53 98.94 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.424 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.31 -47.91 82.19 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.829 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.2 t80 -63.92 -34.83 78.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.512 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -57.22 -45.56 83.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.291 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 29.8 mm -64.73 -42.61 95.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.75 -34.01 88.75 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.0 tp . . . . . 0 C--N 1.328 -0.365 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.571 -179.827 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 45.5 mm . . . . . 0 CA--C 1.532 0.285 0 CA-C-O 120.467 0.175 . . . . 0.0 111.391 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.79 -20.31 61.88 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.759 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -66.98 -43.59 89.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 CA-C-O 120.811 0.339 . . . . 0.0 110.21 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.61 -40.78 96.15 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.23 -39.22 92.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.83 0.348 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 384' ' ' ALA . . . . . 0.438 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -63.83 -45.11 91.08 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.585 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -66.57 -41.41 88.62 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.558 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.67 -38.29 90.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.26 -39.16 96.8 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 388' ' ' VAL . . . . . 0.438 HG23 ' O ' ' B' ' 384' ' ' ALA . 96.0 t -66.71 -41.76 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.15 0.5 . . . . 0.0 110.103 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -58.62 -40.22 82.72 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.857 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.59 -42.07 86.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.142 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.1 mt -61.09 -41.89 97.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.721 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.52 -41.46 92.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.714 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.29 -40.83 95.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.611 -179.419 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.42 -42.45 98.77 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.459 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.49 -49.79 76.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.866 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -63.89 -34.29 77.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.357 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -58.32 -44.67 88.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.269 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 398' ' ' ILE . . . . . 0.409 HD13 ' HA ' ' B' ' 398' ' ' ILE . 30.8 mm -64.64 -42.64 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.855 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.382 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.865 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.502 ' O ' ' N ' ' C' ' 381' ' ' VAL . 94.6 mt . . . . . 0 CA--C 1.533 0.29 0 CA-C-O 120.429 0.157 . . . . 0.0 111.167 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.11 -19.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.829 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.533 HG13 ' N ' ' C' ' 382' ' ' GLY . 7.9 p -58.97 -44.34 90.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 382' ' ' GLY . . . . . 0.533 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.46 -39.11 97.35 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.5 -41.47 98.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 384' ' ' ALA . . . . . 0.414 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -65.56 -35.39 80.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.359 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.632 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.45 -44.28 97.39 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.111 0.482 . . . . 0.0 110.086 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.63 -37.4 87.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.519 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.76 -41.71 97.48 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 388' ' ' VAL . . . . . 0.414 HG23 ' O ' ' C' ' 384' ' ' ALA . 97.9 t -65.75 -41.55 90.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.898 0.38 . . . . 0.0 110.28 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 tt -58.39 -41.7 85.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.618 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 80.7 mt -65.85 -42.44 92.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.857 0.36 . . . . 0.0 110.393 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -60.88 -39.43 89.22 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.547 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 61.9 t -62.23 -41.7 92.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.675 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -60.92 -41.44 96.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.399 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.45 -44.46 96.36 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 120.09 -0.644 . . . . 0.0 109.648 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.35 -36.54 84.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.108 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -59.52 -43.65 93.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.604 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -63.87 -41.0 97.85 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.562 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 83.2 mt -63.53 -42.39 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.778 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.565 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.581 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.538 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.5 mt . . . . . 0 CA--C 1.531 0.244 0 CA-C-O 120.546 0.212 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.07 -20.0 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.871 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.3 p -60.82 -42.53 92.76 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 120.717 0.294 . . . . 0.0 110.362 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.496 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -61.81 -39.25 97.23 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.77 -40.89 94.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.819 0.342 . . . . 0.0 110.581 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.77 -35.69 81.89 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.474 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.653 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.5 tt -61.59 -44.38 97.12 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 121.057 0.456 . . . . 0.0 110.002 -179.629 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.81 -36.53 83.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.445 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.8 -37.38 94.76 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.2 t -67.53 -42.08 86.53 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-O 121.076 0.465 . . . . 0.0 109.943 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -59.18 -41.7 89.09 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.778 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -66.72 -42.0 88.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.178 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.35 -41.26 93.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.613 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.3 t -64.29 -40.94 90.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.63 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.3 mt -61.6 -40.35 94.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.515 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -62.04 -43.76 98.15 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.31 -0.556 . . . . 0.0 109.581 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.55 -36.77 84.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.018 179.34 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -60.69 -44.22 96.79 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.657 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -62.32 -43.47 98.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.658 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 86.6 mt -63.83 -42.7 96.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.799 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.06 -38.18 93.79 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.0 tp . . . . . 0 C--N 1.328 -0.349 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.438 -179.803 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt . . . . . 0 CA--C 1.531 0.221 0 CA-C-O 120.425 0.155 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.71 -19.93 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.897 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.537 ' N ' ' O ' ' B' ' 379' ' ' ILE . 7.8 p -60.97 -40.96 87.25 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-O 120.773 0.321 . . . . 0.0 110.265 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 382' ' ' GLY . . . . . 0.447 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -62.75 -38.57 96.7 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.537 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.27 -40.4 93.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.802 0.334 . . . . 0.0 110.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -35.46 81.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.503 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 385' ' ' LEU . . . . . 0.656 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.1 tt -61.12 -45.32 95.18 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.065 0.459 . . . . 0.0 110.004 -179.575 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.26 -35.88 82.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.422 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.86 -40.6 98.5 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -66.55 -42.3 89.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.85 0.357 . . . . 0.0 110.276 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 389' ' ' LEU . . . . . 0.542 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.9 tt -60.1 -41.36 92.35 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.419 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -65.73 -41.98 91.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.78 0.324 . . . . 0.0 110.156 179.013 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -60.06 -41.4 92.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.626 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.3 t -63.77 -41.62 93.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.754 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.11 -41.27 96.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.477 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.48 -43.56 98.65 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 120.276 -0.569 . . . . 0.0 109.573 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.3 -36.98 84.34 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.144 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -60.48 -44.09 96.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.647 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -62.94 -41.81 99.61 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.605 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.8 mt -63.09 -42.55 97.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.742 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.541 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.839 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 95.0 mt . . . . . 0 N--CA 1.464 0.256 0 CA-C-O 120.662 0.268 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.19 -20.15 60.95 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.899 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -64.3 -43.21 97.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.245 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.94 -41.97 99.7 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.98 -37.58 88.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.757 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 384' ' ' ALA . . . . . 0.405 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -60.16 -44.77 94.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.45 -40.4 93.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.424 179.335 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.47 91.31 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.46 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.99 -41.37 97.34 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 388' ' ' VAL . . . . . 0.405 HG23 ' O ' ' C' ' 384' ' ' ALA . 88.9 t -64.56 -42.87 96.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-O 120.77 0.319 . . . . 0.0 110.296 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.587 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.4 tt -60.29 -39.06 85.54 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.897 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 6.5 mm -63.41 -42.27 95.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.07 -40.82 95.13 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.651 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.1 t -62.61 -41.9 93.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.69 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.37 -42.28 98.44 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.67 -42.4 99.6 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.16 -48.57 73.55 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.0 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -63.97 -34.86 78.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.547 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -58.17 -44.33 87.93 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.366 -179.336 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.4 mm -65.52 -41.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.797 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.486 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -179.828 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.377 0.132 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.16 -20.23 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.347 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.832 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' A' ' 379' ' ' ILE . 45.4 t -65.6 -43.98 93.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.515 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.32 -37.39 94.44 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.8 -42.28 98.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.77 0.319 . . . . 0.0 110.471 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.57 -37.17 85.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.568 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.656 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.3 tt -61.53 -44.17 97.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.419 . . . . 0.0 109.976 -179.443 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.94 -37.08 85.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.592 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.84 -39.96 97.57 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.0 t -64.0 -43.39 97.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.756 0.312 . . . . 0.0 110.541 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.591 HD23 ' O ' ' A' ' 389' ' ' LEU . 5.0 tt -60.6 -39.31 87.66 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 7.7 mm -63.75 -42.54 96.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.12 -40.36 93.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.351 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.5 t -63.99 -41.41 92.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.758 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.42 97.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.441 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.68 -41.56 97.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.49 -48.93 73.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.808 179.511 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.67 -35.34 80.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.31 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.1 t80 -58.34 -46.11 86.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.388 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.1 mt -64.45 -42.56 95.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.225 179.407 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.99 -32.65 84.88 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.2 tp . . . . . 0 C--N 1.329 -0.303 0 C-N-CA 120.925 -0.31 . . . . 0.0 110.383 -179.529 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.8 mt . . . . . 0 CA--C 1.531 0.218 0 CA-C-O 120.46 0.171 . . . . 0.0 110.782 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.61 -19.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.583 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.8 t -63.9 -43.65 97.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 C-N-CA 120.941 -0.304 . . . . 0.0 110.377 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.48 -43.02 98.78 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.89 87.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.758 0.313 . . . . 0.0 110.697 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 384' ' ' ALA . . . . . 0.421 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -61.26 -44.85 96.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.698 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.26 -40.68 94.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.416 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.8 -37.41 84.3 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.376 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -39.21 96.01 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 388' ' ' VAL . . . . . 0.421 HG23 ' O ' ' B' ' 384' ' ' ALA . 88.0 t -63.87 -42.12 94.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 11.9 mt -62.75 -42.03 99.49 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.807 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.6 mt -66.79 -40.62 86.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.942 0.401 . . . . 0.0 110.067 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -59.15 -41.97 89.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.472 -179.4 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.04 -42.08 93.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.814 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.55 -41.6 97.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.454 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.82 -44.02 97.69 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.308 -0.557 . . . . 0.0 109.646 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.27 -36.61 83.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.143 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.22 -44.29 95.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.527 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -62.99 -44.45 95.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.405 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.27 -42.69 97.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.21 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.636 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.856 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.2 mt . . . . . 0 CA--C 1.532 0.274 0 CA-C-O 120.441 0.162 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.41 -19.94 60.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 121.044 -0.262 . . . . 0.0 110.846 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.5 t -66.26 -43.16 91.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.084 0 CA-C-O 120.761 0.315 . . . . 0.0 110.484 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.38 -36.65 93.68 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.59 -41.0 98.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.424 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.13 83.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.658 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.8 tt -61.3 -43.74 98.37 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.32 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.45 -36.92 85.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.591 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.97 -39.99 97.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.52 -42.72 96.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.5 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.509 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.9 tt -60.5 -39.22 86.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.914 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.98 -42.32 95.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.0 -41.8 97.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.589 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -63.91 -41.27 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.14 -41.37 96.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.559 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.4 -44.41 97.19 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.418 -0.513 . . . . 0.0 109.663 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.78 84.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.189 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -60.33 -43.97 95.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.477 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -64.56 -45.56 86.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.365 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -64.54 -42.15 94.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.371 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.608 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.505 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 46.7 mm . . . . . 0 CA--C 1.527 0.093 0 CA-C-O 120.599 0.238 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.17 -20.18 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 120.518 0.199 . . . . 0.0 110.791 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.0 p -60.78 -42.03 90.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.462 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -60.28 -43.16 98.82 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.57 -37.49 85.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.752 0.31 . . . . 0.0 110.738 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 384' ' ' ALA . . . . . 0.409 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -60.64 -43.52 97.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.694 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.41 -41.38 93.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.395 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.49 -39.06 89.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.174 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.48 -41.04 96.52 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 388' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 384' ' ' ALA . 91.0 t -67.34 -42.04 87.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.845 0.355 . . . . 0.0 110.245 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.532 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.6 tt -59.61 -41.74 91.08 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.41 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.9 mt -65.58 -42.11 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-O 120.931 0.396 . . . . 0.0 110.231 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.51 -40.89 96.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.601 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.6 t -64.18 -41.38 92.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.45 -41.55 97.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.434 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.92 -42.58 99.26 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.458 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.64 -47.0 77.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.804 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -64.19 -35.23 80.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.514 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -57.7 -46.22 84.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.396 -179.202 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 92.1 mt -64.66 -42.43 95.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.49 -33.05 86.2 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.5 tp . . . . . 0 C--N 1.328 -0.364 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.437 -179.496 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.532 0.285 0 CA-C-O 120.72 0.295 . . . . 0.0 111.099 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.25 -20.26 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.618 -0.264 . . . . 0.0 111.007 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' B' ' 379' ' ' ILE . 10.6 p -59.36 -42.77 88.51 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 382' ' ' GLY . . . . . 0.495 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -63.14 -40.23 98.9 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -67.95 -35.84 79.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.716 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 384' ' ' ALA . . . . . 0.402 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -60.16 -44.04 95.32 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.683 -179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.51 -40.45 93.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.42 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.17 -37.86 88.71 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.526 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.33 -39.6 97.99 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 388' ' ' VAL . . . . . 0.402 HG23 ' O ' ' B' ' 384' ' ' ALA . 99.3 t -67.94 -42.13 85.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.675 0.274 . . . . 0.0 110.4 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -60.0 -40.86 90.68 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.209 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.8 mt -64.93 -42.26 94.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.913 0.387 . . . . 0.0 110.366 179.209 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.35 -40.03 89.28 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.516 -179.231 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 68.9 t -62.06 -41.25 90.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.652 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.48 -41.03 93.36 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.433 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.79 -43.99 97.41 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.646 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.48 86.44 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.118 179.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.49 -44.34 96.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.888 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -62.24 -44.48 96.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.692 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.0 mt -63.27 -42.35 96.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.616 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.496 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.887 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.445 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt . . . . . 0 CA--C 1.533 0.292 0 CA-C-O 120.657 0.265 . . . . 0.0 111.117 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -44.43 -19.87 0.03 OUTLIER 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.8 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.445 ' N ' ' O ' ' C' ' 379' ' ' ILE . 61.3 t -64.28 -43.15 97.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.196 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.13 -42.06 99.67 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.19 85.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.756 0.313 . . . . 0.0 110.777 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.31 -44.96 95.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.796 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.2 -42.08 93.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.547 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.47 87.74 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.514 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.51 99.82 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 80.1 t -66.43 -42.09 89.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 0.0 110.336 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -60.74 -40.93 94.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.518 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 84.9 mt -66.47 -42.06 89.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.935 0.397 . . . . 0.0 110.275 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.3 -40.97 87.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.517 -179.12 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 72.5 t -63.11 -42.06 95.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.726 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.9 -41.59 96.36 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.588 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.11 -42.52 99.3 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.565 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.44 -48.01 75.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.099 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 93.9 t80 -63.36 -36.34 83.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.664 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -57.7 -44.56 85.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.492 -179.217 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 39.7 mm -66.75 -40.45 86.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.779 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.797 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 CA--C 1.532 0.258 0 CA-C-O 120.542 0.211 . . . . 0.0 110.981 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.05 -20.03 61.06 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.872 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.4 t -66.4 -43.55 91.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.072 0 CA-C-O 120.633 0.254 . . . . 0.0 110.359 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.15 -40.97 97.19 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.98 -39.2 90.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.742 0.306 . . . . 0.0 110.77 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.35 -44.68 96.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.651 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.2 mt -65.2 -40.6 94.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.386 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.77 -37.26 86.71 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.44 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.65 -39.72 97.84 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.03 -42.24 95.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.62 -38.09 80.38 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.353 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.99 -42.76 95.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.396 . . . . 0.0 110.093 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.9 mt -61.61 -42.18 98.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.58 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.7 t -66.07 -41.94 90.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.89 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.73 -41.13 97.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.463 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.48 -44.1 97.69 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.347 -0.541 . . . . 0.0 109.688 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.42 -37.37 86.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.98 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -61.89 -44.78 96.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.696 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -62.94 -45.37 92.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.49 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.9 mt -64.26 -42.58 95.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.062 179.319 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.42 -42.8 95.73 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.6 tp . . . . . 0 C--N 1.327 -0.385 0 CA-C-O 120.781 0.324 . . . . 0.0 110.534 -179.919 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 CA--C 1.532 0.258 0 CA-C-O 120.485 0.183 . . . . 0.0 111.049 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -72.2 -20.44 61.57 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.742 -0.208 . . . . 0.0 110.652 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 60.3 t -66.89 -43.39 89.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.658 0.266 . . . . 0.0 110.414 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.1 -39.55 98.13 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.04 -41.61 96.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.86 -35.38 80.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.511 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 385' ' ' LEU . . . . . 0.65 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.0 tt -61.41 -44.29 97.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.295 -0.412 . . . . 0.0 109.92 -179.418 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.98 -36.91 85.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.567 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.45 -39.48 97.35 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.67 -42.36 94.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.922 0.392 . . . . 0.0 110.191 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 389' ' ' LEU . . . . . 0.581 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.3 tt -59.63 -38.32 81.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.263 -179.68 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.11 -42.16 94.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.853 0.359 . . . . 0.0 110.207 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.09 -41.03 95.9 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.625 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 86.3 t -63.5 -41.07 91.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.665 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.31 -41.44 96.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.503 -179.446 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.74 -42.7 99.31 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.89 75.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.833 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -65.0 -35.59 81.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.431 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.9 t80 -57.53 -45.94 84.45 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.273 -179.314 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.04 -42.3 95.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.128 179.404 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.643 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.914 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.2 mt . . . . . 0 CA--C 1.53 0.186 0 CA-C-O 120.578 0.227 . . . . 0.0 110.718 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.63 -19.79 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.766 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.3 p -60.88 -43.06 94.9 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.62 0.248 . . . . 0.0 110.474 -179.73 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 382' ' ' GLY . . . . . 0.511 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -62.51 -45.53 95.68 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.53 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.2 85.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.79 0.329 . . . . 0.0 110.719 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.22 -43.66 98.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.654 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.82 -41.14 92.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.485 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.38 94.21 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.452 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.81 -41.11 98.96 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -66.0 -42.73 92.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 110.645 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.595 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.8 tt -59.59 -41.39 90.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.088 -179.082 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.0 mt -65.43 -42.08 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.9 0.381 . . . . 0.0 110.367 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.7 mt -60.45 -40.86 92.66 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.534 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.06 -41.41 92.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.685 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.09 -41.43 96.65 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.487 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.74 -41.94 98.31 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.87 -48.93 74.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.763 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -63.69 -36.27 83.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.483 179.173 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -57.64 -45.32 85.61 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.269 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.57 -42.29 95.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.094 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.678 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.639 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.467 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.528 0.112 0 CA-C-O 120.593 0.235 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.87 -19.62 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.545 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.467 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.2 t -64.83 -43.4 96.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.446 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.78 -36.72 93.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.66 -40.86 98.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.408 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.63 -36.47 83.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.633 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.653 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.0 tt -61.42 -44.04 97.82 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.992 0.425 . . . . 0.0 109.925 -179.441 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.82 -37.06 85.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.447 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.56 -39.32 97.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.2 t -65.99 -42.0 90.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.115 0.483 . . . . 0.0 110.243 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -59.55 -41.01 89.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.595 -179.207 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.8 mt -67.75 -41.63 85.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.053 0.454 . . . . 0.0 110.387 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.03 -41.23 91.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.636 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.8 t -64.3 -41.81 93.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.796 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.39 -41.52 97.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.497 -179.398 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.72 -42.08 98.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.1 -48.52 75.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.537 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -64.89 -36.5 84.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.373 179.176 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -57.26 -45.65 83.81 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.182 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -63.7 -42.59 96.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.63 -37.17 94.33 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 43.7 tp . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 120.812 0.339 . . . . 0.0 110.553 -179.92 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt . . . . . 0 CA--C 1.528 0.121 0 CA-C-O 120.534 0.207 . . . . 0.0 110.914 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.13 -19.77 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 121.013 -0.275 . . . . 0.0 110.651 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.521 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.2 t -64.31 -43.71 97.19 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.41 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.69 -38.43 96.21 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.15 -41.14 97.99 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.912 0.387 . . . . 0.0 110.404 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.55 -36.24 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.511 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 385' ' ' LEU . . . . . 0.643 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.6 tt -61.5 -44.43 97.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.02 0.438 . . . . 0.0 110.021 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.81 82.76 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.392 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.15 -37.72 95.37 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.68 -41.99 93.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.991 0.424 . . . . 0.0 110.075 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 389' ' ' LEU . . . . . 0.579 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.1 tt -60.57 -38.1 83.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.224 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.87 -42.12 94.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.822 0.344 . . . . 0.0 110.201 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.86 -40.38 92.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.471 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 92.9 t -63.86 -40.92 90.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.822 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.32 -41.15 96.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.394 -179.487 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.46 -42.18 98.37 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.21 -46.19 89.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.772 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -63.62 -37.68 88.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.357 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.52 -45.96 84.39 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.243 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -63.52 -42.4 96.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.194 179.328 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.618 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -179.79 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 37.9 mm . . . . . 0 CA--C 1.529 0.149 0 CA-C-O 120.628 0.251 . . . . 0.0 110.777 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -80.17 -19.73 46.47 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.528 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 52.4 t -65.4 -43.37 94.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.292 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.62 -41.62 99.61 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -38.07 88.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.743 0.306 . . . . 0.0 110.643 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.16 -43.91 96.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.674 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -66.0 -40.7 91.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.497 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.95 91.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.549 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.05 -39.35 97.14 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.8 t -64.06 -42.52 95.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 0.0 110.457 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.647 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.5 tt -60.26 -38.37 83.3 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.772 -179.496 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.03 -42.48 95.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-O 120.846 0.355 . . . . 0.0 110.052 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.18 -40.41 93.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.436 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.6 -41.08 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.742 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.27 -41.27 96.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.435 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.5 -42.24 98.5 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -47.96 81.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.916 -0.583 . . . . 0.0 109.832 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -63.12 -35.82 81.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.217 179.406 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -59.1 -45.26 91.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.321 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.1 mt -63.15 -42.5 96.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.244 179.445 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.685 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.862 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.8 mm . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.696 0.284 . . . . 0.0 111.57 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.4 -20.26 62.95 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.804 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.37 -42.32 90.35 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.992 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.52 -40.17 98.33 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.15 -38.21 90.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.74 0.305 . . . . 0.0 110.743 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.7 -45.7 91.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.671 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.28 -41.57 94.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.511 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.35 -38.17 90.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.293 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.6 -41.79 99.77 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.7 t -67.11 -42.36 88.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.823 0.344 . . . . 0.0 110.159 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.626 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -60.0 -40.8 90.44 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.3 -179.021 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.7 mt -66.42 -41.75 89.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.959 0.409 . . . . 0.0 110.351 178.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.54 -40.55 91.95 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.579 -179.292 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.4 t -64.33 -41.15 91.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.752 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.93 -41.57 98.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.537 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.41 -42.49 99.48 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.242 -0.583 . . . . 0.0 109.476 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.09 -48.95 72.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.981 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -64.13 -35.79 81.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.422 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -57.38 -45.8 84.07 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.282 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.2 mt -64.89 -42.43 94.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.48 -33.69 87.92 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.8 tp . . . . . 0 C--N 1.327 -0.387 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.411 -179.572 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.507 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.9 mt . . . . . 0 CA--C 1.529 0.169 0 CA-C-O 120.786 0.327 . . . . 0.0 111.315 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.14 -20.1 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.752 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.507 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.38 -43.9 94.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 120.904 0.383 . . . . 0.0 110.178 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.73 -35.77 91.42 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.23 -41.86 98.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.861 0.363 . . . . 0.0 110.662 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.4 84.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.45 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 385' ' ' LEU . . . . . 0.646 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.3 tt -61.23 -44.47 97.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.922 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.23 83.65 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.548 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.74 -41.09 97.37 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 62.1 t -67.24 -43.35 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.668 0.27 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.29 -40.37 93.91 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 119.536 -0.866 . . . . 0.0 109.771 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 79.2 mt -64.04 -42.4 95.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 120.872 0.368 . . . . 0.0 110.572 178.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.08 -41.4 96.59 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.588 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.6 t -65.94 -42.33 91.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.076 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.67 -40.47 95.08 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.4 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.18 -42.94 99.75 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.588 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.74 -36.82 84.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.157 179.395 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -60.36 -44.38 95.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.601 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.0 -43.79 98.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.61 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 91.2 mt -63.55 -42.61 96.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.717 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.494 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.862 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.0 mt . . . . . 0 CA--C 1.531 0.212 0 CA-C-O 120.77 0.319 . . . . 0.0 111.234 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.42 -20.02 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.816 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.9 p -61.82 -42.72 95.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.704 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 382' ' ' GLY . . . . . 0.486 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -64.46 -42.15 97.69 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.19 86.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.86 0.362 . . . . 0.0 110.787 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.56 -45.34 94.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.676 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -64.5 -40.43 95.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.433 179.413 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.93 -37.26 87.05 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.466 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.95 -40.2 97.02 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.98 -43.27 96.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.926 0.394 . . . . 0.0 110.318 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.8 -38.59 88.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.17 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.86 -42.09 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.9 mt -61.41 -41.68 97.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.573 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 90.2 t -65.73 -42.24 92.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.51 -41.82 97.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.625 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -62.27 -43.55 98.56 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.66 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.58 -36.42 82.59 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -61.12 -44.96 96.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.805 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -62.47 -43.69 98.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.645 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.4 mt -64.92 -42.69 95.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.882 179.472 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.376 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 180.0 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt . . . . . 0 C--O 1.233 0.216 0 CA-C-O 120.566 0.222 . . . . 0.0 110.847 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.87 -20.48 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.657 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' A' ' 379' ' ' ILE . 43.6 t -67.97 -43.62 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.413 179.144 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 379' ' ' ILE . . . -64.96 -38.15 95.13 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.94 98.46 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.713 0.292 . . . . 0.0 110.743 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.76 -48.07 82.35 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.92 0.391 . . . . 0.0 110.565 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.6 -40.95 93.22 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.37 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.51 -39.14 89.91 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.232 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.56 -37.57 94.97 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -63.74 -43.14 97.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.989 0.423 . . . . 0.0 110.243 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.4 mp -61.89 -38.0 86.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.345 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 28.9 mm -63.13 -42.13 95.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -61.16 -42.47 98.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.569 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.3 t -65.62 -42.17 92.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.983 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.94 -40.62 96.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.596 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -60.88 -41.89 96.89 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.95 -49.47 73.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.877 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -65.72 -35.41 80.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.329 179.163 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -58.0 -45.8 86.26 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.308 -179.415 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.04 -42.94 97.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.231 179.2 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.84 -41.83 98.66 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.4 tp . . . . . 0 C--N 1.327 -0.375 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.302 -179.981 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.2 mt . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.57 0.224 . . . . 0.0 110.797 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -39.93 -20.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.665 -179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.4 t -67.23 -43.8 88.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 CA-C-O 120.659 0.266 . . . . 0.0 110.567 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 382' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' B' ' 379' ' ' ILE . . . -65.26 -37.74 94.32 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.1 -38.53 91.54 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.327 . . . . 0.0 110.66 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.28 -48.05 79.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.848 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.54 -41.6 92.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.429 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.84 -36.98 85.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.327 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.62 -40.09 98.26 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 77.9 t -63.2 -43.46 98.81 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.975 0.417 . . . . 0.0 110.244 179.736 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.2 -38.01 87.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.361 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.77 -42.15 95.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.4 mt -60.84 -42.63 98.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.557 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.62 -42.31 92.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.56 -41.4 97.33 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.374 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.97 -42.44 99.13 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 120.288 -0.565 . . . . 0.0 109.546 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.59 -38.16 86.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.017 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -62.13 -44.8 95.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.477 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -68.43 -45.54 72.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.866 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.11 -42.03 94.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.068 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.612 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.941 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt . . . . . 0 CA--C 1.531 0.225 0 CA-C-O 120.651 0.262 . . . . 0.0 111.085 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -58.44 -24.65 60.76 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.653 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 56.0 t -68.86 -43.55 82.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.094 0 CA-C-O 120.73 0.3 . . . . 0.0 110.585 179.339 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.17 -36.17 92.9 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.58 -40.15 95.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.718 0.294 . . . . 0.0 110.751 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 384' ' ' ALA . . . . . 0.402 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -60.82 -48.59 81.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.8 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.97 -40.86 95.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.47 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.11 -37.74 86.27 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.422 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.11 -38.01 94.81 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 388' ' ' VAL . . . . . 0.402 HG23 ' O ' ' C' ' 384' ' ' ALA . 98.3 t -65.03 -43.17 96.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 120.75 0.309 . . . . 0.0 110.539 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 mp -61.36 -39.39 90.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.042 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.12 -42.42 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.073 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -61.11 -41.76 97.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.529 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.6 t -65.43 -41.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.53 -40.44 94.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.439 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.42 -42.06 98.15 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.47 76.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.725 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -64.59 -35.88 82.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.373 179.209 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -57.67 -45.12 85.99 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.275 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.8 mt -63.81 -42.65 96.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.117 179.286 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.603 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.673 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 381' ' ' VAL . 94.9 mt . . . . . 0 CA--C 1.53 0.205 0 CA-C-O 120.535 0.207 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.48 -19.81 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.962 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.526 ' N ' ' O ' ' A' ' 379' ' ' ILE . 7.8 p -60.53 -43.65 94.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.749 0.309 . . . . 0.0 110.41 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.52 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -64.81 -36.45 93.12 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -41.3 98.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.738 0.304 . . . . 0.0 110.669 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.36 -36.24 83.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.612 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.623 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.4 tt -61.65 -45.31 94.58 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.056 0.455 . . . . 0.0 110.106 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -37.7 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.5 -42.44 97.64 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.2 t -67.12 -42.49 88.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.738 0.304 . . . . 0.0 110.627 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.57 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.9 tt -59.97 -40.99 90.99 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.223 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -65.33 -42.17 93.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.872 0.368 . . . . 0.0 110.234 179.09 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.85 -41.14 95.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.685 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.1 t -63.88 -41.49 92.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.682 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.34 -41.02 96.36 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.598 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.46 -41.8 97.79 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.295 -0.562 . . . . 0.0 109.545 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.54 -49.63 74.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.882 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -65.01 -34.88 79.5 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.365 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -58.21 -45.56 87.43 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.351 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.3 mt -63.63 -42.74 97.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.34 -38.53 95.97 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.9 tp . . . . . 0 C--N 1.327 -0.391 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.434 -179.905 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.496 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.532 0.284 0 CA-C-O 120.658 0.266 . . . . 0.0 111.044 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.62 -20.06 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.682 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.496 ' N ' ' O ' ' B' ' 379' ' ' ILE . 62.2 t -65.17 -43.11 95.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.361 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.19 -39.63 98.15 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -40.48 96.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.513 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.49 -35.48 81.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.512 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 385' ' ' LEU . . . . . 0.653 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.8 tt -61.41 -44.05 97.81 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 121.1 0.476 . . . . 0.0 109.988 -179.679 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -37.05 85.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.421 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.11 -39.97 96.52 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.96 -43.2 92.85 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.938 0.399 . . . . 0.0 110.218 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -60.36 -40.67 91.63 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.806 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 80.1 mt -67.33 -41.37 86.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.146 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -60.12 -40.93 91.44 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.696 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 75.7 t -63.84 -41.38 92.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.666 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.27 -41.29 96.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.521 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.4 -42.82 99.33 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.558 179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.25 -47.9 74.76 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.836 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 85.0 t80 -64.36 -34.7 78.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.448 179.371 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -58.57 -44.87 89.91 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.41 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 42.3 mm -65.09 -40.99 90.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.83 179.467 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.619 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.869 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.6 mm . . . . . 0 CA--C 1.53 0.191 0 CA-C-O 120.631 0.253 . . . . 0.0 111.352 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.95 -20.08 61.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.005 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 54.5 t -65.9 -43.71 92.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 CA-C-O 120.744 0.307 . . . . 0.0 110.344 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.72 -41.86 99.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.04 -36.98 86.09 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.792 0.329 . . . . 0.0 110.713 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.43 -46.04 89.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.672 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -64.7 -41.05 96.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.416 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.23 -37.51 85.67 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.397 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.26 -36.41 92.76 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.4 t -64.23 -43.59 97.29 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-O 120.746 0.307 . . . . 0.0 110.458 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 mp -61.63 -39.02 89.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.222 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.24 -41.94 93.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 8.4 mt -60.76 -42.51 97.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.729 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 82.0 t -65.15 -42.44 94.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.834 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.98 -42.73 99.46 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.731 -179.431 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.08 -43.81 98.03 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.04 -36.86 84.39 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.087 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -61.53 -44.59 96.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.67 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -62.73 -45.34 93.17 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.566 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 87.7 mt -64.55 -42.67 95.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.867 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.564 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -179.78 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 44.2 mm . . . . . 0 CA--C 1.531 0.249 0 CA-C-O 120.634 0.254 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.07 -20.51 63.22 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.784 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.3 t -66.8 -42.98 90.03 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.372 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.24 -37.68 94.94 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.24 96.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.871 0.367 . . . . 0.0 110.439 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.8 -36.11 82.83 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.416 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.616 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.7 tt -62.17 -44.1 97.35 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.085 0.469 . . . . 0.0 110.018 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.03 -37.07 81.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.594 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.82 -39.07 96.99 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 95.5 t -63.63 -42.07 94.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.217 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.56 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.9 tt -60.7 -37.81 82.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.511 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.8 mm -64.4 -41.79 93.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.97 0.414 . . . . 0.0 110.196 179.4 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.4 mt -60.75 -40.94 94.31 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.53 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.8 t -64.26 -40.8 90.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.45 -40.78 95.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.407 -179.5 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.03 -41.54 96.76 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.41 -48.35 74.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.756 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.7 t80 -65.57 -35.61 81.35 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.602 -0.727 . . . . 0.0 110.488 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -56.78 -45.69 81.98 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.381 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.01 -42.27 94.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.137 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.63 -33.24 84.33 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.5 tp . . . . . 0 C--N 1.328 -0.348 0 C-N-CA 120.801 -0.359 . . . . 0.0 110.469 -179.824 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt . . . . . 0 CA--C 1.53 0.203 0 CA-C-O 120.516 0.198 . . . . 0.0 111.267 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -74.62 -19.99 60.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.763 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.09 -43.19 88.94 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.21 -40.62 97.53 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.63 -37.87 89.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.743 0.306 . . . . 0.0 110.659 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.88 -46.63 88.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.602 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.68 -41.87 91.95 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.539 179.5 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -39.05 93.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.433 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.8 -42.85 99.66 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 89.5 t -66.51 -43.17 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 121.168 -0.213 . . . . 0.0 111.02 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 389' ' ' LEU . . . . . 0.56 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.0 tt -60.64 -41.27 94.6 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.349 -0.541 . . . . 0.0 109.739 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -63.87 -42.23 95.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 0.0 110.319 178.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.8 -40.09 91.35 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.507 -179.69 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.8 t -63.95 -41.86 93.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.97 -40.8 94.78 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.238 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.45 -43.42 98.91 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.132 -0.627 . . . . 0.0 109.502 179.771 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.16 -37.11 86.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.125 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -61.62 -44.86 96.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.621 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 36.5 m-85 -63.43 -41.67 98.68 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.578 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.3 mm -63.76 -42.16 95.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.013 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.688 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.857 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.1 mm . . . . . 0 CA--C 1.53 0.206 0 CA-C-O 120.54 0.21 . . . . 0.0 111.137 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.86 -20.34 62.54 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.783 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 63.5 t -67.5 -43.2 87.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.87 -38.49 96.19 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.46 95.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.734 0.302 . . . . 0.0 110.731 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.29 88.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.772 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -64.98 -41.93 94.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.417 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.7 -36.46 83.92 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.346 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.8 -42.21 99.72 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 94.2 t -64.0 -42.96 97.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.885 0.374 . . . . 0.0 110.242 179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.585 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.1 tt -60.89 -37.99 84.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.832 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.8 mm -63.4 -42.59 96.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.138 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.42 -40.4 94.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.414 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 91.0 t -63.01 -40.8 90.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.666 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.95 -41.24 95.91 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.435 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.48 -43.5 98.75 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.524 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.5 -37.39 84.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -60.17 -43.96 95.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -62.65 -45.22 93.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.492 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.9 -42.87 97.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.976 179.415 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.541 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.779 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.4 mm . . . . . 0 CA--C 1.528 0.112 0 CA-C-O 120.623 0.249 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.44 -20.1 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.738 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -67.19 -43.45 88.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.442 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.62 93.43 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.11 -41.71 98.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.847 0.356 . . . . 0.0 110.4 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -36.52 83.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.646 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.659 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.2 tt -61.47 -43.9 98.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.42 -37.4 87.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.87 -42.62 99.76 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.56 -42.78 93.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.91 0.386 . . . . 0.0 110.522 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -61.04 -40.94 95.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.493 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.24 -41.7 89.63 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.107 0 CA-C-O 120.896 0.379 . . . . 0.0 110.268 179.009 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.8 -40.84 89.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.557 -179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.9 -41.7 93.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.682 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.12 -41.57 96.95 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.485 -179.486 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.55 -41.93 98.08 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.638 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.81 -48.55 79.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.707 179.377 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -64.43 -35.32 80.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.211 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -57.58 -46.02 84.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.19 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.6 mt -63.77 -42.68 96.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.69 -32.55 84.57 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp . . . . . 0 C--N 1.329 -0.297 0 C-N-CA 121.106 -0.238 . . . . 0.0 110.359 -179.501 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 120.569 0.223 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.22 -20.08 62.3 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.79 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 61.4 t -67.84 -43.21 86.26 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.473 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -37.76 95.02 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.56 -40.67 97.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.395 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.02 -36.04 83.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.583 179.758 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 385' ' ' LEU . . . . . 0.646 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.7 tt -61.52 -44.13 97.61 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.431 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -38.26 90.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.491 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.3 -43.15 99.49 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 90.7 t -67.11 -42.83 88.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.738 0.304 . . . . 0.0 110.715 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 389' ' ' LEU . . . . . 0.509 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.6 tt -59.97 -41.07 91.17 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.021 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 85.4 mt -64.9 -42.16 94.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.829 0.347 . . . . 0.0 110.296 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.7 mt -60.71 -41.49 95.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.603 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 80.0 t -64.05 -40.96 90.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.689 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.47 97.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.384 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 7.2 tt -61.67 -42.09 98.44 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.6 -47.8 78.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.532 . . . . 0.0 109.732 179.423 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.98 -35.99 82.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.392 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -57.34 -45.38 84.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.231 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.3 mm -64.94 -41.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.123 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.759 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.991 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' C' ' 381' ' ' VAL . 95.2 mt . . . . . 0 C--O 1.23 0.061 0 CA-C-O 120.694 0.283 . . . . 0.0 110.626 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.75 -19.6 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.65 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.534 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.8 p -61.72 -38.46 80.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.745 0.307 . . . . 0.0 110.541 -179.492 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 382' ' ' GLY . . . . . 0.446 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -61.37 -40.51 98.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.36 98.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.882 0.372 . . . . 0.0 110.301 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 384' ' ' ALA . . . . . 0.412 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -64.81 -35.81 82.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.5 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.659 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.9 tt -61.41 -43.2 99.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.908 -179.587 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.47 -39.19 92.61 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.517 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.85 -42.18 98.54 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 388' ' ' VAL . . . . . 0.412 HG23 ' O ' ' C' ' 384' ' ' ALA . 86.6 t -66.71 -42.46 89.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.828 0.347 . . . . 0.0 110.769 -179.795 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.5 -40.56 91.83 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.29 -179.374 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.7 mt -66.08 -42.04 90.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 120.903 0.382 . . . . 0.0 110.173 179.055 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.4 -40.91 92.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.594 -179.653 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 70.4 t -63.36 -41.65 93.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.703 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.99 -41.81 97.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.478 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.1 -42.43 99.22 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.62 -48.4 81.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.636 179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -64.06 -35.38 80.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.417 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.34 -46.56 79.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.28 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.57 -42.48 95.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.219 179.305 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.544 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.868 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 96.4 mt . . . . . 0 CA--C 1.532 0.259 0 CA-C-O 120.58 0.228 . . . . 0.0 111.261 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.86 -20.26 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.837 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.39 -43.19 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.262 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.84 -41.61 99.65 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -38.97 93.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.826 0.346 . . . . 0.0 110.719 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.63 -44.91 92.51 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.675 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.64 -40.19 92.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.389 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.3 -40.06 95.03 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.428 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -38.91 96.81 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 79.3 t -64.69 -41.85 93.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.887 0.375 . . . . 0.0 110.188 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.94 -37.8 80.57 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.206 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.74 -42.52 95.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.926 0.394 . . . . 0.0 110.121 179.127 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.51 -42.5 98.89 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.703 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.5 t -65.94 -42.51 92.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -62.04 -42.06 98.77 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.57 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.4 -43.19 99.41 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.635 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.02 -47.53 82.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.918 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -65.57 -34.29 77.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.493 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -56.99 -45.87 82.66 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.322 -179.265 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.48 -42.35 93.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.384 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.36 -31.15 79.78 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.1 tp . . . . . 0 C--N 1.326 -0.438 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.474 -179.594 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 379' ' ' ILE . . . . . 0.468 ' O ' ' N ' ' B' ' 381' ' ' VAL . 45.8 mm . . . . . 0 CA--C 1.53 0.195 0 CA-C-O 120.548 0.213 . . . . 0.0 111.118 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.37 -20.26 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.71 -0.223 . . . . 0.0 110.766 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.468 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.35 -42.97 94.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.266 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -36.12 92.85 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.3 -43.26 99.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.814 0.34 . . . . 0.0 110.587 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.64 -36.77 84.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.436 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 385' ' ' LEU . . . . . 0.651 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.1 tt -62.41 -43.68 98.25 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.938 -179.495 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.7 88.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.491 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.31 -42.1 99.72 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 56.3 t -66.1 -43.98 92.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.895 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -60.88 -41.71 96.54 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.922 -179.242 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 92.7 mt -65.73 -42.2 92.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 CA-C-O 121.003 0.43 . . . . 0.0 110.431 179.063 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -58.42 -41.59 85.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.518 -178.887 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.71 -40.99 90.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.596 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.94 -41.4 96.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.485 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.23 -42.89 99.39 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.94 -48.31 80.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.972 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.06 -35.65 80.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.49 179.369 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -56.59 -44.82 81.45 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.316 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.2 mm -65.7 -41.54 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.544 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.858 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.534 0.349 0 CA-C-O 120.48 0.181 . . . . 0.0 110.991 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.33 -20.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.647 0.26 . . . . 0.0 110.803 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.471 ' N ' ' O ' ' C' ' 379' ' ' ILE . 54.3 t -63.8 -43.76 98.0 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.183 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.68 -39.75 98.31 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.62 -39.9 95.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.868 0.366 . . . . 0.0 110.659 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -66.12 -34.31 77.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.457 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.655 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.87 -45.17 94.92 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.998 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.01 -36.51 84.22 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.2 -40.37 98.47 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 83.9 t -67.27 -42.76 88.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.807 0.337 . . . . 0.0 110.314 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.5 tt -60.46 -41.08 93.41 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.561 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.7 mt -66.04 -42.01 90.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.85 0.357 . . . . 0.0 110.342 178.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.02 -40.05 87.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 74.9 t -63.73 -42.19 95.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.5 -41.16 96.87 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.483 -179.515 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.3 tt -62.28 -43.71 98.21 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.608 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.46 -36.7 84.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.072 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -60.22 -44.53 95.11 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.652 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 27.6 m-85 -62.11 -43.77 98.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.664 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.0 mt -63.23 -41.88 94.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.521 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.512 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.916 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 44.6 mm . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 120.477 0.179 . . . . 0.0 110.744 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.33 -20.02 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.59 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 54.9 t -65.27 -42.9 95.02 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 C-N-CA 121.026 -0.27 . . . . 0.0 110.468 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.13 -40.15 96.79 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.16 -41.99 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.835 0.35 . . . . 0.0 110.579 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.0 -35.66 81.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.57 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.657 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.1 tt -61.3 -43.47 98.83 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.68 -39.78 95.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.886 0.374 . . . . 0.0 110.51 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.15 97.81 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 72.8 t -63.79 -43.31 97.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 O-C-N 122.946 -0.15 . . . . 0.0 111.332 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.22 -37.86 81.59 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.336 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -62.94 -42.34 96.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 178.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.5 mt -60.86 -39.85 90.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.392 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.2 t -61.09 -40.72 86.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.468 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.99 -41.6 96.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.323 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.79 -44.2 97.33 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.335 -0.546 . . . . 0.0 109.73 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.22 -36.73 83.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.002 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -60.09 -44.79 94.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.685 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -62.42 -44.9 95.33 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.331 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.45 -42.86 97.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.05 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.09 -33.08 84.34 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 43.9 tp . . . . . 0 C--N 1.331 -0.223 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.502 -179.659 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 CA--C 1.531 0.218 0 CA-C-O 120.51 0.195 . . . . 0.0 111.008 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.96 -20.11 61.79 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.987 -0.285 . . . . 0.0 110.828 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 52.9 t -67.06 -43.12 89.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.419 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.29 -41.57 99.73 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.54 84.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.729 0.3 . . . . 0.0 110.65 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.17 -43.85 98.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.721 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.49 -40.96 93.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.291 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.14 -37.83 88.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -38.97 97.12 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 84.6 t -64.3 -42.12 94.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.108 0.48 . . . . 0.0 110.167 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.2 tp -60.38 -38.08 82.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.247 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -63.5 -42.53 96.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -61.6 -42.07 98.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.495 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 88.5 t -66.03 -42.19 91.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.985 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.67 -41.2 97.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.405 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.66 -43.07 99.55 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.99 -47.82 83.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.695 179.341 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -63.9 -35.81 81.87 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.25 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.86 -45.55 82.37 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.084 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.72 -42.6 96.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.222 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.635 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.945 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt . . . . . 0 CA--C 1.531 0.23 0 CA-C-O 120.508 0.194 . . . . 0.0 111.04 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.03 -20.16 59.72 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 121.053 -0.259 . . . . 0.0 110.736 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.28 -43.38 91.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 121.001 -0.28 . . . . 0.0 110.557 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.59 -37.62 95.04 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.68 -41.03 98.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.857 0.36 . . . . 0.0 110.564 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.79 -35.56 81.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.459 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.658 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.6 tt -61.68 -43.62 98.5 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.896 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.12 -38.7 92.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.674 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -40.2 98.72 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.52 -42.65 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.509 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.534 ' O ' HD23 ' C' ' 389' ' ' LEU . 5.1 tt -59.71 -39.07 83.4 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.823 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.38 -42.38 95.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.829 0.347 . . . . 0.0 110.141 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.34 -41.07 96.45 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.414 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.21 -41.52 92.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.717 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.67 -41.99 98.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.542 -179.586 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.04 -41.96 98.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.67 -49.28 77.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.627 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -64.83 -35.01 79.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.229 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.98 -45.66 86.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.349 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.1 mt -63.55 -42.72 97.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.733 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.989 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.474 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.8 mt . . . . . 0 CA--C 1.528 0.109 0 CA-C-O 120.546 0.212 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.57 -19.63 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.654 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.533 HG13 ' N ' ' A' ' 382' ' ' GLY . 9.2 p -59.15 -44.26 91.32 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-O 120.682 0.277 . . . . 0.0 110.806 -179.34 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.533 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.2 -41.35 99.66 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.718 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.11 98.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.842 0.353 . . . . 0.0 110.284 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 384' ' ' ALA . . . . . 0.435 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -66.42 -35.93 81.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.722 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.641 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.6 tt -60.53 -44.52 95.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.931 -179.208 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.11 93.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.421 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.41 -42.91 97.44 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 388' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 384' ' ' ALA . 91.6 t -65.6 -43.19 94.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.223 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.55 -39.88 89.54 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.448 -0.501 . . . . 0.0 110.114 -179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.9 -42.05 93.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.81 0.338 . . . . 0.0 110.11 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.87 -40.65 93.78 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.664 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.9 t -62.2 -41.18 90.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.725 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.1 mt -61.09 -41.31 96.42 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.421 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.64 -43.21 99.28 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.8 82.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.25 179.086 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 396' ' ' TYR . . . . . 0.418 ' CZ ' ' CD1' ' A' ' 400' ' ' LEU . 92.6 t80 -60.3 -44.52 95.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.5 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -63.89 -46.56 84.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.417 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.5 mt -64.43 -42.1 94.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.377 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -53.14 -57.2 15.69 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 400' ' ' LEU . . . . . 0.418 ' CD1' ' CZ ' ' A' ' 396' ' ' TYR . 8.7 mt . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 110.432 179.403 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.2 mt . . . . . 0 CA--C 1.529 0.153 0 CA-C-O 120.583 0.23 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.47 -20.06 60.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.626 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.2 -43.39 88.39 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-O 120.72 0.295 . . . . 0.0 110.461 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.86 -41.59 99.84 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.16 89.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.855 0.36 . . . . 0.0 110.67 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.79 -44.14 96.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.71 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -65.71 -39.6 91.37 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.338 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.96 -38.79 89.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.398 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.09 -42.57 99.5 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 87.4 t -66.88 -42.66 89.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.651 0.263 . . . . 0.0 111.081 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 389' ' ' LEU . . . . . 0.598 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.3 tt -60.08 -41.53 92.64 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.076 -179.348 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 87.8 mt -64.31 -42.25 94.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.897 0.379 . . . . 0.0 110.26 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.97 -41.28 96.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.564 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.7 t -63.69 -41.09 91.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.738 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.12 -40.94 95.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.421 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -41.59 97.25 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.75 80.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.652 179.348 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.11 -36.01 82.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.668 -0.697 . . . . 0.0 110.338 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -56.86 -45.87 82.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.165 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.0 mt -63.88 -42.62 96.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.308 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.633 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.95 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.5 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.51 0.195 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.59 -19.64 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' C' ' 379' ' ' ILE . 51.1 t -63.47 -43.87 98.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.85 -36.1 92.86 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.78 -40.71 96.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.791 0.329 . . . . 0.0 110.301 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -36.88 85.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.373 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 385' ' ' LEU . . . . . 0.643 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.0 tt -61.57 -44.48 96.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.903 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -36.98 85.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.539 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.16 -38.38 95.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 85.2 t -65.76 -42.62 92.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.879 0.371 . . . . 0.0 110.528 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 389' ' ' LEU . . . . . 0.555 ' O ' HD23 ' C' ' 389' ' ' LEU . 5.3 tt -61.1 -38.92 88.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.019 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.85 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.169 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.14 -40.97 95.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.64 -40.91 90.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.649 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.68 -41.6 97.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.591 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.56 -42.62 99.12 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.57 -49.14 78.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.74 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.71 -34.74 78.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.273 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -58.05 -45.56 86.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.151 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.3 mt -63.44 -42.4 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.1 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.643 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.779 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 379' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.9 mm . . . . . 0 CA--C 1.528 0.134 0 CA-C-O 120.652 0.263 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.1 -20.25 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.708 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.506 ' N ' ' O ' ' A' ' 379' ' ' ILE . 55.7 t -65.27 -43.51 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.335 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -66.27 -40.78 94.86 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.3 -38.96 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.763 0.316 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 384' ' ' ALA . . . . . 0.43 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -62.37 -44.86 95.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.33 -40.17 89.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.405 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.81 -37.68 88.3 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.555 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.28 -39.93 97.46 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 388' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 384' ' ' ALA . 80.5 t -66.24 -42.86 91.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.912 0.387 . . . . 0.0 110.596 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.3 mt -62.15 -41.85 98.68 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.413 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.4 mt -64.11 -41.9 93.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.35 -42.61 96.07 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.698 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.1 t -65.34 -41.86 92.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.52 -39.93 92.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.472 -179.381 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.72 -44.23 96.86 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.52 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.94 -38.02 89.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.077 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -61.76 -43.74 98.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.717 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -63.02 -41.53 99.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.65 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 398' ' ' ILE . . . . . 0.423 HD13 ' HA ' ' A' ' 398' ' ' ILE . 30.2 mm -63.61 -42.52 96.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.891 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -77.14 -21.08 74.45 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.4 tp . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 120.807 0.337 . . . . 0.0 110.543 -179.836 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 78.8 mt . . . . . 0 CA--C 1.531 0.229 0 CA-C-O 120.576 0.227 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -57.85 -20.26 35.03 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.881 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 381' ' ' VAL . . . . . 0.501 HG13 ' N ' ' B' ' 382' ' ' GLY . 8.9 p -60.87 -43.48 95.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-O 120.783 0.325 . . . . 0.0 110.371 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 382' ' ' GLY . . . . . 0.501 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -64.68 -42.34 97.29 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.404 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.77 88.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.805 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 384' ' ' ALA . . . . . 0.415 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -60.04 -46.5 89.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.625 -179.797 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -64.09 -41.05 97.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.412 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.95 89.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.46 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.96 -36.34 93.16 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 388' ' ' VAL . . . . . 0.415 HG23 ' O ' ' B' ' 384' ' ' ALA . 95.1 t -64.82 -42.23 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-O 121.069 0.462 . . . . 0.0 110.243 179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 10.9 mt -62.18 -39.78 93.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.35 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.6 mm -65.16 -41.67 92.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.329 -0.396 . . . . 0.0 109.964 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.52 -41.86 95.26 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.622 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 90.0 t -65.06 -42.7 95.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.874 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.7 mt -62.13 -43.32 99.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 -179.549 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.74 -42.89 99.89 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.93 85.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.169 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.61 -44.37 96.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.847 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 30.6 m-85 -62.2 -42.47 99.32 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.508 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 83.6 mt -63.66 -42.33 95.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.844 179.341 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.576 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 -179.554 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' C' C ' 379' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' C' ' 381' ' ' VAL . 45.1 mm . . . . . 0 N--CA 1.462 0.154 0 CA-C-O 120.593 0.235 . . . . 0.0 111.361 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.55 -19.9 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.799 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 381' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' C' ' 379' ' ' ILE . 8.1 p -59.57 -43.98 92.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 120.737 0.303 . . . . 0.0 110.294 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 382' ' ' GLY . . . . . 0.519 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.62 -43.0 98.6 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.47 -38.78 88.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.744 0.307 . . . . 0.0 110.845 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.84 -44.49 96.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.683 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.14 -40.15 94.0 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.413 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.55 -38.86 89.02 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.411 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.42 -38.46 94.92 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.3 t -62.97 -43.51 99.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.738 0.304 . . . . 0.0 110.281 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -60.59 -39.44 88.13 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.089 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.9 mm -64.01 -42.02 94.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.134 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.07 -40.58 94.23 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.581 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 83.6 t -61.85 -41.02 89.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.699 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.17 -42.12 98.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.426 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.85 -42.93 99.94 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.618 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.95 82.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.259 179.459 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -59.78 -44.97 93.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -63.04 -46.74 86.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.623 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.5 mt -64.88 -42.1 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.857 179.444 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.447 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.557 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 44.9 m . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -68.62 143.5 54.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.62 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 55.34 35.59 25.29 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.572 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.429 ' O ' ' OD1' ' A' ' 372' ' ' ASP . 64.6 t0 -62.23 -36.26 81.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.446 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -62.34 -42.39 99.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.434 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 376' ' ' LEU . 57.8 t-20 -85.01 109.88 18.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.55 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -62.77 -40.84 98.53 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.669 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.609 HD12 ' N ' ' A' ' 376' ' ' LEU . 9.6 mp -88.66 130.99 35.18 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.308 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.518 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 18.6 m -153.08 50.25 0.58 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.244 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.518 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 30.1 Cg_endo -63.89 142.14 80.84 Favored 'Trans proline' 0 N--CA 1.497 1.678 0 C-N-CA 122.764 2.31 . . . . 0.0 111.894 179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.3 mm -65.99 -43.2 92.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.069 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.09 -20.07 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.592 -0.277 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.4 p -59.94 -43.8 93.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.111 0 CA-C-O 120.818 0.342 . . . . 0.0 110.226 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.516 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.03 -36.3 93.28 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.86 -40.91 94.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 0.0 110.615 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.92 -36.31 83.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.467 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.9 tt -61.2 -45.42 94.65 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.135 0.493 . . . . 0.0 110.032 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.16 -36.65 80.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.403 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.03 -36.41 93.42 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.354 -0.699 . . . . 0.0 111.354 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.57 -42.11 92.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.983 0.421 . . . . 0.0 110.185 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 9.9 mt -62.1 -39.05 91.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.582 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.2 mm -63.04 -42.15 95.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -61.0 -41.24 96.13 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.404 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.3 t -65.3 -42.6 94.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.897 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.57 -41.89 98.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.621 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.45 -42.5 99.51 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.572 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.79 -49.22 75.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.818 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.29 -35.17 80.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.337 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.6 t80 -58.61 -45.44 89.16 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.385 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -64.0 -42.52 95.97 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.05 -33.82 88.16 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.495 ' O ' ' CE1' ' A' ' 403' ' ' HIS . 56.6 tp -62.35 -40.76 97.47 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.396 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 57.35 10.88 1.0 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.609 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 402' ' ' HIS . . . . . 0.419 ' H ' ' HG ' ' A' ' 400' ' ' LEU . 83.3 t60 43.59 82.76 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.662 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 403' ' ' HIS . . . . . 0.495 ' CE1' ' O ' ' A' ' 400' ' ' LEU . 78.4 m80 -77.61 135.47 38.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.429 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -82.35 134.23 35.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.549 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.92 -11.61 60.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.505 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.01 -37.59 95.21 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -111.6 136.94 50.12 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 408' ' ' GLU . . . . . 0.526 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.5 mp0 -102.16 127.33 49.13 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 110.218 -0.29 . . . . 0.0 110.218 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -52.63 145.25 12.24 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.574 -179.93 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 14.2 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -161.28 154.21 20.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.431 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -139.6 101.08 4.13 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.404 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 51.5 t0 56.63 47.08 19.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.715 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 373' ' ' ASP . . . . . 0.412 ' O ' ' OD1' ' B' ' 373' ' ' ASP . 64.2 t0 -62.22 -38.87 90.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.389 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -83.09 109.72 17.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.458 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -60.3 -43.2 96.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.479 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 376' ' ' LEU . . . . . 0.555 ' N ' HD12 ' B' ' 376' ' ' LEU . 10.6 mp -98.33 126.81 43.98 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.024 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.538 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 16.1 m -146.17 49.29 0.85 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.233 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 378' ' ' PRO . . . . . 0.538 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 24.8 Cg_endo -61.79 145.77 97.02 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 122.917 2.411 . . . . 0.0 111.986 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' B' ' 381' ' ' VAL . 42.9 mm -69.34 -26.73 32.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.151 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.15 -19.96 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.661 0.267 . . . . 0.0 110.786 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' B' ' 379' ' ' ILE . 57.7 t -64.06 -43.52 97.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.328 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.72 -38.28 95.42 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.93 -39.99 93.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.769 0.319 . . . . 0.0 110.554 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.25 -35.49 81.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.486 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 385' ' ' LEU . . . . . 0.638 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.0 tt -61.49 -44.6 96.79 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.049 0.452 . . . . 0.0 110.01 -179.577 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.29 -37.51 87.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.424 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.13 -39.68 97.47 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 91.5 t -64.32 -41.97 93.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 389' ' ' LEU . . . . . 0.594 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.8 tt -59.55 -38.72 81.82 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.245 -179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.63 -42.09 94.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.815 0.34 . . . . 0.0 110.221 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.27 -40.72 95.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.692 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 73.6 t -62.98 -41.34 92.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.755 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.21 -41.8 97.48 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.613 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.88 -41.75 98.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.32 -48.6 76.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.876 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -62.83 -35.78 81.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.449 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.48 -44.58 85.01 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.219 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 42.2 mm -65.83 -41.32 89.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.337 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.2 -37.34 94.73 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 57.0 tp -62.84 -41.3 99.29 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.386 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 64.2 tttp 57.76 113.01 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.558 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -72.42 133.99 45.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.475 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -75.98 128.45 35.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.31 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -74.88 135.54 41.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.436 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.02 -11.3 59.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.598 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.91 -35.22 91.73 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -107.79 134.95 50.01 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 408' ' ' GLU . . . . . 0.527 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 56.0 mp0 -105.13 125.33 50.86 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 23.7 mm100 -128.52 129.28 45.8 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.885 0.374 . . . . 0.0 110.063 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 410' ' ' PHE . . . . . 0.477 ' CD2' ' O ' ' B' ' 410' ' ' PHE . 91.7 t80 . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.51 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 83.5 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.54 -38.93 91.04 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.45 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 371' ' ' ASP . . . . . 0.407 ' O ' ' OD1' ' C' ' 371' ' ' ASP . 38.2 p-10 -93.84 109.25 20.95 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.352 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -66.43 143.66 56.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.582 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -62.16 -41.48 98.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.631 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 57.99 35.38 25.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.604 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 91.3 t80 -60.75 -46.24 91.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.64 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 57.5 tp -82.92 126.09 32.1 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.49 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 60.8 t 44.12 73.34 0.97 Allowed Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.509 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.528 ' O ' HG12 ' C' ' 381' ' ' VAL . 48.5 Cg_endo -74.0 -13.91 23.77 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.491 2.127 . . . . 0.0 112.141 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.8 mt -62.91 -43.24 98.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.169 -178.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.7 -19.82 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.831 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.547 ' N ' ' O ' ' C' ' 379' ' ' ILE . 9.1 p -61.13 -43.64 96.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 382' ' ' GLY . . . . . 0.51 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.39 -40.07 98.48 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.85 -39.99 91.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 110.598 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.45 -35.19 80.19 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.623 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.652 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.5 tt -61.18 -44.84 96.65 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.108 0.48 . . . . 0.0 110.005 -179.498 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.36 -36.73 84.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.377 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.71 97.77 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.0 -43.15 98.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.666 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.6 tt -58.91 -37.42 76.59 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.067 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.01 -42.69 96.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.26 -40.14 92.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.433 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.1 t -63.46 -40.66 89.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.664 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.8 mt -61.99 -41.65 98.27 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.709 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.84 -42.35 98.93 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.17 -48.87 75.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.93 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.9 t80 -64.93 -34.56 78.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.435 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -58.81 -44.86 90.9 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.255 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.4 mt -65.04 -42.41 94.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.86 -19.32 69.48 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 44.2 tp -61.65 -40.26 94.27 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.936 -0.306 . . . . 0.0 110.515 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -36.48 151.2 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.917 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 49.47 92.24 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.55 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -77.16 143.68 38.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.346 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -75.12 141.33 43.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.549 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.3 -12.89 60.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.568 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.29 -35.89 92.09 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -85.56 128.49 34.77 Favored 'General case' 0 C--N 1.33 -0.269 0 O-C-N 122.87 -0.194 . . . . 0.0 110.513 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -91.17 117.0 29.26 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.658 0.266 . . . . 0.0 110.313 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.579 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 1.9 pm0 -75.05 137.14 41.26 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.66 179.901 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 44.6 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -153.5 154.58 34.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.442 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -99.76 108.18 20.44 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.42 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 54.3 p-10 -75.31 148.53 39.26 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.74 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.448 ' O ' ' O ' ' A' ' 376' ' ' LEU . 98.9 m-20 -69.3 142.66 54.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.674 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -65.05 -40.81 95.32 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.716 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -61.8 -45.39 94.05 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.966 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.448 ' O ' ' O ' ' A' ' 373' ' ' ASP . 62.7 mt -118.42 126.79 52.81 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.356 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 3.5 m -135.84 150.0 70.35 Favored Pre-proline 0 CA--C 1.532 0.271 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.615 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -65.29 -22.48 60.39 Favored 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.465 2.11 . . . . 0.0 112.055 179.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.95 -44.56 97.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.867 -0.333 . . . . 0.0 111.134 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.18 -20.25 60.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.851 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.1 t -67.02 -43.54 88.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.116 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.317 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.07 -41.05 99.9 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.16 96.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.462 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.68 -35.95 82.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.529 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.625 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.9 tt -61.38 -44.32 97.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.865 -179.286 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -37.5 87.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.488 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.72 -40.67 98.76 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.81 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.783 0.325 . . . . 0.0 110.225 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.521 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.7 tt -59.74 -38.6 82.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 31.4 mm -64.29 -42.59 95.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 0.0 110.183 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.75 -40.95 96.91 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.584 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 91.1 t -64.17 -41.02 91.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.79 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.34 -40.87 95.84 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.527 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.23 -42.12 98.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.02 -48.19 79.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.827 179.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 396' ' ' TYR . . . . . 0.429 ' CD2' HD11 ' A' ' 400' ' ' LEU . 21.5 t80 -66.76 -34.25 77.41 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.258 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -58.35 -45.65 87.78 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.196 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -64.54 -42.62 95.7 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.081 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.69 -33.52 87.47 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.429 HD11 ' CD2' ' A' ' 396' ' ' TYR . 8.6 mt -63.19 -39.86 95.85 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.646 0.26 . . . . 0.0 110.553 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 65.0 mttp 56.96 22.36 7.13 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.492 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 54.6 t-80 43.76 88.84 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.736 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -75.19 136.72 41.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.593 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -81.82 135.97 35.42 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.31 -11.78 59.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.494 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.68 -38.9 96.91 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 83.4 t80 -80.98 132.55 35.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.602 0.239 . . . . 0.0 110.411 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 48.0 tp10 -73.24 121.69 20.74 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.221 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -54.02 142.82 23.76 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.688 -0.405 . . . . 0.0 109.982 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.493 179.523 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 6.0 t . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.72 145.95 51.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.722 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -61.09 -44.02 97.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.378 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -70.76 143.29 51.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.645 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 48.3 t0 56.82 35.42 26.24 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.4 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 48.5 t30 -64.35 -39.75 94.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.575 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -62.53 83.94 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.628 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 54.4 mt -119.49 131.02 55.5 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.62 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.493 HG12 ' H ' ' B' ' 380' ' ' ALA . 5.9 t 47.65 72.2 1.34 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.528 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -55.2 -34.61 88.58 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.744 2.296 . . . . 0.0 111.935 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.84 -43.41 97.84 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.184 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 380' ' ' ALA . . . . . 0.493 ' H ' HG12 ' B' ' 377' ' ' VAL . . . -51.49 -20.38 1.85 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.61 -179.154 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 76.2 t -66.29 -43.11 91.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.38 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.85 -37.84 94.81 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.61 94.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 0.0 110.689 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 384' ' ' ALA . . . . . 0.4 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -63.46 -38.74 92.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.313 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 385' ' ' LEU . . . . . 0.656 HD13 ' O ' ' B' ' 385' ' ' LEU . 1.7 tm? -62.5 -47.64 83.09 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.436 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -37.31 86.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.947 0.404 . . . . 0.0 110.519 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.24 -42.51 99.8 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 388' ' ' VAL . . . . . 0.4 HG23 ' O ' ' B' ' 384' ' ' ALA . 93.6 t -66.54 -42.85 90.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.299 . . . . 0.0 110.76 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.84 -40.44 88.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.282 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.7 mt -65.6 -42.26 92.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.832 0.349 . . . . 0.0 110.221 178.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.6 mt -60.7 -40.92 94.05 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.594 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 78.6 t -62.72 -41.7 93.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.691 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.24 -41.7 97.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.472 -179.402 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.77 -42.27 98.77 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.28 75.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.857 179.602 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -66.01 -35.04 79.49 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.342 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.45 -45.94 84.16 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.331 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.27 -42.45 95.48 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.989 179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.52 -33.76 87.43 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp -62.22 -40.46 96.2 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.471 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 68.7 mttm 57.67 86.35 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.647 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -70.48 131.28 43.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.384 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 54.5 p-80 -68.46 140.55 55.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.575 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -72.41 138.68 47.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.437 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.41 -11.42 59.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.623 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.54 -38.27 96.05 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -81.21 133.46 35.45 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 408' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 54.7 mp0 -105.98 118.76 37.45 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.748 0.309 . . . . 0.0 110.518 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -52.69 145.24 12.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.958 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 410' ' ' PHE . . . . . 0.401 ' OXT' ' CG ' ' B' ' 410' ' ' PHE . 85.1 t80 . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.872 -1.061 . . . . 0.0 110.463 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 41.6 t . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -156.63 150.23 24.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.445 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 46.1 t0 -130.89 97.96 4.48 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.345 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 54.99 30.25 13.79 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.457 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -66.77 141.93 57.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.579 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -83.36 133.47 34.95 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.4 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -102.24 7.92 40.64 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.501 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 61.4 mt -114.89 132.38 56.55 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.584 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.62 ' O ' HG13 ' C' ' 377' ' ' VAL . 7.6 p -156.16 77.42 4.44 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.433 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -60.86 145.13 99.48 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 122.643 2.229 . . . . 0.0 111.926 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.529 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt -63.8 -43.7 97.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.916 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.64 -19.88 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.529 ' N ' ' O ' ' C' ' 379' ' ' ILE . 55.1 t -64.77 -43.52 96.47 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.269 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.68 -36.89 93.92 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.56 -40.8 96.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 110.544 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.19 83.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.467 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.661 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.3 tt -61.38 -45.15 95.57 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.49 -37.11 86.02 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.529 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.5 98.89 Favored Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -63.47 -42.51 96.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.505 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.9 tt -60.1 -38.63 83.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.871 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.0 mm -63.33 -42.52 96.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.899 0.38 . . . . 0.0 110.061 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.0 -40.85 95.12 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.479 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.17 -41.79 93.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.794 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.28 -41.17 96.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.426 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.71 -43.13 99.44 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.547 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.15 90.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.01 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -60.97 -44.94 96.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.668 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -63.58 -43.72 96.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.545 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 31.8 mm -63.9 -42.23 95.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.85 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.46 -36.06 92.61 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 400' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' C' ' 401' ' ' LYS . 55.1 tp -62.74 -41.96 99.44 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.508 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 401' ' ' LYS . . . . . 0.428 ' O ' ' O ' ' C' ' 400' ' ' LEU . 38.8 ttmt 54.81 111.61 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.62 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -66.87 -38.06 85.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.496 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 80.1 t60 -73.8 132.64 42.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.388 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -70.85 138.13 50.0 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.506 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.59 -11.65 59.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.481 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.44 -38.78 96.9 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 83.2 t80 -82.38 136.89 34.88 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 121.164 -0.215 . . . . 0.0 110.422 179.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -85.06 117.56 24.1 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.709 0.29 . . . . 0.0 110.402 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.54 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 0.0 OUTLIER -62.58 140.18 58.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.086 179.717 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 410' ' ' PHE . . . . . 0.416 ' O ' ' O ' ' C' ' 409' ' ' GLN . 93.6 t80 . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.4 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 51.1 m . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.64 -36.98 85.61 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.284 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -84.61 107.15 16.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.207 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 37.1 p-10 -92.48 1.25 57.35 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.519 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.426 ' O ' ' O ' ' A' ' 376' ' ' LEU . 41.9 p-10 -80.8 -1.44 43.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.249 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.59 -42.01 99.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.379 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -62.37 -44.47 96.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.482 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' A' ' 373' ' ' ASP . 6.0 tp -107.57 112.79 25.71 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.36 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.654 ' H ' ' CD ' ' A' ' 378' ' ' PRO . 0.3 OUTLIER -105.77 -40.6 0.17 Allowed Pre-proline 0 N--CA 1.464 0.247 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.314 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.654 ' CD ' ' H ' ' A' ' 377' ' ' VAL . 38.0 Cg_endo -84.8 111.92 1.48 Allowed 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.652 2.235 . . . . 0.0 112.012 -179.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.558 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -65.44 -42.86 94.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.085 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.13 -20.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.959 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.558 ' N ' ' O ' ' A' ' 379' ' ' ILE . 37.2 t -63.82 -43.46 97.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.453 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.63 -41.29 98.82 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.79 82.98 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.773 0.321 . . . . 0.0 110.698 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 384' ' ' ALA . . . . . 0.458 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -59.02 -45.08 91.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.711 -179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.31 -40.82 96.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.393 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.68 88.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.238 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -67.16 -40.88 92.66 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 388' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 384' ' ' ALA . 92.1 t -66.5 -41.88 89.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.106 0.479 . . . . 0.0 110.042 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.552 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.6 tt -58.81 -41.0 85.74 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.778 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.1 mt -66.4 -42.08 89.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.963 0.411 . . . . 0.0 110.073 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.89 -41.59 96.33 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.549 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.09 -41.46 92.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.698 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.35 -41.63 97.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.448 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -61.96 -42.61 99.32 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.28 -0.568 . . . . 0.0 109.476 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.65 -47.89 82.92 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.881 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.37 -36.31 83.3 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.43 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.02 -45.13 79.21 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.16 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -64.45 -42.09 94.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.915 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.06 -32.54 80.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.1 tp -61.84 -40.01 93.83 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.405 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -50.67 133.67 25.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.603 -179.271 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.0 t60 44.61 85.48 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.703 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 62.8 t-80 -79.12 129.05 34.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.506 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 5.2 p-80 -70.0 131.49 44.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.405 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.87 -11.34 59.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.44 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.17 -38.84 97.17 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 407' ' ' TYR . . . . . 0.471 ' CE2' ' O ' ' A' ' 408' ' ' GLU . 81.9 t80 -78.85 135.66 37.1 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.337 -0.246 . . . . 0.0 110.337 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 408' ' ' GLU . . . . . 0.471 ' O ' ' CE2' ' A' ' 407' ' ' TYR . 85.2 tt0 -73.24 117.78 15.39 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.838 -0.345 . . . . 0.0 110.396 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.508 ' OE1' ' N ' ' A' ' 410' ' ' PHE . 4.2 tp-100 -67.59 123.57 20.83 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.699 -0.401 . . . . 0.0 109.968 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 410' ' ' PHE . . . . . 0.508 ' N ' ' OE1' ' A' ' 409' ' ' GLN . 90.3 t80 . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.467 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 95.6 p . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.62 -37.8 88.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.412 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 53.4 t0 58.58 38.42 25.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.41 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -71.19 -19.24 62.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.709 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 55.18 34.44 22.68 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.332 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 374' ' ' ASN . . . . . 0.415 ' ND2' ' O ' ' B' ' 376' ' ' LEU . 67.0 t30 -75.89 147.7 38.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.666 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -60.95 -42.99 99.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.612 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 376' ' ' LEU . . . . . 0.415 ' O ' ' ND2' ' B' ' 374' ' ' ASN . 58.9 mt -116.61 131.09 57.04 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.616 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.655 HG13 ' O ' ' B' ' 377' ' ' VAL . 10.5 p -157.07 75.02 4.36 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.319 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -59.02 -23.75 70.14 Favored 'Trans proline' 0 C--N 1.303 -1.867 0 C-N-CA 122.66 2.24 . . . . 0.0 111.871 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt -62.92 -44.54 99.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.223 -178.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 380' ' ' ALA . . . . . 0.475 ' H ' HG22 ' B' ' 377' ' ' VAL . . . -75.91 -20.3 58.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.799 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.1 -43.32 92.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.256 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.86 99.0 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.03 93.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.744 0.307 . . . . 0.0 110.65 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.81 -45.75 91.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.669 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.31 -40.23 93.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.412 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.58 -38.06 88.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.24 -37.97 95.26 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 88.4 t -66.15 -42.89 92.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.569 0.224 . . . . 0.0 110.66 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -58.92 -39.22 80.87 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.835 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.9 mm -63.74 -42.68 96.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.228 179.469 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.6 -40.27 94.21 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.588 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.42 -39.12 83.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.513 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.48 -41.23 96.95 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.502 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -60.69 -42.86 98.0 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.9 -46.91 87.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.859 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -62.41 -34.49 76.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.347 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -59.46 -44.99 92.87 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.467 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 38.2 mm -68.2 -41.6 84.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.032 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.67 -33.14 86.45 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 49.1 tp -62.28 -41.47 98.51 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.473 -179.667 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 63.8 tttp -89.39 119.91 30.27 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.889 0.376 . . . . 0.0 110.227 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 64.2 t-80 -158.35 142.26 15.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.183 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -106.57 125.87 51.55 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.152 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -105.41 128.17 53.38 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.361 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 405' ' ' ALA . . . . . 0.437 ' O ' ' OE2' ' B' ' 408' ' ' GLU . . . -76.89 -37.38 55.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.566 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.43 -35.15 91.67 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -104.96 136.44 44.44 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.703 0.287 . . . . 0.0 110.42 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 408' ' ' GLU . . . . . 0.521 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 55.2 mp0 -130.91 146.41 52.32 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.165 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 8.5 tp-100 -70.67 130.58 42.15 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.631 -0.428 . . . . 0.0 109.978 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 81.6 t80 . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.422 179.938 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -155.42 153.81 30.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.462 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 54.3 p30 -150.59 175.54 11.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.245 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -89.41 110.78 21.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.502 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 373' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' C' ' 376' ' ' LEU . 98.0 m-20 -64.13 141.36 58.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.693 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -64.26 -40.24 95.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.643 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -60.47 -41.93 95.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.409 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 376' ' ' LEU . . . . . 0.443 ' O ' ' O ' ' C' ' 373' ' ' ASP . 22.9 tp -104.17 120.77 41.85 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.337 -179.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.703 ' O ' HG13 ' C' ' 377' ' ' VAL . 7.1 p -172.8 58.33 0.23 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.353 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -67.18 -19.7 50.43 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 C-N-CA 122.308 2.006 . . . . 0.0 111.965 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.6 mt -63.81 -44.84 98.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 C-N-CA 120.824 -0.35 . . . . 0.0 111.349 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.721 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -67.19 -43.43 88.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.33 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.24 -39.36 97.8 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -40.61 97.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.865 0.364 . . . . 0.0 110.489 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 384' ' ' ALA . . . . . 0.401 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -65.21 -35.79 82.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.506 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.624 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.3 tt -61.07 -45.13 96.02 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-O 121.053 0.454 . . . . 0.0 110.008 -179.371 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.96 -37.33 87.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.649 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.96 -39.6 98.27 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 388' ' ' VAL . . . . . 0.401 HG23 ' O ' ' C' ' 384' ' ' ALA . 88.5 t -63.83 -42.68 96.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 110.272 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.6 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.5 tt -60.08 -38.61 83.42 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.996 -179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -63.5 -42.46 96.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.899 0.381 . . . . 0.0 110.117 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 9.7 mt -61.54 -40.4 94.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.479 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.0 t -63.26 -40.57 89.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.6 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.91 -41.77 96.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.338 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.03 -44.0 97.63 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.613 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.89 83.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.179 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -59.67 -44.45 93.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.662 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -62.97 -45.15 93.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.616 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -63.94 -42.52 96.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.816 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.16 -36.13 92.85 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 47.6 tp -62.45 -42.07 99.2 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.563 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -84.66 100.48 11.48 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.853 0.359 . . . . 0.0 110.654 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -67.96 -37.58 81.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.449 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -98.78 135.51 40.14 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.433 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -73.85 149.55 41.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.604 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.23 -12.26 59.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.514 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.59 -36.32 93.2 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -81.84 131.66 35.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.74 0.305 . . . . 0.0 110.404 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -135.57 146.44 48.0 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.714 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.61 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 0.4 OUTLIER -52.8 146.28 10.86 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.92 179.707 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.427 -179.801 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 84.8 p . . . . . 0 N--CA 1.492 1.65 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.81 -37.43 87.59 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.377 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -98.28 110.95 23.45 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.47 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -63.3 -38.36 90.85 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.705 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -67.32 144.58 55.78 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.63 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 375' ' ' PHE . 58.6 t-20 -60.39 144.9 49.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.501 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 375' ' ' PHE . . . . . 0.472 ' N ' ' OD1' ' A' ' 374' ' ' ASN . 95.7 m-85 -61.77 -43.33 99.07 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.701 -179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 47.0 mt -115.53 132.72 56.54 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.556 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.426 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 3.4 t 60.94 54.99 3.36 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.453 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.426 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 37.8 Cg_endo -66.56 148.24 83.24 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.823 2.349 . . . . 0.0 111.935 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 72.7 mt -67.7 -26.11 34.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.064 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -53.33 -20.38 4.31 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.599 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -67.89 -43.66 85.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.623 0.249 . . . . 0.0 110.472 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -67.39 -43.95 86.04 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.87 -39.87 87.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.751 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 384' ' ' ALA . . . . . 0.43 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -64.13 -43.6 94.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.728 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -66.12 -41.43 90.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.49 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.54 93.61 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.48 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.75 -43.45 98.93 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 388' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 384' ' ' ALA . 94.8 t -67.41 -42.0 86.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.723 0.297 . . . . 0.0 110.851 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tp -59.59 -40.87 88.89 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.073 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.07 -42.76 95.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.85 0.357 . . . . 0.0 110.23 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -61.89 -42.74 99.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.831 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.2 t -65.55 -41.97 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.84 -41.18 97.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.559 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -61.49 -44.06 97.76 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -62.28 -47.45 84.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.972 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.13 -35.72 79.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.224 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -57.92 -45.91 85.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.307 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.66 -41.15 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.162 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.53 -27.37 60.98 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.4 tp -63.18 -39.23 94.05 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.397 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -65.94 148.54 51.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.68 -179.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 53.29 97.1 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.513 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -75.24 139.9 42.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.551 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -72.98 141.01 47.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.488 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.23 -13.6 59.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.554 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.3 -38.89 97.15 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -118.02 140.08 50.27 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -82.67 118.25 23.2 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.152 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 44.9 tp60 -96.68 131.9 42.89 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.837 0.351 . . . . 0.0 110.087 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 87.7 t80 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.452 179.991 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 27.2 t . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -62.15 -41.14 98.0 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.464 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 53.5 p-10 -154.55 172.51 17.7 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.243 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -70.59 144.75 51.11 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.792 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -62.55 -42.16 99.36 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.591 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -83.75 144.53 29.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.356 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -114.76 102.74 10.3 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.466 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 57.2 tp -63.04 -41.86 99.61 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.275 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 2.7 m -129.63 80.46 71.69 Favored Pre-proline 0 N--CA 1.465 0.325 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.219 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -59.25 146.07 95.81 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 C-N-CA 122.818 2.345 . . . . 0.0 111.884 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.5 mt -63.67 -43.6 98.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.817 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.93 -20.0 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.613 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.459 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.2 t -64.15 -43.3 97.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.14 -40.49 99.22 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.64 -37.42 86.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.803 0.335 . . . . 0.0 110.673 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.7 91.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.787 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -64.92 -41.78 95.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.49 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.92 89.19 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.465 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.98 99.52 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 85.5 t -66.92 -43.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.903 0.382 . . . . 0.0 110.189 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 389' ' ' LEU . . . . . 0.547 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.8 tt -59.63 -41.26 90.06 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.503 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.3 mt -65.68 -42.11 91.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.98 0.419 . . . . 0.0 110.194 179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -60.04 -41.27 91.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.563 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 82.4 t -64.43 -41.43 92.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.68 -42.2 98.6 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.48 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.13 -42.4 99.2 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.05 -49.26 76.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.799 179.639 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -64.38 -35.45 80.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.36 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -57.37 -45.57 84.29 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.322 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 5.2 mm -63.93 -42.4 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.074 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.13 -35.11 91.56 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 52.0 tp -62.55 -41.33 98.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.876 0.369 . . . . 0.0 110.391 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 88.5 tttt 55.95 103.73 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.573 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 59.9 t-80 -80.66 129.67 34.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.328 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 63.5 t-80 -84.38 126.37 33.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.534 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -79.5 141.88 36.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.581 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.37 -14.62 59.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.655 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.65 -37.62 95.01 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -78.84 133.87 36.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.538 0.209 . . . . 0.0 110.508 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -83.25 118.21 23.48 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 120.734 0.302 . . . . 0.0 110.376 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.522 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 1.8 pm0 -68.07 134.4 50.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.169 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 93.5 t80 . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.528 179.936 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 369' ' ' SER . . . . . 0.42 ' O ' ' OD1' ' C' ' 372' ' ' ASP . 5.5 t . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.04 -36.92 85.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.326 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 371' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 38.1 p30 -66.63 -24.66 66.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.527 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 99.7 m-20 55.5 35.84 25.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.57 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 39.2 p-10 -86.24 -0.97 57.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.516 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -91.59 0.86 57.46 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.435 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 375' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' C' ' 376' ' ' LEU . 90.1 t80 -60.14 -45.91 91.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.518 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 376' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' C' ' 375' ' ' PHE . 45.5 tp 58.81 145.18 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.642 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.457 HG22 ' H ' ' C' ' 377' ' ' VAL . 2.0 m -71.11 151.01 94.79 Favored Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.644 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.481 ' O ' HG12 ' C' ' 381' ' ' VAL . 36.9 Cg_endo -65.4 146.53 85.73 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.712 2.275 . . . . 0.0 111.874 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt -63.99 -43.87 97.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.808 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.94 -19.88 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.737 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.4 p -59.68 -42.84 89.85 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 CA-C-O 120.615 0.245 . . . . 0.0 110.419 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 382' ' ' GLY . . . . . 0.5 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.81 -39.79 97.77 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.22 -40.9 97.65 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.886 0.374 . . . . 0.0 110.542 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.47 -35.9 82.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.546 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.666 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.19 -44.33 97.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.876 -179.441 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.4 90.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.605 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.73 -41.63 99.63 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 91.2 t -67.08 -42.48 88.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.629 0.252 . . . . 0.0 110.453 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.538 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.6 tt -59.69 -41.43 90.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.156 -179.001 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.7 mt -64.45 -42.45 95.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.857 0.36 . . . . 0.0 110.28 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.01 -41.2 96.07 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 -179.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.1 -40.68 89.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.59 -40.32 94.36 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.326 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.8 -42.84 99.52 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -49.18 77.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.933 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -63.93 -34.8 78.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.392 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.89 -45.31 82.67 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.16 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 84.8 mt -64.7 -42.27 94.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.068 178.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.42 -30.28 75.85 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.014 -0.835 . . . . 0.0 111.014 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 54.4 tp -61.85 -40.07 94.06 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.304 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -50.77 136.26 22.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.596 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 18.7 p-80 -78.49 -13.68 59.72 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.437 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -69.89 134.9 48.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.35 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -98.21 124.94 43.05 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.469 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -103.05 -26.54 13.02 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.334 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.4 -39.74 97.19 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 82.7 t80 -85.31 130.26 34.63 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.63 0.252 . . . . 0.0 110.384 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -135.38 148.67 49.45 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.815 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 7.9 tp-100 -70.83 127.96 34.42 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.705 -0.398 . . . . 0.0 109.941 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 84.6 t80 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.555 179.983 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 21.7 m . . . . . 0 N--CA 1.492 1.656 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.47 -37.42 87.22 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.348 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -61.13 -39.66 90.88 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.175 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -64.33 -37.26 86.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.596 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -89.2 108.85 19.84 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.383 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -86.99 103.7 15.6 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.441 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -63.8 -41.48 97.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.735 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.56 HD12 ' N ' ' A' ' 376' ' ' LEU . 10.7 mp -63.21 -40.24 96.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.206 -179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 35.0 t 59.08 74.65 0.57 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.496 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.527 ' O ' HG12 ' A' ' 381' ' ' VAL . 24.6 Cg_exo -61.24 147.85 94.48 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.915 2.41 . . . . 0.0 111.998 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.525 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -63.17 -43.59 98.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.855 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.97 -20.01 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.936 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 378' ' ' PRO . 8.4 p -61.04 -43.12 95.51 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 120.679 0.276 . . . . 0.0 110.392 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.514 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.68 -38.92 96.95 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.92 -41.06 95.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.703 0.287 . . . . 0.0 110.563 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.66 -35.71 81.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.518 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.1 tt -61.14 -44.35 97.46 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.024 0.44 . . . . 0.0 109.963 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.35 86.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.408 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.74 97.9 Favored Glycine 0 CA--C 1.531 1.066 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.3 t -63.52 -42.17 95.25 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.706 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -59.73 -37.53 79.17 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.467 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.0 mm -64.6 -42.22 94.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.884 0.374 . . . . 0.0 110.072 179.266 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.14 -40.02 92.24 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.602 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.7 t -62.69 -41.1 91.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.784 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.15 -40.93 95.71 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.444 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.88 -41.84 98.36 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.548 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.82 -48.84 77.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.766 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -64.09 -35.88 82.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.424 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -57.47 -45.52 84.71 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.392 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.74 -42.46 96.04 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.88 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.88 -35.47 92.05 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.1 tp -63.14 -41.69 99.33 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.614 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.3 134.46 52.66 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.619 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 85.3 t60 52.71 79.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.607 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 23.2 p80 -69.14 145.37 53.38 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.483 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -74.51 143.68 44.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.531 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.23 -16.63 58.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.511 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.21 -38.99 97.39 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.941 -0.863 . . . . 0.0 110.941 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 84.7 t80 -104.46 130.24 52.38 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.772 0.32 . . . . 0.0 110.388 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -135.49 143.65 45.93 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.842 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -56.53 141.97 40.89 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.078 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.9 t80 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.45 179.626 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 38.9 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -66.88 142.76 57.2 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.402 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -132.41 99.48 4.68 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.355 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 38.8 p-10 -91.61 110.76 22.09 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.448 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -85.88 98.96 11.07 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.289 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 374' ' ' ASN . . . . . 0.498 HD21 HG21 ' B' ' 381' ' ' VAL . 54.9 t30 -154.43 11.47 0.39 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.604 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -61.68 -42.15 98.53 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.333 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 376' ' ' LEU . . . . . 0.588 HD22 ' N ' ' B' ' 376' ' ' LEU . 3.5 mm? -66.86 135.47 53.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.158 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.442 ' C ' ' O ' ' B' ' 376' ' ' LEU . 4.0 m 29.97 69.05 0.66 Allowed Pre-proline 0 N--CA 1.468 0.458 0 O-C-N 123.834 0.709 . . . . 0.0 110.936 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_exo -53.56 -38.89 84.15 Favored 'Trans proline' 0 C--N 1.302 -1.897 0 C-N-CA 122.431 2.087 . . . . 0.0 112.081 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.497 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.0 mt -63.61 -44.45 98.55 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.309 -178.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.51 -20.21 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.808 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.498 HG21 HD21 ' B' ' 374' ' ' ASN . 55.0 t -64.68 -44.06 96.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.435 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.25 -40.83 96.89 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.04 85.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.738 0.304 . . . . 0.0 110.655 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.45 -45.77 92.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.659 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.91 -42.3 94.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.509 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.81 -37.26 87.02 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.48 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.63 -40.6 99.36 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -67.14 -42.72 88.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.485 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.6 tt -59.36 -40.56 86.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.486 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.2 mt -65.72 -42.21 92.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.829 0.347 . . . . 0.0 110.188 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.25 -40.58 94.57 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.632 -179.364 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.7 t -62.4 -41.15 90.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.783 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.17 -41.16 96.28 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.471 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -42.85 99.36 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.978 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -64.37 -37.27 86.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.346 179.499 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -58.22 -45.41 87.75 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.0 mt -63.35 -41.96 94.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.93 -31.71 77.24 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 59.8 tp -62.39 -40.57 96.93 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.363 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -57.68 136.72 56.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.601 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 86.3 t60 45.63 79.15 0.05 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.515 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -81.43 153.44 26.91 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.544 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -77.1 137.14 38.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.556 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.87 -12.46 59.98 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.524 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.49 -37.43 94.78 Favored Glycine 0 CA--C 1.529 0.936 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -114.58 141.08 48.22 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.754 0.312 . . . . 0.0 110.173 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 408' ' ' GLU . . . . . 0.52 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 55.4 mp0 -104.42 123.12 46.89 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.052 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 24.9 mm100 -130.45 140.16 50.55 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.305 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 88.1 t80 . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.534 -179.708 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 96.8 p . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . 59.15 117.03 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.621 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 371' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 34.4 p-10 -64.49 -35.09 79.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.506 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.483 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 99.0 m-20 54.85 31.33 15.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.559 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -62.22 -41.32 98.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.522 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 374' ' ' ASN . . . . . 0.437 ' O ' ' O ' ' C' ' 375' ' ' PHE . 49.6 p-10 -96.89 10.09 40.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.504 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 375' ' ' PHE . . . . . 0.437 ' O ' ' O ' ' C' ' 374' ' ' ASN . 97.7 m-85 49.78 102.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.56 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 59.5 mt -115.68 132.66 56.57 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.504 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.469 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 3.7 t 59.68 53.25 3.97 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.345 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.469 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 35.6 Cg_endo -65.62 -20.66 59.91 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.585 2.19 . . . . 0.0 112.046 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.91 -44.63 98.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.182 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.55 -20.22 60.69 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.995 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.64 -43.5 90.33 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.394 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.04 -39.24 97.04 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.06 -41.69 98.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.814 0.34 . . . . 0.0 110.545 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.3 83.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.467 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.632 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.0 tt -61.59 -45.23 95.01 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.136 0.493 . . . . 0.0 110.051 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.17 -36.76 85.11 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.45 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.07 -42.26 98.37 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 62.7 t -67.43 -42.61 87.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.787 0.327 . . . . 0.0 110.429 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.509 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.3 tt -61.02 -41.54 96.75 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.182 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.0 mt -64.38 -41.95 93.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.241 178.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -60.49 -41.44 94.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.683 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 78.7 t -64.71 -41.4 92.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.735 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.8 mt -61.7 -41.58 97.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.611 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.84 -42.83 99.51 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.368 -0.533 . . . . 0.0 109.687 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.59 93.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.841 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -63.75 -39.29 93.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.553 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -56.61 -45.36 81.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.337 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.7 mm -66.71 -40.83 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.895 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.74 -28.64 71.96 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 50.9 tp -62.53 -40.13 95.81 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.445 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -63.62 136.68 57.69 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.671 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -78.65 157.66 28.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.524 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -69.83 143.57 52.84 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.593 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -74.76 137.29 41.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.605 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.46 -11.89 59.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.587 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.96 -35.2 91.74 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -108.2 136.37 47.98 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.82 0.343 . . . . 0.0 110.284 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -135.42 145.48 47.31 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.688 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.528 ' OE1' ' N ' ' C' ' 410' ' ' PHE . 4.2 tp-100 -71.42 123.6 22.72 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.413 -0.515 . . . . 0.0 109.895 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 410' ' ' PHE . . . . . 0.528 ' N ' ' OE1' ' C' ' 409' ' ' GLN . 94.3 t80 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.494 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 48.2 m . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 48.11 41.84 16.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.478 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 34.4 p30 -86.47 -1.78 57.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.399 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 55.1 33.39 20.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.564 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.522 ' OD1' ' CZ ' ' A' ' 375' ' ' PHE . 54.5 p-10 -80.7 166.79 20.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.456 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 52.8 t30 -86.89 112.74 22.06 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.469 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 375' ' ' PHE . . . . . 0.522 ' CZ ' ' OD1' ' A' ' 373' ' ' ASP . 86.0 m-85 -83.95 -146.18 0.09 Allowed 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 120.964 0.411 . . . . 0.0 110.469 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 51.7 tp -64.05 -44.36 92.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.317 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.452 HG12 ' H ' ' A' ' 380' ' ' ALA . 5.2 t 39.66 74.58 0.67 Allowed Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.738 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -52.64 -34.39 63.39 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.733 2.289 . . . . 0.0 112.04 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt -63.07 -44.2 99.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.121 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 380' ' ' ALA . . . . . 0.452 ' H ' HG12 ' A' ' 377' ' ' VAL . . . -74.52 -20.3 60.03 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.644 0.259 . . . . 0.0 110.859 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.32 -43.68 87.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.79 0.329 . . . . 0.0 110.397 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.05 -42.96 99.48 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.876 -0.889 . . . . 0.0 110.876 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.79 -39.49 93.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.747 0.308 . . . . 0.0 110.777 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.4 -44.37 97.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.7 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.62 -41.63 92.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.53 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.72 -40.25 91.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.377 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.36 -42.83 99.04 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.43 -42.5 87.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.825 0.345 . . . . 0.0 110.567 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.26 -41.11 88.07 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.406 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 84.5 mt -65.4 -42.55 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 CA-C-O 120.934 0.397 . . . . 0.0 110.326 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 13.0 mt -60.7 -40.0 90.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.51 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.4 t -63.02 -41.34 92.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.721 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -60.96 -40.84 94.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.494 -179.494 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.51 -42.53 98.94 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.424 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.31 -47.91 82.19 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.829 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.2 t80 -63.92 -34.83 78.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.512 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -57.22 -45.56 83.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.291 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 29.8 mm -64.73 -42.61 95.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.75 -34.01 88.75 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.44 ' O ' ' O ' ' A' ' 401' ' ' LYS . 49.0 tp -62.93 -41.84 99.6 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.571 -179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 401' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' A' ' 400' ' ' LEU . 87.5 tttt 59.19 140.65 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.542 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -67.54 132.85 48.38 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.202 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 15.8 p80 -115.37 156.99 24.53 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.436 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -75.68 148.7 38.45 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.545 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.09 -11.1 59.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.484 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.85 -39.27 97.8 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -79.83 131.88 35.99 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 64.5 mm-40 -135.38 146.31 48.21 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.454 0.169 . . . . 0.0 110.555 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -72.57 128.39 35.44 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 120.627 -0.429 . . . . 0.0 109.858 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 88.0 t80 . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.507 179.889 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -151.66 152.3 32.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.51 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -62.46 -40.31 96.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.257 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -68.62 142.16 55.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.698 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 55.17 37.09 28.37 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.501 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 374' ' ' ASN . . . . . 0.433 ' OD1' ' CD2' ' B' ' 375' ' ' PHE . 50.5 p30 -98.5 6.52 47.1 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.64 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 375' ' ' PHE . . . . . 0.433 ' CD2' ' OD1' ' B' ' 374' ' ' ASN . 99.0 m-85 -98.14 -3.72 37.17 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.403 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 376' ' ' LEU . . . . . 0.55 ' N ' HD12 ' B' ' 376' ' ' LEU . 10.3 mp -63.41 -40.36 96.99 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.241 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 2.4 m -45.43 150.64 0.84 Allowed Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.768 -179.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -64.18 -22.32 67.17 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.575 2.183 . . . . 0.0 112.258 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 45.5 mm -64.88 -46.2 92.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.391 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.79 -20.31 61.88 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.759 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -66.98 -43.59 89.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 CA-C-O 120.811 0.339 . . . . 0.0 110.21 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.61 -40.78 96.15 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.23 -39.22 92.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.83 0.348 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 384' ' ' ALA . . . . . 0.438 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -63.83 -45.11 91.08 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.585 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -66.57 -41.41 88.62 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.558 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.67 -38.29 90.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.26 -39.16 96.8 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 388' ' ' VAL . . . . . 0.438 HG23 ' O ' ' B' ' 384' ' ' ALA . 96.0 t -66.71 -41.76 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.15 0.5 . . . . 0.0 110.103 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -58.62 -40.22 82.72 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.857 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.59 -42.07 86.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.142 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.1 mt -61.09 -41.89 97.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.721 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.52 -41.46 92.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.714 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.29 -40.83 95.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.611 -179.419 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.42 -42.45 98.77 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.459 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.49 -49.79 76.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.866 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -63.89 -34.29 77.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.357 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -58.32 -44.67 88.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.269 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 398' ' ' ILE . . . . . 0.409 HD13 ' HA ' ' B' ' 398' ' ' ILE . 30.8 mm -64.64 -42.64 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.855 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.25 -37.2 94.2 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 400' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' B' ' 402' ' ' HIS . 51.8 tp -63.4 -42.27 98.78 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.498 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 401' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' B' ' 400' ' ' LEU . 61.5 pttt 35.16 32.61 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 121.005 0.431 . . . . 0.0 111.084 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 402' ' ' HIS . . . . . 0.459 ' N ' ' O ' ' B' ' 400' ' ' LEU . 49.7 t-80 -148.41 141.83 25.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.349 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -118.22 123.53 45.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.482 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -77.71 133.1 38.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.47 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.04 -34.78 57.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.547 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.9 -35.27 91.78 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 84.0 t80 -78.35 134.14 37.49 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 110.414 -0.217 . . . . 0.0 110.414 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -135.39 146.33 48.22 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 120.425 0.155 . . . . 0.0 110.61 179.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.466 ' OE1' ' N ' ' B' ' 410' ' ' PHE . 7.4 tp-100 -68.35 132.79 47.68 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 410' ' ' PHE . . . . . 0.466 ' N ' ' OE1' ' B' ' 409' ' ' GLN . 96.5 m-85 . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.511 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 6.9 t . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.66 -37.72 87.32 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.438 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 59.1 t0 55.93 33.39 21.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.418 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -87.56 112.68 22.52 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.675 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -87.62 113.3 23.18 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.343 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -63.39 -41.5 98.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.663 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -118.28 102.39 8.93 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.644 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 376' ' ' LEU . . . . . 0.551 ' N ' HD12 ' C' ' 376' ' ' LEU . 10.4 mp -64.46 -40.98 96.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.361 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 2.8 m -134.75 77.38 57.84 Favored Pre-proline 0 N--CA 1.464 0.236 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.397 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.514 ' O ' HG12 ' C' ' 381' ' ' VAL . 51.0 Cg_endo -75.83 -14.74 19.28 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.629 2.219 . . . . 0.0 111.972 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.502 ' O ' ' N ' ' C' ' 381' ' ' VAL . 94.6 mt -63.07 -44.05 99.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.167 -179.112 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.11 -19.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.829 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.533 HG13 ' N ' ' C' ' 382' ' ' GLY . 7.9 p -58.97 -44.34 90.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 382' ' ' GLY . . . . . 0.533 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.46 -39.11 97.35 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.5 -41.47 98.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 384' ' ' ALA . . . . . 0.414 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -65.56 -35.39 80.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.359 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.632 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.45 -44.28 97.39 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.111 0.482 . . . . 0.0 110.086 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.63 -37.4 87.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.519 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.76 -41.71 97.48 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 388' ' ' VAL . . . . . 0.414 HG23 ' O ' ' C' ' 384' ' ' ALA . 97.9 t -65.75 -41.55 90.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.898 0.38 . . . . 0.0 110.28 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 tt -58.39 -41.7 85.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.618 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 80.7 mt -65.85 -42.44 92.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.857 0.36 . . . . 0.0 110.393 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -60.88 -39.43 89.22 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.547 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 61.9 t -62.23 -41.7 92.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.675 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -60.92 -41.44 96.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.399 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.45 -44.46 96.36 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 120.09 -0.644 . . . . 0.0 109.648 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.35 -36.54 84.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.108 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -59.52 -43.65 93.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.604 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -63.87 -41.0 97.85 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.562 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 83.2 mt -63.53 -42.39 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.778 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -59.65 -58.95 11.61 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 400' ' ' LEU . . . . . 0.489 HD22 ' N ' ' C' ' 400' ' ' LEU . 3.9 mm? -65.43 -42.86 92.0 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.806 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 401' ' ' LYS . . . . . 0.413 ' C ' ' O ' ' C' ' 400' ' ' LEU . 24.5 pttm 34.88 39.82 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.941 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -70.23 127.56 33.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.194 -179.489 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 403' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' C' ' 404' ' ' HIS . 61.0 t-80 -75.76 151.98 37.48 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.524 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 404' ' ' HIS . . . . . 0.401 ' O ' ' ND1' ' C' ' 403' ' ' HIS . 9.4 t-80 -76.54 132.38 39.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.543 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.88 -12.64 60.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.616 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.08 -36.67 93.77 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 75.2 m-85 -105.31 134.58 48.19 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -88.32 116.58 26.63 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -52.59 138.38 28.34 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.675 -0.41 . . . . 0.0 109.913 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 55.2 p90 . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.563 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 369' ' ' SER . . . . . 0.504 ' N ' ' CE1' ' A' ' 375' ' ' PHE . 40.3 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 48.79 12.93 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.545 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.473 ' N ' ' C ' ' A' ' 369' ' ' SER . 99.1 m-20 55.94 33.68 22.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.445 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -67.16 142.45 57.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.627 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -67.97 144.26 55.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.656 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 376' ' ' LEU . 65.7 t30 56.64 42.38 27.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.584 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 375' ' ' PHE . . . . . 0.524 ' C ' ' H ' ' A' ' 377' ' ' VAL . 68.9 t80 -69.21 8.68 0.54 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.535 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.479 ' H ' ' C ' ' A' ' 374' ' ' ASN . 4.0 tp 70.83 -15.96 0.36 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.467 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.524 ' H ' ' C ' ' A' ' 375' ' ' PHE . 7.3 t 45.05 72.66 1.16 Allowed Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.689 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.529 ' O ' HG12 ' A' ' 381' ' ' VAL . 33.4 Cg_exo -59.78 145.6 97.79 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.87 2.38 . . . . 0.0 111.824 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.538 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.5 mt -63.1 -43.28 98.85 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.968 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.07 -20.0 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.871 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.3 p -60.82 -42.53 92.76 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 120.717 0.294 . . . . 0.0 110.362 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.496 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -61.81 -39.25 97.23 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.77 -40.89 94.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.819 0.342 . . . . 0.0 110.581 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.77 -35.69 81.89 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.474 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.653 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.5 tt -61.59 -44.38 97.12 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 121.057 0.456 . . . . 0.0 110.002 -179.629 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.81 -36.53 83.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.445 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.8 -37.38 94.76 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.2 t -67.53 -42.08 86.53 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-O 121.076 0.465 . . . . 0.0 109.943 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -59.18 -41.7 89.09 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.778 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -66.72 -42.0 88.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.178 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.35 -41.26 93.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.613 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.3 t -64.29 -40.94 90.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.63 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.3 mt -61.6 -40.35 94.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.515 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -62.04 -43.76 98.15 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.31 -0.556 . . . . 0.0 109.581 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.55 -36.77 84.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.018 179.34 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -60.69 -44.22 96.79 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.657 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -62.32 -43.47 98.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.658 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 86.6 mt -63.83 -42.7 96.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.799 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.06 -38.18 93.79 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.0 tp -62.58 -41.37 98.91 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.438 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 49.7 tttp 57.87 164.25 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.59 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 54.47 93.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.443 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -79.86 144.41 33.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.515 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 75.9 m80 -77.73 139.9 39.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.547 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.26 -13.25 59.97 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.537 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.45 -39.37 97.64 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 81.9 t80 -82.5 134.33 35.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.582 0.23 . . . . 0.0 110.428 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -83.45 117.22 22.93 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.406 179.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.513 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 2.0 pm0 -66.41 136.16 55.35 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 410' ' ' PHE . . . . . 0.508 ' CG ' ' O ' ' A' ' 410' ' ' PHE . 93.7 t80 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.339 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 13.3 p . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.15 141.4 54.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.552 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -62.11 -34.49 76.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.181 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -67.65 143.18 56.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.551 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -90.94 -0.66 57.79 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.58 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 12.4 m120 56.24 35.23 25.42 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.56 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 51.7 t80 -60.65 -43.31 97.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.484 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 27.1 mt -100.29 133.81 44.15 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.441 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 3.7 m -137.79 74.92 44.08 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.419 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 378' ' ' PRO . . . . . 0.487 ' O ' HG12 ' B' ' 381' ' ' VAL . 25.5 Cg_exo -61.16 150.47 84.35 Favored 'Trans proline' 0 N--CA 1.494 1.55 0 C-N-CA 122.98 2.453 . . . . 0.0 111.805 179.706 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt -63.03 -43.18 98.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.929 -179.536 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.71 -19.93 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.897 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.537 ' N ' ' O ' ' B' ' 379' ' ' ILE . 7.8 p -60.97 -40.96 87.25 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-O 120.773 0.321 . . . . 0.0 110.265 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 382' ' ' GLY . . . . . 0.447 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -62.75 -38.57 96.7 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.537 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.27 -40.4 93.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.802 0.334 . . . . 0.0 110.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -35.46 81.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.503 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 385' ' ' LEU . . . . . 0.656 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.1 tt -61.12 -45.32 95.18 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.065 0.459 . . . . 0.0 110.004 -179.575 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.26 -35.88 82.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.422 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.86 -40.6 98.5 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -66.55 -42.3 89.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.85 0.357 . . . . 0.0 110.276 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 389' ' ' LEU . . . . . 0.542 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.9 tt -60.1 -41.36 92.35 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.419 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -65.73 -41.98 91.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.78 0.324 . . . . 0.0 110.156 179.013 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -60.06 -41.4 92.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.626 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.3 t -63.77 -41.62 93.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.754 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.11 -41.27 96.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.477 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.48 -43.56 98.65 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 120.276 -0.569 . . . . 0.0 109.573 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.3 -36.98 84.34 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.144 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -60.48 -44.09 96.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.647 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -62.94 -41.81 99.61 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.605 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.8 mt -63.09 -42.55 97.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.742 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.71 -35.65 92.2 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 53.3 tp -62.6 -41.18 98.82 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.51 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -64.62 135.94 56.47 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.607 -179.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 84.4 t60 48.82 93.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.517 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -69.91 143.33 52.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.547 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 61.1 m170 -73.54 142.66 46.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.59 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.14 -11.43 59.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.561 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.76 -36.86 93.62 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 90.6 t80 -82.26 132.75 35.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.621 0.248 . . . . 0.0 110.507 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.5 146.99 48.69 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.78 0.324 . . . . 0.0 110.756 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.635 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 3.0 pm0 -52.6 146.03 10.78 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.611 -0.435 . . . . 0.0 109.923 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.368 -179.642 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 25.5 p . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.68 -38.58 91.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.447 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -99.06 110.62 23.18 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.351 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -62.72 -39.23 93.42 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.608 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -88.2 113.91 24.29 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.456 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 374' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' C' ' 376' ' ' LEU . 42.7 p-10 -83.96 138.98 32.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.553 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -62.54 -43.79 97.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.615 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 376' ' ' LEU . . . . . 0.464 ' O ' ' ND2' ' C' ' 374' ' ' ASN . 33.1 tp -104.86 131.62 52.12 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.076 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 27.0 t -118.71 83.43 22.31 Favored Pre-proline 0 CA--C 1.534 0.329 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.344 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -81.05 109.89 2.24 Favored 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.635 2.223 . . . . 0.0 111.859 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 95.0 mt -94.64 -75.28 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.9 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.19 -20.15 60.95 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.899 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -64.3 -43.21 97.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.245 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.94 -41.97 99.7 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.98 -37.58 88.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.757 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 384' ' ' ALA . . . . . 0.405 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -60.16 -44.77 94.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.45 -40.4 93.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.424 179.335 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.47 91.31 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.46 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.99 -41.37 97.34 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 388' ' ' VAL . . . . . 0.405 HG23 ' O ' ' C' ' 384' ' ' ALA . 88.9 t -64.56 -42.87 96.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-O 120.77 0.319 . . . . 0.0 110.296 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.587 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.4 tt -60.29 -39.06 85.54 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.897 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 6.5 mm -63.41 -42.27 95.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.07 -40.82 95.13 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.651 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.1 t -62.61 -41.9 93.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.69 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.37 -42.28 98.44 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.67 -42.4 99.6 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.16 -48.57 73.55 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.0 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -63.97 -34.86 78.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.547 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -58.17 -44.33 87.93 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.366 -179.336 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.4 mm -65.52 -41.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.797 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.86 -35.61 92.24 Favored Glycine 0 CA--C 1.522 0.486 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 400' ' ' LEU . . . . . 0.437 ' O ' ' O ' ' C' ' 401' ' ' LYS . 51.9 tp -62.52 -42.25 99.39 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.597 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 401' ' ' LYS . . . . . 0.437 ' O ' ' O ' ' C' ' 400' ' ' LEU . 38.6 ttmt 59.49 140.85 0.01 OUTLIER 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.694 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -66.95 140.66 57.75 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.403 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -77.39 129.82 36.29 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.261 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -102.83 125.31 49.52 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.527 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.25 -11.33 59.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.428 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.14 -39.34 97.86 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -82.31 132.87 35.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.64 0.257 . . . . 0.0 110.42 179.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -81.31 118.68 22.84 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.245 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -52.69 144.39 14.14 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.657 -0.417 . . . . 0.0 109.967 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 54.8 p90 . . . . . 0 C--O 1.219 -0.543 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.552 179.914 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 68.6 m . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.66 -39.58 94.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.472 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -100.39 113.24 25.84 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.42 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.482 ' O ' HD21 ' A' ' 376' ' ' LEU . 42.2 t0 -90.1 113.22 24.92 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.649 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -62.67 -40.79 98.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.492 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.439 ' O ' ' O ' ' A' ' 375' ' ' PHE . 98.3 m-20 -85.92 142.28 28.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.484 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 375' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' A' ' 374' ' ' ASN . 82.3 t80 56.99 118.08 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.431 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.482 HD21 ' O ' ' A' ' 372' ' ' ASP . 97.9 mt -133.39 131.3 39.85 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.934 0.397 . . . . 0.0 110.37 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.472 ' H ' HG22 ' A' ' 377' ' ' VAL . 1.3 m -54.61 152.03 13.42 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.707 -179.352 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -64.61 149.55 89.65 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.604 2.202 . . . . 0.0 111.94 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -63.94 -42.58 96.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.874 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.16 -20.23 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.347 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.832 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' A' ' 379' ' ' ILE . 45.4 t -65.6 -43.98 93.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.515 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.32 -37.39 94.44 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.8 -42.28 98.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.77 0.319 . . . . 0.0 110.471 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.57 -37.17 85.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.568 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.656 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.3 tt -61.53 -44.17 97.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.419 . . . . 0.0 109.976 -179.443 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.94 -37.08 85.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.592 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.84 -39.96 97.57 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.0 t -64.0 -43.39 97.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.756 0.312 . . . . 0.0 110.541 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.591 HD23 ' O ' ' A' ' 389' ' ' LEU . 5.0 tt -60.6 -39.31 87.66 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 7.7 mm -63.75 -42.54 96.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.12 -40.36 93.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.351 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.5 t -63.99 -41.41 92.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.758 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.42 97.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.441 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.68 -41.56 97.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.49 -48.93 73.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.808 179.511 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.67 -35.34 80.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.31 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 397' ' ' PHE . . . . . 0.476 ' CZ ' ' NE2' ' A' ' 402' ' ' HIS . 24.1 t80 -58.34 -46.11 86.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.388 -179.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.1 mt -64.45 -42.56 95.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.225 179.407 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.99 -32.65 84.88 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.2 tp -61.31 -41.44 97.0 Favored 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 120.925 -0.31 . . . . 0.0 110.383 -179.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.1 mttt 55.32 95.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.539 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 402' ' ' HIS . . . . . 0.476 ' NE2' ' CZ ' ' A' ' 397' ' ' PHE . 95.0 m-70 -73.77 141.22 46.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.362 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 403' ' ' HIS . . . . . 0.432 ' O ' ' CG ' ' A' ' 403' ' ' HIS . 55.3 p-80 -83.1 120.43 25.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.523 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -78.57 133.62 37.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.545 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.2 -12.12 59.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.63 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.93 -34.92 91.22 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -82.06 130.37 35.06 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.39 -0.226 . . . . 0.0 110.39 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -91.87 117.08 29.45 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.359 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 43.3 tp60 -78.65 131.06 36.53 Favored 'General case' 0 C--N 1.333 -0.131 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.393 179.96 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 10.9 p . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -68.63 146.82 52.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.709 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -60.91 -42.53 98.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.291 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 372' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' B' ' 373' ' ' ASP . 42.5 p-10 -66.83 -33.78 76.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.704 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 373' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' B' ' 372' ' ' ASP . 47.3 t0 -90.65 108.89 20.1 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.451 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -147.9 105.82 3.72 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.394 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -116.45 101.49 8.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.836 0.35 . . . . 0.0 110.25 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 53.0 mt -116.86 128.47 55.28 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.328 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 15.3 t 51.17 72.89 1.09 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.633 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -60.36 147.09 95.17 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 122.935 2.423 . . . . 0.0 111.857 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.8 mt -63.9 -43.63 97.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.782 -179.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.61 -19.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.583 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.8 t -63.9 -43.65 97.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 C-N-CA 120.941 -0.304 . . . . 0.0 110.377 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.48 -43.02 98.78 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.89 87.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.758 0.313 . . . . 0.0 110.697 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 384' ' ' ALA . . . . . 0.421 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -61.26 -44.85 96.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.698 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.26 -40.68 94.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.416 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.8 -37.41 84.3 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.376 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -39.21 96.01 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 388' ' ' VAL . . . . . 0.421 HG23 ' O ' ' B' ' 384' ' ' ALA . 88.0 t -63.87 -42.12 94.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 11.9 mt -62.75 -42.03 99.49 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.807 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.6 mt -66.79 -40.62 86.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.942 0.401 . . . . 0.0 110.067 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -59.15 -41.97 89.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.472 -179.4 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.04 -42.08 93.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.814 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.55 -41.6 97.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.454 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.82 -44.02 97.69 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.308 -0.557 . . . . 0.0 109.646 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.27 -36.61 83.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.143 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.22 -44.29 95.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.527 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -62.99 -44.45 95.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.405 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.27 -42.69 97.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.21 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.57 -34.79 90.89 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 400' ' ' LEU . . . . . 0.553 HD13 ' O ' ' B' ' 400' ' ' LEU . 0.2 OUTLIER -62.43 -43.42 98.87 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.029 -179.128 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -142.61 123.43 14.3 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.477 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 43.9 p-80 -157.7 159.7 37.16 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.061 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -124.17 128.33 49.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.227 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 404' ' ' HIS . . . . . 0.471 ' O ' ' ND1' ' B' ' 404' ' ' HIS . 21.6 p80 -125.97 124.84 41.64 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.203 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -101.77 -22.53 14.37 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.334 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.07 -40.93 97.32 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -83.66 133.43 34.82 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 110.351 -0.241 . . . . 0.0 110.351 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -70.83 117.78 12.78 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.222 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -53.48 146.26 13.08 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.035 -0.984 . . . . 0.0 110.291 179.694 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 68.5 m . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -155.39 150.51 26.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.445 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 34.6 p30 -89.72 -1.93 58.13 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.354 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 37.8 p30 -88.99 -0.61 57.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.355 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 373' ' ' ASP . . . . . 0.444 ' O ' ' O ' ' C' ' 376' ' ' LEU . 97.6 m-20 -68.12 140.66 56.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.521 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -63.62 -40.14 96.15 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.514 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 90.7 t80 -59.88 -46.37 89.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.85 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 376' ' ' LEU . . . . . 0.444 ' O ' ' O ' ' C' ' 373' ' ' ASP . 42.9 tp -100.03 125.18 46.05 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 120.871 0.367 . . . . 0.0 110.28 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.41 HG22 ' H ' ' C' ' 377' ' ' VAL . 1.2 m -94.43 151.85 39.65 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.479 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.84 -21.56 57.55 Favored 'Trans proline' 0 N--CA 1.495 1.579 0 C-N-CA 122.612 2.208 . . . . 0.0 112.023 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.2 mt -64.68 -44.58 96.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.1 -179.42 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.41 -19.94 60.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 121.044 -0.262 . . . . 0.0 110.846 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.5 t -66.26 -43.16 91.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.084 0 CA-C-O 120.761 0.315 . . . . 0.0 110.484 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.38 -36.65 93.68 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.59 -41.0 98.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.424 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.13 83.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.658 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.8 tt -61.3 -43.74 98.37 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.32 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.45 -36.92 85.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.591 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.97 -39.99 97.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.52 -42.72 96.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.5 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.509 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.9 tt -60.5 -39.22 86.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.914 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.98 -42.32 95.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.0 -41.8 97.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.589 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -63.91 -41.27 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.14 -41.37 96.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.559 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.4 -44.41 97.19 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.418 -0.513 . . . . 0.0 109.663 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.78 84.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.189 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 396' ' ' TYR . . . . . 0.564 ' CZ ' HD11 ' C' ' 400' ' ' LEU . 78.5 t80 -60.33 -43.97 95.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.477 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -64.56 -45.56 86.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.365 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -64.54 -42.15 94.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.371 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.51 -36.02 90.35 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 400' ' ' LEU . . . . . 0.564 HD11 ' CZ ' ' C' ' 396' ' ' TYR . 8.2 mt -63.88 -38.82 92.5 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.376 -0.231 . . . . 0.0 110.376 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 99.7 mttt 58.63 1.88 0.2 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.67 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 402' ' ' HIS . . . . . 0.501 ' ND1' ' CE1' ' C' ' 404' ' ' HIS . 56.3 t-80 -152.62 135.64 15.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.408 179.676 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 403' ' ' HIS . . . . . 0.421 ' O ' ' CG ' ' C' ' 403' ' ' HIS . 44.4 p-80 -106.48 117.78 34.94 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.264 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 404' ' ' HIS . . . . . 0.501 ' CE1' ' ND1' ' C' ' 402' ' ' HIS . 77.5 m80 -102.59 124.89 48.97 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.409 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.06 -14.69 59.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.581 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.23 -38.75 96.99 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 79.4 m-85 -107.44 137.55 45.28 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 110.382 -0.229 . . . . 0.0 110.382 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -84.06 118.14 23.88 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.146 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.611 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 0.4 OUTLIER -52.97 145.97 11.86 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.816 -0.353 . . . . 0.0 110.049 179.835 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 91.5 t80 . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.755 -179.797 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.64 148.01 20.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.364 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -100.03 109.47 21.79 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.042 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -64.19 -38.21 90.25 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.521 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -85.89 110.34 19.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.417 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -95.67 142.17 28.3 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.374 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -62.29 -43.05 99.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.583 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.564 HD12 ' N ' ' A' ' 376' ' ' LEU . 10.2 mp -84.64 131.31 34.61 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.443 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 2.1 m -79.64 150.91 73.68 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.608 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.544 ' O ' HG12 ' A' ' 381' ' ' VAL . 37.3 Cg_endo -66.51 150.41 84.11 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.766 2.31 . . . . 0.0 112.215 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 46.7 mm -64.21 -44.14 97.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.969 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.17 -20.18 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 120.518 0.199 . . . . 0.0 110.791 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 378' ' ' PRO . 9.0 p -60.78 -42.03 90.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.462 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -60.28 -43.16 98.82 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.57 -37.49 85.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.752 0.31 . . . . 0.0 110.738 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 384' ' ' ALA . . . . . 0.409 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -60.64 -43.52 97.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.694 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.41 -41.38 93.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.395 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.49 -39.06 89.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.174 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.48 -41.04 96.52 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 388' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 384' ' ' ALA . 91.0 t -67.34 -42.04 87.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.845 0.355 . . . . 0.0 110.245 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.532 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.6 tt -59.61 -41.74 91.08 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.41 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.9 mt -65.58 -42.11 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-O 120.931 0.396 . . . . 0.0 110.231 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.51 -40.89 96.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.601 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.6 t -64.18 -41.38 92.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.45 -41.55 97.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.434 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.92 -42.58 99.26 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.458 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.64 -47.0 77.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.804 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -64.19 -35.23 80.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.514 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -57.7 -46.22 84.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.396 -179.202 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 92.1 mt -64.66 -42.43 95.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.49 -33.05 86.2 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.5 tp -61.67 -40.67 95.77 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.437 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 63.6 mttp 56.81 104.95 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.707 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 59.9 t-80 -60.62 -41.79 95.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.341 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -76.73 130.56 37.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.286 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -70.63 140.07 51.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.64 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.17 -11.25 59.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.497 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.59 -40.09 98.29 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 79.6 t80 -80.43 131.15 35.55 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 121.094 -0.243 . . . . 0.0 110.495 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 68.1 mm-40 -135.68 144.79 46.18 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-O 120.763 0.316 . . . . 0.0 110.576 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 43.8 tp60 -68.81 131.06 44.53 Favored 'General case' 0 C--N 1.332 -0.179 0 C-N-CA 120.477 -0.489 . . . . 0.0 109.812 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 55.8 p90 . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.607 -179.959 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.85 -39.11 93.45 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.539 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -99.77 112.08 24.36 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.416 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -67.02 140.6 57.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.559 -179.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -61.73 -42.62 99.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.495 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 60.9 t-20 -88.86 109.38 20.15 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.501 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -61.85 -43.25 99.23 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.665 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 2.2 mt 55.42 85.09 0.07 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.322 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 20.3 t -146.23 73.08 13.22 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.303 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 378' ' ' PRO . . . . . 0.514 ' O ' HG12 ' B' ' 381' ' ' VAL . 32.6 Cg_exo -59.78 144.31 99.47 Favored 'Trans proline' 0 N--CA 1.496 1.667 0 C-N-CA 122.876 2.384 . . . . 0.0 111.988 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt -64.29 -43.48 97.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.099 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.25 -20.26 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.618 -0.264 . . . . 0.0 111.007 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' B' ' 379' ' ' ILE . 10.6 p -59.36 -42.77 88.51 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 382' ' ' GLY . . . . . 0.495 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -63.14 -40.23 98.9 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -67.95 -35.84 79.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.716 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 384' ' ' ALA . . . . . 0.402 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -60.16 -44.04 95.32 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.683 -179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.51 -40.45 93.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.42 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.17 -37.86 88.71 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.526 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.33 -39.6 97.99 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 388' ' ' VAL . . . . . 0.402 HG23 ' O ' ' B' ' 384' ' ' ALA . 99.3 t -67.94 -42.13 85.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.675 0.274 . . . . 0.0 110.4 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -60.0 -40.86 90.68 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.209 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.8 mt -64.93 -42.26 94.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.913 0.387 . . . . 0.0 110.366 179.209 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.35 -40.03 89.28 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.516 -179.231 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 68.9 t -62.06 -41.25 90.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.652 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.48 -41.03 93.36 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.433 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.79 -43.99 97.41 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.646 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.48 86.44 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.118 179.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.49 -44.34 96.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.888 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -62.24 -44.48 96.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.692 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.0 mt -63.27 -42.35 96.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.616 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.6 -33.08 85.2 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 54.3 tp -61.79 -40.03 93.76 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.986 -0.286 . . . . 0.0 110.456 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 69.0 mttm 55.6 92.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.714 -179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -65.02 -42.66 94.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.334 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -81.85 128.0 33.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.453 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -78.58 131.05 36.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.598 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.93 -11.87 59.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.425 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.88 -37.59 94.87 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -108.63 132.17 54.16 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -93.02 119.08 31.89 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 46.7 tp60 -73.11 132.0 42.76 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.58 -0.448 . . . . 0.0 109.958 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 88.0 t80 . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.85 -1.071 . . . . 0.0 110.512 -179.972 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 50.7 m . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . 48.13 37.04 7.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.076 0.465 . . . . 0.0 110.521 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -61.96 -38.69 89.46 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.357 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -64.62 -37.97 89.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.519 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -61.49 -42.15 98.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.384 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -83.34 105.97 14.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.379 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -94.17 0.72 55.94 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.374 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 58.1 tp -63.23 -42.47 99.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.415 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.63 ' O ' HG13 ' C' ' 377' ' ' VAL . 7.4 p -172.03 77.06 0.48 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.01 -179.528 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -59.52 145.15 98.85 Favored 'Trans proline' 0 C--N 1.302 -1.916 0 C-N-CA 122.564 2.176 . . . . 0.0 112.05 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.445 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt -63.77 -43.68 98.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.117 -179.592 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -44.43 -19.87 0.03 OUTLIER 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.8 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.445 ' N ' ' O ' ' C' ' 379' ' ' ILE . 61.3 t -64.28 -43.15 97.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.196 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.13 -42.06 99.67 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.19 85.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.756 0.313 . . . . 0.0 110.777 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.31 -44.96 95.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.796 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.2 -42.08 93.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.547 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.47 87.74 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.514 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.51 99.82 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 80.1 t -66.43 -42.09 89.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 0.0 110.336 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -60.74 -40.93 94.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.518 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 84.9 mt -66.47 -42.06 89.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.935 0.397 . . . . 0.0 110.275 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.3 -40.97 87.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.517 -179.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 72.5 t -63.11 -42.06 95.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.726 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.9 -41.59 96.36 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.588 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.11 -42.52 99.3 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.565 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.44 -48.01 75.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.099 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 93.9 t80 -63.36 -36.34 83.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.664 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -57.7 -44.56 85.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.492 -179.217 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 39.7 mm -66.75 -40.45 86.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.779 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.02 -30.31 73.17 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 54.7 tp -63.16 -39.97 96.21 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.494 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -61.83 141.61 57.83 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.488 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 70.0 m80 54.9 92.48 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.589 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -76.03 137.46 40.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.526 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -79.55 129.53 34.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.369 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.47 -11.67 59.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.431 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.33 -38.95 96.55 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.868 -0.893 . . . . 0.0 110.868 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 77.0 t80 -83.43 129.42 34.99 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -135.47 146.57 48.31 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.526 ' O ' ' CG ' ' C' ' 410' ' ' PHE . 8.7 tp-100 -126.01 120.55 30.59 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.932 0.396 . . . . 0.0 110.186 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 410' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' C' ' 409' ' ' GLN . 90.0 m-85 . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.454 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -156.04 154.18 30.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.536 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.407 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 37.5 p-10 -86.24 -1.5 57.53 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.36 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.437 ' O ' ' OD1' ' A' ' 372' ' ' ASP . 43.4 p-10 -134.53 106.11 6.86 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.557 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -70.26 140.31 52.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.486 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -63.49 -40.64 97.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.793 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -109.23 101.77 10.77 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.202 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 42.8 tp -111.51 111.65 22.81 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.152 179.463 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 10.6 t 39.26 58.64 6.18 Favored Pre-proline 0 N--CA 1.462 0.15 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.68 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -67.04 -19.68 51.31 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.526 2.15 . . . . 0.0 112.124 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt -64.51 -44.46 96.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.981 -179.407 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.05 -20.03 61.06 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.872 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.4 t -66.4 -43.55 91.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.072 0 CA-C-O 120.633 0.254 . . . . 0.0 110.359 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.15 -40.97 97.19 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.98 -39.2 90.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.742 0.306 . . . . 0.0 110.77 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.35 -44.68 96.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.651 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.2 mt -65.2 -40.6 94.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.386 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.77 -37.26 86.71 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.44 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.65 -39.72 97.84 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.03 -42.24 95.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.62 -38.09 80.38 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.353 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.99 -42.76 95.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.396 . . . . 0.0 110.093 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.9 mt -61.61 -42.18 98.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.58 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.7 t -66.07 -41.94 90.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.89 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.73 -41.13 97.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.463 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.48 -44.1 97.69 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.347 -0.541 . . . . 0.0 109.688 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.42 -37.37 86.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.98 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -61.89 -44.78 96.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.696 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -62.94 -45.37 92.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.49 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.9 mt -64.26 -42.58 95.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.062 179.319 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.42 -42.8 95.73 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.6 tp -63.83 -41.85 97.75 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.781 0.324 . . . . 0.0 110.534 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.45 131.93 47.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.687 -179.554 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -167.18 134.14 2.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.286 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -107.93 122.91 47.78 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.312 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -81.55 127.88 33.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.415 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -76.92 -37.68 54.92 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.678 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.2 -38.34 96.35 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -80.71 133.64 35.72 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -84.86 116.26 23.22 Favored 'General case' 0 C--O 1.232 0.145 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 43.7 tp60 -73.6 134.24 43.66 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 92.2 t80 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.31 -179.902 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 56.2 p . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 370' ' ' ALA . . . . . 0.536 ' O ' ' N ' ' B' ' 372' ' ' ASP . . . -65.04 -37.68 88.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.496 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 65.8 t0 46.48 -87.69 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.685 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 372' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' B' ' 370' ' ' ALA . 57.2 t0 -90.37 113.49 25.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.447 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 373' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' B' ' 373' ' ' ASP . 44.2 p-10 -90.46 107.07 18.92 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.402 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 51.6 p30 -89.48 162.45 15.71 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.265 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -111.26 101.11 9.63 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.925 0.393 . . . . 0.0 110.329 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 34.5 mt -105.26 -1.04 25.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.475 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.433 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 4.1 t -129.32 55.08 16.35 Favored Pre-proline 0 C--N 1.331 -0.205 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.328 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 378' ' ' PRO . . . . . 0.433 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 36.0 Cg_endo -66.11 -18.47 56.52 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.606 2.204 . . . . 0.0 111.999 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.9 mt -64.19 -44.57 97.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.049 -179.397 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -72.2 -20.44 61.57 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.742 -0.208 . . . . 0.0 110.652 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 60.3 t -66.89 -43.39 89.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.658 0.266 . . . . 0.0 110.414 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.1 -39.55 98.13 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.04 -41.61 96.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.86 -35.38 80.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.511 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 385' ' ' LEU . . . . . 0.65 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.0 tt -61.41 -44.29 97.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.295 -0.412 . . . . 0.0 109.92 -179.418 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.98 -36.91 85.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.567 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.45 -39.48 97.35 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.67 -42.36 94.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.922 0.392 . . . . 0.0 110.191 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 389' ' ' LEU . . . . . 0.581 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.3 tt -59.63 -38.32 81.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.263 -179.68 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.11 -42.16 94.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.853 0.359 . . . . 0.0 110.207 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.09 -41.03 95.9 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.625 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 86.3 t -63.5 -41.07 91.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.665 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.31 -41.44 96.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.503 -179.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.74 -42.7 99.31 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.89 75.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.833 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -65.0 -35.59 81.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.431 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.9 t80 -57.53 -45.94 84.45 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.273 -179.314 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.04 -42.3 95.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.128 179.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.89 -37.08 94.31 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 44.8 tp -62.96 -41.64 99.59 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.438 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 401' ' ' LYS . . . . . 0.407 ' O ' ' O ' ' B' ' 402' ' ' HIS . 62.5 tttp 59.13 80.1 0.2 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.654 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 402' ' ' HIS . . . . . 0.486 ' CG ' ' N ' ' B' ' 403' ' ' HIS . 56.5 t-80 55.42 163.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.632 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 403' ' ' HIS . . . . . 0.486 ' N ' ' CG ' ' B' ' 402' ' ' HIS . 80.6 m80 -74.52 139.98 44.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.577 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 404' ' ' HIS . . . . . 0.571 ' ND1' ' N ' ' B' ' 404' ' ' HIS . 0.0 OUTLIER -70.03 142.51 52.74 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.579 179.99 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.14 -12.71 59.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.535 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.19 -37.95 95.73 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 87.2 t80 -77.92 133.15 38.13 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.566 0.222 . . . . 0.0 110.428 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -135.41 147.1 48.89 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.718 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 44.1 tp60 -66.87 128.48 36.49 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 91.1 t80 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.07 -0.966 . . . . 0.0 110.607 -179.89 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 85.5 p . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.5 152.11 25.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.539 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -88.58 -2.89 58.84 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.318 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' C' ' 373' ' ' ASP . 40.2 p-10 -64.84 -35.7 81.96 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.788 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 373' ' ' ASP . . . . . 0.52 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 95.8 m-20 -62.8 -39.93 95.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 64.1 t30 58.96 51.01 7.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.684 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 375' ' ' PHE . . . . . 0.46 ' CE2' ' CB ' ' C' ' 373' ' ' ASP . 73.7 m-85 -60.63 -43.34 97.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.631 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 5.0 tp -94.17 133.27 37.85 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.298 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.477 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 3.3 t 65.59 51.79 0.87 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.421 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.498 ' O ' HG12 ' C' ' 381' ' ' VAL . 36.4 Cg_endo -65.05 151.44 85.75 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.912 2.408 . . . . 0.0 111.877 179.657 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.2 mt -63.53 -43.55 98.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.718 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.63 -19.79 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.766 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.3 p -60.88 -43.06 94.9 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.62 0.248 . . . . 0.0 110.474 -179.73 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 382' ' ' GLY . . . . . 0.511 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -62.51 -45.53 95.68 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.53 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.2 85.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.79 0.329 . . . . 0.0 110.719 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.22 -43.66 98.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.654 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.82 -41.14 92.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.485 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.38 94.21 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.452 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.81 -41.11 98.96 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -66.0 -42.73 92.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 110.645 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.595 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.8 tt -59.59 -41.39 90.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.088 -179.082 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.0 mt -65.43 -42.08 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.9 0.381 . . . . 0.0 110.367 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.7 mt -60.45 -40.86 92.66 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.534 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.06 -41.41 92.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.685 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.09 -41.43 96.65 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.487 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.74 -41.94 98.31 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.87 -48.93 74.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.763 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -63.69 -36.27 83.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.483 179.173 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -57.64 -45.32 85.61 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.269 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.57 -42.29 95.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.094 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.64 -34.04 88.86 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 49.6 tp -62.09 -41.92 98.69 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.811 0.339 . . . . 0.0 110.407 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 66.0 tttm 53.81 95.9 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.575 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 57.1 p-80 -77.38 132.23 38.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.361 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -77.66 136.1 38.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.577 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -78.57 140.22 38.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.416 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.53 -11.9 59.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.411 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.18 -37.57 94.73 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 83.6 m-85 -109.65 136.67 48.63 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 110.255 -0.276 . . . . 0.0 110.255 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -88.4 117.64 27.47 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 45.0 tp60 -70.85 130.4 41.56 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 94.5 t80 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.444 179.973 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 45.95 41.93 8.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.564 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.42 ' OD1' ' N ' ' A' ' 371' ' ' ASP . 32.9 p-10 -88.41 111.79 22.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.426 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.403 ' O ' ' OD1' ' A' ' 372' ' ' ASP . 62.5 t0 -62.9 -35.88 81.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.585 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -92.52 110.95 22.38 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.463 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -62.67 -40.96 98.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.644 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -114.95 101.98 9.54 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.23 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 34.2 tp -115.6 134.0 55.48 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.041 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 16.4 t -117.8 81.37 15.21 Favored Pre-proline 0 N--CA 1.466 0.341 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.637 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.55 -10.94 17.26 Favored 'Trans proline' 0 N--CA 1.491 1.329 0 C-N-CA 122.381 2.054 . . . . 0.0 112.362 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.467 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -63.77 -43.54 97.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.974 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.87 -19.62 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.545 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.467 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.2 t -64.83 -43.4 96.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.446 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.78 -36.72 93.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.66 -40.86 98.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.408 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.63 -36.47 83.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.633 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.653 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.0 tt -61.42 -44.04 97.82 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.992 0.425 . . . . 0.0 109.925 -179.441 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.82 -37.06 85.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.447 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.56 -39.32 97.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.2 t -65.99 -42.0 90.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.115 0.483 . . . . 0.0 110.243 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -59.55 -41.01 89.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.595 -179.207 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.8 mt -67.75 -41.63 85.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.053 0.454 . . . . 0.0 110.387 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.03 -41.23 91.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.636 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.8 t -64.3 -41.81 93.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.796 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.39 -41.52 97.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.497 -179.398 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.72 -42.08 98.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.1 -48.52 75.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.537 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -64.89 -36.5 84.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.373 179.176 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -57.26 -45.65 83.81 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.182 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -63.7 -42.59 96.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.63 -37.17 94.33 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 43.7 tp -62.85 -42.07 99.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.812 0.339 . . . . 0.0 110.553 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -65.95 136.42 56.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.734 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 63.6 t-80 46.79 87.74 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.526 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -69.87 141.82 53.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.567 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.9 m-70 -75.96 137.12 40.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.583 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.21 -13.12 60.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.625 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.26 -36.98 94.15 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -78.46 132.39 37.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.716 0.293 . . . . 0.0 110.537 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 408' ' ' GLU . . . . . 0.505 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.5 mp0 -104.12 125.14 50.2 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.463 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.487 ' N ' ' CD ' ' A' ' 409' ' ' GLN . 1.9 pm0 -63.84 135.4 56.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.224 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 410' ' ' PHE . . . . . 0.438 ' OXT' ' CG ' ' A' ' 410' ' ' PHE . 91.7 t80 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.014 -0.993 . . . . 0.0 110.323 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 46.3 t . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.81 -38.14 89.98 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.488 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -93.96 110.43 22.11 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.364 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -70.25 141.5 52.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.634 -179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -65.8 138.16 57.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.618 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 374' ' ' ASN . . . . . 0.505 ' O ' ' N ' ' B' ' 378' ' ' PRO . 95.2 m-20 -64.27 -39.82 94.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.718 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -59.72 -46.57 88.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.737 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 376' ' ' LEU . . . . . 0.492 ' N ' HD12 ' B' ' 376' ' ' LEU . 9.8 mp -64.6 -40.32 95.3 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.449 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 3.3 m -144.0 75.35 15.81 Favored Pre-proline 0 CA--C 1.531 0.221 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.389 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 378' ' ' PRO . . . . . 0.505 ' N ' ' O ' ' B' ' 374' ' ' ASN . 57.7 Cg_endo -75.36 -11.17 20.85 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 122.571 2.181 . . . . 0.0 112.156 -179.513 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt -63.6 -43.65 98.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.914 -179.377 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.13 -19.77 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 121.013 -0.275 . . . . 0.0 110.651 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.521 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.2 t -64.31 -43.71 97.19 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.41 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.69 -38.43 96.21 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.15 -41.14 97.99 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.912 0.387 . . . . 0.0 110.404 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.55 -36.24 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.511 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 385' ' ' LEU . . . . . 0.643 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.6 tt -61.5 -44.43 97.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.02 0.438 . . . . 0.0 110.021 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.81 82.76 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.392 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.15 -37.72 95.37 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.68 -41.99 93.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.991 0.424 . . . . 0.0 110.075 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 389' ' ' LEU . . . . . 0.579 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.1 tt -60.57 -38.1 83.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.224 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.87 -42.12 94.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.822 0.344 . . . . 0.0 110.201 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.86 -40.38 92.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.471 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 92.9 t -63.86 -40.92 90.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.822 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.32 -41.15 96.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.394 -179.487 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.46 -42.18 98.37 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.21 -46.19 89.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.772 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -63.62 -37.68 88.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.357 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.52 -45.96 84.39 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.243 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -63.52 -42.4 96.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.194 179.328 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.75 -24.62 62.55 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 400' ' ' LEU . . . . . 0.531 HD13 ' O ' ' B' ' 400' ' ' LEU . 0.2 OUTLIER -62.63 -41.88 99.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.893 0.378 . . . . 0.0 110.039 -179.465 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -70.11 152.04 44.78 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.506 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 55.1 t-80 45.83 92.87 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.579 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 81.1 t60 -78.67 128.2 33.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.282 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -76.27 137.58 40.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.515 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.85 -11.67 60.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.644 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.05 -36.86 94.04 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 83.6 t80 -84.86 132.16 34.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.727 0.298 . . . . 0.0 110.419 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -81.72 119.56 24.01 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.193 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.441 ' OE1' ' N ' ' B' ' 410' ' ' PHE . 7.9 tp-100 -66.43 133.35 50.25 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 410' ' ' PHE . . . . . 0.441 ' N ' ' OE1' ' B' ' 409' ' ' GLN . 88.3 t80 . . . . . 0 C--O 1.219 -0.539 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.515 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 1.5 t . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' C' C ' 370' ' ' ALA . . . . . 0.438 ' O ' ' OD1' ' C' ' 373' ' ' ASP . . . -69.42 140.1 54.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.653 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -64.15 -35.23 80.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.297 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.437 ' OD1' ' O ' ' C' ' 372' ' ' ASP . 66.3 t0 -61.87 -35.55 78.62 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.585 -179.724 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 373' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' C' ' 370' ' ' ALA . 99.5 m-20 56.8 34.33 24.51 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.475 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 58.6 t-20 -87.0 105.41 17.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.375 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -113.98 103.43 11.15 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.182 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 86.1 mt -130.4 139.39 50.62 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.412 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.638 ' O ' HG13 ' C' ' 377' ' ' VAL . 12.6 p -171.05 62.64 0.38 Allowed Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.365 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -74.65 89.08 1.14 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.557 2.171 . . . . 0.0 111.823 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 37.9 mm -76.68 -70.43 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.777 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -80.17 -19.73 46.47 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.528 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 52.4 t -65.4 -43.37 94.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.292 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.62 -41.62 99.61 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -38.07 88.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.743 0.306 . . . . 0.0 110.643 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.16 -43.91 96.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.674 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -66.0 -40.7 91.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.497 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.95 91.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.549 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.05 -39.35 97.14 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.8 t -64.06 -42.52 95.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 0.0 110.457 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.647 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.5 tt -60.26 -38.37 83.3 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.772 -179.496 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.03 -42.48 95.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-O 120.846 0.355 . . . . 0.0 110.052 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.18 -40.41 93.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.436 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.6 -41.08 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.742 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.27 -41.27 96.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.435 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.5 -42.24 98.5 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -47.96 81.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.916 -0.583 . . . . 0.0 109.832 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -63.12 -35.82 81.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.217 179.406 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -59.1 -45.26 91.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.321 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.1 mt -63.15 -42.5 96.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.244 179.445 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.71 -37.4 94.31 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 49.0 tp -62.89 -42.18 99.68 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.368 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 52.8 tttp 54.1 103.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.441 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -75.59 129.33 37.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.103 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 33.3 p80 -127.63 142.96 51.21 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.432 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -75.64 139.63 42.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.485 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.37 -12.02 59.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.695 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.01 -37.11 94.43 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 79.4 t80 -78.14 132.41 37.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.773 0.321 . . . . 0.0 110.488 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -87.18 117.36 25.87 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.772 0.32 . . . . 0.0 110.278 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -52.94 142.24 19.99 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.011 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 89.4 t80 . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.773 179.997 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 65.2 p . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.32 151.53 29.19 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.546 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.505 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 36.7 p-10 -66.29 -36.0 81.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.553 179.852 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.505 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 68.3 t0 -91.53 111.99 23.73 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.542 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 52.4 p30 -79.31 166.34 22.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.458 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -94.21 6.38 48.79 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.522 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -115.78 102.78 10.03 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.319 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.576 HD12 ' N ' ' A' ' 376' ' ' LEU . 9.9 mp -95.55 131.48 41.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.162 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.483 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 14.7 m -149.36 52.74 1.17 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.344 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.483 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 26.0 Cg_endo -62.81 -23.24 74.36 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.733 2.288 . . . . 0.0 111.844 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.8 mm -66.92 -44.83 88.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.57 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.4 -20.26 62.95 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.804 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.37 -42.32 90.35 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.992 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.52 -40.17 98.33 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.15 -38.21 90.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.74 0.305 . . . . 0.0 110.743 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.7 -45.7 91.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.671 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.28 -41.57 94.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.511 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.35 -38.17 90.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.293 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.6 -41.79 99.77 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.7 t -67.11 -42.36 88.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.823 0.344 . . . . 0.0 110.159 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.626 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -60.0 -40.8 90.44 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.3 -179.021 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.7 mt -66.42 -41.75 89.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.959 0.409 . . . . 0.0 110.351 178.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.54 -40.55 91.95 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.579 -179.292 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.4 t -64.33 -41.15 91.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.752 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.93 -41.57 98.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.537 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.41 -42.49 99.48 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.242 -0.583 . . . . 0.0 109.476 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.09 -48.95 72.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.981 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -64.13 -35.79 81.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.422 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -57.38 -45.8 84.07 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.282 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.2 mt -64.89 -42.43 94.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.48 -33.69 87.92 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.8 tp -61.33 -40.81 95.59 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.411 -179.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 57.17 45.19 21.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.796 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 402' ' ' HIS . . . . . 0.48 ' CE1' ' O ' ' A' ' 403' ' ' HIS . 39.7 t-80 -70.45 124.61 24.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.194 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 403' ' ' HIS . . . . . 0.48 ' O ' ' CE1' ' A' ' 402' ' ' HIS . 99.4 m-70 -78.4 142.52 37.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.547 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -78.47 142.49 37.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.506 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.36 -14.07 59.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.537 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.59 -40.58 96.09 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -109.42 133.47 53.03 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 408' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 55.3 mp0 -106.73 123.97 48.92 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 120.893 0.378 . . . . 0.0 110.064 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.621 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 0.4 OUTLIER -52.86 146.21 11.14 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 410' ' ' PHE . . . . . 0.498 ' CG ' ' O ' ' A' ' 410' ' ' PHE . 91.1 t80 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.111 -0.947 . . . . 0.0 110.38 -179.627 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 6.5 t . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.0 -38.16 90.03 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.449 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 55.0 t0 55.06 33.36 20.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.554 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -68.9 141.88 54.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.629 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -61.66 -41.33 97.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.457 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 374' ' ' ASN . . . . . 0.429 ' ND2' ' O ' ' B' ' 377' ' ' VAL . 63.9 t30 59.79 39.19 21.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.693 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 92.4 t80 -65.26 -23.52 67.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.469 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 46.6 tp -64.51 -43.75 93.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.463 -179.705 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.429 ' O ' ' ND2' ' B' ' 374' ' ' ASN . 0.9 OUTLIER -148.15 69.25 10.68 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.239 -179.449 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -74.95 -16.17 20.48 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.717 2.278 . . . . 0.0 112.025 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.507 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.9 mt -63.36 -43.88 98.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.315 -178.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.14 -20.1 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.752 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.507 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.38 -43.9 94.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 120.904 0.383 . . . . 0.0 110.178 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.73 -35.77 91.42 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.23 -41.86 98.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.861 0.363 . . . . 0.0 110.662 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.4 84.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.45 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 385' ' ' LEU . . . . . 0.646 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.3 tt -61.23 -44.47 97.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.922 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.23 83.65 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.548 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.74 -41.09 97.37 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 62.1 t -67.24 -43.35 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.668 0.27 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.29 -40.37 93.91 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 119.536 -0.866 . . . . 0.0 109.771 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 79.2 mt -64.04 -42.4 95.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 120.872 0.368 . . . . 0.0 110.572 178.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.08 -41.4 96.59 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.588 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.6 t -65.94 -42.33 91.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.076 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.67 -40.47 95.08 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.4 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.18 -42.94 99.75 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.588 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.74 -36.82 84.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.157 179.395 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -60.36 -44.38 95.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.601 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.0 -43.79 98.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.61 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 91.2 mt -63.55 -42.61 96.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.717 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.98 -34.28 89.46 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 52.5 tp -62.26 -39.65 93.61 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 121.006 -0.277 . . . . 0.0 110.397 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 401' ' ' LYS . . . . . 0.437 ' O ' ' O ' ' B' ' 402' ' ' HIS . 99.2 mttt 56.91 103.73 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.596 -179.794 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 402' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' B' ' 401' ' ' LYS . 78.9 m80 55.48 160.61 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.548 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -73.96 141.25 45.92 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.498 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -78.24 131.37 37.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.474 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.52 -12.67 59.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.538 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.45 -36.09 92.92 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 73.9 m-85 -103.02 135.1 45.32 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.325 -0.25 . . . . 0.0 110.325 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.42 148.61 49.37 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 120.718 0.294 . . . . 0.0 110.514 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.53 ' OE1' ' N ' ' B' ' 410' ' ' PHE . 3.9 tp-100 -74.02 123.7 24.85 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.476 -0.49 . . . . 0.0 109.795 179.663 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 410' ' ' PHE . . . . . 0.53 ' N ' ' OE1' ' B' ' 409' ' ' GLN . 96.5 m-85 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.11 -0.948 . . . . 0.0 110.618 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -61.78 -39.09 90.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.397 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.79 33.09 18.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.435 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -62.31 -38.48 89.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.44 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -65.79 141.58 58.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.573 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 374' ' ' ASN . . . . . 0.489 ' C ' ' H ' ' C' ' 376' ' ' LEU . 94.8 m-20 -91.21 6.75 43.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.44 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 49.48 10.77 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.668 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 376' ' ' LEU . . . . . 0.489 ' H ' ' C ' ' C' ' 374' ' ' ASN . 99.4 mt -137.46 105.38 5.64 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.263 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.651 ' O ' HG13 ' C' ' 377' ' ' VAL . 9.0 p -174.94 74.28 0.3 Allowed Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.198 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.536 ' O ' HG12 ' C' ' 381' ' ' VAL . 29.7 Cg_exo -60.55 143.5 99.44 Favored 'Trans proline' 0 C--N 1.302 -1.913 0 C-N-CA 122.709 2.273 . . . . 0.0 112.033 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.0 mt -64.84 -43.69 96.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.234 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.42 -20.02 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.816 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.536 HG12 ' O ' ' C' ' 378' ' ' PRO . 7.9 p -61.82 -42.72 95.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.704 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 382' ' ' GLY . . . . . 0.486 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -64.46 -42.15 97.69 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.19 86.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.86 0.362 . . . . 0.0 110.787 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.56 -45.34 94.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.676 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -64.5 -40.43 95.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.433 179.413 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.93 -37.26 87.05 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.466 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.95 -40.2 97.02 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.98 -43.27 96.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.926 0.394 . . . . 0.0 110.318 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.8 -38.59 88.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.17 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.86 -42.09 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.9 mt -61.41 -41.68 97.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.573 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 90.2 t -65.73 -42.24 92.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.51 -41.82 97.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.625 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -62.27 -43.55 98.56 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.66 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.58 -36.42 82.59 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -61.12 -44.96 96.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.805 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -62.47 -43.69 98.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.645 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.4 mt -64.92 -42.69 95.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.882 179.472 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.47 -39.65 97.93 Favored Glycine 0 CA--C 1.52 0.376 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 400' ' ' LEU . . . . . 0.45 ' O ' ' N ' ' C' ' 402' ' ' HIS . 57.4 tp -62.81 -41.16 99.18 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.876 -0.329 . . . . 0.0 110.418 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 401' ' ' LYS . . . . . 0.489 ' HB3' ' CE1' ' C' ' 403' ' ' HIS . 49.9 tttm 44.56 19.43 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.681 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 402' ' ' HIS . . . . . 0.45 ' N ' ' O ' ' C' ' 400' ' ' LEU . 98.1 m-70 43.47 90.53 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.553 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 403' ' ' HIS . . . . . 0.489 ' CE1' ' HB3' ' C' ' 401' ' ' LYS . 44.9 m80 -102.32 127.8 49.15 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.479 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -80.43 144.2 32.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.475 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.0 -35.1 57.39 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.508 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.02 -35.09 91.62 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 53.6 t80 -81.49 134.65 35.56 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 121.059 -0.256 . . . . 0.0 110.381 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 408' ' ' GLU . . . . . 0.517 ' OE1' ' N ' ' C' ' 408' ' ' GLU . 56.6 mp0 -109.71 129.18 55.63 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-O 120.863 0.363 . . . . 0.0 110.316 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.526 ' OE1' ' N ' ' C' ' 410' ' ' PHE . 3.8 tp-100 -70.54 120.97 16.95 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.575 -0.45 . . . . 0.0 109.883 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 410' ' ' PHE . . . . . 0.526 ' N ' ' OE1' ' C' ' 409' ' ' GLN . 89.1 t80 . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.605 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 84.1 p . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -159.93 153.21 22.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.6 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -60.58 -43.96 96.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.33 -179.779 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -62.91 -37.27 86.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.529 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -86.8 113.44 22.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.493 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -95.5 143.44 26.82 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.32 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -59.61 -45.63 91.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.465 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 34.6 mt -119.88 125.42 48.45 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.474 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.645 ' O ' HG22 ' A' ' 377' ' ' VAL . 7.5 p -173.42 48.79 0.08 OUTLIER Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.385 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 21.8 Cg_endo -60.7 143.43 99.4 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 C-N-CA 122.669 2.246 . . . . 0.0 111.872 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt -64.44 -43.39 96.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.847 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.87 -20.48 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.657 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' A' ' 379' ' ' ILE . 43.6 t -67.97 -43.62 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.413 179.144 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 379' ' ' ILE . . . -64.96 -38.15 95.13 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.94 98.46 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.713 0.292 . . . . 0.0 110.743 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.76 -48.07 82.35 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.92 0.391 . . . . 0.0 110.565 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.6 -40.95 93.22 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.37 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.51 -39.14 89.91 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.232 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.56 -37.57 94.97 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -63.74 -43.14 97.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.989 0.423 . . . . 0.0 110.243 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.4 mp -61.89 -38.0 86.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.345 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 28.9 mm -63.13 -42.13 95.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -61.16 -42.47 98.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.569 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.3 t -65.62 -42.17 92.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.983 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.94 -40.62 96.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.596 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -60.88 -41.89 96.89 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.95 -49.47 73.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.877 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -65.72 -35.41 80.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.329 179.163 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 397' ' ' PHE . . . . . 0.487 ' CE2' ' CE1' ' A' ' 402' ' ' HIS . 24.4 t80 -58.0 -45.8 86.26 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.308 -179.415 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.04 -42.94 97.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.231 179.2 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.84 -41.83 98.66 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.405 HD23 ' CE1' ' A' ' 402' ' ' HIS . 52.4 tp -62.75 -41.03 99.02 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.302 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 62.4 tttp 58.54 94.0 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.549 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 402' ' ' HIS . . . . . 0.487 ' CE1' ' CE2' ' A' ' 397' ' ' PHE . 77.8 m80 -76.73 135.47 39.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.369 179.73 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -78.88 128.36 33.23 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.316 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.9 m-70 -77.18 139.84 40.02 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.539 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.56 -14.21 59.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.518 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.36 -40.26 96.34 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -105.39 133.65 49.8 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.919 0.39 . . . . 0.0 110.15 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -135.32 145.29 47.32 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.71 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -52.77 142.55 18.54 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.427 179.841 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 19.4 p . . . . . 0 N--CA 1.489 1.509 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . 51.97 100.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.45 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -100.0 111.54 23.84 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.337 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 37.8 p30 -71.63 -10.15 59.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.623 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -63.1 -43.63 97.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.652 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -156.32 167.99 28.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.263 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 89.0 t80 -138.19 111.92 8.28 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.082 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 49.4 tp -107.9 129.28 55.1 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 120.967 0.413 . . . . 0.0 110.256 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 1.4 m -43.87 151.89 0.49 Allowed Pre-proline 0 CA--C 1.535 0.402 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.765 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.51 152.3 82.29 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 122.536 2.158 . . . . 0.0 111.954 179.566 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.2 mt -63.31 -42.85 97.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.797 -179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -39.93 -20.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.665 -179.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.4 t -67.23 -43.8 88.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 CA-C-O 120.659 0.266 . . . . 0.0 110.567 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 382' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' B' ' 379' ' ' ILE . . . -65.26 -37.74 94.32 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.1 -38.53 91.54 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.327 . . . . 0.0 110.66 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.28 -48.05 79.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.848 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.54 -41.6 92.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.429 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.84 -36.98 85.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.327 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.62 -40.09 98.26 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 77.9 t -63.2 -43.46 98.81 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.975 0.417 . . . . 0.0 110.244 179.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.2 -38.01 87.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.361 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.77 -42.15 95.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.4 mt -60.84 -42.63 98.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.557 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.62 -42.31 92.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.56 -41.4 97.33 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.374 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.97 -42.44 99.13 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 120.288 -0.565 . . . . 0.0 109.546 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.59 -38.16 86.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.017 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 396' ' ' TYR . . . . . 0.553 ' CZ ' HD11 ' B' ' 400' ' ' LEU . 91.3 t80 -62.13 -44.8 95.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.477 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -68.43 -45.54 72.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.866 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.11 -42.03 94.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.068 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.85 -42.37 96.59 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 400' ' ' LEU . . . . . 0.553 HD11 ' CZ ' ' B' ' 396' ' ' TYR . 9.8 mt -64.68 -40.78 95.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.955 0.407 . . . . 0.0 110.535 179.503 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -67.71 -3.26 8.68 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.691 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -58.24 -44.27 88.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.519 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 403' ' ' HIS . . . . . 0.5 ' CE1' ' O ' ' B' ' 400' ' ' LEU . 52.7 p-80 -92.57 119.13 31.72 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.223 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -82.65 132.0 35.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.542 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.12 -12.7 60.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.442 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.02 -37.46 95.0 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 83.7 t80 -81.81 131.78 35.27 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.816 0.341 . . . . 0.0 110.341 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -135.41 148.44 49.33 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.544 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -101.02 129.14 46.82 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.887 0.375 . . . . 0.0 110.263 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 88.7 t80 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.585 -179.983 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 33.4 t . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' C' C ' 370' ' ' ALA . . . . . 0.443 ' O ' ' OD1' ' C' ' 374' ' ' ASN . . . -155.03 156.91 36.78 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.547 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 371' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 40.1 p-10 -65.49 -35.42 80.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.532 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.512 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 54.7 p-10 -80.62 150.81 29.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.522 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 55.17 49.13 17.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.464 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 374' ' ' ASN . . . . . 0.481 ' ND2' ' O ' ' C' ' 371' ' ' ASP . 99.2 m-20 -75.27 138.51 41.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.652 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -62.19 -44.06 97.43 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.603 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 89.8 mt -133.38 145.63 50.52 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.493 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 1.5 m -49.71 155.33 1.46 Allowed Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.927 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.457 ' HB2' HG23 ' C' ' 381' ' ' VAL . 50.8 Cg_exo -48.48 147.6 8.95 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 122.227 1.951 . . . . 0.0 112.419 178.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt -65.52 -43.56 94.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.085 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -58.44 -24.65 60.76 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.653 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.457 HG23 ' HB2' ' C' ' 378' ' ' PRO . 56.0 t -68.86 -43.55 82.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.094 0 CA-C-O 120.73 0.3 . . . . 0.0 110.585 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.17 -36.17 92.9 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.58 -40.15 95.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.718 0.294 . . . . 0.0 110.751 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 384' ' ' ALA . . . . . 0.402 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -60.82 -48.59 81.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.8 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.97 -40.86 95.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.47 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.11 -37.74 86.27 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.422 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.11 -38.01 94.81 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 388' ' ' VAL . . . . . 0.402 HG23 ' O ' ' C' ' 384' ' ' ALA . 98.3 t -65.03 -43.17 96.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 120.75 0.309 . . . . 0.0 110.539 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 mp -61.36 -39.39 90.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.042 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.12 -42.42 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.073 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -61.11 -41.76 97.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.529 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.6 t -65.43 -41.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.53 -40.44 94.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.439 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.42 -42.06 98.15 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.47 76.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.725 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -64.59 -35.88 82.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.373 179.209 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -57.67 -45.12 85.99 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.275 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.8 mt -63.81 -42.65 96.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.117 179.286 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.93 -39.27 97.84 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 54.7 tp -63.72 -42.37 97.92 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.529 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -73.95 132.83 42.83 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.744 -179.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -76.71 138.67 40.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.293 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -80.36 139.6 36.47 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.493 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -106.42 127.35 53.22 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.251 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.0 -37.57 54.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.413 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.28 -39.52 97.95 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 80.8 m-85 -107.75 133.76 51.68 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 46.1 tp10 -90.75 118.41 30.15 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.007 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 8.4 pt20 -52.83 140.6 23.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.051 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 88.1 t80 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.443 179.891 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 13.1 m . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.85 152.69 30.1 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.605 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.544 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 40.2 p-10 -65.09 -37.4 87.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.507 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.544 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 99.6 m-20 -67.5 142.47 56.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.609 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -68.66 143.42 54.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.59 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.409 ' O ' ' OD1' ' A' ' 374' ' ' ASN . 48.8 t-20 -62.34 -39.87 94.53 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.582 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -60.33 -42.13 94.98 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.595 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.574 ' N ' HD22 ' A' ' 376' ' ' LEU . 3.2 mm? -80.5 140.41 35.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.722 -179.463 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 1.5 m -70.55 155.12 93.88 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.827 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.507 ' O ' HG12 ' A' ' 381' ' ' VAL . 53.0 Cg_exo -49.53 137.57 32.56 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.252 1.968 . . . . 0.0 112.119 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 381' ' ' VAL . 94.9 mt -63.73 -43.15 97.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.008 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.48 -19.81 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.962 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.526 ' N ' ' O ' ' A' ' 379' ' ' ILE . 7.8 p -60.53 -43.65 94.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.749 0.309 . . . . 0.0 110.41 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.52 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -64.81 -36.45 93.12 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -41.3 98.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.738 0.304 . . . . 0.0 110.669 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.36 -36.24 83.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.612 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.623 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.4 tt -61.65 -45.31 94.58 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.056 0.455 . . . . 0.0 110.106 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -37.7 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.5 -42.44 97.64 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.2 t -67.12 -42.49 88.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.738 0.304 . . . . 0.0 110.627 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.57 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.9 tt -59.97 -40.99 90.99 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.223 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -65.33 -42.17 93.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.872 0.368 . . . . 0.0 110.234 179.09 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.85 -41.14 95.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.685 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.1 t -63.88 -41.49 92.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.682 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.34 -41.02 96.36 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.598 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.46 -41.8 97.79 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.295 -0.562 . . . . 0.0 109.545 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.54 -49.63 74.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.882 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -65.01 -34.88 79.5 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.365 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -58.21 -45.56 87.43 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.351 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.3 mt -63.63 -42.74 97.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.34 -38.53 95.97 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.9 tp -63.38 -41.54 98.79 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.434 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 54.4 tttm 59.1 69.72 0.7 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.601 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 402' ' ' HIS . . . . . 0.511 ' ND1' ' N ' ' A' ' 403' ' ' HIS . 64.5 t-80 57.86 162.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.455 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 403' ' ' HIS . . . . . 0.511 ' N ' ' ND1' ' A' ' 402' ' ' HIS . 54.9 t-80 -83.85 126.6 33.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.491 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 21.4 t-80 -82.24 132.38 35.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.612 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.22 -11.37 59.81 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.524 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.21 -40.35 98.98 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -81.67 136.22 35.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.627 0.251 . . . . 0.0 110.371 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -85.23 117.35 24.12 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.8 0.334 . . . . 0.0 110.345 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.642 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 3.0 pm0 -53.9 145.27 16.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.112 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.5 t80 . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.969 -1.015 . . . . 0.0 110.59 -179.86 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 16.6 t . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.38 144.53 53.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.559 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 371' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' B' ' 372' ' ' ASP . 35.2 p-10 -64.51 -34.97 79.47 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.422 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 372' ' ' ASP . . . . . 0.467 ' N ' ' OD1' ' B' ' 371' ' ' ASP . 52.7 t0 -88.93 111.66 22.38 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.405 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 52.1 p-10 -77.46 167.35 21.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.397 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -94.06 9.34 38.07 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.561 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -129.03 104.63 7.69 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.538 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 90.3 mt -135.86 140.97 44.55 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.175 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 19.7 t -143.31 72.82 17.91 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.415 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_exo -60.86 145.02 99.64 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 C-N-CA 123.01 2.473 . . . . 0.0 111.929 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.496 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt -64.27 -44.14 97.3 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.044 -179.627 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.62 -20.06 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.682 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.496 ' N ' ' O ' ' B' ' 379' ' ' ILE . 62.2 t -65.17 -43.11 95.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.361 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.19 -39.63 98.15 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -40.48 96.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.513 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.49 -35.48 81.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.512 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 385' ' ' LEU . . . . . 0.653 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.8 tt -61.41 -44.05 97.81 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 121.1 0.476 . . . . 0.0 109.988 -179.679 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -37.05 85.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.421 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.11 -39.97 96.52 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.96 -43.2 92.85 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.938 0.399 . . . . 0.0 110.218 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -60.36 -40.67 91.63 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.806 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 80.1 mt -67.33 -41.37 86.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.146 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -60.12 -40.93 91.44 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.696 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 75.7 t -63.84 -41.38 92.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.666 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.27 -41.29 96.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.521 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.4 -42.82 99.33 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.558 179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.25 -47.9 74.76 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.836 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 85.0 t80 -64.36 -34.7 78.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.448 179.371 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -58.57 -44.87 89.91 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.41 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 42.3 mm -65.09 -40.99 90.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.83 179.467 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.55 -34.86 87.59 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 400' ' ' LEU . . . . . 0.429 ' O ' ' O ' ' B' ' 401' ' ' LYS . 53.4 tp -62.14 -40.93 97.58 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.458 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 401' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' B' ' 400' ' ' LEU . 88.5 tttt 59.76 139.67 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.772 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 70.5 m80 -75.36 137.55 41.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.265 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -82.17 126.13 31.7 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.099 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 404' ' ' HIS . . . . . 0.51 ' CE1' ' HA3' ' B' ' 406' ' ' GLY . 22.8 t-80 -121.06 124.87 45.87 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.279 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.23 -15.34 58.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.598 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 406' ' ' GLY . . . . . 0.51 ' HA3' ' CE1' ' B' ' 404' ' ' HIS . . . -65.6 -36.56 92.59 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -78.23 131.72 37.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.755 0.312 . . . . 0.0 110.419 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -135.44 144.97 46.76 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.815 0.34 . . . . 0.0 110.755 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -52.74 144.0 15.16 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.58 -0.448 . . . . 0.0 109.82 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 117.965 -1.016 . . . . 0.0 110.514 179.646 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 9.3 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.58 154.36 28.37 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.613 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 54.71 37.85 29.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.46 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' C' ' 374' ' ' ASN . 55.4 t0 -89.24 109.96 20.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.515 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -62.27 -42.05 99.0 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.49 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 374' ' ' ASN . . . . . 0.513 ' ND2' HG11 ' C' ' 377' ' ' VAL . 20.5 p30 -155.73 162.44 40.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.499 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.78 -59.19 2.58 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.66 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 93.8 mt -136.35 133.54 36.92 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.459 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.513 HG11 ' ND2' ' C' ' 374' ' ' ASN . 18.2 m -152.46 52.16 0.85 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.411 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.475 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 36.3 Cg_endo -65.78 -21.59 57.97 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.76 2.307 . . . . 0.0 111.998 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.6 mm -65.69 -44.41 93.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.352 -179.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.95 -20.08 61.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.005 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 54.5 t -65.9 -43.71 92.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 CA-C-O 120.744 0.307 . . . . 0.0 110.344 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.72 -41.86 99.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.04 -36.98 86.09 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.792 0.329 . . . . 0.0 110.713 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.43 -46.04 89.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.672 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -64.7 -41.05 96.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.416 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.23 -37.51 85.67 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.397 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.26 -36.41 92.76 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.4 t -64.23 -43.59 97.29 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-O 120.746 0.307 . . . . 0.0 110.458 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 mp -61.63 -39.02 89.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.222 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.24 -41.94 93.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 8.4 mt -60.76 -42.51 97.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.729 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 82.0 t -65.15 -42.44 94.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.834 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.98 -42.73 99.46 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.731 -179.431 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.08 -43.81 98.03 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.04 -36.86 84.39 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.087 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -61.53 -44.59 96.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.67 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -62.73 -45.34 93.17 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.566 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 398' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' C' ' 401' ' ' LYS . 87.7 mt -64.55 -42.67 95.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.867 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.23 -41.84 96.6 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 48.4 tp -63.17 -42.18 99.36 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.606 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 401' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' C' ' 398' ' ' ILE . 68.7 mttm -91.25 143.76 26.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.502 -179.635 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 66.1 t-80 46.12 94.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.647 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 56.8 p-80 -71.91 141.65 49.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.567 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -78.14 125.67 29.69 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.47 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -89.46 -11.13 43.92 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.507 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.92 -39.02 97.52 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -79.03 130.22 35.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.792 0.33 . . . . 0.0 110.347 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -135.43 143.86 46.18 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.77 0.319 . . . . 0.0 110.894 179.696 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 44.0 tp60 -74.7 129.62 38.04 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.537 -0.465 . . . . 0.0 109.914 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 94.1 t80 . . . . . 0 C--N 1.326 -0.44 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.466 179.996 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.4 t . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.88 154.6 32.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.41 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -105.74 106.9 17.61 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.368 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.534 ' OD1' ' N ' ' A' ' 373' ' ' ASP . 42.4 p-10 -63.68 -34.85 78.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.62 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.534 ' N ' ' OD1' ' A' ' 372' ' ' ASP . 53.9 t0 -89.35 109.25 20.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.214 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -98.02 8.46 44.72 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.638 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -93.92 1.21 56.37 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.4 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 47.3 mt -106.89 5.64 28.55 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.383 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.429 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 2.7 t -129.78 54.6 14.94 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.482 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.429 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 36.3 Cg_endo -66.63 -17.57 52.93 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.573 2.182 . . . . 0.0 111.789 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 44.2 mm -66.43 -44.97 90.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.211 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.07 -20.51 63.22 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.784 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.3 t -66.8 -42.98 90.03 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.372 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.24 -37.68 94.94 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.24 96.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.871 0.367 . . . . 0.0 110.439 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.8 -36.11 82.83 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.416 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.616 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.7 tt -62.17 -44.1 97.35 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.085 0.469 . . . . 0.0 110.018 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.03 -37.07 81.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.594 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.82 -39.07 96.99 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 95.5 t -63.63 -42.07 94.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.217 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.56 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.9 tt -60.7 -37.81 82.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.511 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.8 mm -64.4 -41.79 93.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.97 0.414 . . . . 0.0 110.196 179.4 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.4 mt -60.75 -40.94 94.31 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.53 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.8 t -64.26 -40.8 90.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.45 -40.78 95.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.407 -179.5 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.03 -41.54 96.76 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.41 -48.35 74.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.756 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.7 t80 -65.57 -35.61 81.35 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.602 -0.727 . . . . 0.0 110.488 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -56.78 -45.69 81.98 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.381 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.01 -42.27 94.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.137 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.63 -33.24 84.33 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.5 tp -61.84 -42.02 98.53 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.801 -0.359 . . . . 0.0 110.469 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -84.69 153.25 23.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.693 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 402' ' ' HIS . . . . . 0.529 ' O ' ' CG ' ' A' ' 402' ' ' HIS . 48.8 t-80 49.91 43.72 25.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.535 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -79.14 133.78 36.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.351 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -75.11 140.31 43.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.541 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.24 -11.43 59.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.522 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.48 -36.36 93.27 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -111.34 138.2 48.12 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.866 0.365 . . . . 0.0 110.304 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.34 145.07 47.04 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.714 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 47.6 tp60 -73.27 130.87 41.16 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.489 -0.485 . . . . 0.0 109.894 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.2 t80 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.045 -0.978 . . . . 0.0 110.25 -179.699 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 4.4 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.86 149.75 26.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.414 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -99.9 112.3 24.57 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.182 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -88.63 107.01 18.69 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.515 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 373' ' ' ASP . . . . . 0.41 ' OD1' ' N ' ' B' ' 373' ' ' ASP . 33.2 p-10 -88.38 0.11 56.57 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.374 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 58.0 t-20 -82.21 110.76 17.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.343 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -61.19 -43.12 99.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.664 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 376' ' ' LEU . . . . . 0.597 ' N ' HD12 ' B' ' 376' ' ' LEU . 10.1 mp -90.25 131.66 35.94 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.316 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.494 HG22 ' H ' ' B' ' 379' ' ' ILE . 9.2 p -69.81 129.5 91.05 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.824 -179.254 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -70.81 -18.01 32.4 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.115 1.877 . . . . 0.0 112.396 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.494 ' H ' HG22 ' B' ' 377' ' ' VAL . 96.8 mt -63.27 -44.67 99.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 121.019 -0.273 . . . . 0.0 111.267 -178.699 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 380' ' ' ALA . . . . . 0.414 ' H ' HG13 ' B' ' 377' ' ' VAL . . . -74.62 -19.99 60.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.763 -179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.09 -43.19 88.94 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.21 -40.62 97.53 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.63 -37.87 89.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.743 0.306 . . . . 0.0 110.659 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.88 -46.63 88.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.602 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.68 -41.87 91.95 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.539 179.5 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -39.05 93.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.433 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.8 -42.85 99.66 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 89.5 t -66.51 -43.17 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 121.168 -0.213 . . . . 0.0 111.02 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 389' ' ' LEU . . . . . 0.56 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.0 tt -60.64 -41.27 94.6 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.349 -0.541 . . . . 0.0 109.739 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -63.87 -42.23 95.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 0.0 110.319 178.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.8 -40.09 91.35 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.507 -179.69 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.8 t -63.95 -41.86 93.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.97 -40.8 94.78 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.238 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.45 -43.42 98.91 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.132 -0.627 . . . . 0.0 109.502 179.771 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.16 -37.11 86.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.125 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -61.62 -44.86 96.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.621 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 36.5 m-85 -63.43 -41.67 98.68 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.578 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.3 mm -63.76 -42.16 95.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.013 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.22 -58.6 13.7 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 400' ' ' LEU . . . . . 0.525 ' C ' ' H ' ' B' ' 402' ' ' HIS . 4.0 mm? -64.45 -40.91 96.63 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 121.027 -0.269 . . . . 0.0 110.44 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 47.9 tttp 70.61 -34.52 0.3 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.644 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 402' ' ' HIS . . . . . 0.525 ' H ' ' C ' ' B' ' 400' ' ' LEU . 49.1 p-80 -152.74 149.24 28.15 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.327 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -84.29 129.72 34.86 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.365 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -71.45 140.78 50.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.541 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.24 -12.01 59.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.586 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.27 -39.31 97.72 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 81.8 t80 -83.12 132.05 35.11 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 408' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 56.3 mp0 -99.01 133.36 43.39 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.267 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.585 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 0.5 OUTLIER -52.85 145.97 11.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.007 -179.925 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 93.8 t80 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.487 -179.734 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 41.4 t . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.29 -39.01 93.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.572 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 48.3 t0 -121.86 110.17 15.55 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.398 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -87.69 114.77 24.62 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.413 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -91.14 107.59 19.3 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.334 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 374' ' ' ASN . . . . . 0.556 ' O ' ' N ' ' C' ' 376' ' ' LEU . 54.9 p30 -102.86 8.79 39.17 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.536 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 50.47 -83.97 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.727 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 376' ' ' LEU . . . . . 0.556 ' N ' ' O ' ' C' ' 374' ' ' ASN . 3.8 tp 68.07 1.42 2.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.33 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 3.9 t 61.46 75.31 0.45 Allowed Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.511 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -55.37 -31.44 77.36 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.792 2.328 . . . . 0.0 112.053 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.1 mm -64.29 -44.5 97.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.137 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.86 -20.34 62.54 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.783 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 63.5 t -67.5 -43.2 87.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.87 -38.49 96.19 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.46 95.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.734 0.302 . . . . 0.0 110.731 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.29 88.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.772 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -64.98 -41.93 94.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.417 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.7 -36.46 83.92 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.346 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.8 -42.21 99.72 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 94.2 t -64.0 -42.96 97.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.885 0.374 . . . . 0.0 110.242 179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.585 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.1 tt -60.89 -37.99 84.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.832 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.8 mm -63.4 -42.59 96.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.138 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.42 -40.4 94.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.414 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 91.0 t -63.01 -40.8 90.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.666 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.95 -41.24 95.91 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.435 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.48 -43.5 98.75 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.524 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.5 -37.39 84.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -60.17 -43.96 95.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -62.65 -45.22 93.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.492 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.9 -42.87 97.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.976 179.415 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.22 -34.89 90.79 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 400' ' ' LEU . . . . . 0.561 ' O ' HD13 ' C' ' 400' ' ' LEU . 0.2 OUTLIER -63.01 -42.93 99.96 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.002 0.43 . . . . 0.0 110.027 -179.119 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 66.0 tttm 54.9 101.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.491 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 66.6 t-80 -75.92 129.83 37.55 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.3 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -79.24 145.1 33.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.65 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -78.86 147.54 33.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.462 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.2 -11.2 59.79 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.562 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.13 -36.84 93.99 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -78.87 135.44 37.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.568 0.223 . . . . 0.0 110.404 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -77.96 116.92 18.81 Favored 'General case' 0 N--CA 1.463 0.205 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.367 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.527 ' OE1' ' N ' ' C' ' 410' ' ' PHE . 4.5 tp-100 -75.34 123.19 24.92 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 120.684 -0.407 . . . . 0.0 109.99 179.709 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 410' ' ' PHE . . . . . 0.527 ' N ' ' OE1' ' C' ' 409' ' ' GLN . 54.4 p90 . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.482 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 52.3 p . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.23 -37.54 87.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.479 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.427 ' OD1' ' O ' ' A' ' 373' ' ' ASP . 66.9 t0 -131.94 97.4 4.16 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.315 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 373' ' ' ASP . 35.6 p-10 -66.71 -40.52 88.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.881 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 372' ' ' ASP . 42.3 p-10 -98.76 110.7 23.26 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.676 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -90.84 107.41 19.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.539 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 375' ' ' PHE . . . . . 0.484 ' C ' ' H ' ' A' ' 377' ' ' VAL . 86.3 m-85 -62.44 -41.43 98.72 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.607 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 4.8 tp 70.52 -40.19 0.46 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.379 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 375' ' ' PHE . 5.5 t -140.54 56.7 7.45 Favored Pre-proline 0 N--CA 1.464 0.258 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.188 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.406 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 41.0 Cg_endo -68.18 -18.11 45.23 Favored 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.634 2.223 . . . . 0.0 112.09 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.4 mm -65.59 -45.48 92.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.168 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.44 -20.1 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.738 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -67.19 -43.45 88.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.442 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.62 93.43 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.11 -41.71 98.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.847 0.356 . . . . 0.0 110.4 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -36.52 83.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.646 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.659 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.2 tt -61.47 -43.9 98.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.42 -37.4 87.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.87 -42.62 99.76 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.56 -42.78 93.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.91 0.386 . . . . 0.0 110.522 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -61.04 -40.94 95.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.493 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.24 -41.7 89.63 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.107 0 CA-C-O 120.896 0.379 . . . . 0.0 110.268 179.009 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.8 -40.84 89.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.557 -179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.9 -41.7 93.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.682 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.12 -41.57 96.95 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.485 -179.486 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.55 -41.93 98.08 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.638 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.81 -48.55 79.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.707 179.377 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -64.43 -35.32 80.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.211 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -57.58 -46.02 84.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.19 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.6 mt -63.77 -42.68 96.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.69 -32.55 84.57 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp -61.54 -41.07 96.8 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 121.106 -0.238 . . . . 0.0 110.359 -179.501 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.6 mttt 55.58 35.93 26.17 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.579 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 49.27 94.28 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.717 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 49.0 p-80 -70.85 135.59 48.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.438 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -77.66 137.52 38.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.546 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.34 -12.38 59.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.61 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.29 -39.35 97.74 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 82.2 m-85 -109.62 135.88 49.88 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 120.817 0.342 . . . . 0.0 110.315 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -86.04 115.98 23.97 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.344 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 47.2 tp60 -80.0 129.85 34.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.075 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 88.9 t80 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.589 -179.856 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . 49.05 49.99 18.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.351 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -61.44 -43.43 98.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.377 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -90.4 110.23 21.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.569 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -68.55 142.41 55.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.555 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 88.6 m-20 -101.53 140.77 35.37 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.362 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -101.53 8.11 42.06 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.502 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 376' ' ' LEU . . . . . 0.596 ' N ' HD12 ' B' ' 376' ' ' LEU . 10.0 mp -92.97 -1.39 56.73 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.305 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.459 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 8.6 m -141.53 53.04 3.1 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.439 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 378' ' ' PRO . . . . . 0.459 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 36.4 Cg_endo -65.44 -20.98 61.06 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.764 2.309 . . . . 0.0 112.01 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt -64.96 -44.41 96.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 C-N-CA 120.866 -0.333 . . . . 0.0 110.88 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.22 -20.08 62.3 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.79 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 61.4 t -67.84 -43.21 86.26 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.473 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -37.76 95.02 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.56 -40.67 97.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.395 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.02 -36.04 83.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.583 179.758 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 385' ' ' LEU . . . . . 0.646 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.7 tt -61.52 -44.13 97.61 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.431 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -38.26 90.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.491 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.3 -43.15 99.49 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 90.7 t -67.11 -42.83 88.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.738 0.304 . . . . 0.0 110.715 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 389' ' ' LEU . . . . . 0.509 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.6 tt -59.97 -41.07 91.17 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.021 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 85.4 mt -64.9 -42.16 94.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.829 0.347 . . . . 0.0 110.296 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.7 mt -60.71 -41.49 95.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.603 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 80.0 t -64.05 -40.96 90.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.689 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.47 97.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.384 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 7.2 tt -61.67 -42.09 98.44 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.6 -47.8 78.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.532 . . . . 0.0 109.732 179.423 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 396' ' ' TYR . . . . . 0.566 ' CE2' HD23 ' B' ' 400' ' ' LEU . 89.0 t80 -63.98 -35.99 82.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.392 179.44 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -57.34 -45.38 84.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.231 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.3 mm -64.94 -41.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.123 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.58 -33.23 85.94 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 400' ' ' LEU . . . . . 0.566 HD23 ' CE2' ' B' ' 396' ' ' TYR . 0.2 OUTLIER -62.37 -42.17 99.2 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 -179.547 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 401' ' ' LYS . . . . . 0.439 ' O ' ' O ' ' B' ' 400' ' ' LEU . 52.5 mtmt 58.78 145.27 0.01 OUTLIER 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.46 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -58.84 -41.68 87.49 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.468 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -82.23 134.78 35.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.503 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -76.86 133.12 39.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.514 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.19 -12.53 59.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.653 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.67 -37.05 94.14 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -106.36 135.69 47.41 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 120.752 0.311 . . . . 0.0 110.347 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -99.49 117.72 34.5 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.219 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.483 ' CD ' ' N ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -129.83 146.24 51.56 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.326 179.901 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 410' ' ' PHE . . . . . 0.437 ' CD2' ' O ' ' B' ' 410' ' ' PHE . 54.6 p90 . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.658 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 60.9 m . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -150.61 154.06 36.83 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.363 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 371' ' ' ASP . . . . . 0.523 ' OD1' ' ND2' ' C' ' 374' ' ' ASN . 60.4 t0 -122.77 26.86 8.02 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.185 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.417 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 34.3 p-10 -88.44 3.35 50.36 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.564 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -86.83 1.0 53.86 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.423 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 374' ' ' ASN . . . . . 0.523 ' ND2' ' OD1' ' C' ' 371' ' ' ASP . 95.3 m-20 -62.63 -41.2 98.88 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.583 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -122.14 102.22 8.01 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.529 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 57.2 tp -114.73 125.87 54.21 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.042 179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.598 ' O ' HG13 ' C' ' 377' ' ' VAL . 7.5 p -174.35 77.22 0.35 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.411 179.7 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.528 ' O ' HG12 ' C' ' 381' ' ' VAL . 26.9 Cg_exo -60.02 148.56 88.61 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.649 2.232 . . . . 0.0 111.656 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' C' ' 381' ' ' VAL . 95.2 mt -63.08 -43.06 98.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.626 -179.512 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.75 -19.6 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.65 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.534 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.8 p -61.72 -38.46 80.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.745 0.307 . . . . 0.0 110.541 -179.492 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 382' ' ' GLY . . . . . 0.446 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -61.37 -40.51 98.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.36 98.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.882 0.372 . . . . 0.0 110.301 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 384' ' ' ALA . . . . . 0.412 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -64.81 -35.81 82.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.5 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.659 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.9 tt -61.41 -43.2 99.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.908 -179.587 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.47 -39.19 92.61 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.517 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.85 -42.18 98.54 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 388' ' ' VAL . . . . . 0.412 HG23 ' O ' ' C' ' 384' ' ' ALA . 86.6 t -66.71 -42.46 89.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.828 0.347 . . . . 0.0 110.769 -179.795 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.5 -40.56 91.83 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.29 -179.374 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.7 mt -66.08 -42.04 90.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 120.903 0.382 . . . . 0.0 110.173 179.055 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.4 -40.91 92.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.594 -179.653 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 70.4 t -63.36 -41.65 93.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.703 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.99 -41.81 97.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.478 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.1 -42.43 99.22 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.62 -48.4 81.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.636 179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -64.06 -35.38 80.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.417 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.34 -46.56 79.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.28 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.57 -42.48 95.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.219 179.305 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.29 -33.47 87.32 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 55.2 tp -61.82 -42.57 99.19 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.914 -0.314 . . . . 0.0 110.332 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -90.22 134.62 34.18 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.669 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 43.2 p-80 -157.95 161.73 38.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.371 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 79.9 t60 -85.99 122.07 29.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.82 0.343 . . . . 0.0 110.202 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 16.5 p-80 -74.69 138.78 43.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.529 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.6 -11.12 59.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.648 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.9 -38.7 96.99 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 65.9 t80 -84.7 130.63 34.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 110.309 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.33 149.35 49.72 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.496 179.621 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -53.08 137.91 32.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.974 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 55.2 p90 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.456 -179.997 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 35.8 t . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -71.32 140.82 50.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.403 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -99.29 110.9 23.37 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.453 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 65.9 t0 56.53 53.68 8.3 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.66 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 37.2 p-10 -62.07 -36.33 81.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.53 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.521 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 51.9 t30 -87.55 93.1 9.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.605 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -64.21 -43.4 95.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.737 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.598 HD12 ' N ' ' A' ' 376' ' ' LEU . 10.0 mp -84.25 133.47 34.57 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.226 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.495 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 16.3 m -147.79 51.42 1.07 Allowed Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.314 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 32.8 Cg_endo -64.87 -22.36 63.3 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 C-N-CA 122.741 2.294 . . . . 0.0 112.02 179.707 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 96.4 mt -63.67 -44.53 98.48 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.261 -179.153 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.86 -20.26 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.837 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.39 -43.19 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.262 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.84 -41.61 99.65 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -38.97 93.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.826 0.346 . . . . 0.0 110.719 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.63 -44.91 92.51 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.675 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.64 -40.19 92.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.389 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.3 -40.06 95.03 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.428 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -38.91 96.81 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 79.3 t -64.69 -41.85 93.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.887 0.375 . . . . 0.0 110.188 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.94 -37.8 80.57 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.206 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.74 -42.52 95.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.926 0.394 . . . . 0.0 110.121 179.127 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.51 -42.5 98.89 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.703 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.5 t -65.94 -42.51 92.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -62.04 -42.06 98.77 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.57 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.4 -43.19 99.41 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.635 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.02 -47.53 82.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.918 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -65.57 -34.29 77.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.493 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -56.99 -45.87 82.66 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.322 -179.265 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.48 -42.35 93.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.384 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.36 -31.15 79.78 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.1 tp -62.22 -41.65 98.58 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.474 -179.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -105.39 136.12 45.51 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.899 0.381 . . . . 0.0 110.423 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 51.8 p-80 -156.56 159.52 38.61 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.102 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -112.16 127.25 55.88 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.422 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 21.0 t60 -87.14 125.84 34.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.274 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.61 -12.24 59.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.366 -179.662 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.79 -36.77 93.74 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 85.7 t80 -79.33 131.91 36.28 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 408' ' ' GLU . . . . . 0.54 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.8 mp0 -103.77 119.53 39.1 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-O 120.859 0.362 . . . . 0.0 110.309 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 41.1 tp60 -77.98 136.62 38.0 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.689 -0.404 . . . . 0.0 109.927 179.684 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.8 t80 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.936 -1.031 . . . . 0.0 110.46 179.95 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 69.6 p . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . 53.28 40.22 30.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.484 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -105.04 112.09 25.09 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.491 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 54.2 t0 55.99 30.81 16.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.588 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 58.5 t0 58.46 32.12 21.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.52 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -63.22 -39.88 95.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.473 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 58.1 t80 42.01 72.93 0.15 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.628 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 40.8 tp -108.5 101.0 10.21 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.198 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 3.9 m -151.11 74.86 8.28 Favored Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.385 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -60.73 145.11 99.45 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.944 2.43 . . . . 0.0 111.831 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 379' ' ' ILE . . . . . 0.468 ' O ' ' N ' ' B' ' 381' ' ' VAL . 45.8 mm -64.24 -43.65 97.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.118 -179.72 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.37 -20.26 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.71 -0.223 . . . . 0.0 110.766 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.468 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.35 -42.97 94.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.266 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -36.12 92.85 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.3 -43.26 99.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.814 0.34 . . . . 0.0 110.587 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.64 -36.77 84.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.436 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 385' ' ' LEU . . . . . 0.651 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.1 tt -62.41 -43.68 98.25 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.938 -179.495 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.7 88.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.491 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.31 -42.1 99.72 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 56.3 t -66.1 -43.98 92.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.895 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -60.88 -41.71 96.54 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.922 -179.242 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 92.7 mt -65.73 -42.2 92.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 CA-C-O 121.003 0.43 . . . . 0.0 110.431 179.063 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -58.42 -41.59 85.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.518 -178.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.71 -40.99 90.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.596 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.94 -41.4 96.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.485 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.23 -42.89 99.39 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.94 -48.31 80.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.972 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.06 -35.65 80.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.49 179.369 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -56.59 -44.82 81.45 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.316 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.2 mm -65.7 -41.54 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.33 -33.52 86.89 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 53.2 tp -61.9 -42.1 98.68 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.904 -0.318 . . . . 0.0 110.533 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -101.09 144.12 30.38 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.805 0.336 . . . . 0.0 110.315 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -95.12 -3.51 47.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.423 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -74.89 138.61 42.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.293 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -107.32 134.04 50.98 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.557 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.33 -12.91 60.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.466 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.18 -37.9 95.65 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 407' ' ' TYR . . . . . 0.432 ' CE2' ' O ' ' B' ' 408' ' ' GLU . 75.7 t80 -82.35 136.4 35.0 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 408' ' ' GLU . . . . . 0.432 ' O ' ' CE2' ' B' ' 407' ' ' TYR . 80.8 tt0 -72.05 118.3 14.75 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.317 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.608 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 2.8 pm0 -52.91 146.1 11.46 Favored 'General case' 0 N--CA 1.462 0.146 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.082 179.643 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.516 -179.625 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 6.0 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -62.7 -40.25 96.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.482 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -139.78 102.68 4.48 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.152 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.421 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 35.8 p-10 -89.06 -0.17 57.2 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.502 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 47.4 t0 59.54 30.2 19.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.48 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -97.07 7.62 46.24 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.555 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -61.85 -41.05 97.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.62 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 29.7 mt -102.12 2.75 37.81 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.377 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 14.3 t 49.33 72.47 1.25 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.482 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.56 146.14 96.04 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.865 2.376 . . . . 0.0 112.085 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt -63.52 -43.96 98.52 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.991 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.33 -20.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.647 0.26 . . . . 0.0 110.803 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.471 ' N ' ' O ' ' C' ' 379' ' ' ILE . 54.3 t -63.8 -43.76 98.0 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.183 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.68 -39.75 98.31 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.62 -39.9 95.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.868 0.366 . . . . 0.0 110.659 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -66.12 -34.31 77.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.457 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.655 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.87 -45.17 94.92 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.998 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.01 -36.51 84.22 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.2 -40.37 98.47 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 83.9 t -67.27 -42.76 88.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.807 0.337 . . . . 0.0 110.314 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.5 tt -60.46 -41.08 93.41 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.561 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.7 mt -66.04 -42.01 90.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.85 0.357 . . . . 0.0 110.342 178.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.02 -40.05 87.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 74.9 t -63.73 -42.19 95.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.5 -41.16 96.87 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.483 -179.515 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.3 tt -62.28 -43.71 98.21 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.608 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.46 -36.7 84.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.072 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -60.22 -44.53 95.11 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.652 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 27.6 m-85 -62.11 -43.77 98.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.664 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.0 mt -63.23 -41.88 94.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.521 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.89 -34.82 90.97 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 50.1 tp -62.9 -41.48 99.45 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.485 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 88.8 tttt 54.44 105.73 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.629 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -77.44 140.64 39.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.16 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -106.38 127.19 53.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.293 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -104.64 128.72 52.75 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.383 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.09 -12.77 60.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.457 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.31 -40.66 98.08 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 407' ' ' TYR . . . . . 0.47 ' CZ ' ' OE1' ' C' ' 409' ' ' GLN . 88.1 t80 -92.67 117.66 30.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.772 0.32 . . . . 0.0 110.302 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 408' ' ' GLU . . . . . 0.472 ' CD ' ' N ' ' C' ' 408' ' ' GLU . 0.0 OUTLIER -135.43 144.66 46.6 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.558 179.709 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.47 ' OE1' ' CZ ' ' C' ' 407' ' ' TYR . 26.7 mm100 -130.61 126.69 37.3 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.556 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 410' ' ' PHE . . . . . 0.439 ' O ' ' CG ' ' C' ' 410' ' ' PHE . 92.3 t80 . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.485 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 61.29 129.02 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.605 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 55.4 t0 57.07 44.66 22.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.452 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -88.38 114.04 24.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.728 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 52.4 t0 -66.21 144.05 56.87 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.801 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.509 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 65.8 t30 55.91 42.21 29.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.679 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -120.85 102.57 8.46 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.331 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 94.8 mt -135.7 146.55 47.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.435 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 11.4 t -143.79 71.65 17.09 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.456 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -60.88 146.77 97.08 Favored 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.877 2.385 . . . . 0.0 111.826 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 44.6 mm -65.44 -43.7 94.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.744 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.33 -20.02 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.59 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 54.9 t -65.27 -42.9 95.02 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 C-N-CA 121.026 -0.27 . . . . 0.0 110.468 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.13 -40.15 96.79 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.16 -41.99 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.835 0.35 . . . . 0.0 110.579 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.0 -35.66 81.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.57 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.657 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.1 tt -61.3 -43.47 98.83 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.68 -39.78 95.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.886 0.374 . . . . 0.0 110.51 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.15 97.81 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 72.8 t -63.79 -43.31 97.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 O-C-N 122.946 -0.15 . . . . 0.0 111.332 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.22 -37.86 81.59 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.336 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -62.94 -42.34 96.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 178.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.5 mt -60.86 -39.85 90.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.392 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.2 t -61.09 -40.72 86.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.468 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.99 -41.6 96.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.323 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.79 -44.2 97.33 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.335 -0.546 . . . . 0.0 109.73 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.22 -36.73 83.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.002 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -60.09 -44.79 94.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.685 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -62.42 -44.9 95.33 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.331 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.45 -42.86 97.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.05 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.09 -33.08 84.34 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.411 ' O ' ' O ' ' A' ' 401' ' ' LYS . 43.9 tp -61.81 -41.69 98.08 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.502 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 401' ' ' LYS . . . . . 0.411 ' O ' ' O ' ' A' ' 400' ' ' LEU . 62.1 tttm 51.08 101.98 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.337 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 60.4 t-80 -58.45 -40.86 83.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.425 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -73.68 141.14 46.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.502 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -76.83 134.13 39.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.611 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.89 -11.22 59.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.616 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.0 -33.83 88.32 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -107.61 133.65 51.75 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.653 0.263 . . . . 0.0 110.46 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -86.91 117.48 25.67 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.218 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.546 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 2.7 pm0 -62.68 141.15 58.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.093 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.0 t80 . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.001 -0.999 . . . . 0.0 110.458 179.866 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 86.3 p . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -158.75 153.58 24.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.542 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 56.9 m-20 -93.17 111.49 23.14 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.203 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 372' ' ' ASP . . . . . 0.512 ' OD2' ' ND2' ' B' ' 374' ' ' ASN . 36.6 p-10 -87.73 1.12 54.63 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.652 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 52.3 t0 58.62 52.05 7.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.58 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 374' ' ' ASN . . . . . 0.512 ' ND2' ' OD2' ' B' ' 372' ' ' ASP . 99.1 m-20 -67.81 150.25 48.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.484 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 375' ' ' PHE . . . . . 0.521 ' CD2' ' O ' ' B' ' 375' ' ' PHE . 40.1 p90 -146.79 121.42 9.8 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.189 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 45.8 mt -110.17 4.01 20.66 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.362 179.785 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.43 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 15.5 m -131.24 54.82 15.72 Favored Pre-proline 0 N--CA 1.464 0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.435 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 378' ' ' PRO . . . . . 0.43 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 36.5 Cg_endo -65.62 -20.06 59.95 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.745 2.296 . . . . 0.0 111.933 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt -64.6 -44.23 96.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 C-N-CA 120.883 -0.327 . . . . 0.0 111.008 -179.582 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.96 -20.11 61.79 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.987 -0.285 . . . . 0.0 110.828 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 52.9 t -67.06 -43.12 89.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.419 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.29 -41.57 99.73 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.54 84.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.729 0.3 . . . . 0.0 110.65 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.17 -43.85 98.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.721 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.49 -40.96 93.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.291 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.14 -37.83 88.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -38.97 97.12 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 84.6 t -64.3 -42.12 94.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.108 0.48 . . . . 0.0 110.167 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.2 tp -60.38 -38.08 82.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.247 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -63.5 -42.53 96.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -61.6 -42.07 98.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.495 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 88.5 t -66.03 -42.19 91.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.985 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.67 -41.2 97.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.405 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.66 -43.07 99.55 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.99 -47.82 83.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.695 179.341 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -63.9 -35.81 81.87 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.25 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.86 -45.55 82.37 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.084 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.72 -42.6 96.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.222 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.22 -31.22 80.13 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 54.1 tp -61.71 -40.58 95.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.721 0.296 . . . . 0.0 110.348 -179.723 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -48.78 142.07 6.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.57 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 54.6 t-80 -69.38 136.99 52.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.542 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -79.44 149.35 31.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.627 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 10.5 p-80 -66.21 162.77 19.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.489 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.08 -11.84 59.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.454 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.2 -33.57 87.61 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 407' ' ' TYR . . . . . 0.514 ' OH ' ' NE2' ' B' ' 409' ' ' GLN . 72.9 t80 -83.83 126.13 32.65 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.693 0.283 . . . . 0.0 110.456 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 408' ' ' GLU . . . . . 0.431 ' O ' ' OE1' ' B' ' 409' ' ' GLN . 92.8 mt-10 -135.43 149.19 49.55 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.526 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.514 ' NE2' ' OH ' ' B' ' 407' ' ' TYR . 11.5 mm100 -120.19 125.97 49.5 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.073 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 . . . . . 0 C--O 1.219 -0.5 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.68 -179.926 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 56.3 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.74 -37.57 87.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.331 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 371' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 37.1 p-10 -64.44 -36.49 84.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.555 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.52 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 45.0 t0 -89.27 106.9 18.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.38 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -80.77 164.75 22.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.373 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -85.01 136.94 33.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.382 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 375' ' ' PHE . . . . . 0.495 ' CZ ' ' CG2' ' C' ' 377' ' ' VAL . 82.5 t80 -88.62 78.98 7.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.372 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 376' ' ' LEU . . . . . 0.494 ' O ' HG13 ' C' ' 377' ' ' VAL . 22.3 tp -108.19 103.08 12.19 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.495 ' CG2' ' CZ ' ' C' ' 375' ' ' PHE . 16.1 m -157.74 51.92 0.52 Allowed Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.039 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.484 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 26.5 Cg_endo -62.25 -22.75 74.63 Favored 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.759 2.306 . . . . 0.0 112.04 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt -64.19 -44.55 97.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.04 -179.645 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.03 -20.16 59.72 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 121.053 -0.259 . . . . 0.0 110.736 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.28 -43.38 91.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 121.001 -0.28 . . . . 0.0 110.557 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.59 -37.62 95.04 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.68 -41.03 98.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.857 0.36 . . . . 0.0 110.564 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.79 -35.56 81.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.459 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.658 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.6 tt -61.68 -43.62 98.5 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.896 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.12 -38.7 92.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.674 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -40.2 98.72 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.52 -42.65 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.509 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.534 HD23 ' O ' ' C' ' 389' ' ' LEU . 5.1 tt -59.71 -39.07 83.4 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.823 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.38 -42.38 95.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.829 0.347 . . . . 0.0 110.141 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.34 -41.07 96.45 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.414 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.21 -41.52 92.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.717 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.67 -41.99 98.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.542 -179.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.04 -41.96 98.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.67 -49.28 77.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.627 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -64.83 -35.01 79.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.229 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.98 -45.66 86.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.349 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.1 mt -63.55 -42.72 97.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.13 -38.61 95.48 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp -62.83 -42.28 99.67 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.898 -0.321 . . . . 0.0 110.353 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 401' ' ' LYS . . . . . 0.434 ' O ' ' O ' ' C' ' 402' ' ' HIS . 29.9 ttmt 56.96 59.25 3.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.806 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 402' ' ' HIS . . . . . 0.434 ' O ' ' O ' ' C' ' 401' ' ' LYS . 95.7 m-70 56.41 158.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.563 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -78.37 145.81 35.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.426 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 99.4 m-70 -79.34 142.81 35.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.617 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.51 -11.97 59.91 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.538 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.19 -36.76 93.87 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -82.48 132.21 35.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.631 0.253 . . . . 0.0 110.491 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -77.76 117.65 19.36 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.091 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -52.89 137.62 31.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.32 -0.4 . . . . 0.0 109.961 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 83.1 t80 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.474 -179.998 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 19.9 p . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -152.2 152.13 31.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.492 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 47.9 t0 -101.52 107.61 18.95 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.345 179.697 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 35.7 p30 -90.2 2.4 55.42 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.391 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -62.58 -42.91 99.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.566 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 69.3 m-20 56.96 36.13 27.35 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.522 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 53.6 t80 -60.69 -44.3 96.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.403 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 23.0 mt -102.04 131.24 48.6 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.373 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 4.6 m -141.99 71.27 23.67 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.363 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.513 ' O ' HG12 ' A' ' 381' ' ' VAL . 40.2 Cg_exo -55.64 -33.47 87.27 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.876 2.384 . . . . 0.0 112.114 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.474 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.8 mt -62.83 -43.76 99.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.905 -179.109 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.57 -19.63 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.654 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.533 HG13 ' N ' ' A' ' 382' ' ' GLY . 9.2 p -59.15 -44.26 91.32 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-O 120.682 0.277 . . . . 0.0 110.806 -179.34 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.533 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.2 -41.35 99.66 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.718 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.11 98.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.842 0.353 . . . . 0.0 110.284 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 384' ' ' ALA . . . . . 0.435 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -66.42 -35.93 81.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.722 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.641 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.6 tt -60.53 -44.52 95.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.931 -179.208 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.11 93.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.421 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.41 -42.91 97.44 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 388' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 384' ' ' ALA . 91.6 t -65.6 -43.19 94.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.223 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.55 -39.88 89.54 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.448 -0.501 . . . . 0.0 110.114 -179.222 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.9 -42.05 93.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.81 0.338 . . . . 0.0 110.11 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.87 -40.65 93.78 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.664 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.9 t -62.2 -41.18 90.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.725 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.1 mt -61.09 -41.31 96.42 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.421 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.64 -43.21 99.28 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.8 82.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.25 179.086 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 396' ' ' TYR . . . . . 0.418 ' CZ ' ' CD1' ' A' ' 400' ' ' LEU . 92.6 t80 -60.3 -44.52 95.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.5 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -63.89 -46.56 84.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.417 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.5 mt -64.43 -42.1 94.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.377 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -53.14 -57.2 15.69 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.475 ' C ' ' H ' ' A' ' 402' ' ' HIS . 8.7 mt -65.31 -40.93 94.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 110.432 179.403 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 52.1 tttm 51.25 9.86 0.07 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.412 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 402' ' ' HIS . . . . . 0.475 ' H ' ' C ' ' A' ' 400' ' ' LEU . 64.1 t-80 -154.14 139.36 17.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.518 179.742 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 63.9 t-80 -79.43 126.67 31.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.271 179.845 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 404' ' ' HIS . . . . . 0.489 ' CE1' ' HA3' ' A' ' 406' ' ' GLY . 25.9 t-80 -89.87 124.87 35.06 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.373 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.15 -18.22 53.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.687 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 406' ' ' GLY . . . . . 0.489 ' HA3' ' CE1' ' A' ' 404' ' ' HIS . . . -63.62 -36.82 93.85 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 86.3 t80 -86.41 129.16 34.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.602 0.239 . . . . 0.0 110.39 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 43.8 tp10 -108.58 120.39 42.3 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -52.87 141.71 21.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.026 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 . . . . . 0 C--N 1.325 -0.485 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.289 179.863 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 86.3 p . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -149.22 148.52 29.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.542 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -94.7 100.12 12.1 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.256 179.661 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -96.18 83.78 3.67 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.574 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 53.87 34.47 19.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.678 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 40.7 t-20 -90.64 108.49 19.85 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.567 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -119.86 103.44 9.34 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.393 179.845 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 35.7 tp -97.59 86.18 3.77 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.631 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.466 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 16.4 m -152.93 53.05 0.95 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.291 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 378' ' ' PRO . . . . . 0.466 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 34.9 Cg_endo -65.25 -21.44 61.85 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.758 2.305 . . . . 0.0 112.072 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.2 mt -64.37 -44.69 97.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.529 -0.305 . . . . 0.0 111.18 -179.52 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.47 -20.06 60.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.626 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.2 -43.39 88.39 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-O 120.72 0.295 . . . . 0.0 110.461 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.86 -41.59 99.84 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.16 89.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.855 0.36 . . . . 0.0 110.67 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.79 -44.14 96.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.71 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -65.71 -39.6 91.37 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.338 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.96 -38.79 89.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.398 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.09 -42.57 99.5 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 87.4 t -66.88 -42.66 89.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.651 0.263 . . . . 0.0 111.081 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 389' ' ' LEU . . . . . 0.598 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.3 tt -60.08 -41.53 92.64 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.076 -179.348 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 87.8 mt -64.31 -42.25 94.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.897 0.379 . . . . 0.0 110.26 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.97 -41.28 96.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.564 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.7 t -63.69 -41.09 91.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.738 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.12 -40.94 95.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.421 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -41.59 97.25 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.75 80.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.652 179.348 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.11 -36.01 82.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.668 -0.697 . . . . 0.0 110.338 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -56.86 -45.87 82.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.165 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.0 mt -63.88 -42.62 96.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.308 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.02 -36.65 93.3 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 45.6 tp -62.68 -42.12 99.46 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.75 0.31 . . . . 0.0 110.51 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -77.73 134.83 38.0 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.441 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -148.33 139.37 23.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.415 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -74.74 131.19 40.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.231 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -100.91 125.01 47.44 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.311 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.3 -11.41 59.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.632 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.07 -34.68 90.61 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 82.8 t80 -135.93 152.9 51.47 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.83 0.347 . . . . 0.0 110.433 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -135.26 148.37 49.54 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.332 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.485 ' CD ' ' N ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -130.63 144.84 51.7 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.935 -179.718 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.355 179.722 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 14.2 m . . . . . 0 N--CA 1.489 1.476 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -66.09 -39.86 90.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.481 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 49.5 t0 56.36 37.41 28.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.481 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -85.77 110.9 19.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.5 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -92.43 110.14 21.54 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.302 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -92.65 5.46 50.92 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.214 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -62.07 -43.76 98.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.515 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 7.0 tp -112.46 133.53 54.48 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.286 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 3.5 m -123.33 74.6 51.51 Favored Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.579 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -75.1 161.64 38.15 Favored 'Trans proline' 0 N--CA 1.491 1.356 0 C-N-CA 122.658 2.239 . . . . 0.0 112.065 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.5 mt -63.68 -42.85 97.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.683 -179.486 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.59 -19.64 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' C' ' 379' ' ' ILE . 51.1 t -63.47 -43.87 98.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.85 -36.1 92.86 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.78 -40.71 96.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.791 0.329 . . . . 0.0 110.301 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -36.88 85.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.373 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 385' ' ' LEU . . . . . 0.643 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.0 tt -61.57 -44.48 96.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.903 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -36.98 85.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.539 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.16 -38.38 95.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 85.2 t -65.76 -42.62 92.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.879 0.371 . . . . 0.0 110.528 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 389' ' ' LEU . . . . . 0.555 HD23 ' O ' ' C' ' 389' ' ' LEU . 5.3 tt -61.1 -38.92 88.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.019 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.85 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.169 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.14 -40.97 95.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.64 -40.91 90.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.649 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.68 -41.6 97.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.591 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.56 -42.62 99.12 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.57 -49.14 78.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.74 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.71 -34.74 78.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.273 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -58.05 -45.56 86.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.151 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.3 mt -63.44 -42.4 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.1 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.62 -36.28 92.96 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 400' ' ' LEU . . . . . 0.436 ' O ' ' O ' ' C' ' 401' ' ' LYS . 53.0 tp -62.91 -41.79 99.57 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.323 -179.841 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 401' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' C' ' 400' ' ' LEU . 75.6 tttt 53.95 166.68 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 64.2 t-80 -61.42 -43.24 99.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.454 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -77.19 140.57 40.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.333 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -98.96 131.65 44.86 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.417 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.21 -12.24 59.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.505 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.56 -39.42 97.61 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -81.93 131.47 35.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.603 0.239 . . . . 0.0 110.416 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -89.56 114.55 26.13 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.214 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -54.37 141.89 28.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.898 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 85.5 t80 . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.516 179.859 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 67.4 m . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -150.68 149.04 29.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.503 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.411 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 37.7 p-10 -90.44 0.92 57.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.341 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -89.78 107.27 19.0 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.493 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 59.9 m-20 -64.42 -37.5 87.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.037 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -86.61 107.22 18.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.405 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -95.11 -0.44 53.47 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.46 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.531 HD12 ' N ' ' A' ' 376' ' ' LEU . 10.7 mp -62.57 -41.73 99.11 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.305 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.661 ' O ' HG13 ' A' ' 377' ' ' VAL . 8.3 p -153.57 78.07 5.73 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.27 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -59.74 143.7 99.58 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.631 2.22 . . . . 0.0 111.916 179.765 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.9 mm -65.06 -44.02 95.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.083 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.1 -20.25 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.708 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.506 ' N ' ' O ' ' A' ' 379' ' ' ILE . 55.7 t -65.27 -43.51 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.335 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -66.27 -40.78 94.86 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.3 -38.96 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.763 0.316 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 384' ' ' ALA . . . . . 0.43 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -62.37 -44.86 95.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.33 -40.17 89.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.405 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.81 -37.68 88.3 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.555 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.28 -39.93 97.46 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 388' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 384' ' ' ALA . 80.5 t -66.24 -42.86 91.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.912 0.387 . . . . 0.0 110.596 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.3 mt -62.15 -41.85 98.68 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.413 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.4 mt -64.11 -41.9 93.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.35 -42.61 96.07 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.698 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.1 t -65.34 -41.86 92.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.52 -39.93 92.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.472 -179.381 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.72 -44.23 96.86 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.52 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.94 -38.02 89.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.077 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -61.76 -43.74 98.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.717 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -63.02 -41.53 99.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.65 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 398' ' ' ILE . . . . . 0.423 HD13 ' HA ' ' A' ' 398' ' ' ILE . 30.2 mm -63.61 -42.52 96.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.891 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -77.14 -21.08 74.45 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.4 tp -63.73 -40.79 97.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.807 0.337 . . . . 0.0 110.543 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -55.72 132.76 49.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.447 -179.264 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 402' ' ' HIS . . . . . 0.409 ' CE1' ' O ' ' A' ' 403' ' ' HIS . 60.9 t-80 -91.46 128.5 37.31 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.571 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 403' ' ' HIS . . . . . 0.579 ' CE1' ' HZ2' ' C' ' 401' ' ' LYS . 88.4 m-70 -74.14 144.68 44.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.452 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -69.54 132.77 46.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.449 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.73 -11.31 59.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.584 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.86 -34.77 90.76 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 407' ' ' TYR . . . . . 0.475 ' OH ' ' N ' ' C' ' 409' ' ' GLN . 86.4 t80 -82.66 132.14 35.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.599 0.238 . . . . 0.0 110.465 179.645 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 91.3 mt-10 -135.49 147.66 48.94 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.681 0.277 . . . . 0.0 110.694 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.532 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 1.9 pm0 -71.05 134.93 47.47 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.039 179.522 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.9 t80 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.366 -179.915 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 84.4 p . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.381 -0.599 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -67.73 142.25 56.35 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.537 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 371' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' B' ' 371' ' ' ASP . 33.5 p-10 -88.36 -1.11 57.85 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.348 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -64.0 -38.3 90.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.591 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 373' ' ' ASP . . . . . 0.429 ' O ' ' OD1' ' B' ' 373' ' ' ASP . 64.5 t0 57.37 36.28 26.98 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.438 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -87.71 141.56 28.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.436 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -98.97 2.59 46.54 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.416 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 60.0 tp -62.29 -43.51 98.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.357 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 377' ' ' VAL . . . . . 0.627 HG13 ' O ' ' B' ' 377' ' ' VAL . 14.2 p -171.96 61.48 0.31 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.15 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 378' ' ' PRO . . . . . 0.484 ' O ' HG12 ' B' ' 381' ' ' VAL . 42.8 Cg_endo -69.38 148.03 66.63 Favored 'Trans proline' 0 C--N 1.302 -1.885 0 C-N-CA 122.302 2.001 . . . . 0.0 112.001 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 78.8 mt -67.31 -26.49 36.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.045 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -57.85 -20.26 35.03 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.881 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 381' ' ' VAL . . . . . 0.501 HG13 ' N ' ' B' ' 382' ' ' GLY . 8.9 p -60.87 -43.48 95.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-O 120.783 0.325 . . . . 0.0 110.371 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 382' ' ' GLY . . . . . 0.501 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -64.68 -42.34 97.29 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.404 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.77 88.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.805 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 384' ' ' ALA . . . . . 0.415 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -60.04 -46.5 89.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.625 -179.797 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -64.09 -41.05 97.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.412 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.95 89.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.46 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.96 -36.34 93.16 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 388' ' ' VAL . . . . . 0.415 HG23 ' O ' ' B' ' 384' ' ' ALA . 95.1 t -64.82 -42.23 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-O 121.069 0.462 . . . . 0.0 110.243 179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 10.9 mt -62.18 -39.78 93.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.35 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.6 mm -65.16 -41.67 92.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.329 -0.396 . . . . 0.0 109.964 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.52 -41.86 95.26 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.622 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 90.0 t -65.06 -42.7 95.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.874 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.7 mt -62.13 -43.32 99.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 -179.549 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.74 -42.89 99.89 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.93 85.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.169 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.61 -44.37 96.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.847 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 30.6 m-85 -62.2 -42.47 99.32 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.508 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 398' ' ' ILE . . . . . 0.44 ' O ' ' O ' ' B' ' 401' ' ' LYS . 83.6 mt -63.66 -42.33 95.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.844 179.341 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.89 -45.18 95.42 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 35.1 tp -65.08 -41.55 94.95 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.477 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 401' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 398' ' ' ILE . 99.2 mttt -135.31 135.16 40.58 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.318 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -158.48 104.87 1.84 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.195 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -109.4 121.3 44.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.201 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 404' ' ' HIS . . . . . 0.539 ' O ' ' ND1' ' B' ' 404' ' ' HIS . 33.7 p80 -126.2 124.96 41.63 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.404 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -103.89 -42.04 5.71 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.358 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.64 -40.53 98.71 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 88.9 t80 -78.54 135.97 37.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.628 0.251 . . . . 0.0 110.384 179.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.47 146.74 48.47 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.729 0.299 . . . . 0.0 110.803 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 409' ' ' GLN . . . . . 0.621 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 3.0 pm0 -53.94 145.99 15.27 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.664 -0.414 . . . . 0.0 109.95 179.641 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.571 -179.859 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 58.0 p . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.15 -38.85 92.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.517 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 55.39 32.25 18.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.435 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 372' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' C' ' 373' ' ' ASP . 42.0 p-10 -64.98 -34.61 78.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.688 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 373' ' ' ASP . . . . . 0.519 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 98.9 m-20 54.97 32.83 18.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.474 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 374' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' C' ' 376' ' ' LEU . 61.5 t-20 -90.42 116.95 28.75 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.616 -179.83 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -61.7 -44.36 97.09 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.814 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 376' ' ' LEU . . . . . 0.422 ' O ' ' OD1' ' C' ' 374' ' ' ASN . 53.2 mt -113.74 131.15 56.3 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.397 -179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 377' ' ' VAL . . . . . 0.489 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 17.7 m -145.7 51.72 1.36 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.3 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 378' ' ' PRO . . . . . 0.51 ' O ' HG12 ' C' ' 381' ' ' VAL . 28.9 Cg_endo -63.6 -22.05 70.37 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.706 2.271 . . . . 0.0 112.0 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 379' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' C' ' 381' ' ' VAL . 45.1 mm -64.88 -43.91 96.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.361 -179.336 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.55 -19.9 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.799 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 381' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' C' ' 379' ' ' ILE . 8.1 p -59.57 -43.98 92.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 120.737 0.303 . . . . 0.0 110.294 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 382' ' ' GLY . . . . . 0.519 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.62 -43.0 98.6 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.47 -38.78 88.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.744 0.307 . . . . 0.0 110.845 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.84 -44.49 96.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.683 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.14 -40.15 94.0 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.413 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.55 -38.86 89.02 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.411 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.42 -38.46 94.92 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.3 t -62.97 -43.51 99.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.738 0.304 . . . . 0.0 110.281 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -60.59 -39.44 88.13 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.089 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.9 mm -64.01 -42.02 94.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.134 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.07 -40.58 94.23 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.581 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 83.6 t -61.85 -41.02 89.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.699 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.17 -42.12 98.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.426 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.85 -42.93 99.94 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.618 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.95 82.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.259 179.459 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -59.78 -44.97 93.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -63.04 -46.74 86.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.623 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.5 mt -64.88 -42.1 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.857 179.444 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -59.4 -32.71 73.38 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 400' ' ' LEU . . . . . 0.453 ' O ' ' O ' ' C' ' 401' ' ' LYS . 50.7 tp -61.69 -42.3 98.74 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.527 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 401' ' ' LYS . . . . . 0.579 ' HZ2' ' CE1' ' A' ' 403' ' ' HIS . 83.9 tttt 56.17 121.53 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.529 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -59.62 -44.33 93.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.475 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -88.98 131.73 35.04 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.507 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 404' ' ' HIS . . . . . 0.508 ' CE1' ' HA3' ' C' ' 406' ' ' GLY . 23.4 t-80 -70.34 125.75 27.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 405' ' ' ALA . . . . . 0.517 ' HB2' ' HZ3' ' C' ' 401' ' ' LYS . . . -100.34 -11.39 20.33 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.56 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 406' ' ' GLY . . . . . 0.508 ' HA3' ' CE1' ' C' ' 404' ' ' HIS . . . -62.65 -37.7 95.2 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 87.0 t80 -78.41 125.48 29.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.651 0.262 . . . . 0.0 110.395 179.66 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 70.1 mm-40 -135.63 148.18 48.89 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 120.676 0.274 . . . . 0.0 110.81 179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 409' ' ' GLN . . . . . 0.475 ' N ' ' OH ' ' A' ' 407' ' ' TYR . 48.7 tp60 -75.27 130.84 39.77 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 120.499 -0.48 . . . . 0.0 109.821 179.727 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.614 179.889 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.3 mm . . . . . 0 CA--C 1.529 0.168 0 CA-C-O 120.549 0.214 . . . . 0.0 111.069 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.09 -20.07 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.592 -0.277 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.4 p -59.94 -43.8 93.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.111 0 CA-C-O 120.818 0.342 . . . . 0.0 110.226 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.516 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.03 -36.3 93.28 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.86 -40.91 94.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 0.0 110.615 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.92 -36.31 83.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.467 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.9 tt -61.2 -45.42 94.65 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.135 0.493 . . . . 0.0 110.032 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.16 -36.65 80.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.403 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.03 -36.41 93.42 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.354 -0.699 . . . . 0.0 111.354 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.57 -42.11 92.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.983 0.421 . . . . 0.0 110.185 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 9.9 mt -62.1 -39.05 91.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.582 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.2 mm -63.04 -42.15 95.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -61.0 -41.24 96.13 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.404 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.3 t -65.3 -42.6 94.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.897 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.57 -41.89 98.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.621 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.45 -42.5 99.51 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.572 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.79 -49.22 75.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.818 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.29 -35.17 80.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.337 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.6 t80 -58.61 -45.44 89.16 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.385 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -64.0 -42.52 95.97 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.05 -33.82 88.16 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.6 tp . . . . . 0 C--N 1.328 -0.343 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.396 -179.77 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' B' ' 381' ' ' VAL . 42.9 mm . . . . . 0 CA--C 1.531 0.247 0 CA-C-O 120.474 0.178 . . . . 0.0 111.151 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.15 -19.96 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.661 0.267 . . . . 0.0 110.786 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' B' ' 379' ' ' ILE . 57.7 t -64.06 -43.52 97.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.328 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.72 -38.28 95.42 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.93 -39.99 93.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.769 0.319 . . . . 0.0 110.554 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.25 -35.49 81.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.486 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . 0.638 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.0 tt -61.49 -44.6 96.79 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.049 0.452 . . . . 0.0 110.01 -179.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.29 -37.51 87.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.424 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.13 -39.68 97.47 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 91.5 t -64.32 -41.97 93.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . 0.594 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.8 tt -59.55 -38.72 81.82 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.245 -179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.63 -42.09 94.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.815 0.34 . . . . 0.0 110.221 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.27 -40.72 95.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.692 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 73.6 t -62.98 -41.34 92.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.755 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.21 -41.8 97.48 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.613 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.88 -41.75 98.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.32 -48.6 76.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.876 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -62.83 -35.78 81.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.449 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.48 -44.58 85.01 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.219 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 42.2 mm -65.83 -41.32 89.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.814 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.8 mt . . . . . 0 CA--C 1.531 0.22 0 CA-C-O 120.435 0.16 . . . . 0.0 111.169 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.7 -19.82 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.831 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.547 ' N ' ' O ' ' C' ' 379' ' ' ILE . 9.1 p -61.13 -43.64 96.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . 0.51 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.39 -40.07 98.48 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.85 -39.99 91.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 110.598 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.45 -35.19 80.19 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.623 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.652 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.5 tt -61.18 -44.84 96.65 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.108 0.48 . . . . 0.0 110.005 -179.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.36 -36.73 84.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.377 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.71 97.77 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.0 -43.15 98.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.666 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.6 tt -58.91 -37.42 76.59 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.067 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.01 -42.69 96.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.26 -40.14 92.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.433 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.1 t -63.46 -40.66 89.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.664 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.8 mt -61.99 -41.65 98.27 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.709 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.84 -42.35 98.93 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.17 -48.87 75.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.93 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.9 t80 -64.93 -34.56 78.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.435 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -58.81 -44.86 90.9 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.255 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.4 mt -65.04 -42.41 94.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.442 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 -179.78 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.5 mt . . . . . 0 CA--C 1.53 0.209 0 CA-C-O 120.596 0.236 . . . . 0.0 111.134 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.18 -20.25 60.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.851 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.1 t -67.02 -43.54 88.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.116 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.317 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.07 -41.05 99.9 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.16 96.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.462 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.68 -35.95 82.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.529 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.625 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.9 tt -61.38 -44.32 97.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.865 -179.286 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -37.5 87.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.488 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.72 -40.67 98.76 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.81 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.783 0.325 . . . . 0.0 110.225 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.521 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.7 tt -59.74 -38.6 82.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 31.4 mm -64.29 -42.59 95.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 0.0 110.183 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.75 -40.95 96.91 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.584 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 91.1 t -64.17 -41.02 91.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.79 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.34 -40.87 95.84 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.527 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.23 -42.12 98.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.02 -48.19 79.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.827 179.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . 0.429 ' CD2' HD11 ' A' ' 400' ' ' LEU . 21.5 t80 -66.76 -34.25 77.41 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.258 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -58.35 -45.65 87.78 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.196 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -64.54 -42.62 95.7 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.081 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.69 -33.52 87.47 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . 0.429 HD11 ' CD2' ' A' ' 396' ' ' TYR . 8.6 mt . . . . . 0 C--N 1.325 -0.459 0 CA-C-O 120.646 0.26 . . . . 0.0 110.553 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.7 mt . . . . . 0 CA--C 1.533 0.311 0 CA-C-O 120.609 0.242 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -51.49 -20.38 1.85 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.61 -179.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 76.2 t -66.29 -43.11 91.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.38 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.85 -37.84 94.81 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.61 94.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 0.0 110.689 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . 0.4 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -63.46 -38.74 92.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.313 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . 0.656 HD13 ' O ' ' B' ' 385' ' ' LEU . 1.7 tm? -62.5 -47.64 83.09 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.436 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -37.31 86.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.947 0.404 . . . . 0.0 110.519 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.24 -42.51 99.8 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . 0.4 HG23 ' O ' ' B' ' 384' ' ' ALA . 93.6 t -66.54 -42.85 90.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.299 . . . . 0.0 110.76 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.84 -40.44 88.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.282 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.7 mt -65.6 -42.26 92.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.832 0.349 . . . . 0.0 110.221 178.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.6 mt -60.7 -40.92 94.05 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.594 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 78.6 t -62.72 -41.7 93.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.691 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.24 -41.7 97.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.472 -179.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.77 -42.27 98.77 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.28 75.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.857 179.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -66.01 -35.04 79.49 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.342 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.45 -45.94 84.16 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.331 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.27 -42.45 95.48 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.989 179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.658 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.927 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.529 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt . . . . . 0 CA--C 1.53 0.197 0 CA-C-O 120.608 0.242 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.64 -19.88 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.529 ' N ' ' O ' ' C' ' 379' ' ' ILE . 55.1 t -64.77 -43.52 96.47 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.269 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.68 -36.89 93.92 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.56 -40.8 96.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 110.544 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.19 83.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.467 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.661 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.3 tt -61.38 -45.15 95.57 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.49 -37.11 86.02 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.529 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.5 98.89 Favored Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -63.47 -42.51 96.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.505 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.9 tt -60.1 -38.63 83.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.871 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.0 mm -63.33 -42.52 96.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.899 0.38 . . . . 0.0 110.061 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.0 -40.85 95.12 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.479 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.17 -41.79 93.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.794 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.28 -41.17 96.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.426 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.71 -43.13 99.44 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.547 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.15 90.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.01 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -60.97 -44.94 96.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.668 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -63.58 -43.72 96.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.545 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 31.8 mm -63.9 -42.23 95.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.85 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.547 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.956 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.558 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.532 0.251 0 CA-C-O 120.479 0.18 . . . . 0.0 111.085 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.13 -20.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.959 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.558 ' N ' ' O ' ' A' ' 379' ' ' ILE . 37.2 t -63.82 -43.46 97.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.63 -41.29 98.82 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.79 82.98 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.773 0.321 . . . . 0.0 110.698 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . 0.458 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -59.02 -45.08 91.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.711 -179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.31 -40.82 96.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.393 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.68 88.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.238 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -67.16 -40.88 92.66 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 384' ' ' ALA . 92.1 t -66.5 -41.88 89.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.106 0.479 . . . . 0.0 110.042 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.552 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.6 tt -58.81 -41.0 85.74 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.778 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.1 mt -66.4 -42.08 89.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.963 0.411 . . . . 0.0 110.073 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.89 -41.59 96.33 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.549 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.09 -41.46 92.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.698 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.35 -41.63 97.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.448 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -61.96 -42.61 99.32 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.28 -0.568 . . . . 0.0 109.476 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.65 -47.89 82.92 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.881 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.37 -36.31 83.3 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.43 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.02 -45.13 79.21 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.16 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -64.45 -42.09 94.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.915 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.06 -32.54 80.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.1 tp . . . . . 0 C--N 1.328 -0.369 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.405 -179.825 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt . . . . . 0 CA--C 1.533 0.301 0 CA-C-O 120.491 0.186 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.91 -20.3 58.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.799 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.1 -43.32 92.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.256 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.86 99.0 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.03 93.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.744 0.307 . . . . 0.0 110.65 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.81 -45.75 91.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.669 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.31 -40.23 93.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.412 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.58 -38.06 88.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.24 -37.97 95.26 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 88.4 t -66.15 -42.89 92.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.569 0.224 . . . . 0.0 110.66 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -58.92 -39.22 80.87 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.835 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.9 mm -63.74 -42.68 96.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.228 179.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.6 -40.27 94.21 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.588 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.42 -39.12 83.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.513 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.48 -41.23 96.95 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.502 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -60.69 -42.86 98.0 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.9 -46.91 87.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.859 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -62.41 -34.49 76.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.347 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -59.46 -44.99 92.87 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.467 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 38.2 mm -68.2 -41.6 84.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.032 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.585 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.957 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 CA--C 1.533 0.29 0 CA-C-O 120.574 0.226 . . . . 0.0 111.349 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.721 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -67.19 -43.43 88.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.33 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.24 -39.36 97.8 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -40.61 97.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.865 0.364 . . . . 0.0 110.489 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . 0.401 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -65.21 -35.79 82.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.506 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.624 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.3 tt -61.07 -45.13 96.02 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-O 121.053 0.454 . . . . 0.0 110.008 -179.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.96 -37.33 87.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.649 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.96 -39.6 98.27 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . 0.401 HG23 ' O ' ' C' ' 384' ' ' ALA . 88.5 t -63.83 -42.68 96.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 110.272 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.6 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.5 tt -60.08 -38.61 83.42 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.996 -179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -63.5 -42.46 96.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.899 0.381 . . . . 0.0 110.117 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 9.7 mt -61.54 -40.4 94.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.479 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.0 t -63.26 -40.57 89.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.6 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.91 -41.77 96.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.338 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.03 -44.0 97.63 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.613 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.89 83.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.179 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -59.67 -44.45 93.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.662 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -62.97 -45.15 93.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.616 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -63.94 -42.52 96.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.816 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.595 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.817 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 72.7 mt . . . . . 0 C--O 1.232 0.173 0 CA-C-O 120.67 0.271 . . . . 0.0 111.064 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -53.33 -20.38 4.31 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.599 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -67.89 -43.66 85.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.623 0.249 . . . . 0.0 110.472 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -67.39 -43.95 86.04 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.87 -39.87 87.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.751 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . 0.43 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -64.13 -43.6 94.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.728 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -66.12 -41.43 90.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.49 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.54 93.61 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.48 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.75 -43.45 98.93 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 384' ' ' ALA . 94.8 t -67.41 -42.0 86.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.723 0.297 . . . . 0.0 110.851 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tp -59.59 -40.87 88.89 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.073 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.07 -42.76 95.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.85 0.357 . . . . 0.0 110.23 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -61.89 -42.74 99.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.831 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.2 t -65.55 -41.97 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.84 -41.18 97.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.559 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -61.49 -44.06 97.76 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -62.28 -47.45 84.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.972 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.13 -35.72 79.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.224 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -57.92 -45.91 85.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.307 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.66 -41.15 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.162 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.53 -27.37 60.98 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.4 tp . . . . . 0 C--N 1.327 -0.386 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.397 179.958 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.5 mt . . . . . 0 CA--C 1.53 0.21 0 CA-C-O 120.661 0.267 . . . . 0.0 110.817 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.93 -20.0 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.613 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.459 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.2 t -64.15 -43.3 97.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.14 -40.49 99.22 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.64 -37.42 86.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.803 0.335 . . . . 0.0 110.673 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.7 91.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.787 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -64.92 -41.78 95.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.49 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.92 89.19 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.465 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.98 99.52 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 85.5 t -66.92 -43.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.903 0.382 . . . . 0.0 110.189 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . 0.547 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.8 tt -59.63 -41.26 90.06 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.503 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.3 mt -65.68 -42.11 91.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.98 0.419 . . . . 0.0 110.194 179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -60.04 -41.27 91.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.563 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 82.4 t -64.43 -41.43 92.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.68 -42.2 98.6 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.48 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.13 -42.4 99.2 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.05 -49.26 76.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.799 179.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -64.38 -35.45 80.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.36 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -57.37 -45.57 84.29 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.322 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 5.2 mm -63.93 -42.4 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.074 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.69 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 179.675 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.529 0.141 0 CA-C-O 120.781 0.324 . . . . 0.0 110.808 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.94 -19.88 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.737 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.4 p -59.68 -42.84 89.85 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 CA-C-O 120.615 0.245 . . . . 0.0 110.419 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . 0.5 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.81 -39.79 97.77 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.22 -40.9 97.65 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.886 0.374 . . . . 0.0 110.542 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.47 -35.9 82.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.546 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.666 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.19 -44.33 97.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.876 -179.441 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.4 90.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.605 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.73 -41.63 99.63 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 91.2 t -67.08 -42.48 88.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.629 0.252 . . . . 0.0 110.453 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.538 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.6 tt -59.69 -41.43 90.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.156 -179.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.7 mt -64.45 -42.45 95.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.857 0.36 . . . . 0.0 110.28 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.01 -41.2 96.07 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 -179.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.1 -40.68 89.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.59 -40.32 94.36 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.326 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.8 -42.84 99.52 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -49.18 77.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.933 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -63.93 -34.8 78.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.392 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.89 -45.31 82.67 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.16 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 84.8 mt -64.7 -42.27 94.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.068 178.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.679 0 N-CA-C 111.014 -0.835 . . . . 0.0 111.014 -179.994 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.525 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 120.553 0.216 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.97 -20.01 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.936 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.4 p -61.04 -43.12 95.51 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 120.679 0.276 . . . . 0.0 110.392 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.514 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.68 -38.92 96.95 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.92 -41.06 95.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.703 0.287 . . . . 0.0 110.563 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.66 -35.71 81.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.518 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.1 tt -61.14 -44.35 97.46 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.024 0.44 . . . . 0.0 109.963 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.35 86.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.408 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.74 97.9 Favored Glycine 0 CA--C 1.531 1.066 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.3 t -63.52 -42.17 95.25 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.706 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -59.73 -37.53 79.17 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.467 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.0 mm -64.6 -42.22 94.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.884 0.374 . . . . 0.0 110.072 179.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.14 -40.02 92.24 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.602 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.7 t -62.69 -41.1 91.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.784 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.15 -40.93 95.71 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.444 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.88 -41.84 98.36 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.548 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.82 -48.84 77.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.766 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -64.09 -35.88 82.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.424 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -57.47 -45.52 84.71 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.392 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.74 -42.46 96.04 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.88 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.88 -35.47 92.05 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.1 tp . . . . . 0 C--N 1.329 -0.297 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.614 -179.825 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.497 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.0 mt . . . . . 0 CA--C 1.53 0.197 0 CA-C-O 120.665 0.269 . . . . 0.0 111.309 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.51 -20.21 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.808 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.0 t -64.68 -44.06 96.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.435 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.25 -40.83 96.89 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.04 85.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.738 0.304 . . . . 0.0 110.655 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.45 -45.77 92.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.659 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.91 -42.3 94.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.509 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.81 -37.26 87.02 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.48 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.63 -40.6 99.36 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -67.14 -42.72 88.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.485 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.6 tt -59.36 -40.56 86.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.486 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.2 mt -65.72 -42.21 92.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.829 0.347 . . . . 0.0 110.188 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.25 -40.58 94.57 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.632 -179.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.7 t -62.4 -41.15 90.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.783 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.17 -41.16 96.28 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.471 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -42.85 99.36 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.978 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -64.37 -37.27 86.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.346 179.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -58.22 -45.41 87.75 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.0 mt -63.35 -41.96 94.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.567 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 179.904 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 CA--C 1.531 0.247 0 CA-C-O 120.618 0.247 . . . . 0.0 111.182 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.55 -20.22 60.69 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.995 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.64 -43.5 90.33 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.394 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.04 -39.24 97.04 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.06 -41.69 98.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.814 0.34 . . . . 0.0 110.545 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.3 83.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.467 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.632 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.0 tt -61.59 -45.23 95.01 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.136 0.493 . . . . 0.0 110.051 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.17 -36.76 85.11 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.45 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.07 -42.26 98.37 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 62.7 t -67.43 -42.61 87.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.787 0.327 . . . . 0.0 110.429 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.509 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.3 tt -61.02 -41.54 96.75 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.182 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.0 mt -64.38 -41.95 93.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.241 178.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -60.49 -41.44 94.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.683 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 78.7 t -64.71 -41.4 92.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.735 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.8 mt -61.7 -41.58 97.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.611 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.84 -42.83 99.51 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.368 -0.533 . . . . 0.0 109.687 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.59 93.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.841 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -63.75 -39.29 93.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.553 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -56.61 -45.36 81.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.337 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.7 mm -66.71 -40.83 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.895 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.572 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.861 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 CA--C 1.534 0.357 0 CA-C-O 120.534 0.206 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -74.52 -20.3 60.03 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.644 0.259 . . . . 0.0 110.859 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.32 -43.68 87.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.79 0.329 . . . . 0.0 110.397 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.05 -42.96 99.48 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.876 -0.889 . . . . 0.0 110.876 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.79 -39.49 93.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.747 0.308 . . . . 0.0 110.777 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.4 -44.37 97.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.7 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.62 -41.63 92.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.53 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.72 -40.25 91.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.377 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.36 -42.83 99.04 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.43 -42.5 87.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.825 0.345 . . . . 0.0 110.567 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.26 -41.11 88.07 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.406 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 84.5 mt -65.4 -42.55 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 CA-C-O 120.934 0.397 . . . . 0.0 110.326 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 13.0 mt -60.7 -40.0 90.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.51 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.4 t -63.02 -41.34 92.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.721 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -60.96 -40.84 94.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.494 -179.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.51 -42.53 98.94 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.424 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.31 -47.91 82.19 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.829 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.2 t80 -63.92 -34.83 78.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.512 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -57.22 -45.56 83.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.291 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 29.8 mm -64.73 -42.61 95.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.75 -34.01 88.75 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.0 tp . . . . . 0 C--N 1.328 -0.365 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.571 -179.827 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 45.5 mm . . . . . 0 CA--C 1.532 0.285 0 CA-C-O 120.467 0.175 . . . . 0.0 111.391 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.79 -20.31 61.88 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.759 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -66.98 -43.59 89.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 CA-C-O 120.811 0.339 . . . . 0.0 110.21 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.61 -40.78 96.15 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.23 -39.22 92.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.83 0.348 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . 0.438 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -63.83 -45.11 91.08 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.585 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -66.57 -41.41 88.62 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.558 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.67 -38.29 90.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.26 -39.16 96.8 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . 0.438 HG23 ' O ' ' B' ' 384' ' ' ALA . 96.0 t -66.71 -41.76 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.15 0.5 . . . . 0.0 110.103 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -58.62 -40.22 82.72 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.857 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.59 -42.07 86.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.142 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.1 mt -61.09 -41.89 97.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.721 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.52 -41.46 92.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.714 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.29 -40.83 95.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.611 -179.419 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.42 -42.45 98.77 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.459 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.49 -49.79 76.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.866 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -63.89 -34.29 77.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.357 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -58.32 -44.67 88.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.269 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . 0.409 HD13 ' HA ' ' B' ' 398' ' ' ILE . 30.8 mm -64.64 -42.64 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.855 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.382 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.865 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.502 ' O ' ' N ' ' C' ' 381' ' ' VAL . 94.6 mt . . . . . 0 CA--C 1.533 0.29 0 CA-C-O 120.429 0.157 . . . . 0.0 111.167 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.11 -19.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.829 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.533 HG13 ' N ' ' C' ' 382' ' ' GLY . 7.9 p -58.97 -44.34 90.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . 0.533 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.46 -39.11 97.35 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.5 -41.47 98.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . 0.414 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -65.56 -35.39 80.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.359 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.632 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.45 -44.28 97.39 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.111 0.482 . . . . 0.0 110.086 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.63 -37.4 87.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.519 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.76 -41.71 97.48 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . 0.414 HG23 ' O ' ' C' ' 384' ' ' ALA . 97.9 t -65.75 -41.55 90.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.898 0.38 . . . . 0.0 110.28 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 tt -58.39 -41.7 85.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.618 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 80.7 mt -65.85 -42.44 92.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.857 0.36 . . . . 0.0 110.393 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -60.88 -39.43 89.22 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.547 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 61.9 t -62.23 -41.7 92.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.675 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -60.92 -41.44 96.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.399 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.45 -44.46 96.36 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 120.09 -0.644 . . . . 0.0 109.648 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.35 -36.54 84.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.108 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -59.52 -43.65 93.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.604 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -63.87 -41.0 97.85 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.562 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 83.2 mt -63.53 -42.39 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.778 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.565 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.581 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.538 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.5 mt . . . . . 0 CA--C 1.531 0.244 0 CA-C-O 120.546 0.212 . . . . 0.0 110.968 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.07 -20.0 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.871 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.3 p -60.82 -42.53 92.76 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 120.717 0.294 . . . . 0.0 110.362 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.496 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -61.81 -39.25 97.23 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.77 -40.89 94.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.819 0.342 . . . . 0.0 110.581 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.77 -35.69 81.89 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.474 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.653 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.5 tt -61.59 -44.38 97.12 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 121.057 0.456 . . . . 0.0 110.002 -179.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.81 -36.53 83.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.445 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.8 -37.38 94.76 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.2 t -67.53 -42.08 86.53 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-O 121.076 0.465 . . . . 0.0 109.943 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -59.18 -41.7 89.09 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.778 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -66.72 -42.0 88.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.35 -41.26 93.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.613 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.3 t -64.29 -40.94 90.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.63 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.3 mt -61.6 -40.35 94.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.515 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -62.04 -43.76 98.15 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.31 -0.556 . . . . 0.0 109.581 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.55 -36.77 84.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.018 179.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -60.69 -44.22 96.79 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.657 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -62.32 -43.47 98.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.658 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 86.6 mt -63.83 -42.7 96.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.799 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.06 -38.18 93.79 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.0 tp . . . . . 0 C--N 1.328 -0.349 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.438 -179.803 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt . . . . . 0 CA--C 1.531 0.221 0 CA-C-O 120.425 0.155 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.71 -19.93 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.897 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.537 ' N ' ' O ' ' B' ' 379' ' ' ILE . 7.8 p -60.97 -40.96 87.25 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-O 120.773 0.321 . . . . 0.0 110.265 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . 0.447 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -62.75 -38.57 96.7 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.537 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.27 -40.4 93.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.802 0.334 . . . . 0.0 110.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -35.46 81.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.503 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . 0.656 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.1 tt -61.12 -45.32 95.18 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.065 0.459 . . . . 0.0 110.004 -179.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.26 -35.88 82.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.422 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.86 -40.6 98.5 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -66.55 -42.3 89.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.85 0.357 . . . . 0.0 110.276 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . 0.542 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.9 tt -60.1 -41.36 92.35 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.419 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -65.73 -41.98 91.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.78 0.324 . . . . 0.0 110.156 179.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -60.06 -41.4 92.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.626 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.3 t -63.77 -41.62 93.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.754 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.11 -41.27 96.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.477 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.48 -43.56 98.65 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 120.276 -0.569 . . . . 0.0 109.573 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.3 -36.98 84.34 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.144 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -60.48 -44.09 96.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.647 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -62.94 -41.81 99.61 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.605 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.8 mt -63.09 -42.55 97.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.742 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.541 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.839 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 95.0 mt . . . . . 0 N--CA 1.464 0.256 0 CA-C-O 120.662 0.268 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.19 -20.15 60.95 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.899 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -64.3 -43.21 97.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.245 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.94 -41.97 99.7 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.98 -37.58 88.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.757 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . 0.405 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -60.16 -44.77 94.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.45 -40.4 93.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.424 179.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.47 91.31 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.46 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.99 -41.37 97.34 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . 0.405 HG23 ' O ' ' C' ' 384' ' ' ALA . 88.9 t -64.56 -42.87 96.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-O 120.77 0.319 . . . . 0.0 110.296 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.587 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.4 tt -60.29 -39.06 85.54 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.897 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 6.5 mm -63.41 -42.27 95.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.07 -40.82 95.13 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.651 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.1 t -62.61 -41.9 93.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.69 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.37 -42.28 98.44 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.67 -42.4 99.6 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.16 -48.57 73.55 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.0 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -63.97 -34.86 78.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.547 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -58.17 -44.33 87.93 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.366 -179.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.4 mm -65.52 -41.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.797 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.486 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -179.828 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.377 0.132 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.16 -20.23 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.347 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.832 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' A' ' 379' ' ' ILE . 45.4 t -65.6 -43.98 93.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.515 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.32 -37.39 94.44 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.8 -42.28 98.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.77 0.319 . . . . 0.0 110.471 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.57 -37.17 85.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.568 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.656 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.3 tt -61.53 -44.17 97.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.419 . . . . 0.0 109.976 -179.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.94 -37.08 85.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.592 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.84 -39.96 97.57 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.0 t -64.0 -43.39 97.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.756 0.312 . . . . 0.0 110.541 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.591 HD23 ' O ' ' A' ' 389' ' ' LEU . 5.0 tt -60.6 -39.31 87.66 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 7.7 mm -63.75 -42.54 96.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.12 -40.36 93.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.351 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.5 t -63.99 -41.41 92.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.758 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.42 97.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.441 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.68 -41.56 97.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.49 -48.93 73.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.808 179.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.67 -35.34 80.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.31 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.1 t80 -58.34 -46.11 86.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.388 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.1 mt -64.45 -42.56 95.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.225 179.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.99 -32.65 84.88 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.2 tp . . . . . 0 C--N 1.329 -0.303 0 C-N-CA 120.925 -0.31 . . . . 0.0 110.383 -179.529 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.8 mt . . . . . 0 CA--C 1.531 0.218 0 CA-C-O 120.46 0.171 . . . . 0.0 110.782 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.61 -19.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.583 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.8 t -63.9 -43.65 97.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 C-N-CA 120.941 -0.304 . . . . 0.0 110.377 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.48 -43.02 98.78 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.89 87.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.758 0.313 . . . . 0.0 110.697 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . 0.421 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -61.26 -44.85 96.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.698 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.26 -40.68 94.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.416 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.8 -37.41 84.3 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.376 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -39.21 96.01 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . 0.421 HG23 ' O ' ' B' ' 384' ' ' ALA . 88.0 t -63.87 -42.12 94.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 11.9 mt -62.75 -42.03 99.49 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.807 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.6 mt -66.79 -40.62 86.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.942 0.401 . . . . 0.0 110.067 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -59.15 -41.97 89.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.472 -179.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.04 -42.08 93.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.814 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.55 -41.6 97.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.454 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.82 -44.02 97.69 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.308 -0.557 . . . . 0.0 109.646 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.27 -36.61 83.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.143 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.22 -44.29 95.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.527 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -62.99 -44.45 95.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.405 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.27 -42.69 97.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.21 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.636 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.856 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.2 mt . . . . . 0 CA--C 1.532 0.274 0 CA-C-O 120.441 0.162 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.41 -19.94 60.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 121.044 -0.262 . . . . 0.0 110.846 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.5 t -66.26 -43.16 91.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.084 0 CA-C-O 120.761 0.315 . . . . 0.0 110.484 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.38 -36.65 93.68 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.59 -41.0 98.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.424 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.13 83.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.658 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.8 tt -61.3 -43.74 98.37 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.45 -36.92 85.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.591 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.97 -39.99 97.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.52 -42.72 96.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.5 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.509 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.9 tt -60.5 -39.22 86.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.914 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.98 -42.32 95.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.0 -41.8 97.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.589 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -63.91 -41.27 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.14 -41.37 96.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.559 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.4 -44.41 97.19 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.418 -0.513 . . . . 0.0 109.663 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.78 84.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.189 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 78.5 t80 -60.33 -43.97 95.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.477 -179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -64.56 -45.56 86.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.365 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -64.54 -42.15 94.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.371 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.608 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.505 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 46.7 mm . . . . . 0 CA--C 1.527 0.093 0 CA-C-O 120.599 0.238 . . . . 0.0 110.969 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.17 -20.18 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 120.518 0.199 . . . . 0.0 110.791 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.0 p -60.78 -42.03 90.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.462 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -60.28 -43.16 98.82 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.57 -37.49 85.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.752 0.31 . . . . 0.0 110.738 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . 0.409 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -60.64 -43.52 97.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.694 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.41 -41.38 93.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.395 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.49 -39.06 89.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.174 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.48 -41.04 96.52 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 384' ' ' ALA . 91.0 t -67.34 -42.04 87.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.845 0.355 . . . . 0.0 110.245 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.532 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.6 tt -59.61 -41.74 91.08 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.41 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.9 mt -65.58 -42.11 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-O 120.931 0.396 . . . . 0.0 110.231 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.51 -40.89 96.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.601 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.6 t -64.18 -41.38 92.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.45 -41.55 97.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.434 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.92 -42.58 99.26 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.458 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.64 -47.0 77.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.804 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -64.19 -35.23 80.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.514 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -57.7 -46.22 84.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.396 -179.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 92.1 mt -64.66 -42.43 95.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.49 -33.05 86.2 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.5 tp . . . . . 0 C--N 1.328 -0.364 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.437 -179.496 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.532 0.285 0 CA-C-O 120.72 0.295 . . . . 0.0 111.099 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.25 -20.26 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.618 -0.264 . . . . 0.0 111.007 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' B' ' 379' ' ' ILE . 10.6 p -59.36 -42.77 88.51 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . 0.495 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -63.14 -40.23 98.9 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -67.95 -35.84 79.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.716 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . 0.402 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -60.16 -44.04 95.32 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.683 -179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.51 -40.45 93.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.42 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.17 -37.86 88.71 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.526 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.33 -39.6 97.99 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . 0.402 HG23 ' O ' ' B' ' 384' ' ' ALA . 99.3 t -67.94 -42.13 85.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.675 0.274 . . . . 0.0 110.4 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -60.0 -40.86 90.68 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.209 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.8 mt -64.93 -42.26 94.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.913 0.387 . . . . 0.0 110.366 179.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.35 -40.03 89.28 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.516 -179.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 68.9 t -62.06 -41.25 90.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.652 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.48 -41.03 93.36 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.433 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.79 -43.99 97.41 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.646 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.48 86.44 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.118 179.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.49 -44.34 96.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.888 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -62.24 -44.48 96.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.692 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.0 mt -63.27 -42.35 96.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.616 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.496 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.887 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.445 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt . . . . . 0 CA--C 1.533 0.292 0 CA-C-O 120.657 0.265 . . . . 0.0 111.117 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -44.43 -19.87 0.03 OUTLIER 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.8 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.445 ' N ' ' O ' ' C' ' 379' ' ' ILE . 61.3 t -64.28 -43.15 97.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.196 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.13 -42.06 99.67 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.19 85.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.756 0.313 . . . . 0.0 110.777 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.31 -44.96 95.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.796 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.2 -42.08 93.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.547 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.47 87.74 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.514 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.51 99.82 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 80.1 t -66.43 -42.09 89.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 0.0 110.336 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -60.74 -40.93 94.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.518 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 84.9 mt -66.47 -42.06 89.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.935 0.397 . . . . 0.0 110.275 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.3 -40.97 87.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.517 -179.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 72.5 t -63.11 -42.06 95.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.726 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.9 -41.59 96.36 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.588 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.11 -42.52 99.3 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.565 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.44 -48.01 75.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.099 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 93.9 t80 -63.36 -36.34 83.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.664 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -57.7 -44.56 85.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.492 -179.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 39.7 mm -66.75 -40.45 86.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.779 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.797 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 CA--C 1.532 0.258 0 CA-C-O 120.542 0.211 . . . . 0.0 110.981 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.05 -20.03 61.06 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.872 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.4 t -66.4 -43.55 91.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.072 0 CA-C-O 120.633 0.254 . . . . 0.0 110.359 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.15 -40.97 97.19 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.98 -39.2 90.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.742 0.306 . . . . 0.0 110.77 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.35 -44.68 96.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.651 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.2 mt -65.2 -40.6 94.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.386 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.77 -37.26 86.71 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.44 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.65 -39.72 97.84 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.03 -42.24 95.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.62 -38.09 80.38 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.353 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.99 -42.76 95.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.396 . . . . 0.0 110.093 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.9 mt -61.61 -42.18 98.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.58 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.7 t -66.07 -41.94 90.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.89 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.73 -41.13 97.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.463 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.48 -44.1 97.69 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.347 -0.541 . . . . 0.0 109.688 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.42 -37.37 86.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.98 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -61.89 -44.78 96.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.696 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -62.94 -45.37 92.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.49 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.9 mt -64.26 -42.58 95.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.062 179.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.42 -42.8 95.73 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.6 tp . . . . . 0 C--N 1.327 -0.385 0 CA-C-O 120.781 0.324 . . . . 0.0 110.534 -179.919 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.9 mt . . . . . 0 CA--C 1.532 0.258 0 CA-C-O 120.485 0.183 . . . . 0.0 111.049 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -72.2 -20.44 61.57 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.742 -0.208 . . . . 0.0 110.652 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 60.3 t -66.89 -43.39 89.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.658 0.266 . . . . 0.0 110.414 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.1 -39.55 98.13 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.04 -41.61 96.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.86 -35.38 80.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.511 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . 0.65 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.0 tt -61.41 -44.29 97.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.295 -0.412 . . . . 0.0 109.92 -179.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.98 -36.91 85.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.567 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.45 -39.48 97.35 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.67 -42.36 94.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.922 0.392 . . . . 0.0 110.191 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . 0.581 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.3 tt -59.63 -38.32 81.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.263 -179.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.11 -42.16 94.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.853 0.359 . . . . 0.0 110.207 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.09 -41.03 95.9 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.625 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 86.3 t -63.5 -41.07 91.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.665 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.31 -41.44 96.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.503 -179.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.74 -42.7 99.31 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.89 75.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.833 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -65.0 -35.59 81.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.431 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.9 t80 -57.53 -45.94 84.45 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.273 -179.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.04 -42.3 95.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.128 179.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.643 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.914 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.2 mt . . . . . 0 CA--C 1.53 0.186 0 CA-C-O 120.578 0.227 . . . . 0.0 110.718 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.63 -19.79 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.766 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.3 p -60.88 -43.06 94.9 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.62 0.248 . . . . 0.0 110.474 -179.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . 0.511 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -62.51 -45.53 95.68 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.2 85.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.79 0.329 . . . . 0.0 110.719 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.22 -43.66 98.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.654 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.82 -41.14 92.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.485 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.38 94.21 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.452 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.81 -41.11 98.96 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -66.0 -42.73 92.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 110.645 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.595 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.8 tt -59.59 -41.39 90.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.088 -179.082 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.0 mt -65.43 -42.08 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.9 0.381 . . . . 0.0 110.367 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.7 mt -60.45 -40.86 92.66 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.534 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.06 -41.41 92.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.685 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.09 -41.43 96.65 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.487 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.74 -41.94 98.31 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.87 -48.93 74.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.763 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -63.69 -36.27 83.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.483 179.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -57.64 -45.32 85.61 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.269 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.57 -42.29 95.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.094 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.678 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.639 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.467 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.528 0.112 0 CA-C-O 120.593 0.235 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.87 -19.62 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.545 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.467 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.2 t -64.83 -43.4 96.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.446 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.78 -36.72 93.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.66 -40.86 98.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.408 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.63 -36.47 83.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.633 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.653 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.0 tt -61.42 -44.04 97.82 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.992 0.425 . . . . 0.0 109.925 -179.441 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.82 -37.06 85.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.447 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.56 -39.32 97.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.2 t -65.99 -42.0 90.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.115 0.483 . . . . 0.0 110.243 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -59.55 -41.01 89.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.595 -179.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.8 mt -67.75 -41.63 85.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.053 0.454 . . . . 0.0 110.387 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.03 -41.23 91.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.636 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.8 t -64.3 -41.81 93.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.796 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.39 -41.52 97.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.497 -179.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.72 -42.08 98.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.1 -48.52 75.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.537 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -64.89 -36.5 84.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.373 179.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -57.26 -45.65 83.81 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.182 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -63.7 -42.59 96.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.63 -37.17 94.33 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 43.7 tp . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 120.812 0.339 . . . . 0.0 110.553 -179.92 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt . . . . . 0 CA--C 1.528 0.121 0 CA-C-O 120.534 0.207 . . . . 0.0 110.914 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.13 -19.77 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 121.013 -0.275 . . . . 0.0 110.651 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.521 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.2 t -64.31 -43.71 97.19 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.41 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.69 -38.43 96.21 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.15 -41.14 97.99 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.912 0.387 . . . . 0.0 110.404 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.55 -36.24 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.511 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . 0.643 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.6 tt -61.5 -44.43 97.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.02 0.438 . . . . 0.0 110.021 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.81 82.76 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.392 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.15 -37.72 95.37 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.68 -41.99 93.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.991 0.424 . . . . 0.0 110.075 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . 0.579 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.1 tt -60.57 -38.1 83.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.224 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.87 -42.12 94.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.822 0.344 . . . . 0.0 110.201 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.86 -40.38 92.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.471 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 92.9 t -63.86 -40.92 90.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.822 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.32 -41.15 96.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.394 -179.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.46 -42.18 98.37 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.21 -46.19 89.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.772 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -63.62 -37.68 88.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.357 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.52 -45.96 84.39 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.243 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -63.52 -42.4 96.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.194 179.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.618 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -179.79 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 37.9 mm . . . . . 0 CA--C 1.529 0.149 0 CA-C-O 120.628 0.251 . . . . 0.0 110.777 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -80.17 -19.73 46.47 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.528 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 52.4 t -65.4 -43.37 94.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.292 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.62 -41.62 99.61 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -38.07 88.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.743 0.306 . . . . 0.0 110.643 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.16 -43.91 96.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.674 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -66.0 -40.7 91.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.497 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.95 91.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.549 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.05 -39.35 97.14 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.8 t -64.06 -42.52 95.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 0.0 110.457 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.647 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.5 tt -60.26 -38.37 83.3 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.772 -179.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.03 -42.48 95.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-O 120.846 0.355 . . . . 0.0 110.052 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.18 -40.41 93.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.436 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.6 -41.08 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.742 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.27 -41.27 96.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.435 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.5 -42.24 98.5 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -47.96 81.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.916 -0.583 . . . . 0.0 109.832 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -63.12 -35.82 81.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.217 179.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -59.1 -45.26 91.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.321 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.1 mt -63.15 -42.5 96.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.244 179.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.685 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.862 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.8 mm . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.696 0.284 . . . . 0.0 111.57 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.4 -20.26 62.95 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.804 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.37 -42.32 90.35 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.992 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.52 -40.17 98.33 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.15 -38.21 90.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.74 0.305 . . . . 0.0 110.743 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.7 -45.7 91.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.671 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.28 -41.57 94.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.511 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.35 -38.17 90.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.293 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.6 -41.79 99.77 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.7 t -67.11 -42.36 88.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.823 0.344 . . . . 0.0 110.159 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.626 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -60.0 -40.8 90.44 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.3 -179.021 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.7 mt -66.42 -41.75 89.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.959 0.409 . . . . 0.0 110.351 178.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.54 -40.55 91.95 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.579 -179.292 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.4 t -64.33 -41.15 91.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.752 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.93 -41.57 98.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.537 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.41 -42.49 99.48 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.242 -0.583 . . . . 0.0 109.476 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.09 -48.95 72.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.981 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -64.13 -35.79 81.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.422 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -57.38 -45.8 84.07 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.282 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.2 mt -64.89 -42.43 94.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.48 -33.69 87.92 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.8 tp . . . . . 0 C--N 1.327 -0.387 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.411 -179.572 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.507 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.9 mt . . . . . 0 CA--C 1.529 0.169 0 CA-C-O 120.786 0.327 . . . . 0.0 111.315 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.14 -20.1 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.752 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.507 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.38 -43.9 94.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 120.904 0.383 . . . . 0.0 110.178 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.73 -35.77 91.42 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.23 -41.86 98.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.861 0.363 . . . . 0.0 110.662 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.4 84.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.45 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . 0.646 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.3 tt -61.23 -44.47 97.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.922 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.23 83.65 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.548 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.74 -41.09 97.37 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 62.1 t -67.24 -43.35 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.668 0.27 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.29 -40.37 93.91 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 119.536 -0.866 . . . . 0.0 109.771 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 79.2 mt -64.04 -42.4 95.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 120.872 0.368 . . . . 0.0 110.572 178.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.08 -41.4 96.59 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.588 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.6 t -65.94 -42.33 91.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.076 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.67 -40.47 95.08 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.4 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.18 -42.94 99.75 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.588 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.74 -36.82 84.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.157 179.395 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -60.36 -44.38 95.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.601 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.0 -43.79 98.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.61 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 91.2 mt -63.55 -42.61 96.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.717 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.494 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.862 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.0 mt . . . . . 0 CA--C 1.531 0.212 0 CA-C-O 120.77 0.319 . . . . 0.0 111.234 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.42 -20.02 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.816 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.9 p -61.82 -42.72 95.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . 0.486 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -64.46 -42.15 97.69 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.19 86.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.86 0.362 . . . . 0.0 110.787 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.56 -45.34 94.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.676 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -64.5 -40.43 95.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.433 179.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.93 -37.26 87.05 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.466 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.95 -40.2 97.02 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.98 -43.27 96.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.926 0.394 . . . . 0.0 110.318 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.8 -38.59 88.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.17 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.86 -42.09 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.9 mt -61.41 -41.68 97.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.573 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 90.2 t -65.73 -42.24 92.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.51 -41.82 97.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.625 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -62.27 -43.55 98.56 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.66 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.58 -36.42 82.59 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -61.12 -44.96 96.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.805 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -62.47 -43.69 98.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.645 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.4 mt -64.92 -42.69 95.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.882 179.472 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.376 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 180.0 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt . . . . . 0 C--O 1.233 0.216 0 CA-C-O 120.566 0.222 . . . . 0.0 110.847 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.87 -20.48 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.657 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' A' ' 379' ' ' ILE . 43.6 t -67.97 -43.62 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.413 179.144 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 379' ' ' ILE . . . -64.96 -38.15 95.13 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.94 98.46 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.713 0.292 . . . . 0.0 110.743 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.76 -48.07 82.35 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.92 0.391 . . . . 0.0 110.565 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.6 -40.95 93.22 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.37 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.51 -39.14 89.91 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.232 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.56 -37.57 94.97 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -63.74 -43.14 97.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.989 0.423 . . . . 0.0 110.243 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.4 mp -61.89 -38.0 86.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.345 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 28.9 mm -63.13 -42.13 95.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -61.16 -42.47 98.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.569 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.3 t -65.62 -42.17 92.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.983 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.94 -40.62 96.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.596 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -60.88 -41.89 96.89 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.95 -49.47 73.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.877 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -65.72 -35.41 80.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.329 179.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -58.0 -45.8 86.26 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.308 -179.415 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.04 -42.94 97.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.231 179.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.84 -41.83 98.66 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.4 tp . . . . . 0 C--N 1.327 -0.375 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.302 -179.981 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.2 mt . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.57 0.224 . . . . 0.0 110.797 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -39.93 -20.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.665 -179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.4 t -67.23 -43.8 88.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 CA-C-O 120.659 0.266 . . . . 0.0 110.567 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' B' ' 379' ' ' ILE . . . -65.26 -37.74 94.32 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.1 -38.53 91.54 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.327 . . . . 0.0 110.66 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.28 -48.05 79.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.848 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.54 -41.6 92.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.429 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.84 -36.98 85.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.327 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.62 -40.09 98.26 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 77.9 t -63.2 -43.46 98.81 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.975 0.417 . . . . 0.0 110.244 179.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.2 -38.01 87.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.361 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.77 -42.15 95.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.4 mt -60.84 -42.63 98.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.557 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.62 -42.31 92.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.56 -41.4 97.33 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.374 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.97 -42.44 99.13 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 120.288 -0.565 . . . . 0.0 109.546 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.59 -38.16 86.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.017 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -62.13 -44.8 95.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.477 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -68.43 -45.54 72.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.866 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.11 -42.03 94.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.068 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.612 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.941 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt . . . . . 0 CA--C 1.531 0.225 0 CA-C-O 120.651 0.262 . . . . 0.0 111.085 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -58.44 -24.65 60.76 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.653 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 56.0 t -68.86 -43.55 82.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.094 0 CA-C-O 120.73 0.3 . . . . 0.0 110.585 179.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.17 -36.17 92.9 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.58 -40.15 95.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.718 0.294 . . . . 0.0 110.751 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . 0.402 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -60.82 -48.59 81.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.8 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.97 -40.86 95.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.47 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.11 -37.74 86.27 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.422 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.11 -38.01 94.81 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . 0.402 HG23 ' O ' ' C' ' 384' ' ' ALA . 98.3 t -65.03 -43.17 96.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 120.75 0.309 . . . . 0.0 110.539 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 mp -61.36 -39.39 90.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.042 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.12 -42.42 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.073 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -61.11 -41.76 97.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.529 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.6 t -65.43 -41.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.53 -40.44 94.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.439 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.42 -42.06 98.15 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.47 76.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.725 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -64.59 -35.88 82.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.373 179.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -57.67 -45.12 85.99 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.275 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.8 mt -63.81 -42.65 96.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.117 179.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.603 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.673 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 381' ' ' VAL . 94.9 mt . . . . . 0 CA--C 1.53 0.205 0 CA-C-O 120.535 0.207 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.48 -19.81 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.962 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.526 ' N ' ' O ' ' A' ' 379' ' ' ILE . 7.8 p -60.53 -43.65 94.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.749 0.309 . . . . 0.0 110.41 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.52 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -64.81 -36.45 93.12 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -41.3 98.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.738 0.304 . . . . 0.0 110.669 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.36 -36.24 83.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.612 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.623 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.4 tt -61.65 -45.31 94.58 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.056 0.455 . . . . 0.0 110.106 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -37.7 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.5 -42.44 97.64 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.2 t -67.12 -42.49 88.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.738 0.304 . . . . 0.0 110.627 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.57 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.9 tt -59.97 -40.99 90.99 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.223 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -65.33 -42.17 93.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.872 0.368 . . . . 0.0 110.234 179.09 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.85 -41.14 95.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.685 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.1 t -63.88 -41.49 92.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.682 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.34 -41.02 96.36 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.598 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.46 -41.8 97.79 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.295 -0.562 . . . . 0.0 109.545 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.54 -49.63 74.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.882 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -65.01 -34.88 79.5 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.365 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -58.21 -45.56 87.43 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.351 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.3 mt -63.63 -42.74 97.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.34 -38.53 95.97 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.9 tp . . . . . 0 C--N 1.327 -0.391 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.434 -179.905 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.496 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.532 0.284 0 CA-C-O 120.658 0.266 . . . . 0.0 111.044 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.62 -20.06 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.682 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.496 ' N ' ' O ' ' B' ' 379' ' ' ILE . 62.2 t -65.17 -43.11 95.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.361 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.19 -39.63 98.15 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -40.48 96.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.513 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.49 -35.48 81.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.512 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . 0.653 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.8 tt -61.41 -44.05 97.81 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 121.1 0.476 . . . . 0.0 109.988 -179.679 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -37.05 85.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.421 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.11 -39.97 96.52 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.96 -43.2 92.85 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.938 0.399 . . . . 0.0 110.218 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -60.36 -40.67 91.63 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.806 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 80.1 mt -67.33 -41.37 86.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.146 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -60.12 -40.93 91.44 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.696 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 75.7 t -63.84 -41.38 92.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.666 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.27 -41.29 96.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.521 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.4 -42.82 99.33 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.558 179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.25 -47.9 74.76 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.836 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 85.0 t80 -64.36 -34.7 78.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.448 179.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -58.57 -44.87 89.91 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.41 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 42.3 mm -65.09 -40.99 90.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.83 179.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.619 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.869 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.6 mm . . . . . 0 CA--C 1.53 0.191 0 CA-C-O 120.631 0.253 . . . . 0.0 111.352 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.95 -20.08 61.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.005 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 54.5 t -65.9 -43.71 92.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 CA-C-O 120.744 0.307 . . . . 0.0 110.344 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.72 -41.86 99.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.04 -36.98 86.09 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.792 0.329 . . . . 0.0 110.713 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.43 -46.04 89.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.672 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -64.7 -41.05 96.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.416 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.23 -37.51 85.67 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.397 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.26 -36.41 92.76 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.4 t -64.23 -43.59 97.29 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-O 120.746 0.307 . . . . 0.0 110.458 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 mp -61.63 -39.02 89.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.222 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.24 -41.94 93.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 8.4 mt -60.76 -42.51 97.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.729 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 82.0 t -65.15 -42.44 94.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.834 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.98 -42.73 99.46 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.731 -179.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.08 -43.81 98.03 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.04 -36.86 84.39 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.087 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -61.53 -44.59 96.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.67 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -62.73 -45.34 93.17 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.566 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 87.7 mt -64.55 -42.67 95.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.867 179.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.564 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -179.78 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 44.2 mm . . . . . 0 CA--C 1.531 0.249 0 CA-C-O 120.634 0.254 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.07 -20.51 63.22 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.784 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.3 t -66.8 -42.98 90.03 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.372 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.24 -37.68 94.94 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.24 96.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.871 0.367 . . . . 0.0 110.439 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.8 -36.11 82.83 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.416 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.616 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.7 tt -62.17 -44.1 97.35 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.085 0.469 . . . . 0.0 110.018 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.03 -37.07 81.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.594 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.82 -39.07 96.99 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 95.5 t -63.63 -42.07 94.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.217 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.56 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.9 tt -60.7 -37.81 82.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.511 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.8 mm -64.4 -41.79 93.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.97 0.414 . . . . 0.0 110.196 179.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.4 mt -60.75 -40.94 94.31 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.53 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.8 t -64.26 -40.8 90.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.45 -40.78 95.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.407 -179.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.03 -41.54 96.76 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.41 -48.35 74.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.756 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.7 t80 -65.57 -35.61 81.35 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.602 -0.727 . . . . 0.0 110.488 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -56.78 -45.69 81.98 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.381 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.01 -42.27 94.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.137 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.63 -33.24 84.33 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.5 tp . . . . . 0 C--N 1.328 -0.348 0 C-N-CA 120.801 -0.359 . . . . 0.0 110.469 -179.824 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt . . . . . 0 CA--C 1.53 0.203 0 CA-C-O 120.516 0.198 . . . . 0.0 111.267 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -74.62 -19.99 60.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.763 -179.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.09 -43.19 88.94 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.21 -40.62 97.53 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.63 -37.87 89.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.743 0.306 . . . . 0.0 110.659 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.88 -46.63 88.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.602 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.68 -41.87 91.95 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.539 179.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -39.05 93.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.433 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.8 -42.85 99.66 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 89.5 t -66.51 -43.17 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 121.168 -0.213 . . . . 0.0 111.02 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . 0.56 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.0 tt -60.64 -41.27 94.6 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.349 -0.541 . . . . 0.0 109.739 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -63.87 -42.23 95.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 0.0 110.319 178.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.8 -40.09 91.35 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.507 -179.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.8 t -63.95 -41.86 93.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.97 -40.8 94.78 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.238 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.45 -43.42 98.91 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.132 -0.627 . . . . 0.0 109.502 179.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.16 -37.11 86.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.125 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -61.62 -44.86 96.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.621 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 36.5 m-85 -63.43 -41.67 98.68 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.578 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.3 mm -63.76 -42.16 95.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.013 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.688 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.857 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.1 mm . . . . . 0 CA--C 1.53 0.206 0 CA-C-O 120.54 0.21 . . . . 0.0 111.137 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.86 -20.34 62.54 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.783 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 63.5 t -67.5 -43.2 87.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.87 -38.49 96.19 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.46 95.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.734 0.302 . . . . 0.0 110.731 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.29 88.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.772 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -64.98 -41.93 94.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.417 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.7 -36.46 83.92 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.346 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.8 -42.21 99.72 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 94.2 t -64.0 -42.96 97.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.885 0.374 . . . . 0.0 110.242 179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.585 ' O ' HD23 ' C' ' 389' ' ' LEU . 4.1 tt -60.89 -37.99 84.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.832 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.8 mm -63.4 -42.59 96.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.138 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.42 -40.4 94.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.414 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 91.0 t -63.01 -40.8 90.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.666 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.95 -41.24 95.91 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.435 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.48 -43.5 98.75 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.524 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.5 -37.39 84.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -60.17 -43.96 95.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -62.65 -45.22 93.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.492 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.9 -42.87 97.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.976 179.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.541 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.779 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.4 mm . . . . . 0 CA--C 1.528 0.112 0 CA-C-O 120.623 0.249 . . . . 0.0 111.168 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.44 -20.1 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.738 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -67.19 -43.45 88.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.442 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.62 93.43 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.11 -41.71 98.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.847 0.356 . . . . 0.0 110.4 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -36.52 83.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.646 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.659 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.2 tt -61.47 -43.9 98.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.42 -37.4 87.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.87 -42.62 99.76 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.56 -42.78 93.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.91 0.386 . . . . 0.0 110.522 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -61.04 -40.94 95.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.493 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.24 -41.7 89.63 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.107 0 CA-C-O 120.896 0.379 . . . . 0.0 110.268 179.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.8 -40.84 89.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.557 -179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.9 -41.7 93.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.682 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.12 -41.57 96.95 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.485 -179.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.55 -41.93 98.08 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.81 -48.55 79.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.707 179.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -64.43 -35.32 80.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.211 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -57.58 -46.02 84.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.19 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.6 mt -63.77 -42.68 96.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.69 -32.55 84.57 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp . . . . . 0 C--N 1.329 -0.297 0 C-N-CA 121.106 -0.238 . . . . 0.0 110.359 -179.501 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 120.569 0.223 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.22 -20.08 62.3 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.79 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 61.4 t -67.84 -43.21 86.26 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.473 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -37.76 95.02 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.56 -40.67 97.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.395 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.02 -36.04 83.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.583 179.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . 0.646 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.7 tt -61.52 -44.13 97.61 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.431 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -38.26 90.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.491 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.3 -43.15 99.49 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 90.7 t -67.11 -42.83 88.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.738 0.304 . . . . 0.0 110.715 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . 0.509 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.6 tt -59.97 -41.07 91.17 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.021 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 85.4 mt -64.9 -42.16 94.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.829 0.347 . . . . 0.0 110.296 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.7 mt -60.71 -41.49 95.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.603 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 80.0 t -64.05 -40.96 90.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.689 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.47 97.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.384 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 7.2 tt -61.67 -42.09 98.44 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.6 -47.8 78.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.532 . . . . 0.0 109.732 179.423 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.98 -35.99 82.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.392 179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -57.34 -45.38 84.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.231 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.3 mm -64.94 -41.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.123 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.759 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.991 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' C' ' 381' ' ' VAL . 95.2 mt . . . . . 0 C--O 1.23 0.061 0 CA-C-O 120.694 0.283 . . . . 0.0 110.626 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.75 -19.6 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.65 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.534 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.8 p -61.72 -38.46 80.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.745 0.307 . . . . 0.0 110.541 -179.492 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . 0.446 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -61.37 -40.51 98.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.36 98.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.882 0.372 . . . . 0.0 110.301 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . 0.412 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -64.81 -35.81 82.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.5 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.659 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.9 tt -61.41 -43.2 99.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.908 -179.587 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.47 -39.19 92.61 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.517 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.85 -42.18 98.54 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . 0.412 HG23 ' O ' ' C' ' 384' ' ' ALA . 86.6 t -66.71 -42.46 89.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.828 0.347 . . . . 0.0 110.769 -179.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.5 -40.56 91.83 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.29 -179.374 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.7 mt -66.08 -42.04 90.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 120.903 0.382 . . . . 0.0 110.173 179.055 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.4 -40.91 92.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.594 -179.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 70.4 t -63.36 -41.65 93.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.703 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.99 -41.81 97.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.478 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.1 -42.43 99.22 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.62 -48.4 81.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.636 179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -64.06 -35.38 80.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.417 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.34 -46.56 79.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.28 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.57 -42.48 95.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.219 179.305 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.544 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.868 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 96.4 mt . . . . . 0 CA--C 1.532 0.259 0 CA-C-O 120.58 0.228 . . . . 0.0 111.261 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.86 -20.26 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.837 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.39 -43.19 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.262 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.84 -41.61 99.65 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -38.97 93.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.826 0.346 . . . . 0.0 110.719 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.63 -44.91 92.51 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.675 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.64 -40.19 92.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.389 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.3 -40.06 95.03 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.428 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -38.91 96.81 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 79.3 t -64.69 -41.85 93.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.887 0.375 . . . . 0.0 110.188 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.94 -37.8 80.57 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.206 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.74 -42.52 95.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.926 0.394 . . . . 0.0 110.121 179.127 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.51 -42.5 98.89 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.703 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.5 t -65.94 -42.51 92.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -62.04 -42.06 98.77 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.57 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.4 -43.19 99.41 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.635 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.02 -47.53 82.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.918 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -65.57 -34.29 77.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.493 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -56.99 -45.87 82.66 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.322 -179.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.48 -42.35 93.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.36 -31.15 79.78 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.1 tp . . . . . 0 C--N 1.326 -0.438 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.474 -179.594 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . 0.468 ' O ' ' N ' ' B' ' 381' ' ' VAL . 45.8 mm . . . . . 0 CA--C 1.53 0.195 0 CA-C-O 120.548 0.213 . . . . 0.0 111.118 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.37 -20.26 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.71 -0.223 . . . . 0.0 110.766 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.468 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.35 -42.97 94.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.266 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -36.12 92.85 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.3 -43.26 99.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.814 0.34 . . . . 0.0 110.587 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.64 -36.77 84.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.436 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . 0.651 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.1 tt -62.41 -43.68 98.25 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.938 -179.495 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.7 88.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.491 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.31 -42.1 99.72 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 56.3 t -66.1 -43.98 92.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.895 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -60.88 -41.71 96.54 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.922 -179.242 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 92.7 mt -65.73 -42.2 92.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 CA-C-O 121.003 0.43 . . . . 0.0 110.431 179.063 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -58.42 -41.59 85.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.518 -178.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.71 -40.99 90.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.596 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.94 -41.4 96.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.485 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.23 -42.89 99.39 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.94 -48.31 80.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.972 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.06 -35.65 80.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.49 179.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -56.59 -44.82 81.45 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.316 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.2 mm -65.7 -41.54 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.544 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.858 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt . . . . . 0 CA--C 1.534 0.349 0 CA-C-O 120.48 0.181 . . . . 0.0 110.991 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.33 -20.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.647 0.26 . . . . 0.0 110.803 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.471 ' N ' ' O ' ' C' ' 379' ' ' ILE . 54.3 t -63.8 -43.76 98.0 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.183 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.68 -39.75 98.31 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.62 -39.9 95.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.868 0.366 . . . . 0.0 110.659 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -66.12 -34.31 77.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.457 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.655 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.87 -45.17 94.92 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.998 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.01 -36.51 84.22 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.2 -40.37 98.47 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 83.9 t -67.27 -42.76 88.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.807 0.337 . . . . 0.0 110.314 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.5 tt -60.46 -41.08 93.41 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.561 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.7 mt -66.04 -42.01 90.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.85 0.357 . . . . 0.0 110.342 178.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.02 -40.05 87.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 74.9 t -63.73 -42.19 95.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.5 -41.16 96.87 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.483 -179.515 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.3 tt -62.28 -43.71 98.21 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.608 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.46 -36.7 84.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.072 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -60.22 -44.53 95.11 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.652 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 27.6 m-85 -62.11 -43.77 98.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.664 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.0 mt -63.23 -41.88 94.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.521 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.512 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.916 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 44.6 mm . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 120.477 0.179 . . . . 0.0 110.744 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.33 -20.02 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.59 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 54.9 t -65.27 -42.9 95.02 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 C-N-CA 121.026 -0.27 . . . . 0.0 110.468 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.13 -40.15 96.79 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.16 -41.99 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.835 0.35 . . . . 0.0 110.579 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.0 -35.66 81.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.57 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.657 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.1 tt -61.3 -43.47 98.83 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.68 -39.78 95.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.886 0.374 . . . . 0.0 110.51 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.15 97.81 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 72.8 t -63.79 -43.31 97.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 O-C-N 122.946 -0.15 . . . . 0.0 111.332 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.22 -37.86 81.59 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.336 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -62.94 -42.34 96.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 178.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.5 mt -60.86 -39.85 90.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.392 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.2 t -61.09 -40.72 86.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.468 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.99 -41.6 96.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.323 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.79 -44.2 97.33 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.335 -0.546 . . . . 0.0 109.73 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.22 -36.73 83.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.002 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -60.09 -44.79 94.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.685 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -62.42 -44.9 95.33 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.331 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.45 -42.86 97.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.05 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.09 -33.08 84.34 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 43.9 tp . . . . . 0 C--N 1.331 -0.223 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.502 -179.659 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 CA--C 1.531 0.218 0 CA-C-O 120.51 0.195 . . . . 0.0 111.008 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.96 -20.11 61.79 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.987 -0.285 . . . . 0.0 110.828 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 52.9 t -67.06 -43.12 89.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.419 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.29 -41.57 99.73 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.54 84.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.729 0.3 . . . . 0.0 110.65 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.17 -43.85 98.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.721 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.49 -40.96 93.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.291 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.14 -37.83 88.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -38.97 97.12 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 84.6 t -64.3 -42.12 94.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.108 0.48 . . . . 0.0 110.167 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.2 tp -60.38 -38.08 82.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.247 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -63.5 -42.53 96.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -61.6 -42.07 98.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.495 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 88.5 t -66.03 -42.19 91.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.985 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.67 -41.2 97.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.405 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.66 -43.07 99.55 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.99 -47.82 83.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.695 179.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -63.9 -35.81 81.87 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.86 -45.55 82.37 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.084 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.72 -42.6 96.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.222 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.635 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.945 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt . . . . . 0 CA--C 1.531 0.23 0 CA-C-O 120.508 0.194 . . . . 0.0 111.04 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.03 -20.16 59.72 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 121.053 -0.259 . . . . 0.0 110.736 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.28 -43.38 91.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 121.001 -0.28 . . . . 0.0 110.557 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.59 -37.62 95.04 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.68 -41.03 98.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.857 0.36 . . . . 0.0 110.564 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.79 -35.56 81.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.459 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.658 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.6 tt -61.68 -43.62 98.5 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.896 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.12 -38.7 92.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.674 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -40.2 98.72 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.52 -42.65 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.509 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.534 ' O ' HD23 ' C' ' 389' ' ' LEU . 5.1 tt -59.71 -39.07 83.4 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.823 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.38 -42.38 95.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.829 0.347 . . . . 0.0 110.141 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.34 -41.07 96.45 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.414 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.21 -41.52 92.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.717 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.67 -41.99 98.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.542 -179.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.04 -41.96 98.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.67 -49.28 77.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.627 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -64.83 -35.01 79.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.229 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.98 -45.66 86.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.349 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.1 mt -63.55 -42.72 97.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.733 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.989 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.474 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.8 mt . . . . . 0 CA--C 1.528 0.109 0 CA-C-O 120.546 0.212 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.57 -19.63 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.654 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.533 HG13 ' N ' ' A' ' 382' ' ' GLY . 9.2 p -59.15 -44.26 91.32 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-O 120.682 0.277 . . . . 0.0 110.806 -179.34 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.533 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.2 -41.35 99.66 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.11 98.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.842 0.353 . . . . 0.0 110.284 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . 0.435 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -66.42 -35.93 81.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.722 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.641 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.6 tt -60.53 -44.52 95.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.931 -179.208 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.11 93.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.421 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.41 -42.91 97.44 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 384' ' ' ALA . 91.6 t -65.6 -43.19 94.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.223 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.55 -39.88 89.54 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.448 -0.501 . . . . 0.0 110.114 -179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.9 -42.05 93.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.81 0.338 . . . . 0.0 110.11 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.87 -40.65 93.78 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.664 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.9 t -62.2 -41.18 90.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.725 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.1 mt -61.09 -41.31 96.42 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.421 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.64 -43.21 99.28 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.8 82.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.25 179.086 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . 0.418 ' CZ ' ' CD1' ' A' ' 400' ' ' LEU . 92.6 t80 -60.3 -44.52 95.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.5 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -63.89 -46.56 84.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.417 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.5 mt -64.43 -42.1 94.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.377 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -53.14 -57.2 15.69 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . 0.418 ' CD1' ' CZ ' ' A' ' 396' ' ' TYR . 8.7 mt . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 110.432 179.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.2 mt . . . . . 0 CA--C 1.529 0.153 0 CA-C-O 120.583 0.23 . . . . 0.0 111.18 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.47 -20.06 60.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.626 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.2 -43.39 88.39 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-O 120.72 0.295 . . . . 0.0 110.461 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.86 -41.59 99.84 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.16 89.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.855 0.36 . . . . 0.0 110.67 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.79 -44.14 96.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.71 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -65.71 -39.6 91.37 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.338 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.96 -38.79 89.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.398 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.09 -42.57 99.5 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 87.4 t -66.88 -42.66 89.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.651 0.263 . . . . 0.0 111.081 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . 0.598 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.3 tt -60.08 -41.53 92.64 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.076 -179.348 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 87.8 mt -64.31 -42.25 94.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.897 0.379 . . . . 0.0 110.26 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.97 -41.28 96.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.564 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.7 t -63.69 -41.09 91.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.738 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.12 -40.94 95.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.421 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -41.59 97.25 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.75 80.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.652 179.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.11 -36.01 82.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.668 -0.697 . . . . 0.0 110.338 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -56.86 -45.87 82.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.165 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.0 mt -63.88 -42.62 96.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.308 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.633 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.95 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.5 mt . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.51 0.195 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.59 -19.64 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' C' ' 379' ' ' ILE . 51.1 t -63.47 -43.87 98.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.85 -36.1 92.86 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.78 -40.71 96.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.791 0.329 . . . . 0.0 110.301 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -36.88 85.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.373 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . 0.643 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.0 tt -61.57 -44.48 96.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.903 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -36.98 85.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.539 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.16 -38.38 95.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 85.2 t -65.76 -42.62 92.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.879 0.371 . . . . 0.0 110.528 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . 0.555 ' O ' HD23 ' C' ' 389' ' ' LEU . 5.3 tt -61.1 -38.92 88.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.019 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.85 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.14 -40.97 95.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.64 -40.91 90.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.649 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.68 -41.6 97.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.591 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.56 -42.62 99.12 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.57 -49.14 78.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.74 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.71 -34.74 78.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.273 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -58.05 -45.56 86.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.151 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.3 mt -63.44 -42.4 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.1 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.643 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.779 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 379' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.9 mm . . . . . 0 CA--C 1.528 0.134 0 CA-C-O 120.652 0.263 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.1 -20.25 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.708 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.506 ' N ' ' O ' ' A' ' 379' ' ' ILE . 55.7 t -65.27 -43.51 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.335 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -66.27 -40.78 94.86 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.3 -38.96 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.763 0.316 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . 0.43 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -62.37 -44.86 95.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.33 -40.17 89.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.405 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.81 -37.68 88.3 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.555 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.28 -39.93 97.46 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 384' ' ' ALA . 80.5 t -66.24 -42.86 91.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.912 0.387 . . . . 0.0 110.596 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.3 mt -62.15 -41.85 98.68 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.413 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.4 mt -64.11 -41.9 93.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.35 -42.61 96.07 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.698 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.1 t -65.34 -41.86 92.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.52 -39.93 92.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.472 -179.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.72 -44.23 96.86 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.52 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.94 -38.02 89.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.077 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -61.76 -43.74 98.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.717 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -63.02 -41.53 99.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.65 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . 0.423 HD13 ' HA ' ' A' ' 398' ' ' ILE . 30.2 mm -63.61 -42.52 96.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.891 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -77.14 -21.08 74.45 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.4 tp . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 120.807 0.337 . . . . 0.0 110.543 -179.836 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 78.8 mt . . . . . 0 CA--C 1.531 0.229 0 CA-C-O 120.576 0.227 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -57.85 -20.26 35.03 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.881 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 381' ' ' VAL . . . . . 0.501 HG13 ' N ' ' B' ' 382' ' ' GLY . 8.9 p -60.87 -43.48 95.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-O 120.783 0.325 . . . . 0.0 110.371 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 382' ' ' GLY . . . . . 0.501 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -64.68 -42.34 97.29 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.404 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.77 88.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.805 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 384' ' ' ALA . . . . . 0.415 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -60.04 -46.5 89.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.625 -179.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -64.09 -41.05 97.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.412 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.95 89.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.46 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.96 -36.34 93.16 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 388' ' ' VAL . . . . . 0.415 HG23 ' O ' ' B' ' 384' ' ' ALA . 95.1 t -64.82 -42.23 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-O 121.069 0.462 . . . . 0.0 110.243 179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 10.9 mt -62.18 -39.78 93.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.35 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.6 mm -65.16 -41.67 92.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.329 -0.396 . . . . 0.0 109.964 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.52 -41.86 95.26 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.622 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 90.0 t -65.06 -42.7 95.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.874 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.7 mt -62.13 -43.32 99.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 -179.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.74 -42.89 99.89 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.93 85.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.169 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.61 -44.37 96.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.847 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 30.6 m-85 -62.2 -42.47 99.32 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.508 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 83.6 mt -63.66 -42.33 95.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.844 179.341 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.576 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 -179.554 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' C' C ' 379' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' C' ' 381' ' ' VAL . 45.1 mm . . . . . 0 N--CA 1.462 0.154 0 CA-C-O 120.593 0.235 . . . . 0.0 111.361 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.55 -19.9 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.799 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 381' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' C' ' 379' ' ' ILE . 8.1 p -59.57 -43.98 92.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 120.737 0.303 . . . . 0.0 110.294 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 382' ' ' GLY . . . . . 0.519 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.62 -43.0 98.6 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.47 -38.78 88.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.744 0.307 . . . . 0.0 110.845 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.84 -44.49 96.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.683 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.14 -40.15 94.0 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.413 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.55 -38.86 89.02 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.411 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.42 -38.46 94.92 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.3 t -62.97 -43.51 99.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.738 0.304 . . . . 0.0 110.281 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -60.59 -39.44 88.13 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.089 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.9 mm -64.01 -42.02 94.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.134 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.07 -40.58 94.23 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.581 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 83.6 t -61.85 -41.02 89.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.699 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.17 -42.12 98.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.426 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.85 -42.93 99.94 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.618 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.95 82.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.259 179.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -59.78 -44.97 93.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -63.04 -46.74 86.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.623 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.5 mt -64.88 -42.1 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.857 179.444 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.447 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.557 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 44.9 m . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -68.62 143.5 54.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.62 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 55.34 35.59 25.29 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.572 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.429 ' O ' ' OD1' ' A' ' 372' ' ' ASP . 64.6 t0 -62.23 -36.26 81.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.446 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -62.34 -42.39 99.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.434 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 376' ' ' LEU . 57.8 t-20 -85.01 109.88 18.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.55 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -62.77 -40.84 98.53 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.669 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.609 HD12 ' N ' ' A' ' 376' ' ' LEU . 9.6 mp -88.66 130.99 35.18 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.308 -179.652 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.518 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 18.6 m -153.08 50.25 0.58 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.244 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.518 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 30.1 Cg_endo -63.89 142.14 80.84 Favored 'Trans proline' 0 N--CA 1.497 1.678 0 C-N-CA 122.764 2.31 . . . . 0.0 111.894 179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.3 mm -65.99 -43.2 92.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.069 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.09 -20.07 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.592 -0.277 . . . . 0.0 110.914 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.4 p -59.94 -43.8 93.11 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.111 0 CA-C-O 120.818 0.342 . . . . 0.0 110.226 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.516 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.03 -36.3 93.28 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.86 -40.91 94.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.829 0.347 . . . . 0.0 110.615 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.92 -36.31 83.97 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.467 179.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.9 tt -61.2 -45.42 94.65 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.135 0.493 . . . . 0.0 110.032 -179.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.16 -36.65 80.39 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.403 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.03 -36.41 93.42 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.354 -0.699 . . . . 0.0 111.354 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 84.8 t -65.57 -42.11 92.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 120.983 0.421 . . . . 0.0 110.185 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 9.9 mt -62.1 -39.05 91.16 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.582 179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.2 mm -63.04 -42.15 95.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -61.0 -41.24 96.13 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.404 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.3 t -65.3 -42.6 94.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.897 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.57 -41.89 98.05 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.621 -179.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.45 -42.5 99.51 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.572 179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.79 -49.22 75.97 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.818 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.29 -35.17 80.2 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.337 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.6 t80 -58.61 -45.44 89.16 Favored 'General case' 0 C--O 1.233 0.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.385 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -64.0 -42.52 95.97 Favored 'Isoleucine or valine' 0 C--O 1.232 0.141 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.05 -33.82 88.16 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.495 ' O ' ' CE1' ' A' ' 403' ' ' HIS . 56.6 tp -62.35 -40.76 97.47 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.396 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 57.35 10.88 1.0 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.609 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.419 ' H ' ' HG ' ' A' ' 400' ' ' LEU . 83.3 t60 43.59 82.76 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.662 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . 0.495 ' CE1' ' O ' ' A' ' 400' ' ' LEU . 78.4 m80 -77.61 135.47 38.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.429 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -82.35 134.23 35.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.549 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.92 -11.61 60.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.505 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.01 -37.59 95.21 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -111.6 136.94 50.12 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.526 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.5 mp0 -102.16 127.33 49.13 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 110.218 -0.29 . . . . 0.0 110.218 179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -52.63 145.25 12.24 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.574 -179.93 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 14.2 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -161.28 154.21 20.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.431 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -139.6 101.08 4.13 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.404 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 51.5 t0 56.63 47.08 19.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.715 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . 0.412 ' O ' ' OD1' ' B' ' 373' ' ' ASP . 64.2 t0 -62.22 -38.87 90.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.389 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -83.09 109.72 17.39 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.458 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 -60.3 -43.2 96.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.479 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . 0.555 ' N ' HD12 ' B' ' 376' ' ' LEU . 10.6 mp -98.33 126.81 43.98 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.024 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.538 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 16.1 m -146.17 49.29 0.85 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.233 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . 0.538 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 24.8 Cg_endo -61.79 145.77 97.02 Favored 'Trans proline' 0 N--CA 1.496 1.668 0 C-N-CA 122.917 2.411 . . . . 0.0 111.986 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' B' ' 381' ' ' VAL . 42.9 mm -69.34 -26.73 32.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.151 -179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.15 -19.96 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.661 0.267 . . . . 0.0 110.786 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' B' ' 379' ' ' ILE . 57.7 t -64.06 -43.52 97.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.328 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.72 -38.28 95.42 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.93 -39.99 93.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.769 0.319 . . . . 0.0 110.554 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.25 -35.49 81.21 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.486 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . 0.638 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.0 tt -61.49 -44.6 96.79 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.049 0.452 . . . . 0.0 110.01 -179.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.29 -37.51 87.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.424 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.13 -39.68 97.47 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 91.5 t -64.32 -41.97 93.97 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . 0.594 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.8 tt -59.55 -38.72 81.82 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.245 -179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.8 mm -64.63 -42.09 94.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.815 0.34 . . . . 0.0 110.221 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.27 -40.72 95.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.692 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 73.6 t -62.98 -41.34 92.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.755 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.21 -41.8 97.48 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.613 -179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.88 -41.75 98.24 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.32 -48.6 76.38 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.876 179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -62.83 -35.78 81.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.449 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -57.48 -44.58 85.01 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.219 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 42.2 mm -65.83 -41.32 89.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.337 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.2 -37.34 94.73 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 57.0 tp -62.84 -41.3 99.29 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.386 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 64.2 tttp 57.76 113.01 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.558 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -72.42 133.99 45.17 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.475 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -75.98 128.45 35.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.31 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -74.88 135.54 41.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.436 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.02 -11.3 59.78 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.598 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.91 -35.22 91.73 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -107.79 134.95 50.01 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . 0.527 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 56.0 mp0 -105.13 125.33 50.86 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.485 ' NE2' ' O ' ' B' ' 408' ' ' GLU . 83.0 mm-40 -128.52 129.28 45.8 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.885 0.374 . . . . 0.0 110.063 -179.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . 0.477 ' CD2' ' O ' ' B' ' 410' ' ' PHE . 91.7 t80 . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.51 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 83.5 p . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.54 -38.93 91.04 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.45 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . 0.407 ' O ' ' OD1' ' C' ' 371' ' ' ASP . 38.2 p-10 -93.84 109.25 20.95 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.352 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -66.43 143.66 56.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.582 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -62.16 -41.48 98.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.631 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 10.9 m120 57.99 35.38 25.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.604 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 91.3 t80 -60.75 -46.24 91.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.64 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 57.5 tp -82.92 126.09 32.1 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.49 -179.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 60.8 t 44.12 73.34 0.97 Allowed Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.509 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.528 ' O ' HG12 ' C' ' 381' ' ' VAL . 48.5 Cg_endo -74.0 -13.91 23.77 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 122.491 2.127 . . . . 0.0 112.141 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.8 mt -62.91 -43.24 98.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.169 -178.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.7 -19.82 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.552 -0.294 . . . . 0.0 110.831 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.547 ' N ' ' O ' ' C' ' 379' ' ' ILE . 9.1 p -61.13 -43.64 96.72 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . 0.51 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.39 -40.07 98.48 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.85 -39.99 91.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.774 0.321 . . . . 0.0 110.598 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.45 -35.19 80.19 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.623 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.652 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.5 tt -61.18 -44.84 96.65 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.108 0.48 . . . . 0.0 110.005 -179.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.36 -36.73 84.69 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.377 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -39.71 97.77 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -63.0 -43.15 98.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.666 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.6 tt -58.91 -37.42 76.59 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.067 -179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.01 -42.69 96.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.26 -40.14 92.97 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.433 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.1 t -63.46 -40.66 89.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.664 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.8 mt -61.99 -41.65 98.27 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.709 -179.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.84 -42.35 98.93 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.17 -48.87 75.49 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.93 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.9 t80 -64.93 -34.56 78.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.435 179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -58.81 -44.86 90.9 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.255 -179.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.4 mt -65.04 -42.41 94.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.86 -19.32 69.48 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 44.2 tp -61.65 -40.26 94.27 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 120.936 -0.306 . . . . 0.0 110.515 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 61.3 pttt -36.48 151.2 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.917 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 49.47 92.24 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.55 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -77.16 143.68 38.91 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.346 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -75.12 141.33 43.75 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.549 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.3 -12.89 60.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.568 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.29 -35.89 92.09 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -85.56 128.49 34.77 Favored 'General case' 0 C--N 1.33 -0.269 0 O-C-N 122.87 -0.194 . . . . 0.0 110.513 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -91.17 117.0 29.26 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.658 0.266 . . . . 0.0 110.313 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.579 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 1.9 pm0 -75.05 137.14 41.26 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.66 179.901 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 44.6 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -153.5 154.58 34.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.442 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -99.76 108.18 20.44 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.42 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 54.3 p-10 -75.31 148.53 39.26 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.74 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.448 ' O ' ' O ' ' A' ' 376' ' ' LEU . 98.9 m-20 -69.3 142.66 54.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.674 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -65.05 -40.81 95.32 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.716 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -61.8 -45.39 94.05 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.966 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.448 ' O ' ' O ' ' A' ' 373' ' ' ASP . 62.7 mt -118.42 126.79 52.81 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.356 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 3.5 m -135.84 150.0 70.35 Favored Pre-proline 0 CA--C 1.532 0.271 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.615 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -65.29 -22.48 60.39 Favored 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.465 2.11 . . . . 0.0 112.055 179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.95 -44.56 97.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 C-N-CA 120.867 -0.333 . . . . 0.0 111.134 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.18 -20.25 60.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.851 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.1 t -67.02 -43.54 88.93 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.116 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.317 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.07 -41.05 99.9 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.16 96.42 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.781 0.324 . . . . 0.0 110.462 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.68 -35.95 82.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.529 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.625 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.9 tt -61.38 -44.32 97.36 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.865 -179.286 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -37.5 87.51 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.488 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.72 -40.67 98.76 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.5 t -63.81 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.783 0.325 . . . . 0.0 110.225 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.521 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.7 tt -59.74 -38.6 82.19 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 31.4 mm -64.29 -42.59 95.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 0.0 110.183 178.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.75 -40.95 96.91 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.584 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 91.1 t -64.17 -41.02 91.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.79 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.34 -40.87 95.84 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.527 -179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.23 -42.12 98.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.02 -48.19 79.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.827 179.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . 0.429 ' CD2' HD11 ' A' ' 400' ' ' LEU . 21.5 t80 -66.76 -34.25 77.41 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.258 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -58.35 -45.65 87.78 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.196 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -64.54 -42.62 95.7 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.177 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.081 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.69 -33.52 87.47 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.429 HD11 ' CD2' ' A' ' 396' ' ' TYR . 8.6 mt -63.19 -39.86 95.85 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.646 0.26 . . . . 0.0 110.553 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 65.0 mttp 56.96 22.36 7.13 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.492 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 54.6 t-80 43.76 88.84 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.736 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -75.19 136.72 41.01 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.593 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -81.82 135.97 35.42 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.466 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.31 -11.78 59.87 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.494 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.68 -38.9 96.91 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 83.4 t80 -80.98 132.55 35.39 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.602 0.239 . . . . 0.0 110.411 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 48.0 tp10 -73.24 121.69 20.74 Favored 'General case' 0 C--N 1.332 -0.196 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.221 179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -54.02 142.82 23.76 Favored 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 120.688 -0.405 . . . . 0.0 109.982 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.493 179.523 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 6.0 t . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.72 145.95 51.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.722 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -61.09 -44.02 97.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.378 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -70.76 143.29 51.26 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.645 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 48.3 t0 56.82 35.42 26.24 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.4 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 48.5 t30 -64.35 -39.75 94.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.575 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -62.53 83.94 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.628 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 54.4 mt -119.49 131.02 55.5 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.62 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.493 HG12 ' H ' ' B' ' 380' ' ' ALA . 5.9 t 47.65 72.2 1.34 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.528 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -55.2 -34.61 88.58 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.744 2.296 . . . . 0.0 111.935 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.84 -43.41 97.84 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.184 -178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . 0.493 ' H ' HG12 ' B' ' 377' ' ' VAL . . . -51.49 -20.38 1.85 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.61 -179.154 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 76.2 t -66.29 -43.11 91.76 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.38 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.85 -37.84 94.81 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.61 94.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.856 0.36 . . . . 0.0 110.689 -179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . 0.4 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -63.46 -38.74 92.29 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.313 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . 0.656 HD13 ' O ' ' B' ' 385' ' ' LEU . 1.7 tm? -62.5 -47.64 83.09 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.436 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -37.31 86.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.947 0.404 . . . . 0.0 110.519 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.24 -42.51 99.8 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . 0.4 HG23 ' O ' ' B' ' 384' ' ' ALA . 93.6 t -66.54 -42.85 90.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.729 0.299 . . . . 0.0 110.76 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.84 -40.44 88.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.282 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.7 mt -65.6 -42.26 92.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.832 0.349 . . . . 0.0 110.221 178.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.6 mt -60.7 -40.92 94.05 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.594 -179.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 78.6 t -62.72 -41.7 93.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.691 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.24 -41.7 97.33 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.472 -179.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.77 -42.27 98.77 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.28 75.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.857 179.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -66.01 -35.04 79.49 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.342 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.45 -45.94 84.16 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.331 -179.374 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.27 -42.45 95.48 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.989 179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.52 -33.76 87.43 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp -62.22 -40.46 96.2 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.471 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 68.7 mttm 57.67 86.35 0.08 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.647 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -70.48 131.28 43.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.384 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 54.5 p-80 -68.46 140.55 55.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.575 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -72.41 138.68 47.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.437 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.41 -11.42 59.84 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.623 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.54 -38.27 96.05 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 88.6 t80 -81.21 133.46 35.45 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 54.7 mp0 -105.98 118.76 37.45 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.748 0.309 . . . . 0.0 110.518 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 8.7 pt20 -52.69 145.24 12.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.958 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . 0.401 ' OXT' ' CG ' ' B' ' 410' ' ' PHE . 85.1 t80 . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.872 -1.061 . . . . 0.0 110.463 179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 41.6 t . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -156.63 150.23 24.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.445 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 46.1 t0 -130.89 97.96 4.48 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.345 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 54.99 30.25 13.79 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.457 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -66.77 141.93 57.55 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.579 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -83.36 133.47 34.95 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.4 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -102.24 7.92 40.64 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.501 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 61.4 mt -114.89 132.38 56.55 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.584 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.62 ' O ' HG13 ' C' ' 377' ' ' VAL . 7.6 p -156.16 77.42 4.44 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.433 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -60.86 145.13 99.48 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 C-N-CA 122.643 2.229 . . . . 0.0 111.926 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.529 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt -63.8 -43.7 97.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.916 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.64 -19.88 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.787 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.529 ' N ' ' O ' ' C' ' 379' ' ' ILE . 55.1 t -64.77 -43.52 96.47 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.269 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.68 -36.89 93.92 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.56 -40.8 96.02 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 110.544 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.19 83.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.467 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.661 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.3 tt -61.38 -45.15 95.57 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.214 -0.448 . . . . 0.0 109.941 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.49 -37.11 86.02 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.529 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.5 98.89 Favored Glycine 0 CA--C 1.53 0.972 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -63.47 -42.51 96.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.505 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.9 tt -60.1 -38.63 83.54 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.871 -179.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.0 mm -63.33 -42.52 96.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.899 0.38 . . . . 0.0 110.061 179.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.0 -40.85 95.12 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.479 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.17 -41.79 93.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.794 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.28 -41.17 96.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.426 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.71 -43.13 99.44 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.547 179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.15 90.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.01 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -60.97 -44.94 96.62 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.668 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -63.58 -43.72 96.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.545 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 31.8 mm -63.9 -42.23 95.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.85 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.46 -36.06 92.61 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' C' ' 401' ' ' LYS . 55.1 tp -62.74 -41.96 99.44 Favored 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.508 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . 0.428 ' O ' ' O ' ' C' ' 400' ' ' LEU . 38.8 ttmt 54.81 111.61 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.62 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -66.87 -38.06 85.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.496 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 80.1 t60 -73.8 132.64 42.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.388 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -70.85 138.13 50.0 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.506 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.59 -11.65 59.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.481 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.44 -38.78 96.9 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 83.2 t80 -82.38 136.89 34.88 Favored 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 121.164 -0.215 . . . . 0.0 110.422 179.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -85.06 117.56 24.1 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.709 0.29 . . . . 0.0 110.402 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.54 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 0.0 OUTLIER -62.58 140.18 58.65 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.086 179.717 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . 0.416 ' O ' ' O ' ' C' ' 409' ' ' GLN . 93.6 t80 . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.4 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 51.1 m . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.64 -36.98 85.61 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.284 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -84.61 107.15 16.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.207 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 37.1 p-10 -92.48 1.25 57.35 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.519 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.426 ' O ' ' O ' ' A' ' 376' ' ' LEU . 41.9 p-10 -80.8 -1.44 43.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.249 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -62.59 -42.01 99.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.379 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -62.37 -44.47 96.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.482 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' A' ' 373' ' ' ASP . 6.0 tp -107.57 112.79 25.71 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.36 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.654 ' H ' ' CD ' ' A' ' 378' ' ' PRO . 0.3 OUTLIER -105.77 -40.6 0.17 Allowed Pre-proline 0 N--CA 1.464 0.247 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.314 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.654 ' CD ' ' H ' ' A' ' 377' ' ' VAL . 38.0 Cg_endo -84.8 111.92 1.48 Allowed 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.652 2.235 . . . . 0.0 112.012 -179.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.558 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -65.44 -42.86 94.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.085 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.13 -20.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.959 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.558 ' N ' ' O ' ' A' ' 379' ' ' ILE . 37.2 t -63.82 -43.46 97.89 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 179.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.63 -41.29 98.82 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.79 82.98 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.773 0.321 . . . . 0.0 110.698 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . 0.458 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -59.02 -45.08 91.6 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.711 -179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.31 -40.82 96.69 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.393 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.68 88.31 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.238 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -67.16 -40.88 92.66 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 384' ' ' ALA . 92.1 t -66.5 -41.88 89.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 121.106 0.479 . . . . 0.0 110.042 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.552 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.6 tt -58.81 -41.0 85.74 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.778 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.1 mt -66.4 -42.08 89.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.963 0.411 . . . . 0.0 110.073 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.89 -41.59 96.33 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.549 -179.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.09 -41.46 92.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.698 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.35 -41.63 97.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.448 -179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -61.96 -42.61 99.32 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 120.28 -0.568 . . . . 0.0 109.476 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.65 -47.89 82.92 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.881 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.37 -36.31 83.3 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.43 179.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.02 -45.13 79.21 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.16 -179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -64.45 -42.09 94.25 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.155 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.915 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.06 -32.54 80.71 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.1 tp -61.84 -40.01 93.83 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.885 -0.326 . . . . 0.0 110.405 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -50.67 133.67 25.43 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.603 -179.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.0 t60 44.61 85.48 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.703 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 62.8 t-80 -79.12 129.05 34.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.506 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . 0.616 ' CD2' ' H ' ' A' ' 404' ' ' HIS . 3.1 p80 -70.0 131.49 44.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.405 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.87 -11.34 59.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.44 179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.17 -38.84 97.17 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . 0.471 ' CE2' ' O ' ' A' ' 408' ' ' GLU . 81.9 t80 -78.85 135.66 37.1 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 110.337 -0.246 . . . . 0.0 110.337 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.471 ' O ' ' CE2' ' A' ' 407' ' ' TYR . 85.2 tt0 -73.24 117.78 15.39 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.838 -0.345 . . . . 0.0 110.396 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.508 ' OE1' ' N ' ' A' ' 410' ' ' PHE . 4.2 tp-100 -67.59 123.57 20.83 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.699 -0.401 . . . . 0.0 109.968 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . 0.508 ' N ' ' OE1' ' A' ' 409' ' ' GLN . 90.3 t80 . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.467 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 95.6 p . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.62 -37.8 88.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.412 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 53.4 t0 58.58 38.42 25.28 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.41 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -71.19 -19.24 62.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.709 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 97.1 m-20 55.18 34.44 22.68 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.332 -179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . 0.415 ' ND2' ' O ' ' B' ' 376' ' ' LEU . 67.0 t30 -75.89 147.7 38.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.666 -179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -60.95 -42.99 99.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.612 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . 0.415 ' O ' ' ND2' ' B' ' 374' ' ' ASN . 58.9 mt -116.61 131.09 57.04 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.616 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.655 HG13 ' O ' ' B' ' 377' ' ' VAL . 10.5 p -157.07 75.02 4.36 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.319 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -59.02 -23.75 70.14 Favored 'Trans proline' 0 C--N 1.303 -1.867 0 C-N-CA 122.66 2.24 . . . . 0.0 111.871 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt -62.92 -44.54 99.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.223 -178.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . 0.475 ' H ' HG22 ' B' ' 377' ' ' VAL . . . -75.91 -20.3 58.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.799 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.1 -43.32 92.32 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.256 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.86 99.0 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.4 -39.03 93.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.744 0.307 . . . . 0.0 110.65 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.81 -45.75 91.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.669 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.31 -40.23 93.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.412 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.58 -38.06 88.63 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.44 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.24 -37.97 95.26 Favored Glycine 0 CA--C 1.527 0.837 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 88.4 t -66.15 -42.89 92.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.569 0.224 . . . . 0.0 110.66 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 5.1 tt -58.92 -39.22 80.87 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.835 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.9 mm -63.74 -42.68 96.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.228 179.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.6 -40.27 94.21 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.588 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.42 -39.12 83.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.513 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.48 -41.23 96.95 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.502 -179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -60.69 -42.86 98.0 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.9 -46.91 87.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.859 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -62.41 -34.49 76.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.347 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -59.46 -44.99 92.87 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.467 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 38.2 mm -68.2 -41.6 84.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.032 179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.67 -33.14 86.45 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 49.1 tp -62.28 -41.47 98.51 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.473 -179.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 63.8 tttp -89.39 119.91 30.27 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.889 0.376 . . . . 0.0 110.227 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 64.2 t-80 -158.35 142.26 15.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.183 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -106.57 125.87 51.55 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.152 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -105.41 128.17 53.38 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.361 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . 0.437 ' O ' ' OE2' ' B' ' 408' ' ' GLU . . . -76.89 -37.38 55.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.566 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.43 -35.15 91.67 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -104.96 136.44 44.44 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.703 0.287 . . . . 0.0 110.42 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . 0.521 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 55.2 mp0 -130.91 146.41 52.32 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.165 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.434 ' NE2' ' N ' ' B' ' 410' ' ' PHE . 43.5 tp60 -70.67 130.58 42.15 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.631 -0.428 . . . . 0.0 109.978 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . 0.434 ' N ' ' NE2' ' B' ' 409' ' ' GLN . 81.6 t80 . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.422 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -155.42 153.81 30.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.462 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 54.3 p30 -150.59 175.54 11.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.245 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -89.41 110.78 21.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.502 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' C' ' 376' ' ' LEU . 98.0 m-20 -64.13 141.36 58.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.693 -179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -64.26 -40.24 95.59 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.643 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -60.47 -41.93 95.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.409 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . 0.443 ' O ' ' O ' ' C' ' 373' ' ' ASP . 22.9 tp -104.17 120.77 41.85 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.337 -179.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.703 ' O ' HG13 ' C' ' 377' ' ' VAL . 7.1 p -172.8 58.33 0.23 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.353 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -67.18 -19.7 50.43 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 C-N-CA 122.308 2.006 . . . . 0.0 111.965 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.6 mt -63.81 -44.84 98.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 C-N-CA 120.824 -0.35 . . . . 0.0 111.349 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.22 -20.58 60.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.721 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -67.19 -43.43 88.41 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.33 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.24 -39.36 97.8 Favored Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -40.61 97.34 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.865 0.364 . . . . 0.0 110.489 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . 0.401 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -65.21 -35.79 82.17 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.506 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.624 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.3 tt -61.07 -45.13 96.02 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-O 121.053 0.454 . . . . 0.0 110.008 -179.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.96 -37.33 87.03 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.649 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.96 -39.6 98.27 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . 0.401 HG23 ' O ' ' C' ' 384' ' ' ALA . 88.5 t -63.83 -42.68 96.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.781 0.324 . . . . 0.0 110.272 179.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.6 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.5 tt -60.08 -38.61 83.42 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.996 -179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -63.5 -42.46 96.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.899 0.381 . . . . 0.0 110.117 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 9.7 mt -61.54 -40.4 94.52 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.479 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 73.0 t -63.26 -40.57 89.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.6 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.91 -41.77 96.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.338 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.03 -44.0 97.63 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.318 -0.553 . . . . 0.0 109.613 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.89 83.93 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.179 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -59.67 -44.45 93.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.662 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -62.97 -45.15 93.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.616 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 87.6 mt -63.94 -42.52 96.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.816 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.16 -36.13 92.85 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 47.6 tp -62.45 -42.07 99.2 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.563 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -84.66 100.48 11.48 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.853 0.359 . . . . 0.0 110.654 -179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -67.96 -37.58 81.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.449 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -98.78 135.51 40.14 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.433 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 78.3 m80 -73.85 149.55 41.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.604 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.23 -12.26 59.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.514 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.59 -36.32 93.2 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -81.84 131.66 35.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.74 0.305 . . . . 0.0 110.404 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 93.1 mt-10 -135.57 146.44 48.0 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.714 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.61 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 0.4 OUTLIER -52.8 146.28 10.86 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.651 -0.42 . . . . 0.0 109.92 179.707 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.427 -179.801 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 84.8 p . . . . . 0 N--CA 1.492 1.65 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.81 -37.43 87.59 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.377 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -98.28 110.95 23.45 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.47 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -63.3 -38.36 90.85 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.705 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -67.32 144.58 55.78 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.63 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.472 ' OD1' ' N ' ' A' ' 375' ' ' PHE . 58.6 t-20 -60.39 144.9 49.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.501 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . 0.472 ' N ' ' OD1' ' A' ' 374' ' ' ASN . 95.7 m-85 -61.77 -43.33 99.07 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.701 -179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 47.0 mt -115.53 132.72 56.54 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.556 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.426 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 3.4 t 60.94 54.99 3.36 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.453 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.426 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 37.8 Cg_endo -66.56 148.24 83.24 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.823 2.349 . . . . 0.0 111.935 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 72.7 mt -67.7 -26.11 34.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.064 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -53.33 -20.38 4.31 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.599 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -67.89 -43.66 85.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.623 0.249 . . . . 0.0 110.472 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -67.39 -43.95 86.04 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 -179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.87 -39.87 87.67 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.82 0.343 . . . . 0.0 110.751 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . 0.43 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -64.13 -43.6 94.76 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.728 -179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -66.12 -41.43 90.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.49 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -39.54 93.61 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.48 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.75 -43.45 98.93 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 384' ' ' ALA . 94.8 t -67.41 -42.0 86.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.723 0.297 . . . . 0.0 110.851 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tp -59.59 -40.87 88.89 Favored 'General case' 0 C--N 1.328 -0.328 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.073 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.0 mt -65.07 -42.76 95.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.85 0.357 . . . . 0.0 110.23 179.028 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -61.89 -42.74 99.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.831 -179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.2 t -65.55 -41.97 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.778 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.84 -41.18 97.48 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.559 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -61.49 -44.06 97.76 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -62.28 -47.45 84.27 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.972 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.13 -35.72 79.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.224 179.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -57.92 -45.91 85.79 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.307 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 42.8 mm -67.66 -41.15 85.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.162 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.53 -27.37 60.98 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.4 tp -63.18 -39.23 94.05 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.397 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 61.2 mttp -65.94 148.54 51.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.68 -179.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 53.29 97.1 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.513 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -75.24 139.9 42.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.551 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -72.98 141.01 47.75 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.488 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.23 -13.6 59.91 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.554 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.3 -38.89 97.15 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -118.02 140.08 50.27 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -82.67 118.25 23.2 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.152 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 44.9 tp60 -96.68 131.9 42.89 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.837 0.351 . . . . 0.0 110.087 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 87.7 t80 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.452 179.991 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 27.2 t . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -62.15 -41.14 98.0 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.464 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 53.5 p-10 -154.55 172.51 17.7 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.243 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -70.59 144.75 51.11 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.792 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -62.55 -42.16 99.36 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.591 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -83.75 144.53 29.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.356 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 87.4 m-85 -114.76 102.74 10.3 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.466 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 57.2 tp -63.04 -41.86 99.61 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.275 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 2.7 m -129.63 80.46 71.69 Favored Pre-proline 0 N--CA 1.465 0.325 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.219 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -59.25 146.07 95.81 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 C-N-CA 122.818 2.345 . . . . 0.0 111.884 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.5 mt -63.67 -43.6 98.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.817 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.93 -20.0 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.613 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.459 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.2 t -64.15 -43.3 97.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 N-CA-C 110.272 -0.27 . . . . 0.0 110.272 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.14 -40.49 99.22 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.64 -37.42 86.51 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.803 0.335 . . . . 0.0 110.673 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.74 -45.7 91.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.787 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -64.92 -41.78 95.27 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.49 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.95 -37.92 89.19 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.465 -179.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.76 -40.98 99.52 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 85.5 t -66.92 -43.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.903 0.382 . . . . 0.0 110.189 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . 0.547 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.8 tt -59.63 -41.26 90.06 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.503 -179.033 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.3 mt -65.68 -42.11 91.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-O 120.98 0.419 . . . . 0.0 110.194 179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.8 mt -60.04 -41.27 91.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.563 -179.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 82.4 t -64.43 -41.43 92.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.68 -42.2 98.6 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.48 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.13 -42.4 99.2 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.05 -49.26 76.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.799 179.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -64.38 -35.45 80.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.36 179.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -57.37 -45.57 84.29 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.322 -179.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 5.2 mm -63.93 -42.4 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.074 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.13 -35.11 91.56 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.894 -0.883 . . . . 0.0 110.894 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 52.0 tp -62.55 -41.33 98.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.876 0.369 . . . . 0.0 110.391 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 88.5 tttt 55.95 103.73 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.573 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 59.9 t-80 -80.66 129.67 34.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.328 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 63.5 t-80 -84.38 126.37 33.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.534 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -79.5 141.88 36.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.581 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.37 -14.62 59.68 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.655 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.65 -37.62 95.01 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -78.84 133.87 36.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.538 0.209 . . . . 0.0 110.508 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -83.25 118.21 23.48 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 120.734 0.302 . . . . 0.0 110.376 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.522 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 1.8 pm0 -68.07 134.4 50.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.169 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 93.5 t80 . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.528 179.936 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . 0.42 ' O ' ' OD1' ' C' ' 372' ' ' ASP . 5.5 t . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.04 -36.92 85.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.326 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 38.1 p30 -66.63 -24.66 66.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.527 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.533 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 99.7 m-20 55.5 35.84 25.93 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.57 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 39.2 p-10 -86.24 -0.97 57.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.516 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -91.59 0.86 57.46 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.435 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' C' ' 376' ' ' LEU . 90.1 t80 -60.14 -45.91 91.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.518 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' C' ' 375' ' ' PHE . 45.5 tp 58.81 145.18 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.642 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.457 HG22 ' H ' ' C' ' 377' ' ' VAL . 2.0 m -71.11 151.01 94.79 Favored Pre-proline 0 CA--C 1.535 0.389 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.644 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.481 ' O ' HG12 ' C' ' 381' ' ' VAL . 36.9 Cg_endo -65.4 146.53 85.73 Favored 'Trans proline' 0 N--CA 1.496 1.634 0 C-N-CA 122.712 2.275 . . . . 0.0 111.874 179.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt -63.99 -43.87 97.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.808 -179.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.94 -19.88 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.737 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.4 p -59.68 -42.84 89.85 Favored 'Isoleucine or valine' 0 C--O 1.232 0.169 0 CA-C-O 120.615 0.245 . . . . 0.0 110.419 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . 0.5 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.81 -39.79 97.77 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.22 -40.9 97.65 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.886 0.374 . . . . 0.0 110.542 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.47 -35.9 82.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.546 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.666 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.19 -44.33 97.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.221 -0.445 . . . . 0.0 109.876 -179.441 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.4 90.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.605 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.73 -41.63 99.63 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 91.2 t -67.08 -42.48 88.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.629 0.252 . . . . 0.0 110.453 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.538 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.6 tt -59.69 -41.43 90.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.156 -179.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.7 mt -64.45 -42.45 95.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.857 0.36 . . . . 0.0 110.28 178.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.01 -41.2 96.07 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.608 -179.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 76.2 t -64.1 -40.68 89.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.725 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.59 -40.32 94.36 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.326 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.8 -42.84 99.52 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -49.18 77.81 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.933 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -63.93 -34.8 78.78 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.392 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.89 -45.31 82.67 Favored 'General case' 0 CA--C 1.529 0.146 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.16 -179.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 84.8 mt -64.7 -42.27 94.54 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.068 178.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.42 -30.28 75.85 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.014 -0.835 . . . . 0.0 111.014 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 54.4 tp -61.85 -40.07 94.06 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.917 -0.313 . . . . 0.0 110.304 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -50.77 136.26 22.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.596 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . 0.635 ' H ' ' CD2' ' C' ' 402' ' ' HIS . 6.7 p80 -78.49 -13.68 59.72 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.437 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . 0.611 ' CE1' ' CE1' ' C' ' 402' ' ' HIS . 73.1 m80 -69.89 134.9 48.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.35 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . 0.444 ' CD2' ' O ' ' C' ' 404' ' ' HIS . 11.8 p-80 -98.21 124.94 43.05 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.469 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -103.05 -26.54 13.02 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.334 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.4 -39.74 97.19 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 82.7 t80 -85.31 130.26 34.63 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.63 0.252 . . . . 0.0 110.384 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -135.38 148.67 49.45 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.815 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.5 ' NE2' ' N ' ' C' ' 410' ' ' PHE . 38.3 tp60 -70.83 127.96 34.42 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 120.705 -0.398 . . . . 0.0 109.941 179.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . 0.5 ' N ' ' NE2' ' C' ' 409' ' ' GLN . 84.6 t80 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.555 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 21.7 m . . . . . 0 N--CA 1.492 1.656 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.47 -37.42 87.22 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.348 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 80.8 m-20 -61.13 -39.66 90.88 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.175 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 99.3 m-20 -64.33 -37.26 86.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.596 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -89.2 108.85 19.84 Favored 'General case' 0 N--CA 1.462 0.15 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.383 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -86.99 103.7 15.6 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.441 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -63.8 -41.48 97.9 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.735 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.56 HD12 ' N ' ' A' ' 376' ' ' LEU . 10.7 mp -63.21 -40.24 96.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.206 -179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 35.0 t 59.08 74.65 0.57 Allowed Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.496 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.527 ' O ' HG12 ' A' ' 381' ' ' VAL . 24.6 Cg_exo -61.24 147.85 94.48 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 122.915 2.41 . . . . 0.0 111.998 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.525 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -63.17 -43.59 98.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.855 -179.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.97 -20.01 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.936 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.527 HG12 ' O ' ' A' ' 378' ' ' PRO . 8.4 p -61.04 -43.12 95.51 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 120.679 0.276 . . . . 0.0 110.392 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.514 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.68 -38.92 96.95 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.92 -41.06 95.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.703 0.287 . . . . 0.0 110.563 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.66 -35.71 81.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.518 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.665 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.1 tt -61.14 -44.35 97.46 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-O 121.024 0.44 . . . . 0.0 109.963 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.35 86.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.408 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.86 -39.74 97.9 Favored Glycine 0 CA--C 1.531 1.066 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.3 t -63.52 -42.17 95.25 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.192 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.706 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -59.73 -37.53 79.17 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.467 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.0 mm -64.6 -42.22 94.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 120.884 0.374 . . . . 0.0 110.072 179.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.14 -40.02 92.24 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.602 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.7 t -62.69 -41.1 91.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.784 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.15 -40.93 95.71 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.444 -179.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.88 -41.84 98.36 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.548 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.82 -48.84 77.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.766 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.4 t80 -64.09 -35.88 82.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.424 179.186 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -57.47 -45.52 84.71 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.392 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.74 -42.46 96.04 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.88 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.88 -35.47 92.05 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.1 tp -63.14 -41.69 99.33 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.614 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.3 134.46 52.66 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.619 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 85.3 t60 52.71 79.58 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.607 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 23.2 p80 -69.14 145.37 53.38 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.483 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -74.51 143.68 44.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.531 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.23 -16.63 58.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.511 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.21 -38.99 97.39 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.941 -0.863 . . . . 0.0 110.941 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 84.7 t80 -104.46 130.24 52.38 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.772 0.32 . . . . 0.0 110.388 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -135.49 143.65 45.93 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.842 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -56.53 141.97 40.89 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.078 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.9 t80 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.45 179.626 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 38.9 t . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -66.88 142.76 57.2 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.402 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -132.41 99.48 4.68 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.355 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 38.8 p-10 -91.61 110.76 22.09 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.448 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -85.88 98.96 11.07 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.289 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . 0.498 HD21 HG21 ' B' ' 381' ' ' VAL . 54.9 t30 -154.43 11.47 0.39 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.604 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -61.68 -42.15 98.53 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.333 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . 0.588 HD22 ' N ' ' B' ' 376' ' ' LEU . 3.5 mm? -66.86 135.47 53.93 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.158 -179.511 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.442 ' C ' ' O ' ' B' ' 376' ' ' LEU . 4.0 m 29.97 69.05 0.66 Allowed Pre-proline 0 N--CA 1.468 0.458 0 O-C-N 123.834 0.709 . . . . 0.0 110.936 -179.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_exo -53.56 -38.89 84.15 Favored 'Trans proline' 0 C--N 1.302 -1.897 0 C-N-CA 122.431 2.087 . . . . 0.0 112.081 -179.025 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.497 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.0 mt -63.61 -44.45 98.55 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.197 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.309 -178.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.51 -20.21 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.808 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.498 HG21 HD21 ' B' ' 374' ' ' ASN . 55.0 t -64.68 -44.06 96.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.435 179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.25 -40.83 96.89 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.04 85.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.738 0.304 . . . . 0.0 110.655 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.45 -45.77 92.5 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.659 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.91 -42.3 94.83 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.509 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.81 -37.26 87.02 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.48 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.63 -40.6 99.36 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.161 -0.776 . . . . 0.0 111.161 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -67.14 -42.72 88.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.761 0.315 . . . . 0.0 110.485 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.6 tt -59.36 -40.56 86.86 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.486 -179.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.2 mt -65.72 -42.21 92.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 120.829 0.347 . . . . 0.0 110.188 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.25 -40.58 94.57 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.632 -179.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.7 t -62.4 -41.15 90.63 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.783 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.17 -41.16 96.28 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.471 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -42.85 99.36 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.978 179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.5 t80 -64.37 -37.27 86.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.346 179.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -58.22 -45.41 87.75 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.269 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.0 mt -63.35 -41.96 94.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.93 -31.71 77.24 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 59.8 tp -62.39 -40.57 96.93 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.847 -0.341 . . . . 0.0 110.363 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -57.68 136.72 56.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.601 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 86.3 t60 45.63 79.15 0.05 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.515 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 57.8 t-80 -81.43 153.44 26.91 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.544 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -77.1 137.14 38.74 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.556 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.87 -12.46 59.98 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.524 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.49 -37.43 94.78 Favored Glycine 0 CA--C 1.529 0.936 0 N-CA-C 110.985 -0.846 . . . . 0.0 110.985 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -114.58 141.08 48.22 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.754 0.312 . . . . 0.0 110.173 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . 0.52 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 55.4 mp0 -104.42 123.12 46.89 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.052 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.478 ' NE2' ' O ' ' B' ' 408' ' ' GLU . 86.4 mm-40 -130.45 140.16 50.55 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.305 -179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 88.1 t80 . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.534 -179.708 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 96.8 p . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . 59.15 117.03 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.621 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 34.4 p-10 -64.49 -35.09 79.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.506 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.483 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 99.0 m-20 54.85 31.33 15.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.559 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -62.22 -41.32 98.28 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.522 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . 0.437 ' O ' ' O ' ' C' ' 375' ' ' PHE . 49.6 p-10 -96.89 10.09 40.02 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.504 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . 0.437 ' O ' ' O ' ' C' ' 374' ' ' ASN . 97.7 m-85 49.78 102.86 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.56 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 59.5 mt -115.68 132.66 56.57 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.504 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.469 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 3.7 t 59.68 53.25 3.97 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.345 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.469 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 35.6 Cg_endo -65.62 -20.66 59.91 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.585 2.19 . . . . 0.0 112.046 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.91 -44.63 98.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.182 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.55 -20.22 60.69 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.995 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.7 t -66.64 -43.5 90.33 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.394 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.04 -39.24 97.04 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.06 -41.69 98.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.814 0.34 . . . . 0.0 110.545 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.3 83.86 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.467 179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.632 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.0 tt -61.59 -45.23 95.01 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-O 121.136 0.493 . . . . 0.0 110.051 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.17 -36.76 85.11 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.45 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.07 -42.26 98.37 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 62.7 t -67.43 -42.61 87.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.787 0.327 . . . . 0.0 110.429 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.509 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.3 tt -61.02 -41.54 96.75 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.182 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.0 mt -64.38 -41.95 93.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.851 0.358 . . . . 0.0 110.241 178.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -60.49 -41.44 94.27 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.683 -179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 78.7 t -64.71 -41.4 92.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.735 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.8 mt -61.7 -41.58 97.79 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.611 -179.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.84 -42.83 99.51 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.368 -0.533 . . . . 0.0 109.687 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.64 -42.59 93.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.841 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -63.75 -39.29 93.92 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.553 179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -56.61 -45.36 81.51 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.337 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.7 mm -66.71 -40.83 87.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.895 179.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.74 -28.64 71.96 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 50.9 tp -62.53 -40.13 95.81 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.445 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -63.62 136.68 57.69 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.671 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -78.65 157.66 28.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.524 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -69.83 143.57 52.84 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.593 -179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -74.76 137.29 41.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.605 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.46 -11.89 59.98 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.587 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.96 -35.2 91.74 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -108.2 136.37 47.98 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.82 0.343 . . . . 0.0 110.284 179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -135.42 145.48 47.31 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.688 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.528 ' OE1' ' N ' ' C' ' 410' ' ' PHE . 4.2 tp-100 -71.42 123.6 22.72 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 120.413 -0.515 . . . . 0.0 109.895 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . 0.528 ' N ' ' OE1' ' C' ' 409' ' ' GLN . 94.3 t80 . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.494 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 48.2 m . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 48.11 41.84 16.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.478 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 34.4 p30 -86.47 -1.78 57.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.399 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 55.1 33.39 20.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.564 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.522 ' OD1' ' CZ ' ' A' ' 375' ' ' PHE . 54.5 p-10 -80.7 166.79 20.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.456 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 52.8 t30 -86.89 112.74 22.06 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.469 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . 0.522 ' CZ ' ' OD1' ' A' ' 373' ' ' ASP . 86.0 m-85 -83.95 -146.18 0.09 Allowed 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 120.964 0.411 . . . . 0.0 110.469 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 51.7 tp -64.05 -44.36 92.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.317 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.452 HG12 ' H ' ' A' ' 380' ' ' ALA . 5.2 t 39.66 74.58 0.67 Allowed Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.738 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_exo -52.64 -34.39 63.39 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.733 2.289 . . . . 0.0 112.04 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt -63.07 -44.2 99.41 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.121 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . 0.452 ' H ' HG12 ' A' ' 377' ' ' VAL . . . -74.52 -20.3 60.03 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.644 0.259 . . . . 0.0 110.859 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.32 -43.68 87.78 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-O 120.79 0.329 . . . . 0.0 110.397 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.05 -42.96 99.48 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.876 -0.889 . . . . 0.0 110.876 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.79 -39.49 93.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.747 0.308 . . . . 0.0 110.777 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.4 -44.37 97.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.7 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.62 -41.63 92.49 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.53 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.72 -40.25 91.61 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.377 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.36 -42.83 99.04 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 75.2 t -67.43 -42.5 87.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.825 0.345 . . . . 0.0 110.567 -179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -59.26 -41.11 88.07 Favored 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.406 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 84.5 mt -65.4 -42.55 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 CA-C-O 120.934 0.397 . . . . 0.0 110.326 179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 13.0 mt -60.7 -40.0 90.61 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.51 -179.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.4 t -63.02 -41.34 92.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.721 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -60.96 -40.84 94.9 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.494 -179.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.51 -42.53 98.94 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.424 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.31 -47.91 82.19 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.829 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.2 t80 -63.92 -34.83 78.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.512 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -57.22 -45.56 83.75 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.291 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 29.8 mm -64.73 -42.61 95.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.75 -34.01 88.75 Favored Glycine 0 CA--C 1.52 0.383 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.44 ' O ' ' O ' ' A' ' 401' ' ' LYS . 49.0 tp -62.93 -41.84 99.6 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.571 -179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' A' ' 400' ' ' LEU . 87.5 tttt 59.19 140.65 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.542 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 56.3 t-80 -67.54 132.85 48.38 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.202 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 15.8 p80 -115.37 156.99 24.53 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.436 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -75.68 148.7 38.45 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.545 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.09 -11.1 59.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.484 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.85 -39.27 97.8 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -79.83 131.88 35.99 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 110.37 -0.233 . . . . 0.0 110.37 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 64.5 mm-40 -135.38 146.31 48.21 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.454 0.169 . . . . 0.0 110.555 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.477 ' NE2' ' N ' ' A' ' 410' ' ' PHE . 39.3 tp60 -72.57 128.39 35.44 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 120.627 -0.429 . . . . 0.0 109.858 179.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . 0.477 ' N ' ' NE2' ' A' ' 409' ' ' GLN . 88.0 t80 . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.507 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 9.5 t . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -151.66 152.3 32.63 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.51 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -62.46 -40.31 96.21 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.257 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 94.0 m-20 -68.62 142.16 55.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.698 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 55.17 37.09 28.37 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.501 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . 0.433 ' OD1' ' CD2' ' B' ' 375' ' ' PHE . 50.5 p30 -98.5 6.52 47.1 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.317 -0.402 . . . . 0.0 110.64 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . 0.433 ' CD2' ' OD1' ' B' ' 374' ' ' ASN . 99.0 m-85 -98.14 -3.72 37.17 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.403 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . 0.55 ' N ' HD12 ' B' ' 376' ' ' LEU . 10.3 mp -63.41 -40.36 96.99 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.241 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 2.4 m -45.43 150.64 0.84 Allowed Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.768 -179.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -64.18 -22.32 67.17 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.575 2.183 . . . . 0.0 112.258 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 45.5 mm -64.88 -46.2 92.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.391 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.79 -20.31 61.88 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 116.727 -0.215 . . . . 0.0 110.759 -179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.7 t -66.98 -43.59 89.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 CA-C-O 120.811 0.339 . . . . 0.0 110.21 179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.61 -40.78 96.15 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.23 -39.22 92.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.83 0.348 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . 0.438 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -63.83 -45.11 91.08 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.585 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -66.57 -41.41 88.62 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.558 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.67 -38.29 90.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.514 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.26 -39.16 96.8 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . 0.438 HG23 ' O ' ' B' ' 384' ' ' ALA . 96.0 t -66.71 -41.76 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 121.15 0.5 . . . . 0.0 110.103 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -58.62 -40.22 82.72 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.857 -179.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 76.9 mt -67.59 -42.07 86.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.142 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.1 mt -61.09 -41.89 97.5 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.721 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 70.9 t -62.52 -41.46 92.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.714 -179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.29 -40.83 95.6 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.611 -179.419 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.42 -42.45 98.77 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 120.202 -0.599 . . . . 0.0 109.459 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.49 -49.79 76.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.866 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -63.89 -34.29 77.61 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.357 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -58.32 -44.67 88.74 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.269 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . 0.409 HD13 ' HA ' ' B' ' 398' ' ' ILE . 30.8 mm -64.64 -42.64 95.64 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.855 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.25 -37.2 94.2 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' B' ' 402' ' ' HIS . 51.8 tp -63.4 -42.27 98.78 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.498 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . 0.414 ' C ' ' O ' ' B' ' 400' ' ' LEU . 61.5 pttt 35.16 32.61 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 121.005 0.431 . . . . 0.0 111.084 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . 0.459 ' N ' ' O ' ' B' ' 400' ' ' LEU . 49.7 t-80 -148.41 141.83 25.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.349 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -118.22 123.53 45.69 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.482 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -77.71 133.1 38.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.47 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.04 -34.78 57.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.547 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.9 -35.27 91.78 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 84.0 t80 -78.35 134.14 37.49 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 110.414 -0.217 . . . . 0.0 110.414 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -135.39 146.33 48.22 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 120.425 0.155 . . . . 0.0 110.61 179.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.616 ' NE2' ' N ' ' B' ' 410' ' ' PHE . 35.7 tp60 -68.35 132.79 47.68 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . 0.616 ' N ' ' NE2' ' B' ' 409' ' ' GLN . 96.5 m-85 . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.511 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 6.9 t . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.66 -37.72 87.32 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.438 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 59.1 t0 55.93 33.39 21.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.418 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 67.2 t0 -87.56 112.68 22.52 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.675 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -87.62 113.3 23.18 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.343 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -63.39 -41.5 98.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.663 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -118.28 102.39 8.93 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.644 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . 0.551 ' N ' HD12 ' C' ' 376' ' ' LEU . 10.4 mp -64.46 -40.98 96.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.361 179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 2.8 m -134.75 77.38 57.84 Favored Pre-proline 0 N--CA 1.464 0.236 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.397 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.514 ' O ' HG12 ' C' ' 381' ' ' VAL . 51.0 Cg_endo -75.83 -14.74 19.28 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.629 2.219 . . . . 0.0 111.972 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.502 ' O ' ' N ' ' C' ' 381' ' ' VAL . 94.6 mt -63.07 -44.05 99.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.29 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.167 -179.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.11 -19.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.829 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.533 HG13 ' N ' ' C' ' 382' ' ' GLY . 7.9 p -58.97 -44.34 90.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.091 0 N-CA-C 110.302 -0.258 . . . . 0.0 110.302 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . 0.533 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.46 -39.11 97.35 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 179.398 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.5 -41.47 98.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.801 0.334 . . . . 0.0 110.632 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . 0.414 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -65.56 -35.39 80.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.359 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.632 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.45 -44.28 97.39 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.111 0.482 . . . . 0.0 110.086 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.63 -37.4 87.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.519 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.76 -41.71 97.48 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . 0.414 HG23 ' O ' ' C' ' 384' ' ' ALA . 97.9 t -65.75 -41.55 90.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.898 0.38 . . . . 0.0 110.28 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 tt -58.39 -41.7 85.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.618 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 80.7 mt -65.85 -42.44 92.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 120.857 0.36 . . . . 0.0 110.393 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -60.88 -39.43 89.22 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.547 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 61.9 t -62.23 -41.7 92.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.675 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -60.92 -41.44 96.15 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.399 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.45 -44.46 96.36 Favored 'General case' 0 C--N 1.319 -0.735 0 C-N-CA 120.09 -0.644 . . . . 0.0 109.648 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.35 -36.54 84.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.108 179.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -59.52 -43.65 93.38 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.604 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -63.87 -41.0 97.85 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.562 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 83.2 mt -63.53 -42.39 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.778 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -59.65 -58.95 11.61 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . 0.489 HD22 ' N ' ' C' ' 400' ' ' LEU . 3.9 mm? -65.43 -42.86 92.0 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.806 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . 0.413 ' C ' ' O ' ' C' ' 400' ' ' LEU . 24.5 pttm 34.88 39.82 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.941 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -70.23 127.56 33.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.194 -179.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' C' ' 404' ' ' HIS . 61.0 t-80 -75.76 151.98 37.48 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.524 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . 0.401 ' O ' ' ND1' ' C' ' 403' ' ' HIS . 39.0 t60 -76.54 132.38 39.5 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.543 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.88 -12.64 60.0 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.616 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.08 -36.67 93.77 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 75.2 m-85 -105.31 134.58 48.19 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -88.32 116.58 26.63 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -52.59 138.38 28.34 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.675 -0.41 . . . . 0.0 109.913 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 55.2 p90 . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.563 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . 0.504 ' N ' ' CE1' ' A' ' 375' ' ' PHE . 40.3 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 48.79 12.93 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.545 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.473 ' N ' ' C ' ' A' ' 369' ' ' SER . 99.1 m-20 55.94 33.68 22.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.445 179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 97.4 m-20 -67.16 142.45 57.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.627 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -67.97 144.26 55.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.656 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.479 ' C ' ' H ' ' A' ' 376' ' ' LEU . 65.7 t30 56.64 42.38 27.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.584 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . 0.524 ' C ' ' H ' ' A' ' 377' ' ' VAL . 68.9 t80 -69.21 8.68 0.54 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.535 -179.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.479 ' H ' ' C ' ' A' ' 374' ' ' ASN . 4.0 tp 70.83 -15.96 0.36 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.467 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.524 ' H ' ' C ' ' A' ' 375' ' ' PHE . 7.3 t 45.05 72.66 1.16 Allowed Pre-proline 0 C--N 1.327 -0.387 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.689 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.529 ' O ' HG12 ' A' ' 381' ' ' VAL . 33.4 Cg_exo -59.78 145.6 97.79 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.87 2.38 . . . . 0.0 111.824 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.538 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.5 mt -63.1 -43.28 98.85 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.968 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.07 -20.0 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.871 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.538 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.3 p -60.82 -42.53 92.76 Favored 'Isoleucine or valine' 0 C--O 1.232 0.136 0 CA-C-O 120.717 0.294 . . . . 0.0 110.362 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.496 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -61.81 -39.25 97.23 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -60.77 -40.89 94.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.819 0.342 . . . . 0.0 110.581 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.77 -35.69 81.89 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.474 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.653 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.5 tt -61.59 -44.38 97.12 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-O 121.057 0.456 . . . . 0.0 110.002 -179.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.81 -36.53 83.46 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.445 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.8 -37.38 94.76 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.301 -0.72 . . . . 0.0 111.301 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.2 t -67.53 -42.08 86.53 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.225 0 CA-C-O 121.076 0.465 . . . . 0.0 109.943 179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.53 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -59.18 -41.7 89.09 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.778 -179.429 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -66.72 -42.0 88.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.35 -41.26 93.28 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.613 -179.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.3 t -64.29 -40.94 90.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.63 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 8.3 mt -61.6 -40.35 94.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.515 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -62.04 -43.76 98.15 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.31 -0.556 . . . . 0.0 109.581 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.55 -36.77 84.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.018 179.34 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -60.69 -44.22 96.79 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.657 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -62.32 -43.47 98.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.658 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 86.6 mt -63.83 -42.7 96.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.799 179.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.06 -38.18 93.79 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.085 -0.806 . . . . 0.0 111.085 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.0 tp -62.58 -41.37 98.91 Favored 'General case' 0 C--N 1.328 -0.349 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.438 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 49.7 tttp 57.87 164.25 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.59 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 54.47 93.02 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.443 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -79.86 144.41 33.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.515 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 75.9 m80 -77.73 139.9 39.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.547 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.26 -13.25 59.97 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.537 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.45 -39.37 97.64 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 81.9 t80 -82.5 134.33 35.21 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.582 0.23 . . . . 0.0 110.428 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -83.45 117.22 22.93 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.406 179.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.513 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 2.0 pm0 -66.41 136.16 55.35 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 110.142 -0.318 . . . . 0.0 110.142 179.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . 0.508 ' CG ' ' O ' ' A' ' 410' ' ' PHE . 93.7 t80 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.339 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 13.3 p . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.15 141.4 54.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.552 179.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -62.11 -34.49 76.42 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.181 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -67.65 143.18 56.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.551 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -90.94 -0.66 57.79 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.58 179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 12.4 m120 56.24 35.23 25.42 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.56 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 51.7 t80 -60.65 -43.31 97.74 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.484 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 27.1 mt -100.29 133.81 44.15 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.441 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 3.7 m -137.79 74.92 44.08 Favored Pre-proline 0 C--N 1.331 -0.218 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.419 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . 0.487 ' O ' HG12 ' B' ' 381' ' ' VAL . 25.5 Cg_exo -61.16 150.47 84.35 Favored 'Trans proline' 0 N--CA 1.494 1.55 0 C-N-CA 122.98 2.453 . . . . 0.0 111.805 179.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.537 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt -63.03 -43.18 98.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.929 -179.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.71 -19.93 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.897 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.537 ' N ' ' O ' ' B' ' 379' ' ' ILE . 7.8 p -60.97 -40.96 87.25 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 CA-C-O 120.773 0.321 . . . . 0.0 110.265 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . 0.447 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -62.75 -38.57 96.7 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.537 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.27 -40.4 93.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.802 0.334 . . . . 0.0 110.527 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -35.46 81.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.503 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . 0.656 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.1 tt -61.12 -45.32 95.18 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.065 0.459 . . . . 0.0 110.004 -179.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.26 -35.88 82.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.422 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.86 -40.6 98.5 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -66.55 -42.3 89.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.85 0.357 . . . . 0.0 110.276 179.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . 0.542 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.9 tt -60.1 -41.36 92.35 Favored 'General case' 0 CA--C 1.53 0.176 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.419 -179.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.6 mt -65.73 -41.98 91.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.78 0.324 . . . . 0.0 110.156 179.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -60.06 -41.4 92.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.626 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.3 t -63.77 -41.62 93.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.754 179.907 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.11 -41.27 96.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.477 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.48 -43.56 98.65 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 120.276 -0.569 . . . . 0.0 109.573 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.3 -36.98 84.34 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.144 179.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -60.48 -44.09 96.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.647 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -62.94 -41.81 99.61 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.605 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.8 mt -63.09 -42.55 97.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.742 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.71 -35.65 92.2 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 53.3 tp -62.6 -41.18 98.82 Favored 'General case' 0 C--N 1.326 -0.416 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.51 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -64.62 135.94 56.47 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.607 -179.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 84.4 t60 48.82 93.44 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.517 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -69.91 143.33 52.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.547 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 61.1 m170 -73.54 142.66 46.67 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.59 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.14 -11.43 59.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.561 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.76 -36.86 93.62 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 90.6 t80 -82.26 132.75 35.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.621 0.248 . . . . 0.0 110.507 179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.5 146.99 48.69 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.78 0.324 . . . . 0.0 110.756 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.635 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -52.6 146.03 10.78 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.611 -0.435 . . . . 0.0 109.923 179.712 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.368 -179.642 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 25.5 p . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.68 -38.58 91.64 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.447 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -99.06 110.62 23.18 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.351 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -62.72 -39.23 93.42 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.608 -179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -88.2 113.91 24.29 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.456 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' C' ' 376' ' ' LEU . 42.7 p-10 -83.96 138.98 32.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.553 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 90.7 m-85 -62.54 -43.79 97.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.615 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . 0.464 ' O ' ' ND2' ' C' ' 374' ' ' ASN . 33.1 tp -104.86 131.62 52.12 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.076 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 27.0 t -118.71 83.43 22.31 Favored Pre-proline 0 CA--C 1.534 0.329 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.344 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -81.05 109.89 2.24 Favored 'Trans proline' 0 C--N 1.312 -1.38 0 C-N-CA 122.635 2.223 . . . . 0.0 111.859 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 95.0 mt -94.64 -75.28 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.9 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.19 -20.15 60.95 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.899 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.6 t -64.3 -43.21 97.15 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.245 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.94 -41.97 99.7 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.98 -37.58 88.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.873 0.368 . . . . 0.0 110.757 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . 0.405 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -60.16 -44.77 94.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.643 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.45 -40.4 93.17 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.424 179.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.47 91.31 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.46 -179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.99 -41.37 97.34 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.164 -0.775 . . . . 0.0 111.164 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . 0.405 HG23 ' O ' ' C' ' 384' ' ' ALA . 88.9 t -64.56 -42.87 96.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-O 120.77 0.319 . . . . 0.0 110.296 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.587 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.4 tt -60.29 -39.06 85.54 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 116.219 -0.446 . . . . 0.0 109.897 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 6.5 mm -63.41 -42.27 95.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.6 mt -61.07 -40.82 95.13 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.651 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.1 t -62.61 -41.9 93.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.69 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.37 -42.28 98.44 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.486 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.67 -42.4 99.6 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.16 -48.57 73.55 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.0 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -63.97 -34.86 78.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.547 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -58.17 -44.33 87.93 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.366 -179.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 43.4 mm -65.52 -41.53 91.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.797 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.86 -35.61 92.24 Favored Glycine 0 CA--C 1.522 0.486 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . 0.437 ' O ' ' O ' ' C' ' 401' ' ' LYS . 51.9 tp -62.52 -42.25 99.39 Favored 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.597 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . 0.437 ' O ' ' O ' ' C' ' 400' ' ' LEU . 38.6 ttmt 59.49 140.85 0.01 OUTLIER 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.694 -179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -66.95 140.66 57.75 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.403 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -77.39 129.82 36.29 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.261 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -102.83 125.31 49.52 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.527 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.25 -11.33 59.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.428 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.14 -39.34 97.86 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -82.31 132.87 35.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.64 0.257 . . . . 0.0 110.42 179.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -81.31 118.68 22.84 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.245 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -52.69 144.39 14.14 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.657 -0.417 . . . . 0.0 109.967 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 54.8 p90 . . . . . 0 C--O 1.219 -0.543 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.552 179.914 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 68.6 m . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.66 -39.58 94.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.472 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -100.39 113.24 25.84 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.42 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.482 ' O ' HD21 ' A' ' 376' ' ' LEU . 42.2 t0 -90.1 113.22 24.92 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.649 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -62.67 -40.79 98.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.492 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.439 ' O ' ' O ' ' A' ' 375' ' ' PHE . 98.3 m-20 -85.92 142.28 28.95 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.484 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' A' ' 374' ' ' ASN . 82.3 t80 56.99 118.08 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.431 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.482 HD21 ' O ' ' A' ' 372' ' ' ASP . 97.9 mt -133.39 131.3 39.85 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.934 0.397 . . . . 0.0 110.37 179.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.472 ' H ' HG22 ' A' ' 377' ' ' VAL . 1.3 m -54.61 152.03 13.42 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.707 -179.352 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -64.61 149.55 89.65 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.604 2.202 . . . . 0.0 111.94 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -63.94 -42.58 96.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.874 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.16 -20.23 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.347 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.832 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' A' ' 379' ' ' ILE . 45.4 t -65.6 -43.98 93.88 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.515 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.32 -37.39 94.44 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.8 -42.28 98.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.77 0.319 . . . . 0.0 110.471 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.57 -37.17 85.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.568 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.656 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.3 tt -61.53 -44.17 97.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.981 0.419 . . . . 0.0 109.976 -179.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.94 -37.08 85.61 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.592 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.84 -39.96 97.57 Favored Glycine 0 CA--C 1.525 0.672 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.0 t -64.0 -43.39 97.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.756 0.312 . . . . 0.0 110.541 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.591 HD23 ' O ' ' A' ' 389' ' ' LEU . 5.0 tt -60.6 -39.31 87.66 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 7.7 mm -63.75 -42.54 96.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.12 -40.36 93.49 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.351 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.5 t -63.99 -41.41 92.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.758 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.42 97.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.441 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.68 -41.56 97.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.49 -48.93 73.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.808 179.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.67 -35.34 80.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.31 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . 0.476 ' CZ ' ' NE2' ' A' ' 402' ' ' HIS . 24.1 t80 -58.34 -46.11 86.88 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.388 -179.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.1 mt -64.45 -42.56 95.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.225 179.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.99 -32.65 84.88 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.2 tp -61.31 -41.44 97.0 Favored 'General case' 0 C--N 1.329 -0.303 0 C-N-CA 120.925 -0.31 . . . . 0.0 110.383 -179.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.1 mttt 55.32 95.0 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.539 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.476 ' NE2' ' CZ ' ' A' ' 397' ' ' PHE . 95.0 m-70 -73.77 141.22 46.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.362 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . 0.432 ' O ' ' CG ' ' A' ' 403' ' ' HIS . 55.3 p-80 -83.1 120.43 25.76 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.523 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -78.57 133.62 37.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.545 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.2 -12.12 59.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.63 179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.93 -34.92 91.22 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -82.06 130.37 35.06 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 110.39 -0.226 . . . . 0.0 110.39 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -91.87 117.08 29.45 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.359 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 43.3 tp60 -78.65 131.06 36.53 Favored 'General case' 0 C--N 1.333 -0.131 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 88.2 m-85 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.393 179.96 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 10.9 p . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -68.63 146.82 52.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.709 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -60.91 -42.53 98.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.291 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' B' ' 373' ' ' ASP . 42.5 p-10 -66.83 -33.78 76.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.704 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' B' ' 372' ' ' ASP . 47.3 t0 -90.65 108.89 20.1 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.451 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -147.9 105.82 3.72 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.394 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -116.45 101.49 8.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.836 0.35 . . . . 0.0 110.25 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 53.0 mt -116.86 128.47 55.28 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.328 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 15.3 t 51.17 72.89 1.09 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.633 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -60.36 147.09 95.17 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 122.935 2.423 . . . . 0.0 111.857 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.469 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.8 mt -63.9 -43.63 97.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.782 -179.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.61 -19.91 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.583 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.469 ' N ' ' O ' ' B' ' 379' ' ' ILE . 54.8 t -63.9 -43.65 97.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 C-N-CA 120.941 -0.304 . . . . 0.0 110.377 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.48 -43.02 98.78 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.73 -37.89 87.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.758 0.313 . . . . 0.0 110.697 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . 0.421 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -61.26 -44.85 96.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.698 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.26 -40.68 94.29 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.416 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.8 -37.41 84.3 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.376 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -39.21 96.01 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . 0.421 HG23 ' O ' ' B' ' 384' ' ' ALA . 88.0 t -63.87 -42.12 94.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-O 121.275 0.56 . . . . 0.0 110.436 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 11.9 mt -62.75 -42.03 99.49 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.807 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 84.6 mt -66.79 -40.62 86.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.942 0.401 . . . . 0.0 110.067 179.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -59.15 -41.97 89.62 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.472 -179.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.04 -42.08 93.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.814 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.55 -41.6 97.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.454 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.82 -44.02 97.69 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.308 -0.557 . . . . 0.0 109.646 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.27 -36.61 83.43 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.143 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.22 -44.29 95.3 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.527 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 35.5 m-85 -62.99 -44.45 95.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.405 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.27 -42.69 97.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.21 179.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.57 -34.79 90.89 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . 0.553 HD13 ' O ' ' B' ' 400' ' ' LEU . 0.2 OUTLIER -62.43 -43.42 98.87 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.029 -179.128 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -142.61 123.43 14.3 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.477 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 43.9 p-80 -157.7 159.7 37.16 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.061 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 79.2 t60 -124.17 128.33 49.08 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.227 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . 0.471 ' O ' ' ND1' ' B' ' 404' ' ' HIS . 21.6 p80 -125.97 124.84 41.64 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.203 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -101.77 -22.53 14.37 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.334 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.07 -40.93 97.32 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.865 -0.894 . . . . 0.0 110.865 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 88.7 t80 -83.66 133.43 34.82 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 110.351 -0.241 . . . . 0.0 110.351 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -70.83 117.78 12.78 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.222 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 7.4 pt20 -53.48 146.26 13.08 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.035 -0.984 . . . . 0.0 110.291 179.694 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 68.5 m . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -155.39 150.51 26.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.445 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 34.6 p30 -89.72 -1.93 58.13 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.354 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 37.8 p30 -88.99 -0.61 57.56 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.355 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . 0.444 ' O ' ' O ' ' C' ' 376' ' ' LEU . 97.6 m-20 -68.12 140.66 56.2 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.521 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -63.62 -40.14 96.15 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.514 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 90.7 t80 -59.88 -46.37 89.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.85 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . 0.444 ' O ' ' O ' ' C' ' 373' ' ' ASP . 42.9 tp -100.03 125.18 46.05 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 120.871 0.367 . . . . 0.0 110.28 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.41 HG22 ' H ' ' C' ' 377' ' ' VAL . 1.2 m -94.43 151.85 39.65 Favored Pre-proline 0 CA--C 1.533 0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.479 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -65.84 -21.56 57.55 Favored 'Trans proline' 0 N--CA 1.495 1.579 0 C-N-CA 122.612 2.208 . . . . 0.0 112.023 179.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.2 mt -64.68 -44.58 96.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.1 -179.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.41 -19.94 60.86 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 121.044 -0.262 . . . . 0.0 110.846 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 53.5 t -66.26 -43.16 91.82 Favored 'Isoleucine or valine' 0 C--O 1.231 0.084 0 CA-C-O 120.761 0.315 . . . . 0.0 110.484 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.38 -36.65 93.68 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.59 -41.0 98.69 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.805 0.336 . . . . 0.0 110.424 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.13 83.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.618 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.658 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.8 tt -61.3 -43.74 98.37 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 -179.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.45 -36.92 85.33 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.591 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.97 -39.99 97.81 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.52 -42.72 96.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.923 0.392 . . . . 0.0 110.5 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.509 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.9 tt -60.5 -39.22 86.93 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.914 -179.61 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.98 -42.32 95.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.0 -41.8 97.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.589 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -63.91 -41.27 91.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.692 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.14 -41.37 96.62 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.559 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.4 -44.41 97.19 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 120.418 -0.513 . . . . 0.0 109.663 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.78 84.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.189 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . 0.564 ' CZ ' HD11 ' C' ' 400' ' ' LEU . 78.5 t80 -60.33 -43.97 95.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.694 -0.685 . . . . 0.0 110.477 -179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -64.56 -45.56 86.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.365 179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -64.54 -42.15 94.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.371 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.51 -36.02 90.35 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . 0.564 HD11 ' CZ ' ' C' ' 396' ' ' TYR . 8.2 mt -63.88 -38.82 92.5 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.376 -0.231 . . . . 0.0 110.376 179.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 99.7 mttt 58.63 1.88 0.2 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.67 -179.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . 0.501 ' ND1' ' CE1' ' C' ' 404' ' ' HIS . 56.3 t-80 -152.62 135.64 15.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.408 179.676 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . 0.421 ' O ' ' CG ' ' C' ' 403' ' ' HIS . 44.4 p-80 -106.48 117.78 34.94 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.264 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . 0.501 ' CE1' ' ND1' ' C' ' 402' ' ' HIS . 77.5 m80 -102.59 124.89 48.97 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.409 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.06 -14.69 59.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.581 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.23 -38.75 96.99 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 79.4 m-85 -107.44 137.55 45.28 Favored 'General case' 0 N--CA 1.467 0.394 0 N-CA-C 110.382 -0.229 . . . . 0.0 110.382 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -84.06 118.14 23.88 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.146 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.611 ' CD ' ' H ' ' C' ' 409' ' ' GLN . 0.4 OUTLIER -52.97 145.97 11.86 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.816 -0.353 . . . . 0.0 110.049 179.835 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 91.5 t80 . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.755 -179.797 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 33.5 m . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.64 148.01 20.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.364 179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -100.03 109.47 21.79 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.042 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -64.19 -38.21 90.25 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.521 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -85.89 110.34 19.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.417 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -95.67 142.17 28.3 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.374 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.7 m-85 -62.29 -43.05 99.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.583 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.564 HD12 ' N ' ' A' ' 376' ' ' LEU . 10.2 mp -84.64 131.31 34.61 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.443 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 2.1 m -79.64 150.91 73.68 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.608 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.544 ' O ' HG12 ' A' ' 381' ' ' VAL . 37.3 Cg_endo -66.51 150.41 84.11 Favored 'Trans proline' 0 N--CA 1.496 1.67 0 C-N-CA 122.766 2.31 . . . . 0.0 112.215 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 46.7 mm -64.21 -44.14 97.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.969 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.17 -20.18 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 120.518 0.199 . . . . 0.0 110.791 179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 378' ' ' PRO . 9.0 p -60.78 -42.03 90.74 Favored 'Isoleucine or valine' 0 C--O 1.233 0.227 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.462 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -60.28 -43.16 98.82 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.57 -37.49 85.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.752 0.31 . . . . 0.0 110.738 179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . 0.409 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -60.64 -43.52 97.46 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.694 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.41 -41.38 93.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.395 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.49 -39.06 89.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.174 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.48 -41.04 96.52 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 384' ' ' ALA . 91.0 t -67.34 -42.04 87.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.845 0.355 . . . . 0.0 110.245 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.532 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.6 tt -59.61 -41.74 91.08 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.41 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 85.9 mt -65.58 -42.11 92.23 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-O 120.931 0.396 . . . . 0.0 110.231 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.51 -40.89 96.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.601 -179.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.6 t -64.18 -41.38 92.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.832 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.45 -41.55 97.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.434 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.92 -42.58 99.26 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.188 -0.605 . . . . 0.0 109.458 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.64 -47.0 77.34 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.716 -0.674 . . . . 0.0 109.804 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -64.19 -35.23 80.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.514 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -57.7 -46.22 84.65 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.396 -179.202 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 92.1 mt -64.66 -42.43 95.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.135 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 179.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.49 -33.05 86.2 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.5 tp -61.67 -40.67 95.77 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.437 -179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 63.6 mttp 56.81 104.95 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.707 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 59.9 t-80 -60.62 -41.79 95.55 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.341 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -76.73 130.56 37.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.286 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -70.63 140.07 51.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.64 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.17 -11.25 59.79 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.497 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.59 -40.09 98.29 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 79.6 t80 -80.43 131.15 35.55 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 121.094 -0.243 . . . . 0.0 110.495 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 68.1 mm-40 -135.68 144.79 46.18 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-O 120.763 0.316 . . . . 0.0 110.576 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 43.8 tp60 -68.81 131.06 44.53 Favored 'General case' 0 C--N 1.332 -0.179 0 C-N-CA 120.477 -0.489 . . . . 0.0 109.812 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 55.8 p90 . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.607 -179.959 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.85 -39.11 93.45 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.539 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -99.77 112.08 24.36 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.416 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -67.02 140.6 57.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.559 -179.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -61.73 -42.62 99.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.495 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 60.9 t-20 -88.86 109.38 20.15 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.501 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -61.85 -43.25 99.23 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.665 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 2.2 mt 55.42 85.09 0.07 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.322 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 20.3 t -146.23 73.08 13.22 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.303 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . 0.514 ' O ' HG12 ' B' ' 381' ' ' VAL . 32.6 Cg_exo -59.78 144.31 99.47 Favored 'Trans proline' 0 N--CA 1.496 1.667 0 C-N-CA 122.876 2.384 . . . . 0.0 111.988 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt -64.29 -43.48 97.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.099 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.25 -20.26 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.618 -0.264 . . . . 0.0 111.007 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' B' ' 379' ' ' ILE . 10.6 p -59.36 -42.77 88.51 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . 0.495 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -63.14 -40.23 98.9 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -67.95 -35.84 79.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.91 0.386 . . . . 0.0 110.716 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . 0.402 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -60.16 -44.04 95.32 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.683 -179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.51 -40.45 93.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.42 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.17 -37.86 88.71 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.526 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.33 -39.6 97.99 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . 0.402 HG23 ' O ' ' B' ' 384' ' ' ALA . 99.3 t -67.94 -42.13 85.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-O 120.675 0.274 . . . . 0.0 110.4 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 tt -60.0 -40.86 90.68 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.209 -179.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 78.8 mt -64.93 -42.26 94.33 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.913 0.387 . . . . 0.0 110.366 179.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.35 -40.03 89.28 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.516 -179.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 68.9 t -62.06 -41.25 90.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.652 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.48 -41.03 93.36 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.433 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -60.79 -43.99 97.41 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.646 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.78 -37.48 86.44 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.118 179.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -62.49 -44.34 96.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.888 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -62.24 -44.48 96.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.692 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 86.0 mt -63.27 -42.35 96.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.616 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.6 -33.08 85.2 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 54.3 tp -61.79 -40.03 93.76 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.986 -0.286 . . . . 0.0 110.456 -179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 69.0 mttm 55.6 92.39 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.714 -179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -65.02 -42.66 94.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.334 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -81.85 128.0 33.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.453 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -78.58 131.05 36.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.598 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.93 -11.87 59.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.425 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.88 -37.59 94.87 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 79.8 m-85 -108.63 132.17 54.16 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 41.8 tp10 -93.02 119.08 31.89 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 46.7 tp60 -73.11 132.0 42.76 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 120.58 -0.448 . . . . 0.0 109.958 179.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 88.0 t80 . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.85 -1.071 . . . . 0.0 110.512 -179.972 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 50.7 m . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . 48.13 37.04 7.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.076 0.465 . . . . 0.0 110.521 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 87.0 m-20 -61.96 -38.69 89.46 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.357 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -64.62 -37.97 89.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.519 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 63.6 t0 -61.49 -42.15 98.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.384 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 56.1 t30 -83.34 105.97 14.72 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.379 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -94.17 0.72 55.94 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.374 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 58.1 tp -63.23 -42.47 99.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.415 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.63 ' O ' HG13 ' C' ' 377' ' ' VAL . 7.4 p -172.03 77.06 0.48 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.01 -179.528 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_exo -59.52 145.15 98.85 Favored 'Trans proline' 0 C--N 1.302 -1.916 0 C-N-CA 122.564 2.176 . . . . 0.0 112.05 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.445 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.7 mt -63.77 -43.68 98.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.117 -179.592 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -44.43 -19.87 0.03 OUTLIER 'General case' 0 C--O 1.235 0.299 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.8 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.445 ' N ' ' O ' ' C' ' 379' ' ' ILE . 61.3 t -64.28 -43.15 97.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.196 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.13 -42.06 99.67 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.19 85.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.756 0.313 . . . . 0.0 110.777 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.31 -44.96 95.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.796 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.2 -42.08 93.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.547 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.47 87.74 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.514 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.51 99.82 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 80.1 t -66.43 -42.09 89.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.785 0.326 . . . . 0.0 110.336 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -60.74 -40.93 94.25 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.518 -179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 84.9 mt -66.47 -42.06 89.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 120.935 0.397 . . . . 0.0 110.275 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.3 -40.97 87.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.517 -179.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 72.5 t -63.11 -42.06 95.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.726 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -60.9 -41.59 96.36 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.588 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.11 -42.52 99.3 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.565 179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.44 -48.01 75.14 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.099 179.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 93.9 t80 -63.36 -36.34 83.38 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.664 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -57.7 -44.56 85.97 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.492 -179.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 39.7 mm -66.75 -40.45 86.04 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.779 179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.02 -30.31 73.17 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 54.7 tp -63.16 -39.97 96.21 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.494 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -61.83 141.61 57.83 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.488 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 70.0 m80 54.9 92.48 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.589 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -76.03 137.46 40.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.526 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -79.55 129.53 34.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.369 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.47 -11.67 59.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.431 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.33 -38.95 96.55 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.868 -0.893 . . . . 0.0 110.868 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 77.0 t80 -83.43 129.42 34.99 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 179.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -135.47 146.57 48.31 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.277 -0.268 . . . . 0.0 110.277 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.526 ' O ' ' CG ' ' C' ' 410' ' ' PHE . 45.1 tp60 -126.01 120.55 30.59 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.932 0.396 . . . . 0.0 110.186 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . 0.526 ' CG ' ' O ' ' C' ' 409' ' ' GLN . 90.0 m-85 . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.454 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -156.04 154.18 30.61 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.536 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.407 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 37.5 p-10 -86.24 -1.5 57.53 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.36 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.437 ' O ' ' OD1' ' A' ' 372' ' ' ASP . 43.4 p-10 -134.53 106.11 6.86 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.557 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -70.26 140.31 52.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.486 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -63.49 -40.64 97.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.793 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -109.23 101.77 10.77 Favored 'General case' 0 CA--C 1.52 -0.183 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.202 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 42.8 tp -111.51 111.65 22.81 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.152 179.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 10.6 t 39.26 58.64 6.18 Favored Pre-proline 0 N--CA 1.462 0.15 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.68 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -67.04 -19.68 51.31 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.526 2.15 . . . . 0.0 112.124 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt -64.51 -44.46 96.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.981 -179.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.05 -20.03 61.06 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.872 -179.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.4 t -66.4 -43.55 91.14 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.072 0 CA-C-O 120.633 0.254 . . . . 0.0 110.359 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.15 -40.97 97.19 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.98 -39.2 90.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.742 0.306 . . . . 0.0 110.77 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.35 -44.68 96.77 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.651 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.2 mt -65.2 -40.6 94.38 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.386 179.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.77 -37.26 86.71 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.44 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.65 -39.72 97.84 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.4 t -64.03 -42.24 95.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 121.019 0.438 . . . . 0.0 110.21 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.62 -38.09 80.38 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.353 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.99 -42.76 95.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.933 0.396 . . . . 0.0 110.093 179.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.9 mt -61.61 -42.18 98.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.58 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.7 t -66.07 -41.94 90.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.89 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.73 -41.13 97.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.463 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.48 -44.1 97.69 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.347 -0.541 . . . . 0.0 109.688 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.42 -37.37 86.72 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.98 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -61.89 -44.78 96.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.696 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.1 m-85 -62.94 -45.37 92.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.49 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 87.9 mt -64.26 -42.58 95.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.062 179.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.42 -42.8 95.73 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 53.6 tp -63.83 -41.85 97.75 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.781 0.324 . . . . 0.0 110.534 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -66.45 131.93 47.15 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.687 -179.554 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -167.18 134.14 2.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.286 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -107.93 122.91 47.78 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.312 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -81.55 127.88 33.32 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.415 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -76.92 -37.68 54.92 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.678 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.2 -38.34 96.35 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -80.71 133.64 35.72 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -84.86 116.26 23.22 Favored 'General case' 0 C--O 1.232 0.145 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 43.7 tp60 -73.6 134.24 43.66 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 92.2 t80 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.31 -179.902 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 56.2 p . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . 0.536 ' O ' ' N ' ' B' ' 372' ' ' ASP . . . -65.04 -37.68 88.39 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.496 179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 65.8 t0 46.48 -87.69 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.685 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' B' ' 370' ' ' ALA . 57.2 t0 -90.37 113.49 25.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.447 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' B' ' 373' ' ' ASP . 44.2 p-10 -90.46 107.07 18.92 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.402 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 51.6 p30 -89.48 162.45 15.71 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.265 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -111.26 101.11 9.63 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 120.925 0.393 . . . . 0.0 110.329 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 34.5 mt -105.26 -1.04 25.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.475 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.433 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 4.1 t -129.32 55.08 16.35 Favored Pre-proline 0 C--N 1.331 -0.205 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.328 179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . 0.433 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 36.0 Cg_endo -66.11 -18.47 56.52 Favored 'Trans proline' 0 C--N 1.308 -1.561 0 C-N-CA 122.606 2.204 . . . . 0.0 111.999 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.9 mt -64.19 -44.57 97.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.049 -179.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -72.2 -20.44 61.57 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.742 -0.208 . . . . 0.0 110.652 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 60.3 t -66.89 -43.39 89.52 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 120.658 0.266 . . . . 0.0 110.414 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.1 -39.55 98.13 Favored Glycine 0 CA--C 1.523 0.553 0 N-CA-C 110.956 -0.858 . . . . 0.0 110.956 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.04 -41.61 96.91 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.782 0.325 . . . . 0.0 110.474 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.86 -35.38 80.44 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.511 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . 0.65 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.0 tt -61.41 -44.29 97.4 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.295 -0.412 . . . . 0.0 109.92 -179.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.98 -36.91 85.1 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.567 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.45 -39.48 97.35 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.67 -42.36 94.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.922 0.392 . . . . 0.0 110.191 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . 0.581 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.3 tt -59.63 -38.32 81.05 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.263 -179.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.11 -42.16 94.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.853 0.359 . . . . 0.0 110.207 179.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -61.09 -41.03 95.9 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.625 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 86.3 t -63.5 -41.07 91.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.665 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.31 -41.44 96.99 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.503 -179.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.74 -42.7 99.31 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.325 -0.55 . . . . 0.0 109.551 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.89 75.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.824 -0.625 . . . . 0.0 109.833 179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 94.2 t80 -65.0 -35.59 81.69 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.431 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 21.9 t80 -57.53 -45.94 84.45 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.273 -179.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.04 -42.3 95.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.128 179.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.89 -37.08 94.31 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 44.8 tp -62.96 -41.64 99.59 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.438 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . 0.407 ' O ' ' O ' ' B' ' 402' ' ' HIS . 62.5 tttp 59.13 80.1 0.2 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.654 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . 0.486 ' CG ' ' N ' ' B' ' 403' ' ' HIS . 56.5 t-80 55.42 163.87 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.632 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . 0.486 ' N ' ' CG ' ' B' ' 402' ' ' HIS . 80.6 m80 -74.52 139.98 44.18 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.577 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . 0.571 ' ND1' ' N ' ' B' ' 404' ' ' HIS . 0.0 OUTLIER -70.03 142.51 52.74 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.579 179.99 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.14 -12.71 59.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.535 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.19 -37.95 95.73 Favored Glycine 0 CA--C 1.523 0.545 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 87.2 t80 -77.92 133.15 38.13 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.566 0.222 . . . . 0.0 110.428 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -135.41 147.1 48.89 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.718 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 44.1 tp60 -66.87 128.48 36.49 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 91.1 t80 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.07 -0.966 . . . . 0.0 110.607 -179.89 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 85.5 p . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.5 152.11 25.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.539 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -88.58 -2.89 58.84 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.318 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' C' ' 373' ' ' ASP . 40.2 p-10 -64.84 -35.7 81.96 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.788 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . 0.52 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 95.8 m-20 -62.8 -39.93 95.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.483 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 64.1 t30 58.96 51.01 7.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.684 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . 0.46 ' CE2' ' CB ' ' C' ' 373' ' ' ASP . 73.7 m-85 -60.63 -43.34 97.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.631 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 5.0 tp -94.17 133.27 37.85 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.298 -179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.477 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 3.3 t 65.59 51.79 0.87 Allowed Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.421 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.498 ' O ' HG12 ' C' ' 381' ' ' VAL . 36.4 Cg_endo -65.05 151.44 85.75 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.912 2.408 . . . . 0.0 111.877 179.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.519 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.2 mt -63.53 -43.55 98.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.718 -179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.63 -19.79 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.766 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.519 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.3 p -60.88 -43.06 94.9 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-O 120.62 0.248 . . . . 0.0 110.474 -179.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . 0.511 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -62.51 -45.53 95.68 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 179.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.01 -37.2 85.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.79 0.329 . . . . 0.0 110.719 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.22 -43.66 98.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.654 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.82 -41.14 92.18 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.485 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.86 -39.38 94.21 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.452 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.81 -41.11 98.96 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -66.0 -42.73 92.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.801 0.334 . . . . 0.0 110.645 179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.595 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.8 tt -59.59 -41.39 90.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.088 -179.082 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.0 mt -65.43 -42.08 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.9 0.381 . . . . 0.0 110.367 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.7 mt -60.45 -40.86 92.66 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.534 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 77.5 t -64.06 -41.41 92.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.685 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.09 -41.43 96.65 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.487 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 7.1 tt -61.74 -41.94 98.31 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.87 -48.93 74.69 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.763 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -63.69 -36.27 83.31 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.483 179.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -57.64 -45.32 85.61 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.269 -179.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.57 -42.29 95.6 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.094 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.64 -34.04 88.86 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 49.6 tp -62.09 -41.92 98.69 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.811 0.339 . . . . 0.0 110.407 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 66.0 tttm 53.81 95.9 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.575 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 57.1 p-80 -77.38 132.23 38.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.361 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -77.66 136.1 38.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.577 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -78.57 140.22 38.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.416 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.53 -11.9 59.9 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.411 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.18 -37.57 94.73 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 83.6 m-85 -109.65 136.67 48.63 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 110.255 -0.276 . . . . 0.0 110.255 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -88.4 117.64 27.47 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 45.0 tp60 -70.85 130.4 41.56 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 94.5 t80 . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.444 179.973 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 45.95 41.93 8.65 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.564 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.42 ' OD1' ' N ' ' A' ' 371' ' ' ASP . 32.9 p-10 -88.41 111.79 22.17 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.426 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.403 ' O ' ' OD1' ' A' ' 372' ' ' ASP . 62.5 t0 -62.9 -35.88 81.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.585 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -92.52 110.95 22.38 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.463 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -62.67 -40.96 98.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.644 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -114.95 101.98 9.54 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.23 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 34.2 tp -115.6 134.0 55.48 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.041 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 16.4 t -117.8 81.37 15.21 Favored Pre-proline 0 N--CA 1.466 0.341 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.637 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.55 -10.94 17.26 Favored 'Trans proline' 0 N--CA 1.491 1.329 0 C-N-CA 122.381 2.054 . . . . 0.0 112.362 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.467 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -63.77 -43.54 97.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.974 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.87 -19.62 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.545 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.467 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.2 t -64.83 -43.4 96.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.446 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.78 -36.72 93.68 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.66 -40.86 98.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.875 0.369 . . . . 0.0 110.408 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.63 -36.47 83.78 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.633 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.653 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.0 tt -61.42 -44.04 97.82 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.992 0.425 . . . . 0.0 109.925 -179.441 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.82 -37.06 85.24 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.447 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.56 -39.32 97.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.2 t -65.99 -42.0 90.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.115 0.483 . . . . 0.0 110.243 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.3 tt -59.55 -41.01 89.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.595 -179.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.8 mt -67.75 -41.63 85.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.053 0.454 . . . . 0.0 110.387 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.03 -41.23 91.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.636 -179.423 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 76.8 t -64.3 -41.81 93.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.796 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.39 -41.52 97.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.497 -179.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.72 -42.08 98.48 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.1 -48.52 75.99 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.537 179.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -64.89 -36.5 84.56 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.373 179.176 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -57.26 -45.65 83.81 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.182 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.8 mt -63.7 -42.59 96.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.63 -37.17 94.33 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 43.7 tp -62.85 -42.07 99.6 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.812 0.339 . . . . 0.0 110.553 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 38.4 ttmt -65.95 136.42 56.06 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.734 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 63.6 t-80 46.79 87.74 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.526 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -69.87 141.82 53.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.567 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.9 m-70 -75.96 137.12 40.11 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.583 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.21 -13.12 60.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.625 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.26 -36.98 94.15 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -78.46 132.39 37.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.716 0.293 . . . . 0.0 110.537 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.505 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.5 mp0 -104.12 125.14 50.2 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.463 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.487 ' N ' ' CD ' ' A' ' 409' ' ' GLN . 1.9 pm0 -63.84 135.4 56.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.224 179.73 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . 0.438 ' OXT' ' CG ' ' A' ' 410' ' ' PHE . 91.7 t80 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.014 -0.993 . . . . 0.0 110.323 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 46.3 t . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.81 -38.14 89.98 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.488 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -93.96 110.43 22.11 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.364 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -70.25 141.5 52.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.634 -179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -65.8 138.16 57.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.618 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . 0.505 ' O ' ' N ' ' B' ' 378' ' ' PRO . 95.2 m-20 -64.27 -39.82 94.72 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.718 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -59.72 -46.57 88.69 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.737 -179.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . 0.492 ' N ' HD12 ' B' ' 376' ' ' LEU . 9.8 mp -64.6 -40.32 95.3 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.449 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 3.3 m -144.0 75.35 15.81 Favored Pre-proline 0 CA--C 1.531 0.221 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.389 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . 0.505 ' N ' ' O ' ' B' ' 374' ' ' ASN . 57.7 Cg_endo -75.36 -11.17 20.85 Favored 'Trans proline' 0 C--N 1.312 -1.377 0 C-N-CA 122.571 2.181 . . . . 0.0 112.156 -179.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.521 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.5 mt -63.6 -43.65 98.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.914 -179.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.13 -19.77 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 121.013 -0.275 . . . . 0.0 110.651 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.521 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.2 t -64.31 -43.71 97.19 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.157 0 C-N-CA 120.943 -0.303 . . . . 0.0 110.41 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.69 -38.43 96.21 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.15 -41.14 97.99 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.912 0.387 . . . . 0.0 110.404 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.55 -36.24 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.511 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . 0.643 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.6 tt -61.5 -44.43 97.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.02 0.438 . . . . 0.0 110.021 -179.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.81 82.76 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.392 179.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.15 -37.72 95.37 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.68 -41.99 93.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.991 0.424 . . . . 0.0 110.075 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . 0.579 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.1 tt -60.57 -38.1 83.48 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.224 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -63.87 -42.12 94.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-O 120.822 0.344 . . . . 0.0 110.201 179.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.86 -40.38 92.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.471 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 92.9 t -63.86 -40.92 90.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.822 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.32 -41.15 96.54 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.394 -179.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.46 -42.18 98.37 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.21 -46.19 89.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.772 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -63.62 -37.68 88.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.357 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.52 -45.96 84.39 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.243 -179.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.2 mt -63.52 -42.4 96.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.194 179.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.75 -24.62 62.55 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . 0.531 HD13 ' O ' ' B' ' 400' ' ' LEU . 0.2 OUTLIER -62.63 -41.88 99.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.893 0.378 . . . . 0.0 110.039 -179.465 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -70.11 152.04 44.78 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.506 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 55.1 t-80 45.83 92.87 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.579 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 81.1 t60 -78.67 128.2 33.13 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.282 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -76.27 137.58 40.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.515 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.85 -11.67 60.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.644 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.05 -36.86 94.04 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 83.6 t80 -84.86 132.16 34.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.727 0.298 . . . . 0.0 110.419 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -81.72 119.56 24.01 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.193 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.594 ' NE2' ' N ' ' B' ' 410' ' ' PHE . 38.2 tp60 -66.43 133.35 50.25 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 109.954 -0.387 . . . . 0.0 109.954 179.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . 0.594 ' N ' ' NE2' ' B' ' 409' ' ' GLN . 88.3 t80 . . . . . 0 C--O 1.219 -0.539 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.515 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 1.5 t . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . 0.438 ' O ' ' OD1' ' C' ' 373' ' ' ASP . . . -69.42 140.1 54.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.653 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -64.15 -35.23 80.09 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.297 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.437 ' OD1' ' O ' ' C' ' 372' ' ' ASP . 66.3 t0 -61.87 -35.55 78.62 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.585 -179.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' C' ' 370' ' ' ALA . 99.5 m-20 56.8 34.33 24.51 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.475 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 58.6 t-20 -87.0 105.41 17.12 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.375 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -113.98 103.43 11.15 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.182 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 86.1 mt -130.4 139.39 50.62 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.412 179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.638 ' O ' HG13 ' C' ' 377' ' ' VAL . 12.6 p -171.05 62.64 0.38 Allowed Pre-proline 0 C--N 1.331 -0.215 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.365 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -74.65 89.08 1.14 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.557 2.171 . . . . 0.0 111.823 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 37.9 mm -76.68 -70.43 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.777 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -80.17 -19.73 46.47 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.528 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 52.4 t -65.4 -43.37 94.73 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.171 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.292 -179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.62 -41.62 99.61 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -38.07 88.9 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.743 0.306 . . . . 0.0 110.643 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.16 -43.91 96.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.674 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -66.0 -40.7 91.36 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.497 179.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.19 -38.95 91.06 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.549 -179.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.05 -39.35 97.14 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.8 t -64.06 -42.52 95.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 0.0 110.457 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.647 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.5 tt -60.26 -38.37 83.3 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.772 -179.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.03 -42.48 95.8 Favored 'Isoleucine or valine' 0 C--O 1.232 0.165 0 CA-C-O 120.846 0.355 . . . . 0.0 110.052 179.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.1 mt -61.18 -40.41 93.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.436 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.6 -41.08 91.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.742 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.27 -41.27 96.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.435 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.5 -42.24 98.5 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.07 -47.96 81.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.916 -0.583 . . . . 0.0 109.832 179.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -63.12 -35.82 81.54 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.217 179.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -59.1 -45.26 91.33 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.321 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.1 mt -63.15 -42.5 96.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.244 179.445 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.71 -37.4 94.31 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 49.0 tp -62.89 -42.18 99.68 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.368 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 52.8 tttp 54.1 103.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.441 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -75.59 129.33 37.02 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.103 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 33.3 p80 -127.63 142.96 51.21 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.432 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -75.64 139.63 42.12 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.485 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.37 -12.02 59.91 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.695 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.01 -37.11 94.43 Favored Glycine 0 CA--C 1.523 0.571 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 79.4 t80 -78.14 132.41 37.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.773 0.321 . . . . 0.0 110.488 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -87.18 117.36 25.87 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 120.772 0.32 . . . . 0.0 110.278 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -52.94 142.24 19.99 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.011 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 89.4 t80 . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.773 179.997 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 65.2 p . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.32 151.53 29.19 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.546 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.505 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 36.7 p-10 -66.29 -36.0 81.84 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.553 179.852 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.505 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 68.3 t0 -91.53 111.99 23.73 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.542 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 52.4 p30 -79.31 166.34 22.21 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.458 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -94.21 6.38 48.79 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.522 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -115.78 102.78 10.03 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.319 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.576 HD12 ' N ' ' A' ' 376' ' ' LEU . 9.9 mp -95.55 131.48 41.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.162 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.483 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 14.7 m -149.36 52.74 1.17 Allowed Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.344 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.483 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 26.0 Cg_endo -62.81 -23.24 74.36 Favored 'Trans proline' 0 N--CA 1.496 1.648 0 C-N-CA 122.733 2.288 . . . . 0.0 111.844 179.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.8 mm -66.92 -44.83 88.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.57 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.4 -20.26 62.95 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.804 -179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.37 -42.32 90.35 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 CA-C-N 116.362 -0.381 . . . . 0.0 109.992 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.52 -40.17 98.33 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.681 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.15 -38.21 90.25 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.74 0.305 . . . . 0.0 110.743 179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.7 -45.7 91.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.671 -179.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.28 -41.57 94.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.511 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.35 -38.17 90.09 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.293 -179.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.6 -41.79 99.77 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.7 t -67.11 -42.36 88.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.823 0.344 . . . . 0.0 110.159 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.626 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.8 tt -60.0 -40.8 90.44 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 115.65 -0.704 . . . . 0.0 110.3 -179.021 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.7 mt -66.42 -41.75 89.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 120.959 0.409 . . . . 0.0 110.351 178.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.0 mt -60.54 -40.55 91.95 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.579 -179.292 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.4 t -64.33 -41.15 91.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.752 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.93 -41.57 98.09 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.537 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.41 -42.49 99.48 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 120.242 -0.583 . . . . 0.0 109.476 179.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.09 -48.95 72.85 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.981 179.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -64.13 -35.79 81.91 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.422 179.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -57.38 -45.8 84.07 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.282 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.2 mt -64.89 -42.43 94.81 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.48 -33.69 87.92 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.8 tp -61.33 -40.81 95.59 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.411 -179.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 57.17 45.19 21.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.796 -179.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.48 ' CE1' ' O ' ' A' ' 403' ' ' HIS . 39.7 t-80 -70.45 124.61 24.63 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.194 179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . 0.48 ' O ' ' CE1' ' A' ' 402' ' ' HIS . 99.4 m-70 -78.4 142.52 37.55 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.547 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -78.47 142.49 37.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.506 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.36 -14.07 59.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.537 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.59 -40.58 96.09 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -109.42 133.47 53.03 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 110.269 -0.271 . . . . 0.0 110.269 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 55.3 mp0 -106.73 123.97 48.92 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 120.893 0.378 . . . . 0.0 110.064 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.621 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 0.4 OUTLIER -52.86 146.21 11.14 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . 0.498 ' CG ' ' O ' ' A' ' 410' ' ' PHE . 91.1 t80 . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.111 -0.947 . . . . 0.0 110.38 -179.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 6.5 t . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.0 -38.16 90.03 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.449 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 55.0 t0 55.06 33.36 20.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.554 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -68.9 141.88 54.91 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.629 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -61.66 -41.33 97.38 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.457 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . 0.429 ' ND2' ' O ' ' B' ' 377' ' ' VAL . 63.9 t30 59.79 39.19 21.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.693 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 92.4 t80 -65.26 -23.52 67.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.469 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 46.6 tp -64.51 -43.75 93.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.463 -179.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.429 ' O ' ' ND2' ' B' ' 374' ' ' ASN . 0.9 OUTLIER -148.15 69.25 10.68 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.239 -179.449 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -74.95 -16.17 20.48 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.717 2.278 . . . . 0.0 112.025 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.507 ' O ' ' N ' ' B' ' 381' ' ' VAL . 96.9 mt -63.36 -43.88 98.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.315 -178.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.14 -20.1 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.752 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.507 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.38 -43.9 94.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 120.904 0.383 . . . . 0.0 110.178 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -65.73 -35.77 91.42 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.23 -41.86 98.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.861 0.363 . . . . 0.0 110.662 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.06 -36.4 84.22 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.45 179.715 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . 0.646 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.3 tt -61.23 -44.47 97.2 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.922 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.23 83.65 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.548 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.74 -41.09 97.37 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 62.1 t -67.24 -43.35 88.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.668 0.27 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.29 -40.37 93.91 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 119.536 -0.866 . . . . 0.0 109.771 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 79.2 mt -64.04 -42.4 95.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 120.872 0.368 . . . . 0.0 110.572 178.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.08 -41.4 96.59 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.588 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.6 t -65.94 -42.33 91.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.076 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.3 mt -61.67 -40.47 95.08 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.4 -179.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.18 -42.94 99.75 Favored 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.204 -0.598 . . . . 0.0 109.588 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.74 -36.82 84.66 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.157 179.395 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.1 t80 -60.36 -44.38 95.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.601 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.0 -43.79 98.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.61 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 91.2 mt -63.55 -42.61 96.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.717 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.98 -34.28 89.46 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 52.5 tp -62.26 -39.65 93.61 Favored 'General case' 0 C--N 1.327 -0.378 0 C-N-CA 121.006 -0.277 . . . . 0.0 110.397 -179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . 0.437 ' O ' ' O ' ' B' ' 402' ' ' HIS . 99.2 mttt 56.91 103.73 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.596 -179.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . 0.437 ' O ' ' O ' ' B' ' 401' ' ' LYS . 78.9 m80 55.48 160.61 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.548 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -73.96 141.25 45.92 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.498 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 45.6 t60 -78.24 131.37 37.09 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.474 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.52 -12.67 59.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.538 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.45 -36.09 92.92 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 73.9 m-85 -103.02 135.1 45.32 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.325 -0.25 . . . . 0.0 110.325 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.42 148.61 49.37 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 120.718 0.294 . . . . 0.0 110.514 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.53 ' OE1' ' N ' ' B' ' 410' ' ' PHE . 3.9 tp-100 -74.02 123.7 24.85 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.476 -0.49 . . . . 0.0 109.795 179.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . 0.53 ' N ' ' OE1' ' B' ' 409' ' ' GLN . 96.5 m-85 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.11 -0.948 . . . . 0.0 110.618 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -61.78 -39.09 90.47 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.397 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.79 33.09 18.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.435 179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -62.31 -38.48 89.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.44 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -65.79 141.58 58.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.573 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . 0.489 ' C ' ' H ' ' C' ' 376' ' ' LEU . 10.0 m120 -91.21 6.75 43.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.44 -179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 49.48 10.77 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.668 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . 0.489 ' H ' ' C ' ' C' ' 374' ' ' ASN . 99.4 mt -137.46 105.38 5.64 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.263 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.651 ' O ' HG13 ' C' ' 377' ' ' VAL . 9.0 p -174.94 74.28 0.3 Allowed Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.198 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.536 ' O ' HG12 ' C' ' 381' ' ' VAL . 29.7 Cg_exo -60.55 143.5 99.44 Favored 'Trans proline' 0 C--N 1.302 -1.913 0 C-N-CA 122.709 2.273 . . . . 0.0 112.033 179.885 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.0 mt -64.84 -43.69 96.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.234 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.42 -20.02 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.816 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.536 HG12 ' O ' ' C' ' 378' ' ' PRO . 7.9 p -61.82 -42.72 95.63 Favored 'Isoleucine or valine' 0 C--O 1.233 0.22 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . 0.486 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -64.46 -42.15 97.69 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.19 86.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.86 0.362 . . . . 0.0 110.787 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.56 -45.34 94.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.676 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.7 mt -64.5 -40.43 95.64 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.433 179.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.93 -37.26 87.05 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.466 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.95 -40.2 97.02 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.332 -0.707 . . . . 0.0 111.332 -179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.98 -43.27 96.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.926 0.394 . . . . 0.0 110.318 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.8 -38.59 88.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.17 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.86 -42.09 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.9 mt -61.41 -41.68 97.54 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.573 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 90.2 t -65.73 -42.24 92.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.825 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -61.51 -41.82 97.88 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.625 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.9 tt -62.27 -43.55 98.56 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.66 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.58 -36.42 82.59 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.484 -0.78 . . . . 0.0 110.108 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -61.12 -44.96 96.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.805 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -62.47 -43.69 98.2 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.645 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.4 mt -64.92 -42.69 95.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.997 -0.547 . . . . 0.0 109.882 179.472 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.47 -39.65 97.93 Favored Glycine 0 CA--C 1.52 0.376 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . 0.522 ' O ' ' CD2' ' C' ' 403' ' ' HIS . 57.4 tp -62.81 -41.16 99.18 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 120.876 -0.329 . . . . 0.0 110.418 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 49.9 tttm 44.56 19.43 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.681 -179.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . 0.45 ' N ' ' O ' ' C' ' 400' ' ' LEU . 98.1 m-70 43.47 90.53 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.553 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . 0.522 ' CD2' ' O ' ' C' ' 400' ' ' LEU . 96.3 m-70 -102.32 127.8 49.15 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.479 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -80.43 144.2 32.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.475 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.0 -35.1 57.39 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.508 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.02 -35.09 91.62 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 53.6 t80 -81.49 134.65 35.56 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 121.059 -0.256 . . . . 0.0 110.381 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . 0.517 ' OE1' ' N ' ' C' ' 408' ' ' GLU . 56.6 mp0 -109.71 129.18 55.63 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-O 120.863 0.363 . . . . 0.0 110.316 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.526 ' OE1' ' N ' ' C' ' 410' ' ' PHE . 3.8 tp-100 -70.54 120.97 16.95 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.575 -0.45 . . . . 0.0 109.883 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . 0.526 ' N ' ' OE1' ' C' ' 409' ' ' GLN . 89.1 t80 . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.605 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 84.1 p . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -159.93 153.21 22.09 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.6 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -60.58 -43.96 96.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.33 -179.779 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -62.91 -37.27 86.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.529 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -86.8 113.44 22.62 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.493 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -95.5 143.44 26.82 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.32 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -59.61 -45.63 91.36 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.465 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 34.6 mt -119.88 125.42 48.45 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.474 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.645 ' O ' HG22 ' A' ' 377' ' ' VAL . 7.5 p -173.42 48.79 0.08 OUTLIER Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.385 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 21.8 Cg_endo -60.7 143.43 99.4 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 C-N-CA 122.669 2.246 . . . . 0.0 111.872 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt -64.44 -43.39 96.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.847 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.87 -20.48 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.554 -0.293 . . . . 0.0 110.657 -179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' A' ' 379' ' ' ILE . 43.6 t -67.97 -43.62 85.54 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.103 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.413 179.144 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 379' ' ' ILE . . . -64.96 -38.15 95.13 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.94 98.46 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.713 0.292 . . . . 0.0 110.743 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.76 -48.07 82.35 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.92 0.391 . . . . 0.0 110.565 -179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.6 -40.95 93.22 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.37 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.51 -39.14 89.91 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.232 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.56 -37.57 94.97 Favored Glycine 0 CA--C 1.529 0.939 0 N-CA-C 111.241 -0.743 . . . . 0.0 111.241 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.0 t -63.74 -43.14 97.89 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.989 0.423 . . . . 0.0 110.243 179.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.4 mp -61.89 -38.0 86.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.345 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 28.9 mm -63.13 -42.13 95.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -61.16 -42.47 98.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.569 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 84.3 t -65.62 -42.17 92.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.983 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.94 -40.62 96.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.596 -179.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -60.88 -41.89 96.89 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.95 -49.47 73.43 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.877 179.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -65.72 -35.41 80.66 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.329 179.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . 0.487 ' CE2' ' CE1' ' A' ' 402' ' ' HIS . 24.4 t80 -58.0 -45.8 86.26 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.308 -179.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.04 -42.94 97.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.206 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.231 179.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.84 -41.83 98.66 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.405 HD23 ' CE1' ' A' ' 402' ' ' HIS . 52.4 tp -62.75 -41.03 99.02 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.302 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 62.4 tttp 58.54 94.0 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.549 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.487 ' CE1' ' CE2' ' A' ' 397' ' ' PHE . 77.8 m80 -76.73 135.47 39.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.369 179.73 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -78.88 128.36 33.23 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.316 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.9 m-70 -77.18 139.84 40.02 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.539 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.56 -14.21 59.71 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.518 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.36 -40.26 96.34 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -105.39 133.65 49.8 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.919 0.39 . . . . 0.0 110.15 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -135.32 145.29 47.32 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.71 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -52.77 142.55 18.54 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.427 179.841 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 19.4 p . . . . . 0 N--CA 1.489 1.509 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . 51.97 100.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.45 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -100.0 111.54 23.84 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.337 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 37.8 p30 -71.63 -10.15 59.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.623 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -63.1 -43.63 97.93 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.652 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -156.32 167.99 28.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.263 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 89.0 t80 -138.19 111.92 8.28 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.082 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 49.4 tp -107.9 129.28 55.1 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 120.967 0.413 . . . . 0.0 110.256 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 1.4 m -43.87 151.89 0.49 Allowed Pre-proline 0 CA--C 1.535 0.402 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.765 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -65.51 152.3 82.29 Favored 'Trans proline' 0 N--CA 1.497 1.689 0 C-N-CA 122.536 2.158 . . . . 0.0 111.954 179.566 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.556 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.2 mt -63.31 -42.85 97.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.797 -179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -39.93 -20.6 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.665 -179.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.556 ' N ' ' O ' ' B' ' 379' ' ' ILE . 53.4 t -67.23 -43.8 88.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.156 0 CA-C-O 120.659 0.266 . . . . 0.0 110.567 179.121 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' B' ' 379' ' ' ILE . . . -65.26 -37.74 94.32 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.1 -38.53 91.54 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.788 0.327 . . . . 0.0 110.66 -179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.28 -48.05 79.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.848 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.54 -41.6 92.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.429 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.84 -36.98 85.02 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.327 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.62 -40.09 98.26 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 77.9 t -63.2 -43.46 98.81 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.975 0.417 . . . . 0.0 110.244 179.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.2 -38.01 87.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.361 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 5.9 mm -62.77 -42.15 95.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 9.4 mt -60.84 -42.63 98.15 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.557 -179.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -65.62 -42.31 92.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.852 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.56 -41.4 97.33 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.374 -179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -61.97 -42.44 99.13 Favored 'General case' 0 C--N 1.322 -0.608 0 C-N-CA 120.288 -0.565 . . . . 0.0 109.546 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -61.59 -38.16 86.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.017 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . 0.553 ' CZ ' HD11 ' B' ' 400' ' ' LEU . 91.3 t80 -62.13 -44.8 95.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.477 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -68.43 -45.54 72.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.866 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.1 mm -64.11 -42.03 94.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.068 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.85 -42.37 96.59 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . 0.553 HD11 ' CZ ' ' B' ' 396' ' ' TYR . 9.8 mt -64.68 -40.78 95.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.955 0.407 . . . . 0.0 110.535 179.503 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -67.71 -3.26 8.68 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.691 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 83.6 t60 -58.24 -44.27 88.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.519 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . 0.5 ' CE1' ' O ' ' B' ' 400' ' ' LEU . 52.7 p-80 -92.57 119.13 31.72 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.223 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -82.65 132.0 35.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.542 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.12 -12.7 60.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.442 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.02 -37.46 95.0 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 83.7 t80 -81.81 131.78 35.27 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.816 0.341 . . . . 0.0 110.341 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -135.41 148.44 49.33 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.544 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.413 ' NE2' ' N ' ' B' ' 410' ' ' PHE . 44.5 tp60 -101.02 129.14 46.82 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.887 0.375 . . . . 0.0 110.263 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . 0.413 ' N ' ' NE2' ' B' ' 409' ' ' GLN . 88.7 t80 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.585 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 33.4 t . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . 0.443 ' O ' ' OD1' ' C' ' 374' ' ' ASN . . . -155.03 156.91 36.78 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.547 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 40.1 p-10 -65.49 -35.42 80.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.532 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.512 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 54.7 p-10 -80.62 150.81 29.33 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.522 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 98.3 m-20 55.17 49.13 17.99 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.464 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . 0.481 ' ND2' ' O ' ' C' ' 371' ' ' ASP . 99.2 m-20 -75.27 138.51 41.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.652 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -62.19 -44.06 97.43 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.603 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 89.8 mt -133.38 145.63 50.52 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.493 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 1.5 m -49.71 155.33 1.46 Allowed Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.927 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.457 ' HB2' HG23 ' C' ' 381' ' ' VAL . 50.8 Cg_exo -48.48 147.6 8.95 Favored 'Trans proline' 0 N--CA 1.496 1.672 0 C-N-CA 122.227 1.951 . . . . 0.0 112.419 178.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt -65.52 -43.56 94.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.085 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -58.44 -24.65 60.76 Favored 'General case' 0 CA--C 1.534 0.348 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.653 -179.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.457 HG23 ' HB2' ' C' ' 378' ' ' PRO . 56.0 t -68.86 -43.55 82.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.094 0 CA-C-O 120.73 0.3 . . . . 0.0 110.585 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.17 -36.17 92.9 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.58 -40.15 95.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.718 0.294 . . . . 0.0 110.751 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . 0.402 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -60.82 -48.59 81.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.8 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -64.97 -40.86 95.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.47 179.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.11 -37.74 86.27 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.422 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.11 -38.01 94.81 Favored Glycine 0 CA--C 1.53 0.987 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . 0.402 HG23 ' O ' ' C' ' 384' ' ' ALA . 98.3 t -65.03 -43.17 96.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-O 120.75 0.309 . . . . 0.0 110.539 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 mp -61.36 -39.39 90.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.042 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.3 mm -64.12 -42.42 95.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.073 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -61.11 -41.76 97.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.529 -179.621 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 75.6 t -65.43 -41.6 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.9 mt -61.53 -40.44 94.66 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.439 -179.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.42 -42.06 98.15 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.25 -48.47 76.48 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.725 179.477 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 92.0 t80 -64.59 -35.88 82.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.373 179.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -57.67 -45.12 85.99 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.275 -179.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 90.8 mt -63.81 -42.65 96.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.117 179.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.93 -39.27 97.84 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 54.7 tp -63.72 -42.37 97.92 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.529 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -73.95 132.83 42.83 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.744 -179.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -76.71 138.67 40.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.293 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -80.36 139.6 36.47 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.493 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -106.42 127.35 53.22 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.251 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.0 -37.57 54.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.413 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.28 -39.52 97.95 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 80.8 m-85 -107.75 133.76 51.68 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 46.1 tp10 -90.75 118.41 30.15 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.007 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 8.4 pt20 -52.83 140.6 23.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.051 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 88.1 t80 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.443 179.891 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 13.1 m . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.85 152.69 30.1 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.605 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.544 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 40.2 p-10 -65.09 -37.4 87.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.507 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.544 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 99.6 m-20 -67.5 142.47 56.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.609 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -68.66 143.42 54.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.59 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.409 ' O ' ' OD1' ' A' ' 374' ' ' ASN . 48.8 t-20 -62.34 -39.87 94.53 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.582 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -60.33 -42.13 94.98 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.595 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.574 ' N ' HD22 ' A' ' 376' ' ' LEU . 3.2 mm? -80.5 140.41 35.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.722 -179.463 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 1.5 m -70.55 155.12 93.88 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.827 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.507 ' O ' HG12 ' A' ' 381' ' ' VAL . 53.0 Cg_exo -49.53 137.57 32.56 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.252 1.968 . . . . 0.0 112.119 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 381' ' ' VAL . 94.9 mt -63.73 -43.15 97.91 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.205 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.008 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.48 -19.81 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.457 0 CA-C-N 116.487 -0.324 . . . . 0.0 110.962 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.526 ' N ' ' O ' ' A' ' 379' ' ' ILE . 7.8 p -60.53 -43.65 94.87 Favored 'Isoleucine or valine' 0 C--O 1.232 0.134 0 CA-C-O 120.749 0.309 . . . . 0.0 110.41 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.52 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -64.81 -36.45 93.12 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -41.3 98.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.738 0.304 . . . . 0.0 110.669 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.36 -36.24 83.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.612 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.623 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.4 tt -61.65 -45.31 94.58 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.056 0.455 . . . . 0.0 110.106 -179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -65.0 -37.7 88.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.401 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -59.5 -42.44 97.64 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.2 t -67.12 -42.49 88.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.738 0.304 . . . . 0.0 110.627 179.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.57 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.9 tt -59.97 -40.99 90.99 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.223 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -65.33 -42.17 93.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.872 0.368 . . . . 0.0 110.234 179.09 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.85 -41.14 95.28 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.685 -179.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 69.1 t -63.88 -41.49 92.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.682 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.5 mt -61.34 -41.02 96.36 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.598 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.46 -41.8 97.79 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 120.295 -0.562 . . . . 0.0 109.545 179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.54 -49.63 74.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.882 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 85.9 t80 -65.01 -34.88 79.5 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.365 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -58.21 -45.56 87.43 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.351 -179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.3 mt -63.63 -42.74 97.1 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.34 -38.53 95.97 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.9 tp -63.38 -41.54 98.79 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.933 -0.307 . . . . 0.0 110.434 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 54.4 tttm 59.1 69.72 0.7 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.601 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.511 ' ND1' ' N ' ' A' ' 403' ' ' HIS . 64.5 t-80 57.86 162.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.455 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . 0.511 ' N ' ' ND1' ' A' ' 402' ' ' HIS . 54.9 t-80 -83.85 126.6 33.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.491 -179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 21.4 t-80 -82.24 132.38 35.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.612 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.22 -11.37 59.81 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.524 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.21 -40.35 98.98 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -81.67 136.22 35.51 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.627 0.251 . . . . 0.0 110.371 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -85.23 117.35 24.12 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.8 0.334 . . . . 0.0 110.345 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.642 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 3.0 pm0 -53.9 145.27 16.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.112 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.5 t80 . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.969 -1.015 . . . . 0.0 110.59 -179.86 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 16.6 t . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.38 144.53 53.39 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.559 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . 0.467 ' OD1' ' N ' ' B' ' 372' ' ' ASP . 35.2 p-10 -64.51 -34.97 79.47 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.422 179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . 0.467 ' N ' ' OD1' ' B' ' 371' ' ' ASP . 52.7 t0 -88.93 111.66 22.38 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.405 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 52.1 p-10 -77.46 167.35 21.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.397 -179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 -94.06 9.34 38.07 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.561 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -129.03 104.63 7.69 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.538 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 90.3 mt -135.86 140.97 44.55 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.175 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 19.7 t -143.31 72.82 17.91 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.415 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_exo -60.86 145.02 99.64 Favored 'Trans proline' 0 N--CA 1.496 1.646 0 C-N-CA 123.01 2.473 . . . . 0.0 111.929 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.496 ' O ' ' N ' ' B' ' 381' ' ' VAL . 97.1 mt -64.27 -44.14 97.3 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 CA-C-N 116.497 -0.319 . . . . 0.0 111.044 -179.627 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.62 -20.06 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 116.407 -0.36 . . . . 0.0 110.682 -179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.496 ' N ' ' O ' ' B' ' 379' ' ' ILE . 62.2 t -65.17 -43.11 95.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.361 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.19 -39.63 98.15 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.45 -40.48 96.75 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.852 0.358 . . . . 0.0 110.513 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.49 -35.48 81.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.512 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . 0.653 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.8 tt -61.41 -44.05 97.81 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 121.1 0.476 . . . . 0.0 109.988 -179.679 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -37.05 85.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.421 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.11 -39.97 96.52 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 59.2 t -65.96 -43.2 92.85 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-O 120.938 0.399 . . . . 0.0 110.218 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 7.8 tt -60.36 -40.67 91.63 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.806 -179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 80.1 mt -67.33 -41.37 86.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.146 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -60.12 -40.93 91.44 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.696 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 75.7 t -63.84 -41.38 92.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.666 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.27 -41.29 96.69 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.521 -179.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -61.4 -42.82 99.33 Favored 'General case' 0 C--N 1.321 -0.673 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.558 179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.25 -47.9 74.76 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.836 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 85.0 t80 -64.36 -34.7 78.75 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.448 179.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -58.57 -44.87 89.91 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.41 -179.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 42.3 mm -65.09 -40.99 90.72 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.154 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.83 179.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -60.55 -34.86 87.59 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 -179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . 0.429 ' O ' ' O ' ' B' ' 401' ' ' LYS . 53.4 tp -62.14 -40.93 97.58 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.781 -0.368 . . . . 0.0 110.458 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' B' ' 400' ' ' LEU . 88.5 tttt 59.76 139.67 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.772 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 70.5 m80 -75.36 137.55 41.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.265 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -82.17 126.13 31.7 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.099 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 70.4 t60 -121.06 124.87 45.87 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.279 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.23 -15.34 58.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.598 -179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -65.6 -36.56 92.59 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 86.6 t80 -78.23 131.72 37.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.755 0.312 . . . . 0.0 110.419 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -135.44 144.97 46.76 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.815 0.34 . . . . 0.0 110.755 179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . . . . . . . . . 7.6 pt20 -52.74 144.0 15.16 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 120.58 -0.448 . . . . 0.0 109.82 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 117.965 -1.016 . . . . 0.0 110.514 179.646 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 9.3 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.58 154.36 28.37 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.613 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 54.71 37.85 29.02 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.46 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' C' ' 374' ' ' ASN . 55.4 t0 -89.24 109.96 20.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.515 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 92.8 m-20 -62.27 -42.05 99.0 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.49 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . 0.513 ' ND2' HG11 ' C' ' 377' ' ' VAL . 20.5 p30 -155.73 162.44 40.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.499 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.78 -59.19 2.58 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.66 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 93.8 mt -136.35 133.54 36.92 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.459 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.513 HG11 ' ND2' ' C' ' 374' ' ' ASN . 18.2 m -152.46 52.16 0.85 Allowed Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.411 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.475 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 36.3 Cg_endo -65.78 -21.59 57.97 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.76 2.307 . . . . 0.0 111.998 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.6 mm -65.69 -44.41 93.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.352 -179.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.95 -20.08 61.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.005 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 54.5 t -65.9 -43.71 92.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 CA-C-O 120.744 0.307 . . . . 0.0 110.344 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.72 -41.86 99.67 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.827 -0.909 . . . . 0.0 110.827 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.04 -36.98 86.09 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.792 0.329 . . . . 0.0 110.713 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.43 -46.04 89.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.672 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -64.7 -41.05 96.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.416 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.23 -37.51 85.67 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.397 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.26 -36.41 92.76 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 96.4 t -64.23 -43.59 97.29 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.159 0 CA-C-O 120.746 0.307 . . . . 0.0 110.458 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.7 mp -61.63 -39.02 89.79 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.222 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.2 mm -64.24 -41.94 93.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 N-CA-C 110.051 -0.352 . . . . 0.0 110.051 179.146 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 8.4 mt -60.76 -42.51 97.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.729 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 82.0 t -65.15 -42.44 94.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.834 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 8.1 mt -61.98 -42.73 99.46 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.731 -179.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -62.08 -43.81 98.03 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.04 -36.86 84.39 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.087 179.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -61.53 -44.59 96.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.67 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -62.73 -45.34 93.17 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.566 -179.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' C' ' 401' ' ' LYS . 87.7 mt -64.55 -42.67 95.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.867 179.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.23 -41.84 96.6 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.026 -0.829 . . . . 0.0 111.026 -179.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 48.4 tp -63.17 -42.18 99.36 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.606 -179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' C' ' 398' ' ' ILE . 68.7 mttm -91.25 143.76 26.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.502 -179.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 66.1 t-80 46.12 94.14 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.647 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 56.8 p-80 -71.91 141.65 49.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.567 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -78.14 125.67 29.69 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.47 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -89.46 -11.13 43.92 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.507 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.92 -39.02 97.52 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -79.03 130.22 35.29 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.792 0.33 . . . . 0.0 110.347 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -135.43 143.86 46.18 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.77 0.319 . . . . 0.0 110.894 179.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 44.0 tp60 -74.7 129.62 38.04 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.537 -0.465 . . . . 0.0 109.914 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 94.1 t80 . . . . . 0 C--N 1.326 -0.44 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.466 179.996 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.4 t . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.88 154.6 32.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.41 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -105.74 106.9 17.61 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.368 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.534 ' OD1' ' N ' ' A' ' 373' ' ' ASP . 42.4 p-10 -63.68 -34.85 78.76 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.62 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.534 ' N ' ' OD1' ' A' ' 372' ' ' ASP . 53.9 t0 -89.35 109.25 20.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.214 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 53.6 p30 -98.02 8.46 44.72 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.638 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -93.92 1.21 56.37 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.4 179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 47.3 mt -106.89 5.64 28.55 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.383 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.429 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 2.7 t -129.78 54.6 14.94 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.482 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.429 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 36.3 Cg_endo -66.63 -17.57 52.93 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.573 2.182 . . . . 0.0 111.789 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 44.2 mm -66.43 -44.97 90.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.211 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.07 -20.51 63.22 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.784 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.3 t -66.8 -42.98 90.03 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.372 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.24 -37.68 94.94 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -40.24 96.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.871 0.367 . . . . 0.0 110.439 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.8 -36.11 82.83 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.416 179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.616 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.7 tt -62.17 -44.1 97.35 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-O 121.085 0.469 . . . . 0.0 110.018 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.03 -37.07 81.29 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.594 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.82 -39.07 96.99 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 111.111 -0.796 . . . . 0.0 111.111 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 95.5 t -63.63 -42.07 94.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.217 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.56 HD23 ' O ' ' A' ' 389' ' ' LEU . 4.9 tt -60.7 -37.81 82.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.511 -179.519 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.8 mm -64.4 -41.79 93.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.97 0.414 . . . . 0.0 110.196 179.4 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.4 mt -60.75 -40.94 94.31 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.53 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.8 t -64.26 -40.8 90.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.826 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.45 -40.78 95.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.407 -179.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.03 -41.54 96.76 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.41 -48.35 74.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.756 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.7 t80 -65.57 -35.61 81.35 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.602 -0.727 . . . . 0.0 110.488 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -56.78 -45.69 81.98 Favored 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.381 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.2 mt -65.01 -42.27 94.25 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.137 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.63 -33.24 84.33 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.5 tp -61.84 -42.02 98.53 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 120.801 -0.359 . . . . 0.0 110.469 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -84.69 153.25 23.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.693 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.529 ' O ' ' CG ' ' A' ' 402' ' ' HIS . 86.4 t60 49.91 43.72 25.21 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.535 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -79.14 133.78 36.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.351 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -75.11 140.31 43.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.541 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.24 -11.43 59.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.522 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.48 -36.36 93.27 Favored Glycine 0 CA--C 1.529 0.923 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -111.34 138.2 48.12 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.866 0.365 . . . . 0.0 110.304 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.34 145.07 47.04 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.714 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 47.6 tp60 -73.27 130.87 41.16 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.489 -0.485 . . . . 0.0 109.894 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.2 t80 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.045 -0.978 . . . . 0.0 110.25 -179.699 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 4.4 t . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.86 149.75 26.73 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.414 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -99.9 112.3 24.57 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.182 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -88.63 107.01 18.69 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.515 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . 0.41 ' OD1' ' N ' ' B' ' 373' ' ' ASP . 33.2 p-10 -88.38 0.11 56.57 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.374 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 58.0 t-20 -82.21 110.76 17.69 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.343 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -61.19 -43.12 99.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.664 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . 0.597 ' N ' HD12 ' B' ' 376' ' ' LEU . 10.1 mp -90.25 131.66 35.94 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.316 -179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.494 HG22 ' H ' ' B' ' 379' ' ' ILE . 9.2 p -69.81 129.5 91.05 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.824 -179.254 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -70.81 -18.01 32.4 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.115 1.877 . . . . 0.0 112.396 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.494 ' H ' HG22 ' B' ' 377' ' ' VAL . 96.8 mt -63.27 -44.67 99.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 121.019 -0.273 . . . . 0.0 111.267 -178.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . 0.414 ' H ' HG13 ' B' ' 377' ' ' VAL . . . -74.62 -19.99 60.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.616 -0.265 . . . . 0.0 110.763 -179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.8 t -67.09 -43.19 88.94 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.144 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.21 -40.62 97.53 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.63 -37.87 89.04 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.743 0.306 . . . . 0.0 110.659 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -59.88 -46.63 88.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.602 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.68 -41.87 91.95 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.539 179.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.41 -39.05 93.45 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.433 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.8 -42.85 99.66 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 89.5 t -66.51 -43.17 90.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 121.168 -0.213 . . . . 0.0 111.02 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . 0.56 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.0 tt -60.64 -41.27 94.6 Favored 'General case' 0 C--N 1.331 -0.215 0 C-N-CA 120.349 -0.541 . . . . 0.0 109.739 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 82.4 mt -63.87 -42.23 95.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.809 0.338 . . . . 0.0 110.319 178.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.8 -40.09 91.35 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.507 -179.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 77.8 t -63.95 -41.86 93.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.831 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -60.97 -40.8 94.78 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.238 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -61.45 -43.42 98.91 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 120.132 -0.627 . . . . 0.0 109.502 179.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.16 -37.11 86.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.125 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -61.62 -44.86 96.19 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.621 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 36.5 m-85 -63.43 -41.67 98.68 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.578 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 31.3 mm -63.76 -42.16 95.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.013 179.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.22 -58.6 13.7 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . 0.525 ' C ' ' H ' ' B' ' 402' ' ' HIS . 4.0 mm? -64.45 -40.91 96.63 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 121.027 -0.269 . . . . 0.0 110.44 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 47.9 tttp 70.61 -34.52 0.3 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.644 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . 0.525 ' H ' ' C ' ' B' ' 400' ' ' LEU . 49.1 p-80 -152.74 149.24 28.15 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.327 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -84.29 129.72 34.86 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.365 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -71.45 140.78 50.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.541 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.24 -12.01 59.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.586 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.27 -39.31 97.72 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 81.8 t80 -83.12 132.05 35.11 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 110.33 -0.248 . . . . 0.0 110.33 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' B' ' 408' ' ' GLU . 56.3 mp0 -99.01 133.36 43.39 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.267 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.585 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 0.5 OUTLIER -52.85 145.97 11.56 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.007 -179.925 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 93.8 t80 . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.487 -179.734 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 41.4 t . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.29 -39.01 93.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.572 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 48.3 t0 -121.86 110.17 15.55 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.398 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -87.69 114.77 24.62 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.413 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -91.14 107.59 19.3 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.334 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . 0.556 ' O ' ' N ' ' C' ' 376' ' ' LEU . 54.9 p30 -102.86 8.79 39.17 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.536 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 50.47 -83.97 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.727 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . 0.556 ' N ' ' O ' ' C' ' 374' ' ' ASN . 3.8 tp 68.07 1.42 2.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.33 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 3.9 t 61.46 75.31 0.45 Allowed Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.511 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -55.37 -31.44 77.36 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.792 2.328 . . . . 0.0 112.053 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 46.1 mm -64.29 -44.5 97.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.137 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -70.86 -20.34 62.54 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.783 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 63.5 t -67.5 -43.2 87.46 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.121 0 N-CA-C 110.237 -0.283 . . . . 0.0 110.237 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.87 -38.49 96.19 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.862 -0.895 . . . . 0.0 110.862 -179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.83 -40.46 95.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.734 0.302 . . . . 0.0 110.731 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.29 88.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.772 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -64.98 -41.93 94.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.417 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.7 -36.46 83.92 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.346 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.8 -42.21 99.72 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 -179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 94.2 t -64.0 -42.96 97.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-O 120.885 0.374 . . . . 0.0 110.242 179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.585 HD23 ' O ' ' C' ' 389' ' ' LEU . 4.1 tt -60.89 -37.99 84.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.832 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 7.8 mm -63.4 -42.59 96.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.908 0.385 . . . . 0.0 110.138 179.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -61.42 -40.4 94.28 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.414 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 91.0 t -63.01 -40.8 90.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.666 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.95 -41.24 95.91 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.435 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.48 -43.5 98.75 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.524 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.5 -37.39 84.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.13 179.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -60.17 -43.96 95.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.535 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -62.65 -45.22 93.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.492 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.9 -42.87 97.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 0.0 109.976 179.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.22 -34.89 90.79 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . 0.561 ' O ' HD13 ' C' ' 400' ' ' LEU . 0.2 OUTLIER -63.01 -42.93 99.96 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.002 0.43 . . . . 0.0 110.027 -179.119 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 66.0 tttm 54.9 101.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.491 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 66.6 t-80 -75.92 129.83 37.55 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.3 179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -79.24 145.1 33.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.65 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -78.86 147.54 33.12 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.462 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.2 -11.2 59.79 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.562 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.13 -36.84 93.99 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -78.87 135.44 37.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.568 0.223 . . . . 0.0 110.404 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -77.96 116.92 18.81 Favored 'General case' 0 N--CA 1.463 0.205 0 C-N-CA 120.82 -0.352 . . . . 0.0 110.367 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.527 ' OE1' ' N ' ' C' ' 410' ' ' PHE . 4.5 tp-100 -75.34 123.19 24.92 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 120.684 -0.407 . . . . 0.0 109.99 179.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . 0.527 ' N ' ' OE1' ' C' ' 409' ' ' GLN . 54.4 p90 . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.482 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 52.3 p . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.23 -37.54 87.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.479 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.427 ' OD1' ' O ' ' A' ' 373' ' ' ASP . 66.9 t0 -131.94 97.4 4.16 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.315 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 373' ' ' ASP . 35.6 p-10 -66.71 -40.52 88.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.881 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 372' ' ' ASP . 42.3 p-10 -98.76 110.7 23.26 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.676 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 57.5 t-20 -90.84 107.41 19.17 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.539 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . 0.484 ' C ' ' H ' ' A' ' 377' ' ' VAL . 86.3 m-85 -62.44 -41.43 98.72 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.607 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 4.8 tp 70.52 -40.19 0.46 Allowed 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.379 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 375' ' ' PHE . 5.5 t -140.54 56.7 7.45 Favored Pre-proline 0 N--CA 1.464 0.258 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.188 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.406 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 41.0 Cg_endo -68.18 -18.11 45.23 Favored 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.634 2.223 . . . . 0.0 112.09 -179.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 43.4 mm -65.59 -45.48 92.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.168 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.44 -20.1 62.15 Favored 'General case' 0 C--N 1.33 -0.263 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.738 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.2 t -67.19 -43.45 88.42 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.442 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.62 93.43 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.11 -41.71 98.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.847 0.356 . . . . 0.0 110.4 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -36.52 83.85 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.646 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.659 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.2 tt -61.47 -43.9 98.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.42 -37.4 87.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.509 179.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.87 -42.62 99.76 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.56 -42.78 93.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 120.91 0.386 . . . . 0.0 110.522 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -61.04 -40.94 95.54 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.493 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 86.2 mt -66.24 -41.7 89.63 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.107 0 CA-C-O 120.896 0.379 . . . . 0.0 110.268 179.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -59.8 -40.84 89.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.557 -179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.9 -41.7 93.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.682 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.12 -41.57 96.95 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.485 -179.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.55 -41.93 98.08 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.81 -48.55 79.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.707 179.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.6 t80 -64.43 -35.32 80.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.211 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.2 t80 -57.58 -46.02 84.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.19 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 90.6 mt -63.77 -42.68 96.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.273 179.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.69 -32.55 84.57 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp -61.54 -41.07 96.8 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 121.106 -0.238 . . . . 0.0 110.359 -179.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.6 mttt 55.58 35.93 26.17 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.579 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 49.27 94.28 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.717 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 49.0 p-80 -70.85 135.59 48.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.438 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -77.66 137.52 38.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.546 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.34 -12.38 59.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.61 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.29 -39.35 97.74 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 82.2 m-85 -109.62 135.88 49.88 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 120.817 0.342 . . . . 0.0 110.315 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -86.04 115.98 23.97 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.344 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 47.2 tp60 -80.0 129.85 34.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.345 -0.388 . . . . 0.0 110.075 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 88.9 t80 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.589 -179.856 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . 49.05 49.99 18.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.351 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -61.44 -43.43 98.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.377 -179.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 68.3 t0 -90.4 110.23 21.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.569 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -68.55 142.41 55.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.555 179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -101.53 140.77 35.37 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.362 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -101.53 8.11 42.06 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.502 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . 0.596 ' N ' HD12 ' B' ' 376' ' ' LEU . 10.0 mp -92.97 -1.39 56.73 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.305 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.459 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 8.6 m -141.53 53.04 3.1 Favored Pre-proline 0 N--CA 1.464 0.259 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.439 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . 0.459 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 36.4 Cg_endo -65.44 -20.98 61.06 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 122.764 2.309 . . . . 0.0 112.01 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 96.8 mt -64.96 -44.41 96.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 C-N-CA 120.866 -0.333 . . . . 0.0 110.88 -179.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.22 -20.08 62.3 Favored 'General case' 0 C--N 1.329 -0.322 0 C-N-CA 120.884 -0.327 . . . . 0.0 110.79 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 61.4 t -67.84 -43.21 86.26 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 120.791 -0.363 . . . . 0.0 110.473 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -37.76 95.02 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 111.171 -0.771 . . . . 0.0 111.171 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.56 -40.67 97.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.823 0.344 . . . . 0.0 110.395 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.02 -36.04 83.12 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.583 179.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . 0.646 ' O ' HD23 ' B' ' 385' ' ' LEU . 2.7 tt -61.52 -44.13 97.61 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.431 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.57 -38.26 90.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.491 179.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.3 -43.15 99.49 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 90.7 t -67.11 -42.83 88.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.738 0.304 . . . . 0.0 110.715 -179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . 0.509 HD23 ' O ' ' B' ' 389' ' ' LEU . 4.6 tt -59.97 -41.07 91.17 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.021 -178.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 85.4 mt -64.9 -42.16 94.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-O 120.829 0.347 . . . . 0.0 110.296 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.7 mt -60.71 -41.49 95.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.603 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 80.0 t -64.05 -40.96 90.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.689 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.6 mt -61.34 -41.47 97.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.384 -179.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 7.2 tt -61.67 -42.09 98.44 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.6 -47.8 78.81 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.532 . . . . 0.0 109.732 179.423 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . 0.566 ' CE2' HD23 ' B' ' 400' ' ' LEU . 89.0 t80 -63.98 -35.99 82.52 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.392 179.44 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 19.8 t80 -57.34 -45.38 84.39 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.231 -179.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.3 mm -64.94 -41.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.123 179.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.58 -33.23 85.94 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . 0.566 HD23 ' CE2' ' B' ' 396' ' ' TYR . 0.2 OUTLIER -62.37 -42.17 99.2 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 -179.547 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . 0.439 ' O ' ' O ' ' B' ' 400' ' ' LEU . 52.5 mtmt 58.78 145.27 0.01 OUTLIER 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.46 -179.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -58.84 -41.68 87.49 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.468 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -82.23 134.78 35.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.503 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -76.86 133.12 39.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.514 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.19 -12.53 59.96 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.653 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.67 -37.05 94.14 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -106.36 135.69 47.41 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 120.752 0.311 . . . . 0.0 110.347 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -99.49 117.72 34.5 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.219 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.483 ' CD ' ' N ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -129.83 146.24 51.56 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.326 179.901 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . 0.437 ' CD2' ' O ' ' B' ' 410' ' ' PHE . 54.6 p90 . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.658 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 60.9 m . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.387 -0.598 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -150.61 154.06 36.83 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.363 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . 0.523 ' OD1' ' ND2' ' C' ' 374' ' ' ASN . 60.4 t0 -122.77 26.86 8.02 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.185 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.417 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 34.3 p-10 -88.44 3.35 50.36 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.564 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -86.83 1.0 53.86 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.423 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . 0.523 ' ND2' ' OD1' ' C' ' 371' ' ' ASP . 95.3 m-20 -62.63 -41.2 98.88 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.583 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -122.14 102.22 8.01 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.529 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 57.2 tp -114.73 125.87 54.21 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.042 179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.598 ' O ' HG13 ' C' ' 377' ' ' VAL . 7.5 p -174.35 77.22 0.35 Allowed Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.411 179.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.528 ' O ' HG12 ' C' ' 381' ' ' VAL . 26.9 Cg_exo -60.02 148.56 88.61 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.649 2.232 . . . . 0.0 111.656 179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' C' ' 381' ' ' VAL . 95.2 mt -63.08 -43.06 98.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.626 -179.512 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.75 -19.6 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.65 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.534 ' N ' ' O ' ' C' ' 379' ' ' ILE . 7.8 p -61.72 -38.46 80.44 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 CA-C-O 120.745 0.307 . . . . 0.0 110.541 -179.492 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . 0.446 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -61.37 -40.51 98.73 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.54 -41.36 98.83 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.882 0.372 . . . . 0.0 110.301 179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . 0.412 ' O ' HG23 ' C' ' 388' ' ' VAL . . . -64.81 -35.81 82.32 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.5 179.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.659 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.9 tt -61.41 -43.2 99.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 109.908 -179.587 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.47 -39.19 92.61 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.517 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.85 -42.18 98.54 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . 0.412 HG23 ' O ' ' C' ' 384' ' ' ALA . 86.6 t -66.71 -42.46 89.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.828 0.347 . . . . 0.0 110.769 -179.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.5 -40.56 91.83 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.29 -179.374 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 83.7 mt -66.08 -42.04 90.68 Favored 'Isoleucine or valine' 0 C--O 1.233 0.192 0 CA-C-O 120.903 0.382 . . . . 0.0 110.173 179.055 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.4 -40.91 92.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.594 -179.653 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 70.4 t -63.36 -41.65 93.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.703 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.99 -41.81 97.18 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.478 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.9 tt -62.1 -42.43 99.22 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.62 -48.4 81.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.636 179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -64.06 -35.38 80.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.417 179.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.3 t80 -56.34 -46.56 79.9 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.28 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.57 -42.48 95.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.219 179.305 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.29 -33.47 87.32 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 55.2 tp -61.82 -42.57 99.19 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 120.914 -0.314 . . . . 0.0 110.332 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -90.22 134.62 34.18 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.669 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 43.2 p-80 -157.95 161.73 38.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.371 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 79.9 t60 -85.99 122.07 29.51 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.82 0.343 . . . . 0.0 110.202 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 16.5 p-80 -74.69 138.78 43.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.529 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.6 -11.12 59.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.648 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.9 -38.7 96.99 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 65.9 t80 -84.7 130.63 34.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.854 0.359 . . . . 0.0 110.309 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -135.33 149.35 49.72 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.496 179.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -53.08 137.91 32.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 109.974 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 55.2 p90 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.456 -179.997 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 35.8 t . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -71.32 140.82 50.41 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.403 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -99.29 110.9 23.37 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.453 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 65.9 t0 56.53 53.68 8.3 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.66 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 37.2 p-10 -62.07 -36.33 81.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.53 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.521 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 3.1 t-20 -87.55 93.1 9.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.605 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -64.21 -43.4 95.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.737 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.598 HD12 ' N ' ' A' ' 376' ' ' LEU . 10.0 mp -84.25 133.47 34.57 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.226 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.495 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 16.3 m -147.79 51.42 1.07 Allowed Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.314 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 32.8 Cg_endo -64.87 -22.36 63.3 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 C-N-CA 122.741 2.294 . . . . 0.0 112.02 179.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 96.4 mt -63.67 -44.53 98.48 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.261 -179.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.86 -20.26 58.23 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.837 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.4 t -67.39 -43.19 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.202 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.262 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.84 -41.61 99.65 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -38.97 93.09 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.826 0.346 . . . . 0.0 110.719 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -63.63 -44.91 92.51 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.675 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.5 mt -65.64 -40.19 92.23 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.389 179.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.3 -40.06 95.03 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.428 -179.714 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -38.91 96.81 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 79.3 t -64.69 -41.85 93.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 120.887 0.375 . . . . 0.0 110.188 179.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.94 -37.8 80.57 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.206 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.7 mm -64.74 -42.52 95.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 120.926 0.394 . . . . 0.0 110.121 179.127 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.5 mt -61.51 -42.5 98.89 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.703 -179.623 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.5 t -65.94 -42.51 92.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.6 mt -62.04 -42.06 98.77 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.57 -179.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.4 tt -62.4 -43.19 99.41 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.635 179.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.02 -47.53 82.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.918 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -65.57 -34.29 77.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.493 179.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -56.99 -45.87 82.66 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.322 -179.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.48 -42.35 93.06 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.36 -31.15 79.78 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 50.1 tp -62.22 -41.65 98.58 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.474 -179.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -105.39 136.12 45.51 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 120.899 0.381 . . . . 0.0 110.423 -179.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 51.8 p-80 -156.56 159.52 38.61 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.102 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -112.16 127.25 55.88 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.422 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -87.14 125.84 34.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.274 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.61 -12.24 59.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.366 -179.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.79 -36.77 93.74 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 85.7 t80 -79.33 131.91 36.28 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.54 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.8 mp0 -103.77 119.53 39.1 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-O 120.859 0.362 . . . . 0.0 110.309 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 41.1 tp60 -77.98 136.62 38.0 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.689 -0.404 . . . . 0.0 109.927 179.684 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.8 t80 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.936 -1.031 . . . . 0.0 110.46 179.95 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 69.6 p . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . 53.28 40.22 30.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.484 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -105.04 112.09 25.09 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.491 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 54.2 t0 55.99 30.81 16.79 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.588 179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 58.5 t0 58.46 32.12 21.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.52 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 60.5 t-20 -63.22 -39.88 95.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.473 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 58.1 t80 42.01 72.93 0.15 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.628 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 40.8 tp -108.5 101.0 10.21 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.198 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . . . . . . . . . 3.9 m -151.11 74.86 8.28 Favored Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.385 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -60.73 145.11 99.45 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.944 2.43 . . . . 0.0 111.831 179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . 0.468 ' O ' ' N ' ' B' ' 381' ' ' VAL . 45.8 mm -64.24 -43.65 97.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.118 -179.72 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.37 -20.26 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.71 -0.223 . . . . 0.0 110.766 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.468 ' N ' ' O ' ' B' ' 379' ' ' ILE . 55.5 t -65.35 -42.97 94.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.266 179.861 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.12 -36.12 92.85 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.3 -43.26 99.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.814 0.34 . . . . 0.0 110.587 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.64 -36.77 84.66 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.436 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . 0.651 ' O ' HD23 ' B' ' 385' ' ' LEU . 3.1 tt -62.41 -43.68 98.25 Favored 'General case' 0 CA--C 1.53 0.206 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.938 -179.495 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.15 -37.7 88.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.491 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.31 -42.1 99.72 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 56.3 t -66.1 -43.98 92.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.895 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 8.4 tt -60.88 -41.71 96.54 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 119.696 -0.801 . . . . 0.0 109.922 -179.242 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 92.7 mt -65.73 -42.2 92.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 CA-C-O 121.003 0.43 . . . . 0.0 110.431 179.063 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -58.42 -41.59 85.34 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.518 -178.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 81.7 t -62.71 -40.99 90.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.596 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.94 -41.4 96.18 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.485 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.23 -42.89 99.39 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.94 -48.31 80.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.972 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.0 t80 -63.06 -35.65 80.97 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.49 179.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -56.59 -44.82 81.45 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.316 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 44.2 mm -65.7 -41.54 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 179.484 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.33 -33.52 86.89 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 53.2 tp -61.9 -42.1 98.68 Favored 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 120.904 -0.318 . . . . 0.0 110.533 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -101.09 144.12 30.38 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-O 120.805 0.336 . . . . 0.0 110.315 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . 0.454 ' CE1' ' CE1' ' B' ' 403' ' ' HIS . 56.6 p-80 -95.12 -3.51 47.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.423 179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . 0.454 ' CE1' ' CE1' ' B' ' 402' ' ' HIS . 70.7 m80 -74.89 138.61 42.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.293 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -107.32 134.04 50.98 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.557 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.33 -12.91 60.01 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.466 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.18 -37.9 95.65 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . 0.432 ' CE2' ' O ' ' B' ' 408' ' ' GLU . 75.7 t80 -82.35 136.4 35.0 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 110.367 -0.234 . . . . 0.0 110.367 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . 0.432 ' O ' ' CE2' ' B' ' 407' ' ' TYR . 80.8 tt0 -72.05 118.3 14.75 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.317 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.608 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 0.1 OUTLIER -52.91 146.1 11.46 Favored 'General case' 0 N--CA 1.462 0.146 0 C-N-CA 120.618 -0.433 . . . . 0.0 110.082 179.643 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.516 -179.625 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 6.0 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -62.7 -40.25 96.53 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.482 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -139.78 102.68 4.48 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.152 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.421 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 35.8 p-10 -89.06 -0.17 57.2 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.502 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 47.4 t0 59.54 30.2 19.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.48 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -97.07 7.62 46.24 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.555 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -61.85 -41.05 97.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.62 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 29.7 mt -102.12 2.75 37.81 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.377 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 14.3 t 49.33 72.47 1.25 Allowed Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.482 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.56 146.14 96.04 Favored 'Trans proline' 0 N--CA 1.497 1.695 0 C-N-CA 122.865 2.376 . . . . 0.0 112.085 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.471 ' O ' ' N ' ' C' ' 381' ' ' VAL . 97.1 mt -63.52 -43.96 98.52 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.991 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.33 -20.35 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.647 0.26 . . . . 0.0 110.803 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.471 ' N ' ' O ' ' C' ' 379' ' ' ILE . 54.3 t -63.8 -43.76 98.0 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.242 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.183 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.68 -39.75 98.31 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.62 -39.9 95.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.868 0.366 . . . . 0.0 110.659 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -66.12 -34.31 77.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.457 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.655 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.1 tt -61.87 -45.17 94.92 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.998 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.01 -36.51 84.22 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.2 -40.37 98.47 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 83.9 t -67.27 -42.76 88.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.807 0.337 . . . . 0.0 110.314 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.5 tt -60.46 -41.08 93.41 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.561 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 82.7 mt -66.04 -42.01 90.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 120.85 0.357 . . . . 0.0 110.342 178.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -60.02 -40.05 87.96 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 74.9 t -63.73 -42.19 95.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.873 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -61.5 -41.16 96.87 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.483 -179.515 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 5.3 tt -62.28 -43.71 98.21 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.608 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.46 -36.7 84.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.072 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -60.22 -44.53 95.11 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.652 -179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 27.6 m-85 -62.11 -43.77 98.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.664 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.0 mt -63.23 -41.88 94.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.989 -0.55 . . . . 0.0 109.521 179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.89 -34.82 90.97 Favored Glycine 0 CA--C 1.522 0.512 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 50.1 tp -62.9 -41.48 99.45 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.485 -179.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . . . . . . . . . 88.8 tttt 54.44 105.73 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.629 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -77.44 140.64 39.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.16 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -106.38 127.19 53.09 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.293 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -104.64 128.72 52.75 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.383 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.09 -12.77 60.02 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.457 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.31 -40.66 98.08 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . 0.62 ' CZ ' ' NE2' ' C' ' 409' ' ' GLN . 88.1 t80 -92.67 117.66 30.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.772 0.32 . . . . 0.0 110.302 179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . 0.503 ' O ' ' NE2' ' C' ' 409' ' ' GLN . 0.0 OUTLIER -135.43 144.66 46.6 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.558 179.709 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.62 ' NE2' ' CZ ' ' C' ' 407' ' ' TYR . 90.9 mm-40 -130.61 126.69 37.3 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.556 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . 0.439 ' O ' ' CG ' ' C' ' 410' ' ' PHE . 92.3 t80 . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.485 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 2.7 t . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 61.29 129.02 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.605 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 55.4 t0 57.07 44.66 22.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.452 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -88.38 114.04 24.59 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.728 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 52.4 t0 -66.21 144.05 56.87 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.801 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.509 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 65.8 t30 55.91 42.21 29.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.679 179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -120.85 102.57 8.46 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.331 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 94.8 mt -135.7 146.55 47.87 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.435 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 11.4 t -143.79 71.65 17.09 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.456 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -60.88 146.77 97.08 Favored 'Trans proline' 0 N--CA 1.496 1.635 0 C-N-CA 122.877 2.385 . . . . 0.0 111.826 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.501 ' O ' ' N ' ' A' ' 381' ' ' VAL . 44.6 mm -65.44 -43.7 94.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.744 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.33 -20.02 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.59 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.501 ' N ' ' O ' ' A' ' 379' ' ' ILE . 54.9 t -65.27 -42.9 95.02 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 C-N-CA 121.026 -0.27 . . . . 0.0 110.468 179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -60.13 -40.15 96.79 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.16 -41.99 98.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.835 0.35 . . . . 0.0 110.579 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.0 -35.66 81.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.57 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.657 HD23 ' O ' ' A' ' 385' ' ' LEU . 3.1 tt -61.3 -43.47 98.83 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.87 -0.418 . . . . 0.0 109.87 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.68 -39.78 95.18 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.886 0.374 . . . . 0.0 110.51 179.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.13 -40.15 97.81 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.032 -0.827 . . . . 0.0 111.032 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 72.8 t -63.79 -43.31 97.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 O-C-N 122.946 -0.15 . . . . 0.0 111.332 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.22 -37.86 81.59 Favored 'General case' 0 C--N 1.325 -0.479 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.336 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -62.94 -42.34 96.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 178.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 9.5 mt -60.86 -39.85 90.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.392 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 78.2 t -61.09 -40.72 86.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.468 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.7 mt -60.99 -41.6 96.77 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.323 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.2 tt -61.79 -44.2 97.33 Favored 'General case' 0 C--N 1.324 -0.509 0 C-N-CA 120.335 -0.546 . . . . 0.0 109.73 179.741 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.22 -36.73 83.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.002 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -60.09 -44.79 94.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.685 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -62.42 -44.9 95.33 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.331 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 89.8 mt -63.45 -42.86 97.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.05 179.474 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -66.09 -33.08 84.34 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.411 ' O ' ' O ' ' A' ' 401' ' ' LYS . 43.9 tp -61.81 -41.69 98.08 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.502 -179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . 0.411 ' O ' ' O ' ' A' ' 400' ' ' LEU . 62.1 tttm 51.08 101.98 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.337 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 60.4 t-80 -58.45 -40.86 83.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.425 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -73.68 141.14 46.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.502 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -76.83 134.13 39.15 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.611 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.89 -11.22 59.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.616 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.0 -33.83 88.32 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -107.61 133.65 51.75 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.653 0.263 . . . . 0.0 110.46 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -86.91 117.48 25.67 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.218 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.717 ' NE2' ' H ' ' A' ' 409' ' ' GLN . 0.0 OUTLIER -62.68 141.15 58.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.093 179.815 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.0 t80 . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.001 -0.999 . . . . 0.0 110.458 179.866 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 86.3 p . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -158.75 153.58 24.87 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.542 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 56.9 m-20 -93.17 111.49 23.14 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.203 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . 0.512 ' OD2' ' ND2' ' B' ' 374' ' ' ASN . 36.6 p-10 -87.73 1.12 54.63 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.652 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 52.3 t0 58.62 52.05 7.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.58 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . 0.512 ' ND2' ' OD2' ' B' ' 372' ' ' ASP . 99.1 m-20 -67.81 150.25 48.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.484 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . 0.521 ' CD2' ' O ' ' B' ' 375' ' ' PHE . 40.1 p90 -146.79 121.42 9.8 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.189 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 45.8 mt -110.17 4.01 20.66 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.362 179.785 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.43 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 15.5 m -131.24 54.82 15.72 Favored Pre-proline 0 N--CA 1.464 0.268 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.435 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . 0.43 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 36.5 Cg_endo -65.62 -20.06 59.95 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.745 2.296 . . . . 0.0 111.933 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.6 mt -64.6 -44.23 96.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 C-N-CA 120.883 -0.327 . . . . 0.0 111.008 -179.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -71.96 -20.11 61.79 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 120.987 -0.285 . . . . 0.0 110.828 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 52.9 t -67.06 -43.12 89.07 Favored 'Isoleucine or valine' 0 C--O 1.231 0.122 0 C-N-CA 120.878 -0.329 . . . . 0.0 110.419 179.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.29 -41.57 99.73 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.54 84.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.729 0.3 . . . . 0.0 110.65 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.17 -43.85 98.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.721 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -65.49 -40.96 93.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.291 179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.14 -37.83 88.87 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.449 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -38.97 97.12 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 84.6 t -64.3 -42.12 94.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 121.108 0.48 . . . . 0.0 110.167 179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 1.2 tp -60.38 -38.08 82.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.247 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 30.5 mm -63.5 -42.53 96.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 12.8 mt -61.6 -42.07 98.34 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.495 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 88.5 t -66.03 -42.19 91.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.985 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.67 -41.2 97.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.405 -179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.7 tt -61.66 -43.07 99.55 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.99 -47.82 83.81 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.695 179.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -63.9 -35.81 81.87 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.361 179.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -56.86 -45.55 82.37 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.084 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 88.2 mt -63.72 -42.6 96.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.222 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.22 -31.22 80.13 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 54.1 tp -61.71 -40.58 95.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.721 0.296 . . . . 0.0 110.348 -179.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -48.78 142.07 6.69 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.57 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 54.6 t-80 -69.38 136.99 52.44 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.542 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -79.44 149.35 31.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.627 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 10.5 p-80 -66.21 162.77 19.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.489 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.08 -11.84 59.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.454 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.2 -33.57 87.61 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . 0.514 ' OH ' ' NE2' ' B' ' 409' ' ' GLN . 72.9 t80 -83.83 126.13 32.65 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.693 0.283 . . . . 0.0 110.456 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . 0.431 ' O ' ' OE1' ' B' ' 409' ' ' GLN . 92.8 mt-10 -135.43 149.19 49.55 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.526 179.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.514 ' NE2' ' OH ' ' B' ' 407' ' ' TYR . 11.5 mm100 -120.19 125.97 49.5 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.073 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 . . . . . 0 C--O 1.219 -0.5 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.68 -179.926 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 56.3 p . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.74 -37.57 87.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.331 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' C' ' 372' ' ' ASP . 37.1 p-10 -64.44 -36.49 84.33 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.555 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.52 ' N ' ' OD1' ' C' ' 371' ' ' ASP . 45.0 t0 -89.27 106.9 18.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.38 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -80.77 164.75 22.51 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.373 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 -85.01 136.94 33.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.382 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . 0.495 ' CZ ' ' CG2' ' C' ' 377' ' ' VAL . 82.5 t80 -88.62 78.98 7.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.372 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . 0.494 ' O ' HG13 ' C' ' 377' ' ' VAL . 22.3 tp -108.19 103.08 12.19 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.495 ' CG2' ' CZ ' ' C' ' 375' ' ' PHE . 16.1 m -157.74 51.92 0.52 Allowed Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.039 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.484 ' CD ' ' N ' ' C' ' 377' ' ' VAL . 26.5 Cg_endo -62.25 -22.75 74.63 Favored 'Trans proline' 0 N--CA 1.495 1.59 0 C-N-CA 122.759 2.306 . . . . 0.0 112.04 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . . . . . . . . . 97.0 mt -64.19 -44.55 97.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.04 -179.645 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -75.03 -20.16 59.72 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 121.053 -0.259 . . . . 0.0 110.736 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.28 -43.38 91.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.163 0 C-N-CA 121.001 -0.28 . . . . 0.0 110.557 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.59 -37.62 95.04 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.68 -41.03 98.88 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.857 0.36 . . . . 0.0 110.564 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.79 -35.56 81.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.459 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.658 HD23 ' O ' ' C' ' 385' ' ' LEU . 2.6 tt -61.68 -43.62 98.5 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.255 -0.429 . . . . 0.0 109.896 -179.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.12 -38.7 92.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.674 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.32 -40.2 98.72 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 98.6 t -64.52 -42.65 95.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.852 0.358 . . . . 0.0 110.509 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.534 HD23 ' O ' ' C' ' 389' ' ' LEU . 5.1 tt -59.71 -39.07 83.4 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.823 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.38 -42.38 95.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 120.829 0.347 . . . . 0.0 110.141 178.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.34 -41.07 96.45 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.414 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 96.1 t -64.21 -41.52 92.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.717 179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.0 mt -61.67 -41.99 98.31 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.542 -179.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.8 tt -62.04 -41.96 98.67 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.67 -49.28 77.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.627 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -64.83 -35.01 79.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.229 179.289 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.98 -45.66 86.41 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.349 -179.52 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 93.1 mt -63.55 -42.72 97.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.13 -38.61 95.48 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . . . . . . . . . 50.0 tp -62.83 -42.28 99.67 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.898 -0.321 . . . . 0.0 110.353 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . 0.434 ' O ' ' O ' ' C' ' 402' ' ' HIS . 29.9 ttmt 56.96 59.25 3.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.806 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . 0.434 ' O ' ' O ' ' C' ' 401' ' ' LYS . 95.7 m-70 56.41 158.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.563 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -78.37 145.81 35.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.426 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 99.4 m-70 -79.34 142.81 35.73 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.617 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.51 -11.97 59.91 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.538 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.19 -36.76 93.87 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 88.0 t80 -82.48 132.21 35.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.631 0.253 . . . . 0.0 110.491 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -77.76 117.65 19.36 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.091 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 8.6 pt20 -52.89 137.62 31.86 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.32 -0.4 . . . . 0.0 109.961 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 83.1 t80 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.474 -179.998 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 19.9 p . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -152.2 152.13 31.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.492 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 47.9 t0 -101.52 107.61 18.95 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.345 179.697 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 35.7 p30 -90.2 2.4 55.42 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.391 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -62.58 -42.91 99.84 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.566 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 69.3 m-20 56.96 36.13 27.35 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.522 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 53.6 t80 -60.69 -44.3 96.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.403 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 23.0 mt -102.04 131.24 48.6 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.373 179.721 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 4.6 m -141.99 71.27 23.67 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.363 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.513 ' O ' HG12 ' A' ' 381' ' ' VAL . 40.2 Cg_exo -55.64 -33.47 87.27 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.876 2.384 . . . . 0.0 112.114 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.474 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.8 mt -62.83 -43.76 99.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.905 -179.109 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.57 -19.63 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.623 -0.262 . . . . 0.0 110.654 179.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.533 HG13 ' N ' ' A' ' 382' ' ' GLY . 9.2 p -59.15 -44.26 91.32 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-O 120.682 0.277 . . . . 0.0 110.806 -179.34 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.533 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.2 -41.35 99.66 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.79 -41.11 98.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.842 0.353 . . . . 0.0 110.284 179.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . 0.435 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -66.42 -35.93 81.55 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.722 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.641 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.6 tt -60.53 -44.52 95.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.291 -0.413 . . . . 0.0 109.931 -179.208 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -39.11 93.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.421 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.41 -42.91 97.44 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 384' ' ' ALA . 91.6 t -65.6 -43.19 94.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.223 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 8.1 tt -60.55 -39.88 89.54 Favored 'General case' 0 C--N 1.331 -0.239 0 C-N-CA 120.448 -0.501 . . . . 0.0 110.114 -179.222 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.9 -42.05 93.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.81 0.338 . . . . 0.0 110.11 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -60.87 -40.65 93.78 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.664 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 75.9 t -62.2 -41.18 90.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.725 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 7.1 mt -61.09 -41.31 96.42 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.421 -179.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -61.64 -43.21 99.28 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.98 -36.8 82.99 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.25 179.086 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . 0.418 ' CZ ' ' CD1' ' A' ' 400' ' ' LEU . 92.6 t80 -60.3 -44.52 95.32 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.5 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.0 m-85 -63.89 -46.56 84.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.417 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 88.5 mt -64.43 -42.1 94.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.377 179.373 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -53.14 -57.2 15.69 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.475 ' C ' ' H ' ' A' ' 402' ' ' HIS . 8.7 mt -65.31 -40.93 94.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.768 0.318 . . . . 0.0 110.432 179.403 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 52.1 tttm 51.25 9.86 0.07 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.412 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.475 ' H ' ' C ' ' A' ' 400' ' ' LEU . 64.1 t-80 -154.14 139.36 17.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.518 179.742 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 63.9 t-80 -79.43 126.67 31.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.271 179.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 69.9 t60 -89.87 124.87 35.06 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.373 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.15 -18.22 53.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.687 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.62 -36.82 93.85 Favored Glycine 0 CA--C 1.522 0.516 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 86.3 t80 -86.41 129.16 34.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.602 0.239 . . . . 0.0 110.39 179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 43.8 tp10 -108.58 120.39 42.3 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -52.87 141.71 21.03 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.026 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 . . . . . 0 C--N 1.325 -0.485 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.289 179.863 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 86.3 p . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -149.22 148.52 29.69 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.542 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -94.7 100.12 12.1 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.256 179.661 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 67.1 t0 -96.18 83.78 3.67 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.574 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 53.87 34.47 19.45 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.678 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 40.7 t-20 -90.64 108.49 19.85 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.567 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -119.86 103.44 9.34 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.393 179.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 35.7 tp -97.59 86.18 3.77 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.466 ' N ' ' CD ' ' B' ' 378' ' ' PRO . 16.4 m -152.93 53.05 0.95 Allowed Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.291 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . 0.466 ' CD ' ' N ' ' B' ' 377' ' ' VAL . 34.9 Cg_endo -65.25 -21.44 61.85 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.758 2.305 . . . . 0.0 112.072 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 97.2 mt -64.37 -44.69 97.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.529 -0.305 . . . . 0.0 111.18 -179.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -73.47 -20.06 60.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.626 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . . . . . . . . . 54.6 t -67.2 -43.39 88.39 Favored 'Isoleucine or valine' 0 C--O 1.232 0.155 0 CA-C-O 120.72 0.295 . . . . 0.0 110.461 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.86 -41.59 99.84 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.18 -38.16 89.65 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.855 0.36 . . . . 0.0 110.67 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.79 -44.14 96.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.71 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -65.71 -39.6 91.37 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.338 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.96 -38.79 89.85 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.398 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.09 -42.57 99.5 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . . . . . . . . . 87.4 t -66.88 -42.66 89.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.651 0.263 . . . . 0.0 111.081 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . 0.598 HD23 ' O ' ' B' ' 389' ' ' LEU . 5.3 tt -60.08 -41.53 92.64 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.84 -0.344 . . . . 0.0 110.076 -179.348 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 87.8 mt -64.31 -42.25 94.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.897 0.379 . . . . 0.0 110.26 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.97 -41.28 96.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.564 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 69.7 t -63.69 -41.09 91.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.738 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 6.9 mt -61.12 -40.94 95.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.421 -179.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.3 -41.59 97.25 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.37 -47.75 80.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.652 179.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -64.11 -36.01 82.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.668 -0.697 . . . . 0.0 110.338 179.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 22.4 t80 -56.86 -45.87 82.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.165 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . . . . . . . . . 90.0 mt -63.88 -42.62 96.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.308 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -65.02 -36.65 93.3 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 45.6 tp -62.68 -42.12 99.46 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.75 0.31 . . . . 0.0 110.51 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . . . . . . . . . 63.9 tttp -77.73 134.83 38.0 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.441 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -148.33 139.37 23.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.415 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -74.74 131.19 40.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.231 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -100.91 125.01 47.44 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.311 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.3 -11.41 59.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.632 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.07 -34.68 90.61 Favored Glycine 0 CA--C 1.522 0.525 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 82.8 t80 -135.93 152.9 51.47 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.83 0.347 . . . . 0.0 110.433 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -135.26 148.37 49.54 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.332 179.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.485 ' CD ' ' N ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -130.63 144.84 51.7 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 116.182 -0.463 . . . . 0.0 109.935 -179.718 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.101 -0.952 . . . . 0.0 110.355 179.722 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 14.2 m . . . . . 0 N--CA 1.489 1.476 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -66.09 -39.86 90.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.481 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 49.5 t0 56.36 37.41 28.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.481 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -85.77 110.9 19.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.5 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -92.43 110.14 21.54 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.302 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -92.65 5.46 50.92 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.214 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -62.07 -43.76 98.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.515 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . . . . . . . . . 7.0 tp -112.46 133.53 54.48 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.286 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . . . . . . . . . 3.5 m -123.33 74.6 51.51 Favored Pre-proline 0 N--CA 1.465 0.324 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.579 -179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -75.1 161.64 38.15 Favored 'Trans proline' 0 N--CA 1.491 1.356 0 C-N-CA 122.658 2.239 . . . . 0.0 112.065 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' C' ' 381' ' ' VAL . 96.5 mt -63.68 -42.85 97.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.683 -179.486 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.59 -19.64 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' C' ' 379' ' ' ILE . 51.1 t -63.47 -43.87 98.57 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.85 -36.1 92.86 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.78 -40.71 96.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.791 0.329 . . . . 0.0 110.301 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.91 -36.88 85.78 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.373 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . 0.643 HD23 ' O ' ' C' ' 385' ' ' LEU . 3.0 tt -61.57 -44.48 96.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.903 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.1 -36.98 85.39 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.539 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.16 -38.38 95.51 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 85.2 t -65.76 -42.62 92.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.879 0.371 . . . . 0.0 110.528 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . 0.555 HD23 ' O ' ' C' ' 389' ' ' LEU . 5.3 tt -61.1 -38.92 88.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.019 -179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 31.1 mm -63.85 -42.27 95.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 11.8 mt -61.14 -40.97 95.85 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.493 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 84.1 t -63.64 -40.91 90.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.649 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.2 mt -61.68 -41.6 97.78 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.591 -179.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -61.56 -42.62 99.12 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.57 -49.14 78.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.74 179.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.71 -34.74 78.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.273 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -58.05 -45.56 86.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.151 -179.557 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 91.3 mt -63.44 -42.4 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.1 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.62 -36.28 92.96 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . 0.436 ' O ' ' O ' ' C' ' 401' ' ' LYS . 53.0 tp -62.91 -41.79 99.57 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.323 -179.841 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' C' ' 400' ' ' LEU . 75.6 tttt 53.95 166.68 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.47 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 64.2 t-80 -61.42 -43.24 99.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.454 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -77.19 140.57 40.19 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.333 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . . . . . . . . . 80.3 m80 -98.96 131.65 44.86 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.417 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.21 -12.24 59.92 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.505 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.56 -39.42 97.61 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 86.7 t80 -81.93 131.47 35.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.603 0.239 . . . . 0.0 110.416 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -89.56 114.55 26.13 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.214 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . . . . . . . . . 6.1 pt20 -54.37 141.89 28.74 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.898 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 85.5 t80 . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.516 179.859 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 67.4 m . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -150.68 149.04 29.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.503 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.411 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 37.7 p-10 -90.44 0.92 57.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.341 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -89.78 107.27 19.0 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.493 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 59.9 m-20 -64.42 -37.5 87.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.037 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -86.61 107.22 18.07 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.405 -179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 92.0 m-85 -95.11 -0.44 53.47 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.46 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.531 HD12 ' N ' ' A' ' 376' ' ' LEU . 10.7 mp -62.57 -41.73 99.11 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.305 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.661 ' O ' HG13 ' A' ' 377' ' ' VAL . 8.3 p -153.57 78.07 5.73 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.27 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_exo -59.74 143.7 99.58 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.631 2.22 . . . . 0.0 111.916 179.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.506 ' O ' ' N ' ' A' ' 381' ' ' VAL . 45.9 mm -65.06 -44.02 95.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.083 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.1 -20.25 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.708 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.506 ' N ' ' O ' ' A' ' 379' ' ' ILE . 55.7 t -65.27 -43.51 95.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.335 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -66.27 -40.78 94.86 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.3 -38.96 93.18 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.763 0.316 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . 0.43 ' O ' HG23 ' A' ' 388' ' ' VAL . . . -62.37 -44.86 95.46 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.615 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.33 -40.17 89.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.405 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.81 -37.68 88.3 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.555 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.28 -39.93 97.46 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 384' ' ' ALA . 80.5 t -66.24 -42.86 91.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.912 0.387 . . . . 0.0 110.596 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.3 mt -62.15 -41.85 98.68 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.413 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 79.4 mt -64.11 -41.9 93.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -60.35 -42.61 96.07 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.698 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 83.1 t -65.34 -41.86 92.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.922 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.52 -39.93 92.81 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.472 -179.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.72 -44.23 96.86 Favored 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 120.221 -0.592 . . . . 0.0 109.52 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -64.94 -38.02 89.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.077 179.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -61.76 -43.74 98.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.717 179.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -63.02 -41.53 99.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.65 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . 0.423 HD13 ' HA ' ' A' ' 398' ' ' ILE . 30.2 mm -63.61 -42.52 96.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.891 179.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -77.14 -21.08 74.45 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.4 tp -63.73 -40.79 97.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.807 0.337 . . . . 0.0 110.543 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -55.72 132.76 49.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.447 -179.264 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.409 ' CE1' ' O ' ' A' ' 403' ' ' HIS . 60.9 t-80 -91.46 128.5 37.31 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.571 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . 0.773 ' CG ' ' HZ1' ' C' ' 401' ' ' LYS . 80.2 m80 -74.14 144.68 44.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.452 -179.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 97.5 m-70 -69.54 132.77 46.78 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.449 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.73 -11.31 59.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.584 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.86 -34.77 90.76 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 -179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . 0.475 ' OH ' ' N ' ' C' ' 409' ' ' GLN . 86.4 t80 -82.66 132.14 35.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.599 0.238 . . . . 0.0 110.465 179.645 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 91.3 mt-10 -135.49 147.66 48.94 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.681 0.277 . . . . 0.0 110.694 179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.532 ' H ' ' CD ' ' A' ' 409' ' ' GLN . 1.9 pm0 -71.05 134.93 47.47 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.039 179.522 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.9 t80 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.366 -179.915 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 369' ' ' SER . . . . . . . . . . . . . 84.4 p . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.381 -0.599 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 370' ' ' ALA . . . . . . . . . . . . . . . -67.73 142.25 56.35 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.537 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 371' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' B' ' 371' ' ' ASP . 33.5 p-10 -88.36 -1.11 57.85 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.348 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 372' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -64.0 -38.3 90.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.591 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 373' ' ' ASP . . . . . 0.429 ' O ' ' OD1' ' B' ' 373' ' ' ASP . 64.5 t0 57.37 36.28 26.98 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.438 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 374' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -87.71 141.56 28.51 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.436 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 375' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -98.97 2.59 46.54 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.416 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 376' ' ' LEU . . . . . . . . . . . . . 60.0 tp -62.29 -43.51 98.67 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.357 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 377' ' ' VAL . . . . . 0.627 HG13 ' O ' ' B' ' 377' ' ' VAL . 14.2 p -171.96 61.48 0.31 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.15 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 378' ' ' PRO . . . . . 0.484 ' O ' HG12 ' B' ' 381' ' ' VAL . 42.8 Cg_endo -69.38 148.03 66.63 Favored 'Trans proline' 0 C--N 1.302 -1.885 0 C-N-CA 122.302 2.001 . . . . 0.0 112.001 -179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 379' ' ' ILE . . . . . . . . . . . . . 78.8 mt -67.31 -26.49 36.19 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.045 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 380' ' ' ALA . . . . . . . . . . . . . . . -57.85 -20.26 35.03 Favored 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.533 -0.303 . . . . 0.0 110.881 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 381' ' ' VAL . . . . . 0.501 HG13 ' N ' ' B' ' 382' ' ' GLY . 8.9 p -60.87 -43.48 95.76 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-O 120.783 0.325 . . . . 0.0 110.371 -179.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 382' ' ' GLY . . . . . 0.501 ' N ' HG13 ' B' ' 381' ' ' VAL . . . -64.68 -42.34 97.29 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.404 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.38 -37.77 88.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.822 0.344 . . . . 0.0 110.805 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 384' ' ' ALA . . . . . 0.415 ' O ' HG23 ' B' ' 388' ' ' VAL . . . -60.04 -46.5 89.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.625 -179.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -64.09 -41.05 97.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.412 179.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.95 89.26 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.46 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.96 -36.34 93.16 Favored Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 388' ' ' VAL . . . . . 0.415 HG23 ' O ' ' B' ' 384' ' ' ALA . 95.1 t -64.82 -42.23 94.33 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-O 121.069 0.462 . . . . 0.0 110.243 179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 389' ' ' LEU . . . . . . . . . . . . . 10.9 mt -62.18 -39.78 93.86 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.35 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 390' ' ' ILE . . . . . . . . . . . . . 31.6 mm -65.16 -41.67 92.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.329 -0.396 . . . . 0.0 109.964 179.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.52 -41.86 95.26 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.622 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 392' ' ' VAL . . . . . . . . . . . . . 90.0 t -65.06 -42.7 95.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.874 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 393' ' ' LEU . . . . . . . . . . . . . 7.7 mt -62.13 -43.32 99.08 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.622 -179.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 394' ' ' LEU . . . . . . . . . . . . . 6.6 tt -62.74 -42.89 99.89 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.16 -36.93 85.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.169 179.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.61 -44.37 96.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.847 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 397' ' ' PHE . . . . . . . . . . . . . 30.6 m-85 -62.2 -42.47 99.32 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.508 -179.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 398' ' ' ILE . . . . . 0.44 ' O ' ' O ' ' B' ' 401' ' ' LYS . 83.6 mt -63.66 -42.33 95.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.844 179.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 399' ' ' GLY . . . . . . . . . . . . . . . -58.89 -45.18 95.42 Favored Glycine 0 CA--C 1.523 0.576 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 400' ' ' LEU . . . . . . . . . . . . . 35.1 tp -65.08 -41.55 94.95 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.477 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 401' ' ' LYS . . . . . 0.44 ' O ' ' O ' ' B' ' 398' ' ' ILE . 99.2 mttt -135.31 135.16 40.58 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.318 -179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 402' ' ' HIS . . . . . 0.4 ' O ' ' CE1' ' C' ' 404' ' ' HIS . 45.0 t-80 -158.48 104.87 1.84 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.195 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 403' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -109.4 121.3 44.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.201 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 404' ' ' HIS . . . . . 0.539 ' O ' ' ND1' ' B' ' 404' ' ' HIS . 33.7 p80 -126.2 124.96 41.63 Favored 'General case' 0 N--CA 1.464 0.225 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.404 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 405' ' ' ALA . . . . . . . . . . . . . . . -103.89 -42.04 5.71 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.358 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.64 -40.53 98.71 Favored Glycine 0 CA--C 1.528 0.89 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 407' ' ' TYR . . . . . . . . . . . . . 88.9 t80 -78.54 135.97 37.44 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.628 0.251 . . . . 0.0 110.384 179.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.47 146.74 48.47 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.729 0.299 . . . . 0.0 110.803 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 409' ' ' GLN . . . . . 0.621 ' H ' ' CD ' ' B' ' 409' ' ' GLN . 0.0 OUTLIER -53.94 145.99 15.27 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.664 -0.414 . . . . 0.0 109.95 179.641 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 410' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.571 -179.859 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' C' C ' 369' ' ' SER . . . . . . . . . . . . . 58.0 p . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' C' C ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.15 -38.85 92.79 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.517 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 371' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 55.39 32.25 18.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.435 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 372' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' C' ' 373' ' ' ASP . 42.0 p-10 -64.98 -34.61 78.85 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.688 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 373' ' ' ASP . . . . . 0.519 ' N ' ' OD1' ' C' ' 372' ' ' ASP . 98.9 m-20 54.97 32.83 18.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.474 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 374' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' C' ' 376' ' ' LEU . 61.5 t-20 -90.42 116.95 28.75 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.616 -179.83 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 375' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -61.7 -44.36 97.09 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.814 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 376' ' ' LEU . . . . . 0.422 ' O ' ' OD1' ' C' ' 374' ' ' ASN . 53.2 mt -113.74 131.15 56.3 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.397 -179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 377' ' ' VAL . . . . . 0.489 ' N ' ' CD ' ' C' ' 378' ' ' PRO . 17.7 m -145.7 51.72 1.36 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.3 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 378' ' ' PRO . . . . . 0.51 ' O ' HG12 ' C' ' 381' ' ' VAL . 28.9 Cg_endo -63.6 -22.05 70.37 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.706 2.271 . . . . 0.0 112.0 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 379' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' C' ' 381' ' ' VAL . 45.1 mm -64.88 -43.91 96.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.361 -179.336 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.55 -19.9 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.799 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 381' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' C' ' 379' ' ' ILE . 8.1 p -59.57 -43.98 92.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.125 0 CA-C-O 120.737 0.303 . . . . 0.0 110.294 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 382' ' ' GLY . . . . . 0.519 ' N ' HG13 ' C' ' 381' ' ' VAL . . . -63.62 -43.0 98.6 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 179.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.47 -38.78 88.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.744 0.307 . . . . 0.0 110.845 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.84 -44.49 96.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.683 -179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 385' ' ' LEU . . . . . . . . . . . . . 5.4 mt -65.14 -40.15 94.0 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.413 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.55 -38.86 89.02 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.411 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.42 -38.46 94.92 Favored Glycine 0 CA--C 1.529 0.941 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 388' ' ' VAL . . . . . . . . . . . . . 99.3 t -62.97 -43.51 99.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-O 120.738 0.304 . . . . 0.0 110.281 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -60.59 -39.44 88.13 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.089 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 390' ' ' ILE . . . . . . . . . . . . . 30.9 mm -64.01 -42.02 94.36 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 179.134 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -61.07 -40.58 94.23 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.581 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 392' ' ' VAL . . . . . . . . . . . . . 83.6 t -61.85 -41.02 89.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.699 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 393' ' ' LEU . . . . . . . . . . . . . 7.4 mt -61.17 -42.12 98.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.426 -179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.85 -42.93 99.94 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.618 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 395' ' ' ALA . . . . . . . . . . . . . . . -65.51 -35.95 82.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.259 179.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 396' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -59.78 -44.97 93.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.73 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 397' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -63.04 -46.74 86.09 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.623 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 398' ' ' ILE . . . . . . . . . . . . . 89.5 mt -64.88 -42.1 93.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.063 -0.517 . . . . 0.0 109.857 179.444 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 399' ' ' GLY . . . . . . . . . . . . . . . -59.4 -32.71 73.38 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.557 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 400' ' ' LEU . . . . . 0.453 ' O ' ' O ' ' C' ' 401' ' ' LYS . 50.7 tp -61.69 -42.3 98.74 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.527 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 401' ' ' LYS . . . . . 0.773 ' HZ1' ' CG ' ' A' ' 403' ' ' HIS . 83.9 tttt 56.17 121.53 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.529 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 402' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -59.62 -44.33 93.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.475 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 403' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -88.98 131.73 35.04 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.507 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 404' ' ' HIS . . . . . 0.4 ' CE1' ' O ' ' B' ' 402' ' ' HIS . 74.9 t60 -70.34 125.75 27.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 405' ' ' ALA . . . . . . . . . . . . . . . -100.34 -11.39 20.33 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.56 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 406' ' ' GLY . . . . . . . . . . . . . . . -62.65 -37.7 95.2 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 -179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 407' ' ' TYR . . . . . . . . . . . . . 87.0 t80 -78.41 125.48 29.42 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.651 0.262 . . . . 0.0 110.395 179.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 408' ' ' GLU . . . . . . . . . . . . . 70.1 mm-40 -135.63 148.18 48.89 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 120.676 0.274 . . . . 0.0 110.81 179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 409' ' ' GLN . . . . . 0.475 ' N ' ' OH ' ' A' ' 407' ' ' TYR . 48.7 tp60 -75.27 130.84 39.77 Favored 'General case' 0 C--N 1.331 -0.235 0 C-N-CA 120.499 -0.48 . . . . 0.0 109.821 179.727 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 410' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.614 179.889 . . . . . . . . 0 0 . 1 stop_ save_